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Thesis abstract 
Identifying dementia in general practice remains a considerable challenge, with 
mild to moderate stages of dementia potentially underdiagnosed in 30-50% of 
cases. The primary aim of this PhD thesis was to address the question “how can 
we improve the accuracy of brief cognitive assessments when used as part of the 
process for identifying dementia in general practice?”. This was carried out via a 
combination of secondary research through three evidence syntheses, and 
primary research via a survey of general practitioners with results triangulated 
with existing research and thesis findings.  
Through the conduct of a rapid review of clinical practice guidelines (CPGs),I 
found a lack of consistent recommendations for general practice regarding 
selection and application of brief cognitive assessment (BCA) tools There was 
also a paucity of guidance given within the identified CPGs on tailoring BCA 
choice and use for specific populations. The rapid review indicates that greater 
clarity and consistency is needed from CPGs relating specifically to the use of 
BCAs as part of the process for identifying dementia in general practice. The 
systematic review and overview identified an absence of existing evidence. 
Where evidence exists, BCAs performed inconsistently and were broadly 
inadequate as a tool for use in general practice dementia care. Other factors 
beyond diagnostic accuracy render established tests ill-suited for general practice 
such as administration time, cost and acceptability for clinicians and patients. A 
number of areas are identified both in cognitive testing and research methods 
where progress can be made relatively simply. 
This thesis demonstrates that many assumptions underlying current practice are 
without robust foundations, with severe implications for general practice and 
patient care at a time of scarce resource and growing demand.  These 
assumptions need revising as a priority. What is needed is clear, specific, well-
designed primary research to begin to unpick these complexities and realistically 
address the challenges presented by the identification of dementia within general 
practice and primary care. I provide explicit recommendations for the design and 
conduct of a primary comparative accuracy study alongside a trial of 
effectiveness and cost-effectiveness of using brief cognitive assessments as part 
of the process of identifying dementia in general practice in order to objectively 
and systematically assess the suitability of brief cognitive assessments as a tool 
for use in this population and setting. 
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Glossary 
 
6-CIT 6 Item cognitive impairment test 
7MS 7 minute screen 
AD(D) Alzheimer’s disease (dementia) 
AMSTAR Assessment of Multiple Systematic Reviews (quality 
assessment tool) 
AMTS Abbreviated Mental Test Score 
BIMT/Blessed  Blessed information Memory Concentration Test 
CAMDEX  Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CDR Clinical Dementia Rating  
CDT clock drawing test 
CI  Confidence interval 
CVD Cardiovascular disease 
DLB  Dementia with Lewy bodies 
DSM Diagnostic and Statistical Manual III/III-R/IV/IV-R 
DTA Diagnostic test accuracy 
EMBASE Excerpta Medica dataBASE 
FN  False negative 
FTD  Frontotemporal dementia  
G8 Group of Eight (governmental political forum of leading 
industrial countries) 
GMS-AGECAT Geriatric Mental State – Automated Geriatric Examination for  
Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
ICD International Classification of Diseases 
IPA-WHO International Psychogeriatric Association World Health 
Organisation criteria 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
m Minutes  
MCI Mild cognitive impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
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MMSE  Mini mental state examination 
MSQ the Mental Status Questionnaire 
NICE National Institute for Health and Care Excellence (UK) 
NINCDS 
CERAD 
 
National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s Disease and Related 
Disorders Association Consortium to Establish a Registry for 
Alzheimer’s Disease 
NINDS-ADRDA 
 
National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s Disease and Related 
Disorders Association 
NINDS-AIREN National Institute of Neurological Disorders and Stroke and 
Association Internationales pour la Recherche et l´ 
Ensignement en Neurosciences  
NPV  Negative Predictive Value  
NR Not reported 
NSC National Screening Committee  
PCL  Prueba cognitive de leganes [Leganés cognitive test]  
PPV  Positive Predictive Value 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyse 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of psychology. 
QUADAS-2 Quality Assessment in Diagnostic Accuracy Studies 
ROBIS Risk of Bias in Systematic Reviews  
RUDAS The Rowland Universal Dementia Assessment Scale 
s  Seconds 
SASSI Short And Sweet Screening Instrument 
SPMSQ Short portable mental status questionnaire 
TN  True negative 
VaD  Vascular Dementia  
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1. Background 
There is no such thing as a single accurate test at present. Currently GPs would 
use a process of exclusion and series of cognitive tests over time to reach a 
diagnosis 
- ARUK submitted evidence to the All-Party Parliamentary Group on Dementia 
2012 Unlocking Dementia report 
This chapter introduces the background to the thesis question “how can we improve 
the accuracy of brief cognitive assessments when used as part of the process for 
identifying dementia in general practice?” and indicates why this question is important.  
After describing the syndrome of dementia, its natural history and management with 
particular focus on diagnosis, cognitive assessment and dementia diagnosis in primary 
care is discussed, alongside the main tools for diagnosis and evaluation of diagnostic 
tests.  
1.1. Background to the thesis question 
Dementia is a substantial public health problem which will grow with the ageing global 
population. In 2015 there were an estimated 800,000 people with dementia in the UK 
and 46.8 million people worldwide1, with the number set to double by 20402. Dementia 
is a progressive clinical condition, and symptoms - such as memory loss, language 
impairment, disorientation and changes in personality3 - can often be managed4 but 
there is currently no cure. What was referred to in the 1980s as a ‘silent epidemic’5,6 
is now receiving increased attention, and the focus of governments, pressure groups 
and charities has increasingly turned to the importance of identifying people with 
dementia in a timely manner and managing dementia well with medication, health care 
and social care7,8. NHS England figures suggest that in 2016 around 33% of people 
with dementia in the UK were without a diagnosis9. Diagnosis rates have improved in 
recent years, and there are many potential contributory factors: government-driven 
financial incentives such as the £55 payments to general practitioners which ran from 
2014 to 2016 encouraged a rise in referrals to memory clinics10,11. Increased coverage 
across the media and society, and broad improvements in public health generally may 
all have contributed8. Recent survey findings from a sample of 1,409 people across 5 
European countries confirms there remain many practice-driven delays to dementia 
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diagnosis across Europe with significant barriers to earlier diagnosis presented by 
carers such as the first professional seen not considering anything was wrong (33%), 
not believing it was worthwhile pursuing a diagnosis (6.6%) and the person with 
dementia refusing to seek help (37.9%)12. 
One key stage in the process for addressing dementia is often overlooked, which is 
the accurate and careful diagnosis of the condition. We do not know how many people 
are incorrectly identified as having dementia when they do not, or how many people 
are told they do not have dementia when they do. Figures based on 6% disease 
prevalence within an average general practice population suggest false positive 
dementia diagnosis rates (i.e. people told they have dementia when they do not) may 
be around 10%13. Dementia diagnosis is often difficult, particularly in less clearly-
differentiated early stages of the syndrome. Patient, family or clinician reluctance to 
identify a stigmatised condition, perceived lack of treatment options, the belief that 
problems were part of the normal ageing process, and masking or lack of 
differentiation with other conditions combine to make dementia diagnosis one of the 
most challenging and under-recognised complexities of the condition10,14-22. In 2013 
the James Lind Alliance reported findings from a Priority Setting Partnership carried 
out with members of the public, clinicians and specialists to identify priorities for 
dementia research 23. Number three on the top ten priority list was the question “what 
is the impact of an early diagnosis of dementia and how can primary care support a 
more effective route to diagnosis?”. Understanding how to improve the use, and 
specifically the accuracy, of available assessment tools as part of the process for 
identifying dementia in general practice is central to improving dementia diagnosis. 
This key challenge is the focus of this thesis. What follows is a closer exploration of 
what is currently known; the challenges yet to be addressed; and finally an overview 
of the chapters within this thesis, how they link together and how conclusions are 
drawn. 
1.2. Dementia: its natural history and management 
‘Dementia’ is a broad umbrella term used to describe a set of symptoms including 
memory decline, other cognitive deficits such as the inability to make judgements, plan 
ahead and organise, and other changes in social behaviour such as emotional 
instability, irritability, apathy or disinhibition. A number of other conditions can cause 
similar symptoms of cognitive deficits, such as heavy alcohol consumption, 
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depression, urinary infections and thyroid problems, so these changes should be 
sustained for over 6 months to avoid misclassifying another condition as dementia. 
There is no single test for dementia. Instead, the pattern of symptoms that a person 
has, combined with the history of the individual, talking to friends and relatives who 
know the person, expert clinical judgment and other investigations such as brief 
cognitive assessments, neuropsychological tests, blood tests and brain scans will help 
to diagnose an individual with dementia. Differential diagnosis normally takes place in 
a specialist memory clinic with the aid of geriatricians, neuropsychologists and 
psychiatric assessment. 
In most European models of care, two-step triage and diagnostic evaluation pathway 
for dementia is preferred, as endorsed by the European Dementia Consensus 
Network24. Here, the primary care practitioner conducts preliminary assessments 
including cognitive screening tests to identify the presence and extent of any 
impairment. Once a positive identification is made the patient is referred on to 
secondary specialist services for comprehensive assessment and diagnosis. 
Following full diagnosis, the patient is referred back to the primary care practitioner for 
ongoing care25 (see Error! Reference source not found. below).  
Figure 1. Standard diagnostic pathway 
 
Once dementia has been identified and other conditions such as those mentioned 
above have been ruled out, there are limited treatment options for the individual, which 
may help to slow cognitive decline and improve quality of life. Cost-effective drug 
therapy such as acetylcholinesterase inhibitors may be available, although clinical 
effectiveness depends on a number of factors including stage of disease progression 
and dementia sub-type identified. Non-drug interventions such as cognitive stimulation 
therapy are also available in many areas26. Management of the condition is normally 
through a combination of therapeutic treatment, information provision, signposting and 
practical support.  Carer burden is increasingly recognised as an associated issue in 
dementia management, as carers are at additional and increased risk of physical and 
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mental illness as a consequence of the caring role12. Social and legal implications also 
require management for individuals and their carers, such as the ability to drive, loss 
of independence and legal autonomy27.  
A 2012 survey by the Alzheimer’s Society28 found that 68% of respondents with 
dementia waited longer than a year between noticing symptoms and getting a 
diagnosis of dementia, and research has clearly shown that a delay in diagnosis is a 
clear concern to patients29,30. There is some evidence that screening as part of 
dementia diagnosis can bring an unjustifiable degree of stress to the individual and 
their families31, yet other evidence shows that patients and caregivers will already be 
distressed if progressive cognitive decline is present and it would be naive to think that 
the diagnostic process itself is a cause of this stress32. Indeed, many patients and 
caregivers report finding relief in a diagnosis33,34. A recent survey of 446 Australian 
outpatients found that 92% of respondents preferred a diagnosis of dementia to be 
disclosed as soon as possible, with 88% of respondents preferring disclosure as soon 
as possible in a spouse or partner35.  
The process of diagnosis can identify a dementia syndrome (a set of symptoms such 
as memory problems, cognitive impairment and changes in social behaviour for at 
least 6 months), sometimes referred to as ‘syndromal diagnosis’36-38. Subsequent 
specific diagnostic work-up (‘aetiological diagnosis’) can differentiate between 
dementia subtypes such as Alzheimer’s disease, vascular dementia, dementia with 
Lewy bodies, fronto-temporal dementia and mixed dementia. This more detailed 
diagnostic investigation is generally carried out by neurological and gerontological 
experts in e.g. memory clinics following GP referral. The interaction between referral 
pathways can be problematic and often unclear across many countries39.  
1.3. Cognitive assessment in the assessment of dementia 
Cognitive assessment concerns investigation of the higher cortical functions, namely 
memory, attention, orientation, language, planning activities, and sequencing of 
activities40. Cognitive assessment is often positioned as an iterative process 
comprising various stages, in contrast to a single point valuation. This correctly reflects 
the clinical reality of cognitive assessment as a process, but is a challenge when 
considering the purpose of a brief cognitive assessment, and the population in which 
it may be used. Part of the set of broadly low cost and easily-accessed tools 
sometimes colloquially referred to as ‘pen and paper tests’41, brief cognitive 
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assessments measure cognitive function to aid decision making for diagnosis, staging 
of severity, further treatment, management or onwards referral. The addition of ‘brief’ 
is to indicate the tests are relatively quick to administrate, and are generally 
understood to take up to 10 minutes42,43.  This description of ‘brief’ is arbitrary and 
problematic, and will be discussed fully later in this thesis. Brief cognitive assessments 
are often used in primary health care such as general practice to provide information 
on a patient’s cognitive function and are part of the recommended toolkit for clinical 
assessment of dementia within all main national and international guidelines26,39,40,44-
46. Cognitive assessment is useful in assessing many conditions, including dementia, 
which is commonly indicated by a decline in cognitive function. As part of the 
diagnostic process, results from these assessments may guide the general practitioner 
in their decisions on clinical management, treatment and further testing. 
General practice is often the first place people with concerns about their memory will 
seek help27. Across many health care systems (including the USA, Netherlands, the 
UK, Spain, Italy and Ireland), the referral pathway for dementia diagnosis incorporates 
general practitioners (GPs) in a ‘gatekeeper’ role39,47,48. The GP or family doctor 
conducts initial assessments and then refers on as appropriate to specialist services 
for further diagnostic work up and differential diagnosis. Increasingly, policymakers at 
both local and international levels have tried to influence diagnostic practice - 
particularly at the entry level of primary care - in an attempt to increase dementia 
diagnosis rates10,15,49-52. As dementia has received increased focus as a growing 
social and public health issue, governments have sought to increase dementia 
diagnosis rates within general practice using financial incentives and clinical practice 
guidelines2,9,10. An interesting question is to what extent these guidelines are 
consistent in their advice, and how do the various guidelines match current evidence.  
Guidelines and recommendations around tests such as brief cognitive assessments 
should ultimately be based on their ability to improve patient outcome. This is difficult 
in practice where information on the direct effect of tests on patient outcome is rare, 
and common measures relate to aspects of test performance such as diagnostic 
accuracy. The diagnostic accuracy of a test (how well it correctly identifies people with 
and without a disease) relies on many different pieces of information. Influential factors 
include disease prevalence, a reliable reference standard, clear patient 
characterisation and an understanding of the setting the test will be used in – as well 
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as a strong sense of how the test will be used to guide decision making. A test should 
also improve patient outcome, it is important to consider what other aspects of a test’s 
performance may influence outcome beyond test accuracy, such as how long it takes 
to administer, the cost of a test and how acceptable it is to patients53. 
The challenge of testing is heightened when the condition being investigated has a 
mixed presentation, challenging aetiology, and is hard to identify in the early stages 
as is the case with dementia14. As dementia is syndromic (i.e. a collection of 
symptoms), there are some symptoms which manifest in people early on and some 
which will never appear in others.  
Many people have more than one type of dementia-causing condition54-56. Alzheimer’s 
disease is identified in 60-80% of dementia cases, and vascular dementia makes up 
10-17% of cases. Other less common subtypes exist such as frontotemporal 
dementia, dementia with Lewy bodies and Parkinson’s dementia and these have 
varied underlying mechanisms which can drive different symptomatic expressions57-
59.  As these symptoms can vary widely, this presents a challenge for brief cognitive 
assessment aiming to capture a range of presentations43. 
The inadequacy of current tools was recognised in a 2012 report “Unlocking dementia” 
by the UK All-Party Parliamentary Group on Dementia60. In submitted evidence, 
Alzheimer’s Research UK stated: 
There is no such thing as a single accurate test at present. Currently GPs would use 
a process of exclusion and series of cognitive tests over time to reach a diagnosis60. 
Poor performance of assessment tools was acknowledged as a potential barrier to 
dementia diagnosis, and government ministers recommended that “GP training on 
dementia diagnosis should contain information on known problems with assessment 
tools and encourage GPs to use their clinical judgement”. Moreover, the All Party 
Parliamentary Group noted that “GPs should feel confident to use their clinical 
judgement in addition to assessment tools, particularly where there are known 
problems with the tools”60. 
There have been few developments addressing the performance of brief cognitive 
assessment tools, yet there is continuous guidance issued by charities, pressure 
groups, medical associations and government organisations on the availability, 
selection and use of brief cognitive assessments specifically for use in general or 
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family practice61-67. These guidelines, how they harmonise and diverge and the 
evidence base upon which they are established are discussed within Chapter 3. 
Whilst it is undeniably a positive development to recognise the importance of dementia 
identification, current discourse and strategies appear to have bypassed a central 
aspect of diagnosis – that is, the performance of the tests being used to assess 
cognitive function as part of a broader assessment for possible dementia. An overview 
review of the diagnostic accuracy of brief cognitive assessments used as part of the 
process for identifying dementia in primary care identifies the current evidence base 
and is presented in Chapter 4 of this thesis. 
Identifying dementia in general practice is a considerable challenge, with mild to 
moderate stages of the condition potentially underdiagnosed in 30-50% of 
cases9,26,29,68-73. Part of the difficulty encountered in dementia diagnosis – particularly 
before the condition is advanced - is the challenge in differentiating between dementia 
subtypes, availability of reliably predictive biomarkers, technology available for use in 
general practice and recognition of key signs and symptoms that may be masked by 
other conditions often presenting concurrently as people age. Many initiatives 
(including the national dementia plans of Australia, Greece, Indonesia, Ireland, Israel, 
Italy, Luxembourg, Malta, Mexico, Northern Ireland, Scotland, Switzerland, Taiwan, 
and the USA) focus on improving early or timely identification of dementia to allow 
space for planning, help-seeking, symptom modification and allocation of resources26.  
As the diagnostic process is moved to an earlier time point in the dementia profile, the 
challenges presented to clinicians in correctly identifying the signs and symptoms 
presented are intensified and the likelihood of diagnostic errors (such as false 
positives, i.e. incorrectly identifying someone as having dementia when they do not) 
increases. This diagnostic process does not operate in a vacuum, and there are many 
potential personal, health and social implications for the individual, their friends and 
families, the clinician and society more broadly which may influence decisions around 
timely diagnosis of dementia.  
1.4. Evaluation of diagnostic tests 
Diagnostic accuracy is one way of assessing how a ‘new’ test (the index test) 
compares to the best available test (the reference standard). Diagnostic accuracy is 
measured as a test’s ability to correctly identify people with a condition (sensitivity) 
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and to correctly rule out people without a condition (specificity). Sensitivity and 
specificity are generated by the same data and are therefore interrelated so that – 
generally – when one increases, the other lowers. In this sense, there is usually a 
decision to be made about whether it is clinically more meaningful to have higher 
sensitivity and lower specificity, or higher specificity and lower sensitivity. Diagnostic 
accuracy is not a fixed element of a test, and factors such as different patient groups, 
the disease spectrum, the clinical setting, and interpretations placed upon a test all 
influence accuracy. It is therefore essential to define these aspects up front within the 
study question, and ideally place the test within context of previous testing strategies 
and consequent management decisions influenced by test results74,75.   
Diagnostic accuracy data are generated using a binary 2x2 table, where people within 
a study are either: correctly identified by both the reference standard and the index 
test (true positives); correctly ruled out by both the reference standard and the index 
test (true negatives); correctly identified by the reference standard but incorrectly ruled 
out by the index test (false negatives); and correctly ruled out by the reference 
standard but incorrectly identified by the index test (false positives). This is illustrated 
in Table 1 below: 
Table 1. Binary 2x2 table classifying diagnostic accuracy 
   Reference Standard 
+ - 
Index 
test 
+ True Positive False Positive 
- False Negative True Negative 
 
Whilst much discussion revolves around dementia diagnosis and the need to identify 
dementia earlier in the diagnostic pathway, there appears to be relatively little 
discussion of the accuracy of the diagnosis. In their article on the dangers behind new 
diagnostic tests, Hofmann and Welch highlight problems of tests being applied in 
different ways, with different populations and earlier in the investigatory process – all 
issues equally relevant to established tests such as brief cognitive assessments76. In 
the case of dementia, brief cognitive assessments are used as part of the process for 
measuring cognitive function, and this in turn can indicate the possibility of dementia 
alongside other causes. Brief cognitive assessments form part of a clinician’s toolkit 
for assessing a patient, and the results of a brief cognitive test should never be viewed 
in isolation but as part of the broader clinical assessment.  
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The evaluation of tests in secondary research (such as systematic reviews and 
overviews) presents particular challenges due to the greater level of abstraction of the 
test data. Details such as test thresholds, population, sample and disease prevalence 
and nuances of test presentation can be lost during the construction of this ‘second 
level’ evaluation framework. Reporting of test data within secondary research varies 
considerably, and the candidate has been fortunate to have the opportunity to 
contribute to improvements in guidelines for the transparent reporting of systematic 
reviews within the PRISMA-DTA Working Group77 in order to make the results from 
systematic reviews of diagnostic test accuracy studies more useful. This work is 
discussed in more detail in Chapters 2 and 7 in this thesis. 
A range of different language is used to describe dementia assessment and diagnosis, 
and one term commonly used within the literature is ‘screening’. This has several 
meanings depending on who it is applied to, and who is using the term. These issues 
are addressed in detail below. 
Demand for ‘timely’ diagnosis – that is, diagnosis at the point when cognitive and other 
changes an individual is experiencing starts to affect their life and lives of people close 
to them78 - is strong and improved identification in general practice is generally 
supported, but there is robust resistance for dementia screening. Although this term is 
used in different ways, in this thesis screening is used to describe the proactive and 
asymptomatic investigation for a condition at the level of a population. Whilst screening 
has been suggested as a way to identify more cases earlier79, there is little appetite 
for dementia screening globally for a number of reasons: the low disease prevalence 
of around 6% within a general practice population; poor assessment tools; and lack of 
systemic post-diagnostic support2,60,80,81. In 2015 the UK National Screening 
Committee issued clear guidance following a thorough review of the evidence:  
 The UK NSC does not recommend a systematic population 
screening programme for Dementia using cognitive assessment 
tools.  Cognitive assessment tools are insufficiently reliable for use 
in large scale screening programmes and there is insufficient 
evidence on the benefit of interventions to demonstrate that early 
treatment leads to improved outcomes from screening82. 
Instead of screening, a case finding approach is preferred by many13,43,63,68,82-85. In a 
case finding approach, people present to their GP with a symptom or set of symptoms, 
or in ‘proactive’ case finding individuals who fall into higher risk groups (such as those 
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over 65 years old, people with pre-existing vascular conditions or Parkinson’s disease) 
are systematically invited for assessment.  
When used for case finding, brief cognitive assessments have been shown to identify 
a higher proportion of people with a positive test result who actually have dementia 
compared to when they are used for screening81. In either case, evidence for the 
diagnostic accuracy of brief cognitive assessments when used in a primary care 
population is still very unclear (i.e. how good a test is at correctly identifying someone 
with dementia, or correctly ruling out someone without dementia). 
1.4.1. Population screening 
Population screening refers to the comprehensive indiscriminate assessment of a 
given population in order to identify a condition85,86. Despite advocacy for screening 
by a number of test developers79, major organisations such as the US Preventive 
Services Task Force87,88, the US Department of Veteran Affairs89, Alzheimer’s 
Research UK85 and the UK National Screening Committee (NSC)90 do not recommend 
universal screening for dementia for a number of reasons, most prominent of which is 
that the way the condition develops and the beneficial effect of early treatment are still 
uncertain90. In addition, the NSC cites evidence of low population prevalence in people 
over 65 years old (around 7 in 100 people would be affected), and the poor sensitivity 
of available tests.  
Some expert analyses91-93 have highlighted a lack of evidence on the impact of 
initiatives designed to increase asymptomatic screening of dementia within primary 
care such as cost-effectiveness and harms to patients, and this conspicuous 
uncertainty is worth exploring further in future research. 
1.4.2. Targeted screening and case finding 
In the US, initiation of Medicare Annual Wellness Visits63 and in the UK the NHS 
introduction of a Direct Enhanced Service (DES) for dementia assessment raised the 
profile of dementia screening tests and heightened calls for developing the evidence 
base for formal dementia screening (including investigating diagnostic thresholds, 
improving understanding of screening outcomes and further exploration of benefits, 
harms and costs of screening)84.   
‘Targeted screening’ or ‘case finding’ are commonly-used terms referring to the 
identification of ‘cases’ or people who may be symptomatic through particular 
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exposure or higher risk groupings (such as those aged over 65 years old, people who 
have had a stroke or people over 75 years old admitted to hospital). Case finding for 
dementia is currently part of the UK Government’s Dementia Strategy94, although 
supporting evidence is mixed and the approach itself is contentious. 
Targeted screening can exploit standard general practice methods such as the regular 
review of people with long term conditions, and it is argued by some that the 
investigation of people with increased risk of dementia due to age or related medical 
conditions would seem a logical part of the primary care assessment95. In addition, 
general practice is a comfortable environment where people with comorbidities and 
long term conditions will be familiar with both the environment and the health care 
professionals for regular review. It is argued that this is a familiar, cost-effective and 
non-stigmatising environment where people at increased risk of dementia and their 
loved ones can be managed holistically95.  
The case for targeted screening, however, is not met by current evidence according 
to the Wilson and Jungner criteria applied by the UK National Screening Committee in 
their 2015 guidelines recommending against dementia screening90. In order to meet 
appropriate and ethical thresholds, these criteria provide four conditions to be met 
relating to the condition, its diagnosis, treatment, and cost-effectiveness. The condition 
must be considered important, with a clear understanding of aetiology (the underlying 
set of causes96) contributory and risk factors and observable primary prevention 
strategies having taken place. The importance of dementia is increasingly recognised, 
yet evidence on other aspects of aetiology and risk factors remain unclear whilst there 
is still intense discussion around what forms an early stage of dementia, with 
associated conditions such as mild cognitive impairment not converting consistently 
to dementia32,97. 
A clear, safe, precise and validated diagnostic test should be available that is 
acceptable both to the population at large and the test users, with a known course of 
therapeutic action if a test result is positive98. Systematic review evidence has 
consistently shown that there are a limited number of brief cognitive assessments 
available that are demonstrably appropriate or validated for use in primary care 
settings99-106. 
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The process for identifying dementia in general practice is iterative and no single test 
should be used in isolation to give a definitive answer7,26,40,48,60,64,65,84,107,108. As part of 
the standard clinical assessment, GPs take a medical history from the patient, record 
signs and symptoms of disorder and explore possible reasons for these signs and 
symptoms including life events, medication and temporary conditions. Depending on 
the complaint or observed issues, the GP may run tests to rule out causes such as 
depression, thyroid dysfunction or urinary infections62,109.  
If dementia or cognitive impairment is suspected, there are a number of brief cognitive 
assessments recommended by various guidelines including the Mini Mental State 
Examination (MMSE), General Practitioner Assessment of Cognition (GPCOG), the 
Mini-Cog, and the Memory Impairment Screen 62,64,110-112. The criteria for 
recommending different tests varies, and these tests and guidelines are addressed in 
detail in Chapter 2 and 3. 
As with the majority of tests86, the diagnostic accuracy of brief cognitive assessments 
used as part of the process to identify cognitive function in possible dementia cases is 
imperfect and many factors influence test performance. Factors such as disease 
prevalence (how many cases of a condition are present within a stated population), 
setting, intended patient group, test administrator, practice effects and interpretation 
all have an influence on how well a brief cognitive assessment identifies people with 
and without cognitive impairment or dementia7,17,29,39,46,70,113,114.  
Many brief cognitive assessments were developed and validated in populations other 
than general practice44,115,116. This has implications for the applicability of stated 
diagnostic accuracy, as well as for other factors which may influence the suitability 
and performance of a test such as: administration time; economic cost; accessibility; 
acceptability to the patient and clinician; and resource availability42,53,117-119.  
There is solid systematic review evidence assessing the diagnostic accuracy of 
different brief cognitive assessments for identifying dementia41,42,44,99,116,120. The 
picture of which tests are most suitable for general practice, however, remains unclear, 
and guidelines for diagnosis lack consistent direction for health care professionals, 
policy makers and the public.  
This thesis forms a substantial addition to the current body of knowledge by 
establishing what is currently known about the diagnostic accuracy of current brief 
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cognitive assessments when used as part of the process for identifying dementia in 
primary care. This thesis also progresses methods for conducting overviews of 
systematic reviews of diagnostic accuracy, and comparative systematic reviews of 
diagnostic accuracy for specific brief cognitive assessments, as well as bringing clarity 
to understanding of how accurate current brief cognitive assessments are for 
identifying dementia in primary care, how useful they are and what recommendations 
can be made for current use - assessed through a combination of the overview, the 
systematic review of direct test comparisons, and the GP survey.  
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Glossary 
 
6-CIT 6 Item cognitive impairment test 
7MS 7 minute screen 
AD(D) Alzheimer’s disease (dementia) 
AMSTAR Assessment of Multiple Systematic Reviews (quality 
assessment tool) 
AMTS Abbreviated Mental Test Score 
BIMT/Blessed  Blessed information Memory Concentration Test 
CAMDEX  Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CDR Clinical Dementia Rating  
CDT clock drawing test 
CI  Confidence interval 
CVD Cardiovascular disease 
DLB  Dementia with Lewy bodies 
DSM Diagnostic and Statistical Manual III/III-R/IV/IV-R 
DTA Diagnostic test accuracy 
EMBASE Excerpta Medica dataBASE 
FN  False negative 
FTD  Frontotemporal dementia  
G8 Group of Eight (governmental political forum of leading 
industrial countries) 
GMS-AGECAT Geriatric Mental State – Automated Geriatric Examination for  
Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
ICD International Classification of Diseases 
IPA-WHO International Psychogeriatric Association World Health Organisation 
criteria 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
m Minutes  
MCI Mild cognitive impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
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MMSE  Mini mental state examination 
MSQ the Mental Status Questionnaire 
NICE National Institute for Health and Care Excellence (UK) 
NINCDS 
CERAD 
 
National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s Disease and Related 
Disorders Association Consortium to Establish a Registry for 
Alzheimer’s Disease 
NINDS-ADRDA 
 
National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s Disease and Related 
Disorders Association 
NINDS-AIREN 
National Institute of Neurological Disorders and Stroke and 
Association Internationales pour la Recherche et l´ Ensignement en 
Neurosciences  
NPV  Negative Predictive Value  
NR Not reported 
PCL  Prueba cognitive de leganes [Leganés cognitive test]  
PPV  Positive Predictive Value 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyse 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of psychology. 
QUADAS-2 Quality Assessment in Diagnostic Accuracy Studies 
ROBIS Risk of Bias in Systematic Reviews  
RUDAS The Rowland Universal Dementia Assessment Scale 
s  Seconds 
SASSI Short And Sweet Screening Instrument 
SPMSQ Short portable mental status questionnaire 
TN  True negative 
VaD  Vascular Dementia  
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2. Aims and objectives 
Diagnosis is the gateway for care. No drug or non-drug treatment can be given, and 
no specific future planning carried out, without individuals receiving a diagnosis 
Knapp M, Comas-Herera A, Somami A & Banerjee S (2007) Dementia: international 
comparisons. LSE PSSRU 
2.1. Aim and objectives of this PhD research 
The primary aim of this thesis is to address the question “how can we improve the 
accuracy of brief cognitive assessments when used as part of the process for 
identifying dementia in general practice?” by establishing a clear picture of the 
evidence for diagnostic accuracy of brief cognitive assessments for identifying 
dementia within general practice. 
 This is achieved through the following objectives: 
 establishing current clinical practice guidelines relating to the use of brief cognitive 
assessments used to identify dementia in primary care; 
 assessing the diagnostic accuracy of brief cognitive assessments used to identify 
dementia in primary care;  
 reviewing the diagnostic test accuracy evidence by assessing studies that have 
directly compared GPCOG and MMSE for identifying dementia in general practice; 
and 
 exploring the views of general practitioners around dementia screening tests.  
This assessment of the evidence allows the building of practical recommendations for 
improving the accuracy of brief cognitive assessments specifically for use in general 
practice. 
2.2. Background to the thesis question 
Dementia is a substantial public health problem which will grow with the ageing global 
population. In 2015 there were an estimated 800,000 people with dementia in the UK 
and 46.8 million people worldwide1, with the number set to double by 20402. Dementia 
is a progressive clinical condition, and symptoms - such as memory loss, language 
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impairment, disorientation and changes in personality3 - can often be managed4 but 
there is currently no cure. What was referred to in the 1980s as a ‘silent epidemic’5,6 
is now receiving increased attention, and the focus of governments, pressure groups 
and charities has increasingly turned to the importance of identifying people with 
dementia in a timely manner and managing dementia well with medication, health care 
and social care7,8. NHS England figures suggest that in 2016 around 33% of people 
with dementia in the UK were without a diagnosis9. Diagnosis rates have improved in 
recent years, and there are many potential contributory factors: government-driven 
financial incentives such as the £55 payments to general practitioners which ran from 
2014 to 2016 encouraged a rise in referrals to memory clinics10,11. Increased coverage 
across the media and society, and broad improvements in public health generally may 
all have contributed8. Recent survey findings from a sample of 1,409 people across 5 
European countries confirms there remain many practice-driven delays to dementia 
diagnosis across Europe with significant barriers to earlier diagnosis presented by 
carers such as the first professional seen not considering anything was wrong (33%), 
not believing it was worthwhile pursuing a diagnosis (6.6%) and the person with 
dementia refusing to seek help (37.9%)12. 
One key stage in the process for dementia treatment is often overlooked, which is the 
accurate and careful diagnosis of the condition. We do not know how many people are 
incorrectly identified as having dementia when they do not, or are told they do not have 
dementia when they do although figures based on 6% disease prevalence within an 
average general practice population suggest false positive dementia diagnosis rates 
(i.e. people told they have dementia when they do not) may be around 10%13. 
Dementia diagnosis is often difficult, particularly in less clearly-differentiated early 
stages of the syndrome. Patient, family or clinician reluctance to identify a stigmatised 
condition, perceived lack of treatment options, the belief that problems were part of 
the normal ageing process, and masking or lack of differentiation with other conditions 
combine to make dementia diagnosis one of the most challenging and under-
recognised complexities of the condition10,14-22. In 2013 the James Lind Alliance 
reported findings from a Priority Setting Partnership carried out with members of the 
public, clinicians and specialists to identify priorities for dementia research 23. Number 
three on the top ten priority list was the question “what is the impact of an early 
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diagnosis of dementia and how can primary care support a more effective route to 
diagnosis?”. Understanding how to improve the use, and specifically the accuracy, of 
available assessment tools as part of the process for identifying dementia in general 
practice is central to improving dementia diagnosis. This key challenge is the focus of 
this thesis. 
2.3. Thesis structure 
A brief summary of each chapter’s content follows: 
1 
Chapter 1. Background 
Background to the thesis question; dementia, its natural history and 
management, with a particular focus on diagnosis; cognitive assessment in 
the diagnosis of dementia; and the evaluation of diagnostic tests. 
2 Chapter 2. Aims and objectives 
Aims and objectives of the thesis; thesis structure. 
3 
Chapter 3. Rapid review of clinical practice guidelines relating to the 
use of brief cognitive assessments used as part of the process for 
diagnosing dementia within general practice. 
Why a rapid review of guidelines is needed; research protocol; discussion 
of the findings, including limitations of included studies and 
recommendations for practice and research. 
4 
Chapter 4. An overview of systematic reviews summarising the 
accuracy of brief cognitive assessments for identifying dementia in 
primary care.  
Why is an overview needed; key findings; discussion and 
recommendations for research and practice. 
 
5 
Chapter 5. Systematic review - how accurate are GPCOG and MMSE 
in identifying dementia when directly compared to each other?  
Comparative test performance – methods and results; analysis and 
discussion of findings; recommendations for practice and further research 
needed. 
 
6 
Chapter 6. The clinical reality of identifying dementia using brief 
cognitive assessments as part of the primary care consultation: How 
do GPs influence diagnostic performance?  
Survey methods; test selection and GP preferences; barriers and 
facilitators; other issues identified; summary and discussion. 
7 Chapter 7. Summary and discussion.  
Synopsis of main findings; recommendations for research and practice; 
thesis discussion in context; reflection on the PhD. 
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A glossary is included at the beginning of each chapter, and each chapter is detailed 
in the page footer along with page numbers to help the reader orientate throughout 
the thesis.  
The referencing style uses EndNote “Academic Medicine”, or superscript numbers 
(e.g.1). This is because many chapters, in particular the rapid review in Chapter 3, the 
overview in Chapter 4 and the systematic review in Chapter 5, are “reference heavy” 
due to numerous study-level and systematic review-level references. In order to make 
the text readable superscript numbers are used throughout.  
2.4. Publications and scholarship activities arising from this thesis 
Publications, presentations and wider scholarship activities arising from this thesis, 
including those in press, are listed below in order of activity type and date: 
2.4.1. Publications   
McInnes, MD, Moher, D, Thombs, BD, McGrath, TA, Bossuyt, PM, Clifford, T, ...& 
Hunt, HA (2018). Preferred reporting items for a systematic review and meta-
analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA, 
319(4), 388-396. https://jamanetwork.com/journals/jama/fullarticle/2670259  
* PRISMA-DTA Working Group: Tammy Clifford, PhD; Jérémie F. Cohen, MD, PhD; 
Jonathan J. Deeks, PhD; Constantine Gatsonis, PhD; Lotty Hooft, PhD; Harriet A. 
Hunt, MSc; Christopher J. Hyde, PhD; Daniël A. Korevaar, MD, PhD; Mariska M. G. 
Leeflang, PhD; Petra Macaskill, PhD; Johannes B. Reitsma, MD, PhD; Rachel 
Rodin, MD, MPH; Anne W. S. Rutjes, PhD; Jean-Paul Salameh, BSc; Adrienne 
Stevens, MSc; Yemisi Takwoingi, PhD; Marcello Tonelli, MD, SM; Laura Weeks, 
PhD; Penny Whiting, PhD; Brian H. Willis, MD, PhD. 
Hunt, HA, Pollock, A., Campbell, P., Estcourt, L., & Brunton, G. (2018). An 
introduction to overviews of reviews: planning a relevant research question and 
objective for an overview. Systematic Reviews 7(1), 39.  
Pollock A, Campbell P, Brunton G, Hunt HA and Estcourt L (2017) Selecting and 
implementing overview methods: implications from five exemplar overviews. 
Systematic Reviews 6(1), p.145 10.1186/s13643-017-0534 
https://doi.org/10.1186/s13643-017-0534-3 
Hunt HA, van Kampen S, Takwoingi Y, Llewellyn DJ, Pearson M and Hyde CJ, 
2017. The comparative diagnostic accuracy of the Mini Mental State Examination 
(MMSE) and the General Practitioner assessment of Cognition (GPCOG) for 
identifying dementia in primary care: a systematic review protocol. Diagnostic and 
Prognostic Research 1(1), p.14 https://doi.org/10.1186/s41512-017-0014-1 
Hunt HA & Hyde CJ (2017) An overview of systematic reviews summarising the 
accuracy of brief cognitive assessments for identifying dementia in primary care. 
Diagnostic and Prognostic Research 1(Suppl 1):P30 
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2.4.2. Presentations & workshops 
Hunt H, McGrath T, Salameh J, Dehmoobad Sharifabadi A, Frank R, Whiting P 
(2018) Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) for diagnostic test accuracy studies (PRISMA-DTA): workshop for review 
authors. Monday 17th September, 11:00 – 12:30 Cochrane Colloquium, Edinburgh 
2018.  
Weeks L, Hunt HA, Pieper D, Hartling L (2018) HTAi Annual Meeting 2018 
workshop ID #52 "Overviews Of Systematic Reviews: An Emerging Methodology In 
Health Technology Assessment” The Westin Bayshore, Vancouver, Canada  
Hunt HA & Hyde CJ (2017) How to compare medical tests: An example of 
systematic reviews of diagnostic accuracy using within-study comparisons. Global 
Evidence Summit 13-16 September 2017, Cape Town, South Africa (abstract 
accepted for long oral presentation)  
Hunt HA & Hyde CJ (2017) Overviews of diagnostic test accuracy: more research 
versus better research. Global Evidence Summit 13-16 September 2017, Cape 
Town, South Africa (abstract accepted for short oral presentation)  
Hunt HA & Hyde, CJ (2016) Overview (de)generation: a review of reviews on the 
diagnostic accuracy of brief cognitive assessments for identifying dementia in 
primary care. Long oral presentation at 24th Cochrane Colloquium, Seoul, South 
Korea 
Hunt HA (2016) How can primary care support a more effective route to dementia 
diagnosis? Oral presentation at University of Exeter Medical School Academic 
Research Event, Torquay, UK 
Pollock A, Hunt HA, Campbell P, Estcourt L and Brunton G (2016) Cochrane 
overviews of reviews: exploring the methods and challenges. An overview of 
systematic reviews of diagnostic test accuracy (workshop). Workshop presentation 
at Cochrane UK & Ireland Symposium 2016: Impact, Innovation and Ingenuity. 
Birmingham, UK 
Hunt H (2015) Constructing an overview of systematic reviews of diagnostic test 
accuracy. Oral presentation at 23rd Cochrane Colloquium 2015, Vienna, Austria 
2.4.3. Scholarship activities 
 PRISMA-DTA Consensus Working Group invited member [2016 – ONGOING]  
 GRADE in Overviews guidance development invited contributor [2017 – ONGOING] 
 Cochrane Diagnostic Test Accuracy Reviews peer reviewer [2014 – ONGOING] 
 Cochrane Global Ageing Group member [2016 – ONGOING] 
 Peer reviewer for British Medical Journal, Diagnostic & Prognostic Research, 
BMC Medical Research Methodology, BMC Systematic Reviews [2014 – 
ONGOING] 
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Glossary 
 
3MS Modified Mini Mental Exam 
6-CIT 6 Item cognitive impairment test 
7MS 7 minute screen 
10-CS 10 point Cognitive Screener 
ACE Addenbrooke’s Cognitive Evaluation 
ACE-R Addenbrooke’s Cognitive Evaluation - revised 
ACE-III Addenbrooke’s Cognitive Evaluation – version three 
ADAS-Cog The Alzheimer’s Disease Assessment Scale - Cognition 
ADI Alzheimer’s disease International 
AMT(S) Abbreviated Mental Test Score 
BNT Behavioural Neurology Assessment 
CCCDTD Canadian Consensus Conferences on the Diagnosis and 
Treatment of Dementia 
CCG Clinical Commissioning Group 
CDPC Cognitive Decline Partnership Centre 
CDT clock drawing test 
CPG Clinical Practice Guideline 
EMBASE Excerpta Medica dataBASE 
FAB Frontal Assessment Battery 
FAQ Functional Activities Questionnaire 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
KICA-Cog Kimberley Indigenous Cognitive Assessment  
KICA-Screen Kimberley Indigenous Cognitive screening tool 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MeSH Medical Subject Headings 
MIS Memory Impairment Screen 
MMSE  Mini mental state examination 
MoCA Montreal Cognitive Assessment 
NHS  National Health Service (UK) 
NICE National Institute for Health and Care Excellence (UK) 
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PAS Psychogeriatric Assessment Scale 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of psychology. 
RUDAS The Rowland Universal Dementia Assessment Scale 
SIS Six item screener 
SPMSQ Short portable mental status questionnaire 
TICS Telephone Interview for Cognitive Status 
TRIP Turning Research Into Practice database 
TYM Test Your Memory 
VF-an Verbal Fluency - animals 
WHO World Health Organisation 
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3. A rapid review of clinical practice guidelines relating to the 
use of brief cognitive assessments used as part of the 
process for diagnosing dementia within general practice  
MMSE: The gold standard of cognitive tests 
Barrett, A & Burns, A (2014) Dementia revealed. What primary care 
needs to know. Hardwick CCG, NHS England, Department of 
Health, Royal College of General Practitioners [p.39] 
The focus of this chapter is the conduct and results of a rapid review of existing clinical 
practice guidelines (CPGs) relating to the use of BCAs as part of the process for 
diagnosing dementia within general practice. This rapid review emphasised the need 
for greater clarity in CPGs on this specific topic. This review also identified a necessity 
for more informed evidence on demand for CPGs, how they influence practice and 
how they can better support BCA use within this clinical population.  
Context informing the review is initially discussed, followed by definition of the common 
terms used such as brief cognitive assessment, diagnosis in the general practice 
context, case finding and screening at the population level and the level of the 
individual patient. Search methods are described in detail, and results of the rapid 
review are presented relating to general practice, BCAs and CPGs included within the 
review. The discussion considers major and minor findings and their relevance to 
current practice. Recommendations for practice and research are made at the end of 
the discussion.  
3.1. Why do a rapid review of clinical practice guidelines? 
This review is intended to inform understanding of current clinical practice by 
identifying specific CPGs relating explicitly to the use of BCAs used as part of the 
process for diagnosing dementia within general practice.  
3.1.1. What is a rapid review? 
A rapid review is defined here as a type of knowledge synthesis in which standard 
systematic review processes are limited in order to produce a review within a restricted 
scope121.  
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Rapid reviews are created through a transparent, rigorous and reproducible method 
of evidence synthesis that follows the key principles of systematic review. There are a 
number of strategies used to expedite the conduct of a rapid review, and the essential 
challenge is in maintaining robustness and transparency that are central to quality 
knowledge synthesis122. Rapid reviews are considered part of the same ‘family’ as 
systematic reviews. They should include a clear statement up front of the objectives 
of the review, predefine inclusion criteria, appraise the validity of findings, and present 
results and synthesis in a systematic way.  
Whilst there is currently no generally agreed standardised approach to conducting 
rapid reviews123, the key aspects of a rapid review listed above feature in much of the 
mainstream literature on rapid review methodology121,122,124. The three main ways that 
rapid reviews are made more rapid that systematic reviews are by: increasing resource 
above the usual systematic review team (e.g. a larger number of reviewers conduct 
parallel tasks such as screening studies for eligibility, abstracting data and assessing 
quality); applying shortcuts to the review, missing one or more systematic review 
steps; and automating processes within the review to fast-track e.g. data abstraction.   
Within this rapid review, the review protocol was pre-registered on the international 
register for prospective registration of systematic reviews (PROSPERO) but was not 
published in an open access peer reviewed journal as this would have delayed the 
start of the review beyond reasonable timescales. Only papers published in English 
language were included within the review, as there was no additional resorce for 
translation services within the timeframe of the review. The literature search was 
curtailed from a standard 6 databases to 4 main databases, and searches were 
checked with an information specialist but designed and conducted by the single 
reviewer. All tasks were carried out by a single reviewer, meaning the standard 
independent double screening and abstraction that would take place in a systematic 
review was not possible within this rapid review. It is possible that these restrictions 
introduced inequalities including sampling, selection, and data accuracy biases. There 
is little known about the existence and extent of influence of these and other biases 
within the rapid review process, but these factors are considered within the Discussion 
section. 
Detail of the rapid review processes followed here are provided in 3.4.1.  
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3.2. What do we mean by ‘brief cognitive assessment’?     
BCAs are one type of tool available for general practitioners (GPs) to use as part of 
their diagnostic assessment for someone with suspected dementia or other cognitive 
problems. A list of key BCAs currently available for use in contemporary primary care 
and general practice, developed and critically refined throughout this PhD project, is 
shown in Table 2.   
Table 2.Comparison of commonly used assessment tools relative to cognitive 
domains 
Cognitive domain  MMSE  GPCOG  CDT  SIS  Mini-
Cog  
AMT  6-
CIT  
ACE  
Memory    
      
    Semantic  − + + − + + − ++ 
    STM  + ++ − + + + ++ +++ 
    Remote  − − − − − + − ++ 
Visuospatial/ 
constructional 
praxis  
+ ++ ++ − ++ − − +++ 
Frontal/executive  − + + − + − − ++ 
Orientation  +++ + − + − ++ ++ +++ 
Attention/calculation  ++ + + − + ++ ++ ++ 
Language  ++ − − − − − − +++ 
Other aspects    
      
Informant 
component  
− + − − − − − − 
Equipment required  Pen, 
paper 
& 
watch 
Pen & 
paper 
Pen 
& 
paper 
− Pen & 
paper 
− − Pen, 
paper, 
watch & 
specialized 
pictures 
−, Not specifically tested; +, minimal assessment; ++, moderate assessment; +++, relatively extensive 
assessment. Adapted from Woodford and George 2008125 
3.2.1. Brief 
The term “brief cognitive assessment” has been in common use since at least the 
1980s 126-128, yet there is little definition within research literature of what this actually 
means. Undoubtedly subjective in nature, ‘brief’ seems in many cases to mean the 
test is perceived to take up to and including 10 minutes to administrate64,129-131.  
This apparently arbitrary window of time may at one point have represented the 
standard clinical appointment time with the family doctor; however, typical consultation 
time is a contested topic and evidence varies on the average length of general practice 
consultation. A large-scale 2002 study reported a UK general practice mean of 9.4 
minutes (SD 4.7) to a mean of 15.6 minutes (SD 8.7) in Switzerland132. A more recent 
analysis of two practices in the UK suggest average consultation times of 15 minutes 
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or more133, whereas a retrospective analysis of 100 million English GP consultations 
from 2007-2014 reported an average consultation time of 8.86 minutes (SD 8.86-
8.87)134. In summary, there is no minimum GP consultation time in the UK and the 
Royal College of General Practitioners (RCGPs) states the usual length of time is 8-
10 minutes135. 
Clearly, the length of time a test takes to conduct and its suitability for use in different 
populations is a political issue as much as an administrative one. Time within the 
consultation room is increasingly at a premium136 and any test that claims to be ‘brief’ 
may attract greater support and uptake than those which claim otherwise or nothing 
at all, irrespective of the actual evidence base. It has also been suggested that a 
cognitive assessment’s diagnostic accuracy should be balanced against its speed of 
administration, depending on the setting137,138. These challenges around the 
evaluation of test administration time are explored in more depth in the Discussion 
chapter.  
Within this chapter and throughout the thesis, “brief” is used to refer to a test that takes 
up to and including 10 minutes to administrate within the general practice clinical 
setting, based upon empirical measures where possible, as well as (more commonly) 
the judgements of referenced review and study authors. 
3.2.2. Cognitive assessment 
Cognitive assessment concerns investigation of the higher cortical functions, namely 
memory, attention, orientation, language, executive function (planning activities), and 
praxis (sequencing of activities)40. Cognitive assessment is often positioned as an 
iterative process comprising various stages, in contrast to a single point valuation. This 
correctly reflects the clinical reality of cognitive assessment as a process, but poses a 
challenge when considering the purpose of a BCA is to provide a quick initial 
assessment of cognitive function, and the general practice population it may be used 
for, where (in the UK) consultations generally last around 8 minutes132,133 and often 
multiple issues are discussed134. Often BCAs are used to make an initial assessment 
to aid decision making for further treatment, management or onwards referral to a 
specialist assessment unit such as a memory clinic. The diagnostic evaluation is not 
a straightforward concept, and relies on a number of aspects of testing such as test 
reliability (is it stable, does it get the same result time after time?), test validity (does 
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the test measure what it is supposed to measure?) and test accuracy (does the test 
correctly identify people with the condition and correctly rule out people without the 
condition?). These aspects are assessed through different methods, and some rely on 
dichotomous point estimates (e.g. correct/incorrect) which assume that a test is taken 
at one point in time. This sharply contrasts with the procedural reality of cognitive 
assessment within the GP clinic, and is another complexity of the process for 
identifying possible dementia in primary care.  
There is no single “gold standard” cognitive assessment for identifying dementia 
64,139,140 and whilst there is broad agreement amongst numerous guidelines on 
dementia identification within family practice, variation also exists around the different 
tools recommended.  
3.2.3. Single tests vs. batteries 
There are large number of cognitive assessments available, many calling themselves 
‘brief’. These assessments can be categorised further in a number of ways. One of the 
most common distinctions is whether the assessment is a single test (such as the 
Clock Drawing Test (CDT), where the individual is asked to draw a clock face and 
mark a specific time upon it), or a battery such as the Abbreviated Mental Test Score 
(AMTS). Sometimes these are referred to as ‘single domain’ tests which address one 
cognitive domain such as visual-spatial, in the case of the CDT, or ‘multi-domain’ tests 
which address several cognitive domains such as episodic memory, semantic 
memory, short-term memory, attention, and orientation such as the AMTS 141. 
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Table 3 List of BCAs suitable for use in general practice 
BCA name + 
validated study 
reference 
Informant 
section (yes/no) 
Suitable for particular groups  
GPCOG142 Yes Patients with informant (optional) 
CDT143 No Patients who can hold a pencil 
Mini-Cog144 No Non-native speakers and people with low 
levels of education 
IQCODE145 Yes Non-Caucasian populations 
SPMSQ146 No Elderly patients 
AMTS146 No Elderly patients 
6-CIT147 Yes - 
RUDAS148 No Culturally and linguistically diverse populations 
MIS149 No - 
TICS150 No Geographically remote or less mobile 
populations 
GPCOG, General Practitioner Assessment of Cognition; CDT, Clock Drawing Test; IQCODE, 
Informant Questionnaire on Cognitive Decline in the Elderly; SPMSQ, Short Portable Mental Status 
Questionnaire; AMTS, Abbreviated Mental Test Score; RUDAS, Rowland Universal Dementia 
Assessment Scale; 6-CIT, Six Item Cognitive Impairment Test; MIS, Memory Impairment Screen; 
TICS, The Telephone Interview for Cognitive Status. 
Some have argued for reliance on assessing short term memory and executive 
function as these are commonly associated with Alzheimer’s disease as the most 
frequently occurring dementia subtype117. Others125 point to the benefit of single tests 
- used within appropriate populations - as generally simpler and quicker to administer 
than multi-domain assessments, thus improving clinician acceptance of the test as 
demonstrated with the MMSE151.  
Key distinctions between these different types of assessments are the different 
cognitive areas or domains that they assess (e.g. visual-spatial, episodic memory, 
orientation), and the administrative nuances which these distinctions introduce. For 
example, the ‘Verbal Fluency-animals’ (VF-an) test assesses a person’s ability to 
name pictures of different animals presented to them, and is scored on time taken and 
accuracy of the naming. This assesses language domains, but clearly also relies on 
functional hearing, speech and eyesight as well as language skills – aspects that could 
easily be compromised and not necessarily recognised by the healthcare professional 
carrying out the assessment. Measures incorporating behavioural and functional 
assessment are increasingly popular as these factors are recognised as early markers 
for timely dementia diagnosis39.  
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The length of time that single- and multi-domain tests take to carry out is a decisive 
factor in their relevance for use in primary care, and tools such as the 7 Minute Screen 
(taking around 12 minutes 152), the Leganés Cognitive Test153 and the Addenbroke’s 
Cognitive Examination-Revised (ACE-R)154 are considered too long for standard 
general practice consultation lengths. There is also little evidence that tests with longer 
administration times perform better139. 
3.2.4.  Other aspects of cognitive function 
Cognitive assessments can consist of tools completed with or by the individual, and 
some cognitive assessments also incorporate an assessment to be completed by a 
close friend, partner or family member (often referred to as an ‘informant’). These 
informant assessments are generally an addition to the main cognitive assessment, 
and can either sit alongside the main assessment as an additional tool to increase the 
test’s effectiveness, or used as a ‘stepped’ assessment where, if a certain threshold 
is reached on the assessment of the individual, the informant assessment is carried 
out and the scores combined to create a distinct ‘staged’ assessment tool. Examples 
of informant assessments are the ‘Informant’ section of the General Practitioner 
Cognitive Assessment tool (GPCOG)142 and the Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE)103.  
3.2.5. Why settings matter 
The accuracy of tests of cognitive function has been explored across a range of 
settings42,102,116,155-157, and some have also looked at the strength of evidence for these 
accuracy scores91,99,117,156,158. 
Whilst the setting in which these tests are validated has received less scrutiny within 
the research literature, the distinction between the original validation population and 
the population within which the tests are ultimately used is a vital and variable aspect 
of test evaluation. In many countries there is an increased impetus to proactively 
identify dementia earlier in the diagnostic pathway. This is in order to rule out 
potentially treatable alternative and confounding conditions (such as depression, 
urinary tract infections or thyroid disorders), alleviate symptoms and access services 
as soon as possible to increase time for future planning, reduce cost and diminish care 
burdens on the patient and the people around them. This is reinforced by policy within 
the UK healthcare context94 as well as across European systems such as in Spain, 
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Portugal, Ireland, France, the Netherlands and Belgium39, where general practitioners 
or family doctors are often the first place where people present with concerns about 
their own or others’ possible dementia. In contrast, secondary care has a role in 
making a aetiological diagnosis, identifying subtypes and stratifying patients by 
severity of symptoms - although in reality these services overlap considerably88. More 
detailed consideration of these methodological issues are presented in the Discussion 
chapter of this thesis, including worked examples of how prevalence influences false 
discovery rates (numbers of false positives and false negatives).  
When choosing between tests, it is clearly important to take into account the 
population in which the test is intended to be used. Guidance on the suitability of 
different tests for different populations is often unclear159, and the challenges 
underpinning this obscurity will be explored in the next section. 
3.2.6. What are CPGs?  
Guidelines are a general rule, principle or piece of advice160. Some guidelines are 
referred to as strategies, plans or frameworks. The rapid review presented here deals 
specifically with CPGs, defined as “systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific clinical 
circumstances.”161.  
CPGs are often produced within the healthcare context in order to recommend how 
health care professionals can best care for people with a certain condition. These 
guidelines cover many different aspects of a condition and may incorporate 
recommendations for giving information and advice, prevention, diagnosis, treatment 
and longer-term management162. CPGs have been published for many years with 
common aims to improve the selection, use and interpretation of BCAs within the 
intended populations, and can be an important tool for the management of dementia 
although there is mixed evidence of how they are valued by healthcare professionals39.  
3.2.7. Who produces and issues CPGs? 
There has been a significant growth in the creation of national general guidelines for 
general practitioners managing dementia in recent years. Before 2003 there were no 
guidelines for identifying dementia in general practice within some of the major 
European healthcare systems (Ireland, Italy and Portugal)39. Currently Ireland has 
established guidelines163, whereas Italy164 and Portugal165 are developing them as 
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part of their national dementia strategies. Across Europe, there are a large number 
of countries with dementia strategies that incorporate guidelines for clinical practice 
(UK – including separate guidelines for England94, Northern Ireland166, Scotland167 
and Wales168; Ireland163; Norway; Finland; Denmark; Belgium; Luxemburg; Czech 
Republic; Austria; Slovenia; Switzerland; Greece; Sardinia169 and outside of Europe 
countries such as Israel170, Australia111, the USA62, Canada110 - all have dementia-
specific general guidelines.        
Doctors often produce guidelines for other doctors39,171, and whilst this may increase 
usability amongst clinicians this may limit their accessibility for other guideline users 
involved in wider (social, cultural) aspects of care.  Less formally, local general 
practices may have their own implicit guidelines for dementia assessment which are 
not published but may have the greatest impact on what brief cognitive assessment 
procedures are used at the local level.  
It is unclear how many unequivocal formal CPGs there are, guiding the use of BCAs 
in primary care.  This rapid review was therefore conducted in order to systematically 
identify CPGs relating to the use of the BCAs used as part of the process for identifying 
dementia in general practice.  
3.3. Methods 
CPGs are defined here as “systematically developed statements to assist practitioner 
decisions about appropriate health care for specific clinical circumstances.”172 
This is a rapid review and not a full systematic review. It has had restrictions placed 
upon the conduct in terms of timeframe for implementation, limited resources and 
conduct by a single researcher.  However, the review was carried out systematically 
and has many of elements of best practice systematic review methods: the question 
was specified a priori, the protocol was pre-registered on the international register for 
prospective registration of systematic reviews (PROSPERO  reference 
CRD42019139159), the search criteria were explicitly stated, checked with an 
information specialist and published in detail, alongside pre-defined inclusion and 
exclusion criteria, a pre-defined data extraction form was created, and the discussion 
provides limitations of included studies and the review process124.  
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Searches 
Searches were structured by the author to identify the best and most relevant evidence 
likely to help answer the research question within the parameters of the method. This 
search framework was checked with two expert and experienced information 
specialists, with feedback incorporated a priori into the final searches run.  
Terms were based on MeSH headings and were practice guideline; dementia/di 
[Diagnosis]; and general practice/ or family practice. 
Databases searched were EMBASE, MEDLINE, PsychInfo and TRIP. Within the TRIP 
database, the ‘Guidelines’ filter was applied to identify the most relevant evidence 
specifically related to guidelines. There was no date filter used.  
PROSPERO was searched for any systematic reviews already in motion on this 
specific topic. There were no systematic reviews found to be published or registered 
on PROSPERO in this particular area. 
BCAs 
Whilst there is no internationally-accepted single definition of ‘brief cognitive 
assessment’, the term understood for the purposes of this review acknowledges the 
iterative nature of the process, drawing on a number of observations within a set 
(‘brief’) timescale of 10 minutes and their use in general practice to make an initial 
indicative assessment for further investigation within more specialist settings such as 
memory clinics. 
General practice  
General practice as a term is sometimes mistakenly used interchangeably with primary 
care, but is more accurately defined as first line clinical practice delivered by general 
medical clinicians and health care professionals trained in general medicine. In non-
UK settings this is sometimes referred to as family practice. 
Items were only be included if they clearly and explicitly referred to themselves as 
CPGs. Items also related explicitly to general practice or family practice, and explicitly 
referred exclusively to the use of BCAs used as part of the process for identifying 
dementia in this setting. If an identified CPG was superseded entirely by a more recent 
CPG issued by the same body, then the older CPG was excluded. The exception to 
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this would be where the older CPG contained general practice-relevant guidance, and 
the updated CPG referred to the older document. 
Language 
Only guidelines published in English were included. 
Primary outcome 
The single outcome of interest for this rapid review is the CPG produced explicitly for 
general practice relating specifically to the use of BCAs for identifying dementia in 
general practice. 
3.4. Results 
From 558 records identified through database searches, 10 hits were identified for 
inclusion at the title/abstract screening stage. Screening was conducted by one 
researcher (HH).  
At full text screening, 6 papers were excluded; three on the basis that they did not 
directly report CPGs, one because it related to psychologists rather than general 
practice, and one issued by the Dutch College of General Practitioners in 2004 
because it was outdated by a more recent guideline issued by the same organisation 
in 2012, with no additional information useful for the review. The later paper from the 
Dutch College of General Practitioners published in 2012 was excluded as it was not 
available in English. Screening was conducted by one researcher (HH). The review 
flow diagram is shown in  
Figure 2.  
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Figure 2. PRISMA flow diagram for rapid review of CPGs  
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Papers excluded at the full text screening stage are shown in Table 4, along with the 
reasons they were excluded. 
Table 4. Papers excluded at the full text screening stage, with reasons for exclusion 
Full reference Reason for exclusion at 
full text screening stage 
Association AP. Guidelines for the evaluation of dementia 
and age-related cognitive change. The American 
psychologist. 2012;67(1):1. 
Related to psychologists 
rather than general practice 
Clarfield A. Canadian Consensus Conference on the 
Assessment of Dementia reports. Canadian Family 
Physician. 1997;43:1343. 
Does not directly report 
clinical practice guidelines 
Dyer SM, Laver K, Pond CD, Cumming RG, Whitehead C, 
Crotty M. Clinical practice guidelines and principles of care 
for people with dementia in Australia. Australian family 
physician. 2016;45(12):884. 
Does not directly report 
clinical practice guidelines 
Wilcock J, Iliffe S, Turner S, et al. Concordance with 
clinical practice guidelines for dementia in general 
practice. Aging and Mental Health. 2009;13(2):155-161. 
Does not directly report 
clinical practice guidelines 
Boomsma L, Boukes F, Wind A, Assendelft W. Summary 
of the practice guideline'Dementia'(second revision) from 
the Dutch College of General Practitioners. Nederlands 
tijdschrift voor geneeskunde. 2004;148(24):1191-1197. 
Outdated by a more recent 
guideline issued by the same 
organisation in 2012 
Luning-Koster M, Perry M, van Charante Moll E, Vernooij-
Dassen M, Wiersma T, Burgers JS. Summary of Dutch 
College of General Practitioners'(NHG) practice 
guideline'Dementia'. Nederlands tijdschrift voor 
geneeskunde. 2012;156(49):A5323-A5323. 
Not in English 
Overview of results  
Following systematic searches of four international databases, four CPGs were 
identified that were produced explicitly for an audience including general practice 
relating specifically to the use of BCAs for identifying dementia in general 
practice110,173-175. The characteristics of these guidelines are shown in Table 5.  
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Table 5. Summary of characteristics for included guidelines  
Full guideline reference Year of 
issue 
Self-refers 
as CPG? 
Country 
related 
to 
All guidelines 
relevant for 
general practice? 
BCAs 
covered 
Detail given 
National Institute for Health and Care 
Excellence Dementia: Assessment, 
management and support for people 
living with dementia and their carers: 
National Institute for Health and Care 
Excellence London; 2018. 
2018 Yes United 
Kingdom 
No, some relate to 
specialist 
assessment, 
community care, 
hospitals and care 
homes. 
10-CS 
6CIT 
MIS 
TYM 
IQCODE 
In the conduct of cognitive tests, a validated brief 
structured cognitive instrument should be used such as 
those in the examples given. Dementia should not be 
ruled out solely because the person has a normal score 
on a cognitive instrument. 
Guideline Adaptation Committee GA. 
Clinical practice guidelines and 
principles of care for people with 
dementia. Sydney: Guideline 
Adaptation Committee. 2016. 
2016 Yes Australia No, some relate to 
neuroimaging. 
3MS 
MMSE 
ADAS-Cog 
GPCOG 
PAS 
RUDAS 
KICA-Cog  
MoCA 
FAB 
ACE-III 
Based on UK NICE guidelines, adapted for Australian 
context. 
List of BCAs adapted from the Dementia Outcomes 
Measurement Suite [DOMS: www.dementia-
assessment.com.au]  
Gauthier S, Patterson C, Chertkow H, 
et al. Recommendations of the 4th 
Canadian Consensus Conference on 
the Diagnosis and Treatment of 
Dementia (CCCDTD4). Canadian 
Geriatrics Journal. 2012;15(4):120. 
2012 Yes Canada No, but 
symptomatic 
treatments are 
relevant to all 
practitioners. 
Referral to 
previous 
guidelines 
(see 
Kennedy 
2006 
below). 
Only treatments covered, no guidelines for general/family 
practice 
Kennedy HDP. 3rd Canadian 
Consensus Conference on Diagnosis 
and Treatment of Dementia. 2006. 
2006 Yes Canada No, but 
symptomatic 
treatments are 
relevant to all 
practitioners. 
GPCOG 
MoCA 
DemTect 
BNA 
7MS 
 
Brief Cognitive Assessments (BCS); Modified Mini Mental Exam (3MS); Mini Mental State Exam (MMSE); The Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog); General Practitioner 
Assessment of Cognition (GPCOG); Psychogeriatric Assessment Scale (PAS); Rowland Universal Dementia Assessment Scale (RUDAS); Kimberley Indigenous Cognitive Assessment (KICA-Cog); 
Montreal Cognitive Assessment (MoCA); Frontal Assessment Battery (FAB); Addenbrooke’s Cognitive Examination (ACE-R now replaced by ACE-III); the 10-point cognitive screener (10-CS); the 6-
item cognitive impairment test (6CIT); the 6-item screener; the Memory Impairment Screen (MIS); the Mini-Cog; Test Your Memory (TYM); Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE), Behavioural Neurology Assessment (BNA), 7 Minute Screen (7MS) 
. 
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All CPGs were single national guidelines. One was from the UK173, one from 
Australia174 and two from Canada110,175. All were published in the last 13 years, with 
the UK CPG published by the National Institute for Health and Care Excellence (NICE) 
in 2018 being the most up to date. The Canadian CPGs110,175 produced by the 
Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia 
(CCCDTD) combines CPGs with consensus statements, resulting from a consensus 
conference with 80% or more of voting attendees supporting agreed statements. The 
Australian CPG174 produced by the Cognitive Decline Partnership Centre (CDPC) 
combines CPGs with 10 Principles of Care, developed by the Social Care Institute for 
Excellence in the UK based on consultation with members of the public176. The UK 
CPG addresses diagnosis, alongside management and support for people living with 
dementia and their carers173. 
All included CPGs were created for an audience wider than general practice, including 
hospitals, community care, specialist assessment, and care homes. This means there 
are a number of guidelines within all three CPGs that are not applicable to general 
practice.  
The Canadian CPGs110,175 include guidelines on neuroimaging, and the most recent 
Canadian CPG110 covers new diagnostic criteria, neuroimaging and liquid biomarkers. 
This CPG also contains updated guidance on symptomatic treatments. The Australian 
CPG174 includes guidelines on diagnosis including neuroimaging, treatment, and 
social support for people with dementia and carers. The UK CPG173 covers guidelines 
on diagnosis in non-specialist and specialist settings with guidance including 
neuroimaging and detailed neuropsychological evaluation, shared decision making, 
management, treatment and care coordination including training dealing with 
comorbidities.   
Guidance in CPGs relating to diagnosis of dementia in general practice 
The UK CPG recommends that at the initial assessment, a patient history is taken from 
the individual and ideally from someone who knows the person well. If dementia is still 
suspected after this assessment, then the patient should have a physical examination, 
alongside appropriate blood and urine tests to rule out other causes of cognitive 
problems, and cognitive tests should be conducted.  
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The Australian CPG are based closely on the UK CPG, but the guideline committee 
noted some important differences related to indigenous communities in Australia. They 
recognise a higher prevalence of dementia in Indigenous Australians, and the 
possibility that dementia may present at an earlier age in some communities. There 
may be different perceptions of alterations in cognition in some cultures, leading to 
individuals and their carers seeking diagnosis at a later stage of the dementia 
progression.  
The most recent 2012 Canadian CPG does not include any recommendations specific 
to diagnosis in general practice or primary care, and the authors state that general 
clinicians are unlikely to be substantially affected by the guidelines. Previous Canadian 
CPGs175 produced in 2006 make  recommendations for BCAs suitable for general 
practice, but do not give guidance on diagnostic procedure in general practice.  
Guidance in CPGs relating to specific BCAs to use as part of the diagnosis of 
dementia in general practice 
All BCAs included within the CPGs are shown in Table 6. The UK CPG is carefully 
worded to say that no single test is recommended, but when cognitive testing is carried 
out in a non-specialist setting, a validated BCA should be used such as those shown 
in Table 6. The UK guidance does clearly state that dementia should not be ruled out 
because the person has a normal score on a BCA.  
The Australian CPG is more directive, with instructions that professionals conducting 
cognitive assessment should take into account all other factors known to affect 
performance such as age, educational level, non-English speaking status, prior level 
of functioning, aphasia, visual or hearing impairments, psychiatric illness or 
physical/neurological problems when interpreting results. This guidance also 
recommends formal neuropsychological testing in cases where a dementia diagnosis 
is uncertain.  
The 2006 Canadian CPG175 reports a systematic assessment of the strength of 
evidence for recommending the BCA list in Table 6, and concludes that there is 
insufficient evidence for recommending one over another, as replication studies are 
needed.  
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Table 6.CPG recommendations on BCAs to use as part of the diagnostic process for 
identifying dementia in general practice 
BCAs listed in CPG UK173 Australia111 Canada175 Notes on the recommendation 
The 10-point cognitive screener 
(10-CS) 
   Do not rule out dementia solely 
because the person has a 
normal score on a cognitive 
instrument. 
The 6-item cognitive impairment 
test (6CIT) 
   
 
The 6-item screener     
The Memory Impairment Screen 
(MIS) 
   
 
The Mini-Cog     
Test Your Memory (TYM)     
Informant Questionnaire on 
Cognitive Decline in the Elderly 
(IQCODE)  
   When taking a history from 
someone who knows the person 
with suspected dementia, 
consider supplementing this with 
a structured instrument such as 
IQCODE or the FAQ 
Functional Activities Questionnaire 
(FAQ). 
   
 
Kimberley Indigenous Cognitive 
Assessment (KICA-Cog) or 
KICA-Screen tool  
   Recommended for use with 
remote living Indigenous 
Australians for whom the use of 
alternative cognitive assessment 
tools is not considered 
appropriate. 
The Rowland Universal Dementia 
Assessment Scale (RUDAS)  
   Should be considered for 
assessing cognition in culturally 
and linguistically diverse (CALD) 
populations. 
Modified Mini Mental Exam (3MS)     Recommended for assessment 
of cognitive function based on 
the appraisal in the Dementia 
Outcomes Measurement Suite 
[DOMS: www.dementia-
assessment.com.au] 
Mini Mental State Exam (MMSE)      
The Alzheimer’s Disease 
Assessment Scale - Cognition 
(ADAS-Cog)  
   
 
Frontal Assessment Battery (FAB)      
Psychogeriatric Assessment Scale 
(PAS) 
   
 
Addenbrooke’s Cognitive 
Examination (ACE-R now 
replaced by ACE-III 
   
 
General Practitioner Assessment 
of Cognition (GPCOG)  
    
Montreal Cognitive Assessment 
(MoCA 
    
DemTect,     
Behavioural Neurology 
Assessment (BNA) 
    
7 Minute Screen (7MS)     
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Table 6 shows that only two BCAs – MoCA and GPCOG – feature in more than one 
guideline within the CPGs of Canada and Australia, and no tests feature in all three 
guidelines.  
It is particularly interesting that the CPGs of UK and Australia do not recommend any 
of the BCAs, given the Australia CPG is explicitly based upon the UK CPG, although 
adapted for Australian populations.   
Both CPGs from Canada and Australia make reference to the importance of 
recognising indigenous communities within their guidance, but only the Australian 
CPG includes BCAs recommended for use with indigenous and culturally and 
linguistically diverse populations.  
None of the included guidelines give further information on the BCAs listed in Table 5, 
in terms of, for example: time to administrate; cost; resource required; patient and 
clinician acceptability.  
3.5. Discussion/ Conclusion 
Small number of CPGs identified  
It was a surprising finding that so few CPGs were identified within the searches 
presented here. This may be for a number of reasons. The searches may not have 
been sensitive enough, and may have missed guidelines that did not explicitly define 
themselves as CPGs. However, as identifying specific CPGs was the clear focus of 
this rapid review, it was a logical requirement to place on identified evidence that they 
must explicitly self-identify as a CPG.  
It may be that existing CPGs are not indexed within the databases searched, as grey 
literature sources and websites were not included within searches for this review. They 
may instead be published within national government or other organisational websites, 
or even possibly not widely published or available beyond the clinical boundaries 
within which they are widely used. This would, however, be surprising, given the 
breadth of coverage within EMBASE, MEDLINE, PsychInfo and TRIP and the fact that 
CPGs are generally produced with an explicit aim to increase coverage and take-up 
amongst their target population. It is therefore possible, but unlikely, that existing 
CPGs may have been missing from these databases. Placing an English language 
restriction on this review did mean that CPGs not published in English were excluded, 
but there were only two CPGs produced by the Dutch College of General Practitioners 
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in 2012177 and 2004178 that were excluded purely because they were not written in 
English. 
The most compelling explanation that merits some consideration is that the CPGs do 
not yet exist, so could not be identified within this rapid review.. As shown in Table 6, 
out of 21 BCAs listed within the guidelines, only two are common across two guidelines 
– and none of the BCAs feature in all three CPGs. This is a significant result, 
particularly given the currency of these CPGs, all produced within the last 7 years, and 
the fact that the Australian CPG was explicitly based upon the UK CPG yet shared 
none of the recommended BCAs.   
Lack of guidance on CPG tailored to population 
Another notable gap within identified CPGs is the scarcity of guidance on tailoring 
CPGs for specific populations. Given the national reach of these three CPGs, only the 
Australian CPG contains clear guidance on the suitability of BCAs for indigenous 
Australians, urban and rural populations and cultural and linguistically diverse 
populations.  
Neither the Canadian nor UK CPGs make explicit reference to BCAs for different 
populations, nor do they make recommendations on the diagnostic process tailored 
for diverse groups. The UK CPG instead places emphasis on treating patients as 
individuals and respecting their culture and identity as part of that awareness. This 
overlooks the reality that many BCAs contain innate demographic and cultural bias 
within their scoring systems concerning learning difficulties, disabilities (such as 
sensory or physical impairments), level of education, sex and cultural 
background125,148,179. 
Lack of common BCAs within guidance 
The absence of common BCAs recommended across the three identified CPGs 
warrants further exploration. This lack of shared guidance, or even shared recognition 
of BCAs suitable for use as part of the process for identifying dementia in general 
practice, indicates a deeper problem in identifying and recommending suitable tools 
for diagnosis within a general practice setting.  
There are 21 BCAs recommended within the three CPGs identified within this rapid 
review. Of those 21 BCAs, 2 (MoCA and GPCOG) are shared between two CPGs 
(Australia and Canada). Of these 2 BCAs, the MoCA takes between 10-15 
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minutes42,64,180 to administer which is at the limit of the entire 10 minutes allocated for 
most UK and European general practice consultations132-134. It is therefore 
questionable whether any BCA of this length would be suitable for use in general 
practice, where time and clinician resource is at a premium and GP preference is for 
shorter tests133,136,181,182. 
The lack of uniformity in BCAs featured or recommended within the three identified 
CPGs is a strong indicator that there remains a gap in knowledge about which BCAs 
are most suitable for use in a general practice setting and population. This may be 
because the suitability of BCAs within general practice is not fully understood, or it 
may be due to a fundamental lack of suitable BCAs fit for the purpose of aiding 
diagnosis of dementia within a primary care, non-specialist setting. The solution 
probably lies in both these issues; understanding what it is that people value in BCAs, 
above and beyond basic test accuracy but including aspects such as acceptability to 
the patient and to the clinician, accessibility, cost, time to administer and applicability 
for different populations and different settings such as care homes, and in the 
community. These fundamental features of test design, choice and advocacy are 
crucial to understand and apply clearly within CPGs, yet this rapid review has 
highlighted a significant dearth in uniform, unambiguous guidance relating specifically 
to BCA use as part of the process for identifying dementia in general practice.  
These issues are discussed in further detail within the rest of this thesis; in the 
systematic overview of the diagnostic accuracy of BCAs for identifying dementia in 
general practice (Chapter 4), the systematic review directly comparing the diagnostic 
accuracy of MMSE and GPCOG (Chapter 5), and within the main thesis Discussion 
(Chapter 7). 
Recommendations for practice 
The primary recommendation from this rapid review for practice is that greater clarity 
is needed in CPGs on this specific topic. There were only three CPGs that were 
identified within this paid review, all from European style healthcare systems (UK, 
Australia and Canada) with broadly similar general practice populations, excepting 
indigenous communities.  
The lack of diversity and breadth of CPGs from other countries is notable, although it 
should be remembered that CPGs not available in English language were excluded. 
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With this caveat, the apparent limited range of CPGs is something to be explored 
further – not only in order to aid clinicians and general practitioners from other 
countries, but in order to tackle the current gaps in knowledge and understanding of a 
complex process. General practice is regularly highlighted as a ‘choke point’ for 
dementia diagnosis138,183-187 yet the challenges presented that are specific to this 
setting and population mean that tailored guidance is acutely needed within this field.  
Greater concordance amongst CPGs will only improve adoption, help clinical practice 
and improve understanding of the place of BCAs within the diagnostic assessment in 
a non-specialist setting. This may not be possible, however, until we have a better 
understanding of which BCAs are best for these requirements, and how BCAs are 
valued in general practice. These far more difficult questions need to be addressed 
first, in order to help bring consistency and standardisation to CPGs.  
Recommendations for research 
Currently there is insufficient validation and replication of BCAs for use in general 
practice. These pieces of work are urgently needed in order to critically assess BCA 
suitability for different general practice populations, variations in setting, and 
performance in identifying differing levels of severity of cognitive impairment.  
Clear, robust assessment of the validity of BCAs in general practice settings and 
populations is needed, particularly assessments taking account of diversity and 
variation at the population level, not just at the individual level as acknowledged within 
the UK CPG173. 
There is a strong drive to understand the needs of general practice relating to CPGs 
on BCAs. Clearly in order to response to need, maximise practitioner adoption and 
ensure that guidelines are fit for purpose there remains much to be understood about 
CPG usage in general practice, how BCAs are selected and used within general 
practice currently, how GPs decide on BCAs within a clinical consultation, how that 
relates to the patient and how CPGs influence GP, commissioner and patient 
behaviour in choosing and using BCAs.  
Once there is greater understanding of the critical features of BCAs for general 
practice use, it is highly likely that CPGs will be far more available, coherent and 
cohesive for the intended general practice audience. 
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Glossary 
 
3MS Modified Mini Mental Exam 
6-CIT 6 Item cognitive impairment test 
7MS 7 minute screen 
10-CS 10 point Cognitive Screener 
ACE Addenbrooke’s Cognitive Evaluation 
ACE-R Addenbrooke’s Cognitive Evaluation - revised 
ACE-III Addenbrooke’s Cognitive Evaluation – version three 
ADAS-Cog The Alzheimer’s Disease Assessment Scale - Cognition 
ADI Alzheimer’s disease International 
AGECAT Automated Geriatric  
Examination for Computer Assisted Taxonomy 
AMT(S) Abbreviated Mental Test Score 
BIMCT Blessed Information-Memory-Concentration Test 
BNT Behavioural Neurology Assessment 
CAMCOG The Cambridge Cognitive Examination 
CAMDEX Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CCCDTD Canadian Consensus Conferences on the Diagnosis and 
Treatment of Dementia 
CCG Clinical Commissioning Group 
CDPC Cognitive Decline Partnership Centre 
CDR Clinical Dementia Rating 
CDT clock drawing test 
CERAD Consortium to Establish a Registry for Alzheimer's Disease 
CPG Clinical Practice Guideline 
DSM-III  The Diagnostic and Statistical Manual of Mental Disorders 
(version 3) 
DSM-III-R The Diagnostic and Statistical Manual of Mental Disorders 
(version 3 revised) 
DSM-IV The Diagnostic and Statistical Manual of Mental Disorders 
(version 4) 
DSM-IV-R The Diagnostic and Statistical Manual of Mental Disorders 
(version 4 revised) 
EMBASE Excerpta Medica dataBASE 
FAB Frontal Assessment Battery 
FAQ Functional Activities Questionnaire 
FCSRT Free and Cued Selective Reminding Test 
GMS-AGECAT Geriatric Mental State Schedule - Automated Geriatric 
Examination for Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
ICD-10 International Classification of Disease – version 10 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
IPA/WHO 
criteria 
International Psychogeriatric Association/World Health 
organisation criteria 
KICA-Cog Kimberley Indigenous Cognitive Assessment  
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KICA-Screen Kimberley Indigenous Cognitive screening tool 
MCI Mild Cognitive Impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MeSH Medical Subject Headings 
MIS Memory Impairment Screen 
MMSE  Mini mental state examination 
MoCA Montreal Cognitive Assessment 
NHS  National Health Service (UK) 
NICE National Institute for Health and Care Excellence (UK) 
NINDCS-
ADRDA 
National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association 
NINCDS-AIREN National Institute of Neurological Disorders and Stroke–
Association Internationale pour la Recherche et 
l'Enseignement en Neurosciences 
NINCDR-
CERAD 
National Institute of Neurological Disorders Clinical 
Dementia Rating -Consortium to Establish a Registry for 
Alzheimer’s Disease 
PAS Psychogeriatric Assessment Scale 
PCL Prueba cognitive de leganes 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of 
psychology. 
RUDAS The Rowland Universal Dementia Assessment Scale 
SASSI Short and Sweet Screening Instrument 
SIS Six item screener 
SPMSQ Short portable mental status questionnaire 
TICS Telephone Interview for Cognitive Status 
TRIP Turning Research Into Practice database 
TYM Test Your Memory 
VF-an Verbal Fluency - animals 
WHO World Health Organisation 
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4. An overview of systematic reviews summarising the 
accuracy of brief cognitive assessments for identifying 
dementia in primary care  
MMSE: The gold standard of cognitive tests 
Barrett, A & Burns, A (2014) Dementia revealed. What primary care 
needs to know. Hardwick CCG, NHS England, Department of 
Health, Royal College of General Practitioners [p.39] 
In order to understand the spread of existing systematic review evidence on the 
accuracy of brief cognitive assessments used to identify dementia in primary care (and 
specifically in general practice), an overview of systematic reviews was carried out. 
Through the conduct of this review, it was hypothesised that systematic evaluation of 
the evidence would elicit a clear and definitive answer to which brief cognitive 
assessment is most accurate for use in primary care as part of the toolkit for identifying 
dementia. This chapter addresses methodological decisions made, key topic criteria, 
results from the overview and reflections of these methods and findings in the context 
of implications for clinical practice, research and my wider thesis. The overview aimed 
to answer the question: which brief cognitive assessment has the best diagnostic 
accuracy? This question could not be clearly answered within this overview, and the 
reasons for this are discussed within this chapter. 
4.1. What is an overview? 
Overviews are syntheses of systematic review evidence and are known by a variety 
of different names, all potentially reflecting different aspects and aims of the 
syntheses. Terms used include: ‘overview of systematic reviews’ (often shortened to 
‘overview’) umbrella review; meta-review; (systematic) review of (systematic) reviews; 
synthesis of systematic reviews; and summary of systematic reviews.  The common 
feature of the methods associated with all of these terms is the fundamental process 
of synthesising evidence which is derived, often exclusively, from systematic reviews. 
The systematic review forms the primary ‘unit of analysis’ and is the basis upon which 
an overview is built188.  
The term ‘overview of systematic reviews’ (often shortened to ‘overview’) appears to 
have gained the most widespread acceptance189,190. This is the term used by 
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Cochrane to describe a review of systematic reviews published in the Cochrane 
Library191. Here the term ‘overview’ is used within this thesis to describe summaries of 
systematic review evidence, in line with the most commonly-used terminology. 
4.1.1.  Why an overview may add value, and the challenges of overviews  
As with systematic reviews, a primary consideration for producing an overview is 
whether there is sufficient justification for carrying it out192. This means the aims and 
objectives of the overview should be clearly understood and pre-specified before 
synthesis begins, and the methodological rigour employed within systematic reviews 
is (at least) as important when conducting an overview193. Decisions in healthcare 
should be based on the best evidence available rather than the most prominent, most 
recent or largest study. Overviews and systematic reviews may help to avoid research 
waste, duplication of effort, and allow anyone to view the best available evidence 
presented in a systematic way with quality of available evidence clearly presented to 
allow comparison across different studies189,194.   
Other rationales often given are that overviews can form a ‘friendly front end’ to 
existing evidence in order to allow more detailed investigation of systematic review 
evidence189. It has also been suggested that evidence can be gathered more quickly 
and easily from systematic reviews, and so an overview may be a more efficient form 
of evidence synthesis to address a specific research question195 - although this has 
not been supported by the evidence so far.  
There are different types of overviews that may be conducted including overviews 
addressing questions of interventions, prognosis or prevalence, diagnostic test 
accuracy, or qualitative views or experiences. The primary route to addressing an 
overview’s aims and objectives is commonly through the structured clinical research 
question. As an example, when addressing existing evidence of diagnostic accuracy 
an overview may investigate the effect of a single test on a defined population, or may 
summarise evidence of the effect of a number of tests on a defined population. In 
situations where the test or population is ill-defined or cannot be fully known, an 
overview is highly unsuitable as problems inherent with such an approach in 
systematic reviews (such as avoidable heterogeneity and lack of generalisability) are 
magnified when abstracted to the level of an overview. In summary, the ideal overview 
is formed from a clear clinical question which results in a convergence and 
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strengthening of evidence on a given topic. How successful this overview was in 
matching these ideals will be discussed in this chapter, with specific methodological 
challenges addressed in Chapter 7.  
4.1.2. Cochrane & non-Cochrane systematic reviews  
There are two likely approaches to the type of systematic review evidence considered 
within an overview: one which only includes Cochrane reviews, versus a more 
inclusive approach of accepting all systematic reviews that meet the inclusion criteria. 
This could be distilled into two strategies: the ‘best evidence’ approach, where the 
review team assumes that – where compared to other systematic reviews - Cochrane 
reviews represent the best available systematic review evidence on a topic with the 
highest quality standards, most up-to-date evidence and greatest rigour in 
analysis196,197. Alternatively the reviewer can follow the more usual ‘comprehensive’ 
approach where all evidence is sifted for eligibility and refined with large amounts of 
data sifted out at an early stage.  
Whilst the best evidence approach had attractions in terms of greatest efficiency for 
resources and time as searches could be limited to the Cochrane Library, after some 
discussion with the review team it was decided to take the comprehensive approach 
to identifying evidence. It was concluded that there are many reasons that systematic 
review evidence is produced outside of the Cochrane system, including lack of time, 
inefficiency of editorial processes and bureaucracy in review production. Whilst 
systematic review quality is highly mixed and many systematic reviews are 
unnecessary, misleading and/or conflicted193, the reliable supremacy of Cochrane 
reviews is yet to be inviolably established and the risk of missing eligible non-Cochrane 
reviews was too great for the potential benefits of time saved and greater efficiency of 
searching. It was therefore decided to take the comprehensive approach to identifying 
evidence, using the conventional search methods described below. 
4.1.3. The need for an overview of diagnostic test of brief cognitive assessments 
for identifying dementia in primary care 
The rationale behind this overview was to provide a clear and definitive answer to 
which brief cognitive assessment is most accurate for use in primary care as part of 
the toolkit for identifying dementia. Conducting an overview of diagnostic accuracy 
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systematic review evidence also presented the opportunity to explore and develop 
methods for carrying out overviews of diagnostic accuracy.   
A number of Cochrane Reviews have explored the individual value of tests for 
dementia to general practitioners198,199 to secondary care units such as memory clinics  
and acute care settings200, and in the community201-203 - or across a number of these 
settings204-207. These Cochrane reviews and other recent systematic reviews99,120,208 
have explored the diagnostic test accuracy of individual tests across a range of 
populations and settings. Given this current diversity of available systematic review 
evidence, researchers, policy-makers and practitioners would benefit from this 
evidence being summarised further for specific relevance and application to general 
practice. This specific and targeted summary of evidence is the focus of this overview.  
4.2. Method 
The aim of this overview was to summarise existing systematic review evidence for 
the diagnostic test accuracy of brief cognitive assessments, concentrating specifically 
on their use within a primary care setting (usually general practice). Primary care is 
the focus of many current discussions and policy-driven initiatives on increasing 
dementia diagnosis worldwide, yet the evidence underlying many of these debates is 
often unclear. A secondary aim is to summarise existing systematic review evidence 
for the diagnostic accuracy of informant-based brief cognitive assessments in the 
same setting. 
4.2.1. Protocol  
The overview protocol was published in the International Prospective Register for 
Systematic Reviews (PROSPERO) run by NIHR and the Centre of Reviews and 
Dissemination at University of York (registration reference CRD42015022078). The 
full protocol is shown in Error! Reference source not found.. The only change 
between protocol and review was in the search strategy. It was intended to search an 
evidence database being developed by the University of Exeter Medical School. The 
database however was not complete at the time of searching and therefore searches 
were restricted to the priority databases. 
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4.2.2. Inclusion and exclusion criteria  
Types of reviews 
Systematic reviews that examined the accuracy of brief cognitive assessments for 
identifying dementia in primary care, including relevant Cochrane reviews and 
protocols (in order to identify reviews in progess) published in The Cochrane Library 
were eligible for inclusion. 
4.2.3. Types of participants  
Studies that featured adults aged 18 years or over recruited from a primary care or 
general practice population were eligible for inclusion. Whilst patients who were 
selected on the basis of an existing diagnosis or condition which might reasonably be 
expected to feature in primary care (e.g. stroke) were not excluded, these patients 
were treated as a sub-group in the final analysis.  
4.2.4. Target condition being diagnosed  
All cause (non-differentiated) dementia was the target condition. Reviews that focused 
specifically on  dementia subtypes such as Alzheimer’s disease, vascular dementia 
and dementia with Lewy bodies were included, but reviews that focused on mild 
cognitive impairment (MCI) were excluded as this was not the condition of focus and 
both symptoms and aetiology are less well-defined than, and potentially significantly 
different to those of, dementia. Where reviews investigated both dementia and MCI, 
data referring to dementia were extracted and data referring solely to MCI were 
excluded. 
4.2.5. Index tests 
Index tests are the ‘novel’ test or tests introduced and compared against the 
established test or reference standard. All index tests within this overview are brief 
cognitive assessments. This term lacks accepted definition, but for the purposes of 
this overview ‘brief’ islimited to refer to tests which take up to 10 minutes to conduct. 
Analyses include the Mini Mental State Examination (MMSE); whilst the timings for 
this test are contested, it is one of the most commonly used tests and often 
characterised as taking ‘up to’ 10 minutes64,209,210. Brief cognitive assessments plus 
informant ratings were included where used, and a list of all included tests is presented 
within the results section. 
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4.2.6. Reference standards 
There is currently no gold standard test (i.e. close to 100% sensitivity and specificity) 
for identifying dementia in primary care. We therefore included all reference standard 
tests used within the relevant population and setting.  
Reference standards are commonly selected on the basis of many variables such as 
common practice within individual clinics, practitioner preference, specialisation and 
experience of healthcare professionals and practice managers and are subject to 
changes in cost and fashion. Many of the globally-accepted reference standards such 
as the World Health Organisation-supported ICD and the DSM produced by the 
American Psychiatric Association are updated regularly; the DSM-5 (sometimes 
colloquially referred to as DSM-V) was released in 2013, and the ICD-11 is due for 
release by 2018. 
4.3. Search methods for identification of reviews 
4.3.1. Electronic searches 
The Cochrane Database of Systematic Reviews was searched using the search 
strategy shown in Appendix 1. Searches also covered EMBASE, MEDLINE and 
PsychInfo for eligible systematic reviews from inception until August 2015 and search 
strategies are also shown in Appendix 1. Hand searching, and forwards and 
backwards citation searches were carried out using Google Scholar for systematic 
reviews included at full text screening. Date and language restrictions were not 
applied, in line with advice from the Cochrane Handbook of Diagnostic Test 
Accuracy211. Where reviews had been updated, the latest available version was 
chosen. Additional papers were identified through Zetoc alerts and added in to the 
title/abstract screening. Two reviewers (HH and EK) independently screened 
titles/abstract and full texts in parallel and resolved discrepancies through discussion.  
Updated searches were run on the Cochrane Database of Systematic Reviews 
(CDSR) in February 2016, and all eligible Cochrane Reviews of diagnostic accuracy 
are shown in Error! Reference source not found.. Updated searches were only run 
within CDSR as this was a simple and quick way to check whether previously-identified 
protocols may have been published as full reviews. As Cochrane Reviews are 
considered the highest quality of systematic review evidence available, this targeted 
and refined approach to update searches was considered rational within timescales.  
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4.3.2. Quality appraisal and risk of bias 
As there is currently no clear guidance of the quality assessment for overview reviews 
of diagnostic test accuracy studies, and evidence of the best quality assessment tools 
is unclear, it was decided to carry out quality assessment using both the AMSTAR 
checklist212 and the newer risk of bias assessment in systematic reviews (ROBIS) 
tool213 to allow assessment of potential benefits and shortcomings of each measure in 
conducting an overview of diagnostic accuracy.  
Review quality was assessed using the AMSTAR checklist212 and the suitability of this 
tool to assess quality within an overview review of systematic reviews of diagnostic 
test accuracy was critically evaluated. The ROBIS tool213 specifically assesses the 
degree to which review methods minimised risk of bias, and the degree to which the 
aims of the review were addressed by the review authors. As the ROBIS tool is newly 
developed, it was also assessed for its suitability for use in an overview of systematic 
reviews of diagnostic test accuracy. 
The lead reviewer (HH) carried out the assessments, with the second reviewer (EK) 
checking assessments for consistency and agreement. Both tools were piloted 
independently by assessing two reviews99,120 and comparing scoring decisions. When 
both reviewers were content with clear and rational approaches, the lead reviewer 
assessed the remaining reviews and the second reviewer spot-checked assessments. 
This was in order to maintain good systematic reviewing practice and consistency of 
approach whilst also making sure all substantive work was carried out by the lead 
reviewer.   
4.3.3. Planned synthesis 
Data were summarised in text and using summary tables. A summary of findings table 
was produced (Table 13Error! Reference source not found.) displaying review 
reference, component study reference, reference standard, index test, threshold, time 
taken, sample size and key demographic data, target condition, condition prevalence, 
accuracy data reported and notes. Additional summary tables were produced for 
comparisons at review level, non-DTA data reported, and individual brief cognitive 
assessments.  
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4.4. Overall results 
It was not possible to determine which brief cognitive assessments were most 
accurate, or had the highest sensitivity and specificity at a given diagnostic threshold, 
when used as part of the process to identify dementia within a general practice 
population.  
Clear conclusions could not be drawn across the included systematic reviews relating 
to the diagnostic accuracy of individual brief cognitive assessments. Broadly, this was 
due to: a lack of primary research; poor quality where the primary research did exist; 
and inconsistency in reporting results and primary data. Steps required to tackle these 
issues, and the costs of answering these questions weighed against their relative 
importance, are addressed in detail within the Discussion section. 
4.4.1. Population 
It was rare to find consistency amongst individual systematic review populations, as in 
many cases the population of interest was stated as ‘primary care’ or ‘general practice’ 
yet included study data from highly selected clinical populations. This is illustrated 
most clearly in Table 7 showing population data from included reviews against 
dementia prevalence where reported by individual study authors.  
It is clear from Table 7 that whilst many systematic reviews stated their population of 
interest as ‘primary care’ or ‘general practice’, the dementia prevalence in included 
studies was as high as 51%214. This is close to what would be expected in the highly 
selected population of a memory clinic or residential home, rather than the far lower 
prevalence of around 6.5% seen in primary care215. Therefore with this level of 
variation and inconsistency within systematic reviews, there was little opportunity to 
statistically analyse results across included reviews in order to generate more 
meaningful comparisons. 
CHAPTER 4: OVERVIEW  
CHAPTER 4| 68 
 
Table 7 Population data from included reviews and prevalence (where reported) from studies included within those reviews 
Full systematic review 
reference 
Verbatim stated 
review population 
Full source study reference Reported 
dementia 
prevalen
ce 
Arevalo‐Rodriguez, I., 
Smailagic, N., Roqué i 
Figuls, M., Ciapponi, A., 
Sanchez‐Perez, E., 
Giannakou, A., . . . Cullum, 
S. (2015). Mini‐Mental State 
Examination (MMSE) for the 
detection of Alzheimer's 
disease and other dementias 
in people with mild cognitive 
impairment (MCI). The 
Cochrane Library. 
Participants were 
recruited from:  
i) secondary care - 
outpatient clinic;  
ii) secondary care - 
memory clinics; &  
iii) populational 
sources (incl. 
primary care)  
Meguro, K., Ishii, H., Kasuya, M., Akanuma, K., Meguro, M., Kasai, M.. Asada, T. 
(2007). Incidence of dementia and associated risk factors in Japan: The Osaki-Tajiri 
Project. Journal of the neurological sciences, 260(1), 175-182. 
Modrego, P. J., Fayed, N., & Pina, M. A. (2005). Conversion from mild cognitive 
impairment to probable Alzheimer’s disease predicted by brain magnetic resonance 
spectroscopy. American Journal of Psychiatry, 162(4), 667-675.  
Modrego, P. J., & Gazulla, J. (2013). The predictive value of the memory 
impairment screen in patients with subjective memory complaints: a prospective 
study. The primary care companion for CNS disorders, 15(1).  
Nakata, E., Kasai, M., Kasuya, M., Akanuma, K., Meguro, M., Ishii, H., Meguro, K. 
(2009). Combined memory and executive function tests can screen mild cognitive 
impairment and converters to dementia in a community: the Osaki-Tajiri project. 
Neuroepidemiology, 33(2), 103-110.  
Xu, G., Meyer, J. S., Thornby, J., Chowdhury, M., & Quach, M. (2002). Screening 
for mild cognitive impairment (MCI) utilizing combined mini‐mental‐cognitive 
capacity examinations for identifying dementia prodromes. International journal of 
geriatric psychiatry, 17(11), 1027-1033.  
- 
Brodaty, H., Low, L.-F., 
Gibson, L., & Burns, K. 
(2006). What is the best 
dementia screening 
instrument for general 
practitioners to use? The 
American Journal of 
Geriatric Psychiatry, 14(5), 
391-400. 
Validated in “two 
distinct samples” or 
Inpatient or 
Outpatient settings 
All others validated 
in general practice, 
community or 
population settings 
Solomon, P. R., & Pendlebury, W. W. (1998). Recognition of Alzheimer’s disease: 
the 7 Minute Screen. Fam Med, 30(4), 265-271. 
50% 
Kirby, M., Denihan, A., Bruce, I., Coakley, D., & Lawlor, B. A. (2001). The clock 
drawing test in primary care: sensitivity in dementia detection and specificity against 
normal and depressed elderly. International Journal of Geriatric Psychiatry, 16(10), 
935-940 
7% 
Brodaty, H., Pond, D., Kemp, N. M., Luscombe, G., Harding, L., Berman, K., & 
Huppert, F. A. (2002). The GPCOG: a new screening test for dementia designed for 
general practice. Journal of the American Geriatrics Society, 50(3), 530-534.  
29% 
216  21% 
Carnero Pardo, C., Espejo 
Martínez, B., & Montoro 
Rios, M. (2009). Revisión 
sisteámtica y metaanálisis 
de la utilidad diagnóstica del 
Mix including Fase 
III Primary care 
Carnero-Pardo C, Espejo-Martínez B, López-Alcalde S, Espinosa García M, Feria 
Vilar I, & L, M. N. (2008). ¿Es hora de jubilar al Mini-Mental? . Neurologia, 23, 648-
649.  
- 
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Eurotest en la identificación 
de la demencia. 
Alzheimer(42), 14-22.  
Carnero-Pardo, C., Lopez-
Alcalde, S., Allegri, R. F., & 
Russo, M. J. (2014). A 
systematic review and meta-
analysis of the diagnostic 
accuracy of the Phototest 
for cognitive impairment and 
dementia. Dementia & 
Neuropsychologia, 8(2), 141-
147.  
Primary care Carnero-Pardo, C., Sáez-Zea, C., Montiel-Navarro, L., Feria-Vilar, I., & Gurpegui, 
M. (2011). Normative and reliability study of fototest. Neurología (English Edition), 
26(1), 20-25.  
38% 
Creavin, S. T., Wisniewski, 
S., Noel‐Storr, A. H., 
Trevelyan, C. M., Hampton, 
T., Rayment, D., . . . Milligan, 
R. (2016). Mini‐Mental State 
Examination (MMSE) for the 
detection of dementia in 
clinically unevaluated 
people aged 65 and over in 
community and primary care 
populations. The Cochrane 
Library.  
Primary care Brodaty, H., Pond, D., Kemp, N. M., Luscombe, G., Harding, L., Berman, K., & 
Huppert, F. A. (2002). The GPCOG: a new screening test for dementia designed for 
general practice. Journal of the American Geriatrics Society, 50(3), 530-534. 
29% 
Lavery, L. L., Lu, S.-y., Chang, C.-C. H., Saxton, J., & Ganguli, M. (2007). Cognitive 
assessment of older primary care patients with and without memory complaints. 
Journal of general internal medicine, 22(7), 949-954.  
8.9% 
Lourenço, R. A., & Veras, R. P. (2006). Mini-Mental State Examination: 
psychometric characteristics in elderly outpatients. Revista de Saúde Pública, 40(4), 
712-719. 
25.7% 
Pond, C. D., Mant, A., Kehoe, L., Hewitt, H., & Brodaty, H. (1994). General 
practitioner diagnosis of depression and dementia in the elderly: can academic 
detailing make a difference? Family Practice, 11(2), 141-147. 
15.5% 
217 21.4% 
Cruz-Orduña, I., Bellón, J. M., Torrero, P., Aparicio, E., Sanz, A., Mula, N., . . . 
Olazarán, J. (2011). Detecting MCI and dementia in primary care: efficiency of the 
MMS, the FAQ and the IQCODE. Family Practice, 29(4), 401-406.  
9.4% 
Harrison, J. K., Fearon, P., 
Noel‐Storr, A. H., McShane, 
R., Stott, D. J., & Quinn, T. J. 
(2014). Informant 
Questionnaire on Cognitive 
Decline in the Elderly 
(IQCODE) for the diagnosis 
of dementia within a general 
General practice/ 
primary care 
Tokuhara, K. G., Valcour, V. G., Masaki, K. H., & Blanchette, P. L. (2006). Utility of 
the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for 
dementia in a Japanese-American population. Hawaii Med J, 65(3), 72-75. 
7% 
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practice (primary care) 
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3.5.1. Accuracy  
Where accuracy was clearly stated within systematic review evidence, reported 
accuracy differed between individual reviews. There was also little consistency in the 
reported diagnostic accuracy of the same brief cognitive assessments across 
systematic reviews. For the MMSE, one review120 reported individual study sensitivity 
at unspecified thresholds ranging from 0.25 to 1.00, with specificity ranging from 0.54 
to 1.00. The reporting of individual test accuracy data were inconsistent and non-
existent in some cases99,120. This variation is illustrated most clearly in Table 12 Error! 
Reference source not found., which summarises the evidence found across the 
eight included reviews which reported MMSE test accuracy data for identifying 
dementia within primary care. There was a great deal of disparity amongst the 
thresholds investigated, with one review apparently not reporting the MMSE threshold 
used at all141 and one review reporting pooled data without reference to individual 
thresholds for MMSE – except to note that the most common threshold used within 
included studies (in 44% of cases) was <23.  
This level of heterogeneity was found across all included studies, and made 
comparison across different reviews incredibly difficult, as even where there was 
consistency across populations, settings and tests, the thresholds used varied widely.  
4.4.2. Detailed search results 
The results of the searches are presented within a PRISMA flow diagram shown in 
Error! Reference source not found.. Full text exclusions are shown in Error! 
Reference source not found.. The characteristics of the 13 included systematic 
reviews are shown in the Summary of Findings table (Table 13Error! Reference 
source not found.) at the end of this chapter.  
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Figure 3 PRISMA flow diagram of overview 
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There was wide variation in fundamental factors of population, target condition, 
reference standards, index tests, thresholds and aspects not directly related to test 
accuracy such as test administration time. Results are discussed below across these 
factors to illustrate the degree of variation discovered, and the Summary of Findings 
table in Table 13Error! Reference source not found. provides a comprehensive 
overview where individual reviews can be compared and contrasted.  
The 13 included systematic reviews included three Cochrane systematic reviews of 
diagnostic test accuracy198,204,205 and ten non-Cochrane systematic 
reviews99,120,125,141,148,220-222. Excluding the two reviews99,120 where individual study 
data was not reported, included evidence was derived from 28 separate studies. 
Fifteen studies featured in more than one of the included reviews (one study in four 
reviews142, one study in three reviews223, and four studies in two reviews146,216,224,225), 
illustrating a great deal of overlap between study-level evidence included within 
individual systematic reviews.  
Most (8/13) of the assessments of diagnostic test accuracy focussed on the Mini 
Mental State Examination (MMSE) compared against a range of reference standards. 
There was considerable variation in assessed index test thresholds. The MMSE was 
assessed at ten thresholds from 17 to 27, with <23 (signifying that patients with an 
MMSE score below 23 were assessed as having cognitive impairment) the most 
common threshold used across all reviews. The most common reference standard 
used was DSM-IV, with a mixed range of reference standards used from simple clinical 
diagnosis to a combination of several tools. The majority of studies were concerned 
with the diagnosis of dementia reflecting our inclusion strategy, with one review 
focused specifically on conversion from MCI to dementia204. 
All thirteen included reviews were published since 2006, with 6 published since 
2014120,148,198,204,205,221. Included studies were published between 1989 and 2013 
(1989 to 1994, four studies; 1995 to 1999, three studies; 2000 to 2009, 14 studies; 
2009 to 2013, five studies). Two included systematic reviews99,120 only reported 
aggregated study data so it was not possible to identify individual studies from these 
two systematic reviews. This individual study level data is missing from the rest of the 
results and analysis. Where reported, median total study sample size ranged from 49 
participants148,226 to 1178 participants218,222.  
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Of the component studies: nine were based in the USA145,218,224,227-230 (with two studies 
219,225 featured in two separate reviews222,231); six in Spain153,217,232-235; three in 
Australia (with one study142 referenced in five separate reviews125,141,205,222,236); two in 
Japan237,238; two in the United Kingdom239,240; two in the Netherlands146,241 (with one 
study 146 referenced in two reviews141,222 and one study241 referenced in another two 
separate reviews222,236); one in Grenada242; one in Ireland (with one study223 
referenced in three separate reviews222,231,236); one in Malaysia226; one in Brazil243; and 
one study based in Germany244. Two of the included systematic reviews99,120 only 
reported pooled study data, so population data for individual studies were not 
available. 
The low numbers of UK-based population data at the study level is a limitation worth 
noting for this overview, where the focus is on general practice populations relevant to 
the UK primary care setting. This limits the generaliseability of findings yet further, and 
is important to note for the cautious application of current evidence to a UK or mainland 
European general practice population. 
4.4.3. Target condition 
Dementia, all cause dementia, early dementia and dementia in normal and depressed 
elderly were the target conditions within ten reviews99,125,141,148,198,205,221,222,245. One 
review141 concentrated on mixed severity dementia, dementia in multicultural 
populations and dementia in people with a low educational level. In one review204, 
conversion rates were the focus from mild cognitive impairment (MCI) to dementia and 
Alzheimer’s disease or probable Alzheimer’s disease, with one component study227 
addressing conversion from subjective memory complaints to Alzheimer’s disease, 
vascular dementia, dementia with Lewy bodies or frontotemporal dementia. 
Alzheimer’s disease, dementia in normal and depressed elderly and dementia were 
the focus of one review236. Two reviews99,120 reported aggregate study data from a 
number of different countries and settings incorporating community, senior 
communities, assisted living facilities, clinic (undefined), hospital, primary care, and 
‘other’ (undefined). One of these reviews99 reported a mean participant age range of 
65 to 91 years, and dementia prevalence on a range of 1.2% to 47.1%. 
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4.4.4. Reference standards 
Suitability of reference standards  
Whilst our inclusion criteria purposefully included all-cause dementia, reference 
standards of included systematic reviews included highly specific tools designed to 
identify dementia subtypes such as the NINCDS-ADRDA criteria for Alzheimer’s 
disease, NINCDS-AIREN for Vascular dementia, the McKeith criteria for dementia with 
Lewy bodies and the Lund and Manchester criteria for frontotemporal dementia.  
As subtypes are generally not identified at the level of primary care, this provided an 
early indication that included data (at least) at the study level had included specific 
clinical populations not necessarily suited to a general practice population raises an 
early query around the clinical suitability of studies assessed within ostensibly 
community or primary care-focussed reviews.  
Interconnected brief cognitive assessments 
Some tools used as reference standards are interrelated and use elements of other 
measures within their structure. For example, the Cambridge Mental Disorders of the 
Elderly Examination (CAMDEX) has three main sections: A structured clinical patient 
interview to assess their present state, past history and family history; a battery of 
cognitive tests; and a structured interview with a relative or other informant to gain 
information on the patient246. The Cambridge Cognitive Examination (CAMCOG) is a 
self-contained measure consisting of the battery of cognitive tests taken directly from 
the CAMDEX247. The CAMCOG (and thus CAMDEX) incorporates a section with all 
nineteen questions from the Mini Mental State Examination (MMSE)248. One review236 
includes study data that used CAMCOG as an index test with CAMDEX as a reference 
standard in one study142, and MMSE as an index test with CAMDEX as reference 
standard in another study. This clearly raises questions of incorporation bias when 
there is overlap and duplication between the reference standard and index tests. 
Similarly, the Short and Sweet Screening Instrument (SASSI or SAS-SI) used as a 
reference standard within a study218 included in the 2009 systematic review by 
Mitchell222 consists of the MMSE, category fluency for animals and a temporal 
orientation test248. As the index test within this study was the MMSE, here again is 
clear potential for the introduction of systematic bias. 
The Mini-Cog combines the Clock Drawing Test (CDT) and the three-item word 
memory task224, and although it was not used as a reference standard in any of the 
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included studies, diagnostic performance was compared against the CDT and three-
word recall task within one of the component studies224.  
Reference standards within included reviews 
Five reviews141,205,222,236 incorporated a range of reference standards from:  
 clinical diagnosis using NINDCS-ADRDA228,  
 clinical diagnosis using CAMDEX and DSM-IV142  
 GP diagnosis using CAMDEX and GMS-AGECAT216,  
 DSM-IV plus ‘expert consensus’230,  
 to using Mini-Cog with DSM-III-R and NINCDR-CERAD224,  
 GMS-AGECAT plus CAMDEX146,  
 DSM-III and ICD-10249,  
 DSM-III-R with GMS-AGECAT223,  
 DSM-III-R and NINCDR-CERAD244,  
 DSM-IV and ICD-10243,  
 DSM-III-R and IPA/WHO criteria153,  
 SASSI218,  
 GMS-AGECAT216,  
 AGECAT dementia250, 
 DMS-III-R219,225,  
 DSM-IV142,251,  
 DSM-IV-R232,252,253,  
 CAMDEX214,239,240 or  
 CDR229  
Three reviews125,148,245 solely reported DSM-IV as a reference standard (from 
studies142,217,226 with one review125 also using CAMDEX142). 
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One review204 primarily incorporated the NINCDS-ADRDA criteria as reference 
standard for Alzheimer’s disease, with two of the component studies also using 
NINCDS-AIREN as a reference standard for Vascular dementia, the McKeith criteria 
for dementia with Lewy bodies and the Lund and Manchester criteria for 
frontotemporal dementia227 and NINCDS-ADRDA for probable Alzheimer’s disease, 
NINDS-AIREN for possible Alzheimer’s disease with cardiovascular disease, NINDS-
AIREN for probable Vascular dementia, consensus guidelines for dementia with Lewy 
bodies and the Lund & Manchester Groups criteria for frontotemporal dementia238. 
One study238 also used DSM-IV and CDR 1+ as a reference standard for conversion 
from MCI to dementia.  
One review198 described a reference standard of clinical dementia diagnosis using 
Benson and Cummings criteria, informed by cognitive testing (CASI, MMSE and 
Clock-Drawing Task), interview data and an assessment of function145. 
Two reviews reported aggregated data across all included studies99,120. In one of these 
two reviews120 the reference standards used in primary care settings could not be 
disaggregated. Authors of the other review99 selectively reported the most common 
reference standards as criteria from the Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition (DSM-III), the DSM-IV, or the National Institute of Neurological 
and Communicative Disorders and Stroke and Alzheimer’s Disease and Related 
Disorders Association. Formal diagnosis was based on a combination of history, 
examination, neuropsychological testing, and expert consensus. One review221 
reported “clinical diagnosis” as the reference standard without reference to any tool242. 
Index tests 
The MMSE was most frequently assessed, appearing in 8 
reviews99,120,125,141,204,205,222,236, with Eurotest, Fototest, BIMCT, John Brown test, 
Verbal Fluency, Orientation, RUDAS and PCL all featuring in only one review each 
(see Table 8Error! Reference source not found.). The information within this table 
is not an unbiased reflection of frequency, as two of the reviews99,120 only report 
aggregated study data - meaning the studies which had reported data on individual 
index tests could not be identified. 
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Table 8 Frequency of index test use 
Index test Number of review 
inclusions 
Number of unique study inclusions 
MMSE  899,120,125,141,204,205,222,236  
 
22142,218,224,240x3 
146,214,216,223,225,227,229,230,232,234,235,238,239,243,249,250,252 
GPCOG  599,120,125,141,236 2142,251 
CDT  499,120,141,236 2223,224 
Mini-Cog 499,120,125,236 3144,224,254-257 
IQCODE 399,120,198 1145 
MIS 222,23 5149,256,258-260 
SPMSQ  299,141 2146,219  
7MS 299,236 1228 
3 word recall 1141 2224,244 
AMTS  1141 2142,146 
Eurotest 1220 1217 
Fototest 1221 1242 
BIMCT  1141 1219 
John Brown 
test 
1141 1225 
Verbal 
Fluency 
1141 1225 
Orientation 1141 1225 
RUDAS  1148 1226 
PCL  1141 1153 
MMSE, mini mental state examination [standard, Spanish and Portuguese editions]; IQCODE, 
Informant Questionnaire on Cognitive Decline in the Elderly; GPCOG, General Practitioner assessment 
of Cognition; CDT, clock drawing test; MIS, memory impairment screen; SPMSQ, Short portable mental 
status questionnaire; AMTS, Abbreviated Mental Test Score; 7MS, 7 minute screen; BIMCT, Blessed 
Information Memory Concentration Test; RUDAS, The Rowland Universal Dementia Assessment 
Scale; PCL, Prueba cognitive de leganes. 
Three reviews204,205,222 solely assessed the performance of the MMSE at various 
thresholds. A range of index tests were assessed as indirect comparisons in three 
reviews141,222,236, with index tests including the 7 minute screen228, CDT223, 3 word 
recall224,244, GPCOG142, GPCOG ‘combined’ [N.B. combination not specified] 251, 
PCL153, SPMSQ and Blessed Information Memory Concentration Test219, SPMSQ, 
MSQ, AMTS and AMTS combined with MSQ146, John Brown test, verbal fluency – 
animals, orientation225, and MMSE216. One review220 assessed performance of the 
Fototest217, and one related review221 assessed performance of the Eurotest242. 
IQCODE was assessed at various thresholds between 3.2 and 3.7 in one review200. 
The RUDAS tool was assessed148 in one review with a 23 out of 30 cut-off, meaning 
patients had to score below 23 to be assessed as having dementia. GPCOG, AMT 
and MMSE were assessed as direct comparisons in one review125. One review120 
made indirect comparisons between MMSE, CDT-Shulman, CDT-Sunderland, 
MiniCog, MIS, verbal fluency, AMT, GPCOG, MoCA, ACE-R, IQCODE (short and long 
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versions) and 3MS lthough as data were aggregated it was unclear which if any of 
these index tests assessed overlapping populations.  Finally, CDT, MiniCog, MIS/MIS-
T, MSQ/SPMSQ, verbal fluency, MMSE, AMT, FCSRT, 7MS, TICS and IQCODE were 
all assessed indirectly in one review99. As in the previous review the data was 
aggregated across studies and it was not possible to separate between different 
studies and populations, so there may be duplucation across participants within these 
data. 
4.4.5. Other test features recorded in included systematic reviews 
Many of the included systematic reviews noted factors beyond test accuracy in varying 
degrees of detail, and these were recorded for this overview at the stage of data 
extraction. These items were recorded within systematic reviews directly as follows: 
time taken to administer the test99,105,120,125,141,148,221,231,236; language/culture 
bias125,148,236,261; education bias125,148,236; face validity236,261; internal consistency148,236; 
interrater reliability148,236; test-retest reliability148,236; practicability for general 
practice99,125; Clinician preference148; and immigration status148. These aspects are 
noted here for completeness and addressed in detail in the Discussion section. The 
usefulness of diagnostic test accuracy as a measure of a test’s value, and factors of 
value beyond test accuracy across all brief cognitive tests, are also addressed within 
the Discussion. 
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Table 9 What did the reviews say about test accuracy of the MMSE? 
Ref. Reference standard MMSE 
thresholds 
Setting Main findings Other outcomes 
considered 
beyond test 
accuracy 
204 NINCDS-ADRDA or DSM 
or ICD criteria for 
Alzheimer’s disease 
dementia; McKeith criteria 
for Lewy body dementia; 
Lund criteria for 
frontotemporal dementia; 
and NINDS-AIREN 
criteria for vascular 
dementia 
≤ 21,  
≤ 26,  
≤ 28,  
≤ 29 
Participants 
were recruited 
from:  
i) secondary 
care - outpatient 
clinic (n = 3);  
ii) secondary 
care - memory 
clinics (n = 6) 
and  
iii) populational 
sources (n = 2) 
Only dealt with conversion from MCI to dementia. 
No evidence supporting a substantial role of 
MMSE as a stand-alone single-administration test 
in the identification of MCI patients who could 
develop dementia.  
Clinicians could prefer to request additional and 
extensive tests to be sure about the management 
of these patients. An important aspect to assess in 
future updates is if conversion to dementia from 
MCI stages could be predicted better by MMSE 
changes over time instead of single 
measurements. It is also important to assess if a 
set of tests, rather than an isolated one, may be 
more successful in predicting conversion from MCI 
to dementia. 
- 
236 Clinical diagnosis/clinical 
diagnosis combined with  
e.g. DSM-IV 
≤23 Validated in “two 
distinct 
samples” or 
Inpatient or 
Outpatient 
settings 
All others 
validated in 
general practice, 
community or 
population 
settings 
Sensitivity = 69 (95% CI, 0.66-0.73) 
Specificity = 89 (95% CI, 0.87-0.92) 
PPV = 0.63 (95% CI, 0.58 – 0.67) 
NPV = 0.92 (95% CI, 0.90 – 0.94) 
Misclassification = 15% (calculated using DAGStag 
programme) 
The authors recommend that GPs consider using 
the GPCOG, Mini-Cog or MIS when screening for 
cognitive impairment or for case detection. Quick 
and easy to administer whilst having psychometric 
properties similar to the MMSE. 
Time taken 
Face validity 
Internal 
consistency 
Education Bias 
Language/Culture 
Bias 
Interrater Reliability 
Test-Retest 
Reliability 
Ease of 
administration 
Practicability for 
general practice 
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205 
 
Clinical diagnosis defined 
by DSM, ICD or CRS. 
≤17 
≤18 
≤19 
≤20 
≤21 
≤22 
≤23 
≤24 
≤25 
≤26  
Primary care The authors could not estimate summary DTA in 
primary care due to insufficient data. 
“The MMSE contributes to a diagnosis of dementia 
in low prevalence settings, but should not be used 
in isolation to confirm or exclude disease. We 
recommend that future work evaluates the 
diagnostic accuracy of tests in the context of the 
diagnostic pathway experienced by the patient and 
that investigators report how undergoing the 
MMSE changes patient-relevant outcomes”, e.g. 
time to diagnosis, initiation of treatment/care 
package, additional testing and place of care. 
- 
222 Clinical diagnosis using 
DSM III, IIIR or IV 
≤21 
≤22 
≤23 
≤24 
≤25 
≤26 
≤28 
Primary care In those studies conducted purely in primary care: 
Sensitivity = 0.78 
Specificity = 0.88 
PPV = 0.54 
NPV = 0.96 
In non-specialist settings, the MMSE was best at 
ruling out dementia, achieving about 29/30 correct 
reassurances with less than three false negatives 
out of every 100 screens. MMSE offers modest 
accuracy with best value for ruling-out a diagnosis 
of dementia in community and primary care. For all 
other used it should be combined with or replaced 
by other methods. 
- 
141 Clinical diagnosis using 
DSM/IPA-WHO 
criteria/GMS-AGECAT 4 
or 5+ CAMDEX 
NR Primary care The authors conclude that the AMTS was 
preferable to the MMSE for case-finding, whereas 
the SMPSQ was inferior.   
For screening, the MMSE was optimal and…the 
best tool for primary care physicians who want a 
rule in and rule out tool, if length is not a major 
consideration. 
“at least 30 well-studied alternatives to the MMSE 
exist and several seem to be briefer but no less 
accurate than the MMSE…In primary care…these 
Comparative 
accuracy 
conducted with 5 
instruments 
(AMTS/MSQ, 
MSQ, WINDSET, 
PCL and AMTS).  
Time taken given in 
all cases.  
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methods would help detect on 13 of 20 possible 
cases but rule out 18 of 20 healthy individuals 
(overall correct in 17 out of 20) suggesting these 
brief batteries may be ideally suited to a first step 
screen followed by a more comprehensive in those 
who screen positive” (p. 779). 
99 DSM criteria and 
NINCDS-ADRDA 
Various Primary care 
and community 
(primary care-
relevant 
populations) 
Review authors reported on MMSE (n = 12 348).  
…”The best-studied instrument was the MMSE. 
Pooled estimates across 14 studies (n = 10 185) 
resulted in sensitivity of 88.3% (95% CI, 81.3% to 
92.9%) and specificity of 86.2% (CI, 81.8% to 
89.7%) for the most commonly reported cut points 
of 23/24 or 24/25.  
Review authors’ conclusions: 
“…only a handful of instruments have been studied 
in more than 1 study applicable to primary care. 
Although the MMSE is the best-studied instrument, 
it has the longest administration time and is not 
available for public use without cost.  
Other assessments 
of benefits and 
harms, caregiver 
interventions, non-
pharmacological 
interventions aimed 
at the patients  
120 DSM, ICD, NINCDS-
ADRDA, CAMDEX, GMS-
AGECAT, CERAD, CDR 
(not reported individually) 
NR Primary care From the authors –  
“With different cut-off threshold values, we found 
considerable variation in the sensitivity and 
specificity estimates reported by individual studies. 
The sensitivities ranged from 0.25 to 1.00, and the 
specificities ranged from 0.54 to 1.00. The 
heterogeneity among studies was large, with I2 
statistics for sensitivity and specificity of 92% and 
94%, respectively…The combined data in the 
bivariate random-effects model gave a summary 
point with 0.81 sensitivity (95% CI, 0.78-0.84) and 
0.89 specificity (95% CI, 0.87-0.91). The HSROC 
curve was plotted with a diagnostic odds ratio of 
35.4, and the AUC was 92% (95%CI,90%-94%)” 
(p.E4).  
Administration 
time, number of 
questions, 
components of 
screening tests 
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CAMDEX, Cambridge Mental Disorders of the Elderly Examination; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CDR, Clinical 
Dementia Rating; DSM, DSM-IV, MMSE, mini mental state examination; GPCOG, The General Practitioner assessment of Cognition; CI, confidence 
interval;  ICD, International Classification of Diseases; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke – 
Alzheimer’s Disease and Related Disorders Association; GMS-AGECAT, Geriatric Mental State – Automated Geriatric Examination for Computer Assisted 
Taxonomy; n, number in sample; AMTS, Abbreviated Mental Test Score; MSQ, Mental Status Questionnaire; PCL, Prueba cognitive de leganes [Leganés 
cognitive test]; IPA-WHO, International Psychogeriatric Association World Health Organisation criteria; PPV, positive predictive value; NPV, negative 
predictive value;  ICD, CRS, MCI, mild cognitive impairment; NINDS-AIREN, National Institute of Neurological Disorders and Stroke and Association 
Internationales pour la Recherche et l´ Ensignement en Neurosciences
125 CAMDEX, DSM-IV <8 
<25 
General practice Review authors concluded that the GPCOG 
outperformed the MMSE in a general practice 
sample. “However, the composition of the test was 
changed post hoc, and the available data are 
incomplete”[my bold/italics] 
“…the limited cognitive domains that all these tests 
assess may make them prone to miss non-
Alzheimer’s dementias” (p.475) 
Other assessment 
domains 
(language, 
attention, memory, 
visuospatial skills, 
executive function) 
and monitoring 
disease 
progression 
discussed.  
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4.4.6. Quality assessment across all reviews 
Table 10Error! Reference source not found. shows all quality assessment scores 
using the AMSTAR tool, and the full tool is shown in Error! Reference source not 
found.. Across the reviews, Cochrane reviews198,204,205 were of a higher 
methodological quality (all scored 10 out of 11) whereas the non-Cochrane 
reviews120,125,141,148,190,221,222,236,245 were of moderate or low quality (mean score 4.8 
out of 11, range 0-7).  
All three Cochrane reviews prespecified the research question and inclusion criteria in 
the form of a published protocol, and gave clear evidence of duplicate study selection 
and data extraction with a comprehensive literature search including grey literature 
searches. All these provided a clear list of included and excluded studies, containing 
characteristics of included studies and quality assessments reported and incorporated 
into review conclusions. It was judged that the methods used for combining findings 
were appropriate in all cases, and conflicts of interests featured in each Cochrane 
review. The likelihood of publication bias using graphical aids and/or statistical 
methods was not assessed in any of the included Cochrane reviews. However, as all 
the included Cochrane reviews were systematic reviews of diagnostic test accuracy 
and the nature of publication bias in test accuracy studies is still unclear, this may be 
a less applicable measure within this methodological context compared to systematic 
reviews of interventions. This appears to be a weakness of existing tools and worth 
amending in further revisions if they can be tailored for test accuracy reviews. 
None of the non-Cochrane reviews gave evidence of an ‘a priori’ design with 
prespecificed research questions or inclusion criteria. It was not possible to assess 
whether there was duplicate study selection and data extraction in five out of ten non-
Cochrane reviews as there were insufficient data reported. Authors were not contacted 
as the lack of data reported across a number of different areas indicated systemic 
issues with reporting quality rather than individual authorship decisions. 
Comprehensive literature searches were performed in eleven out of thirteen reviews, 
with two reviews125,236 assessed as low quality for the data presented within the 
reviews on their literature searches.  
Four reviews clearly reported included/excluded studies99,198,204,205. Conflicts of 
interest reporting was assessed as poor in seven reviews120,125,141,148,222,236. 
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4.4.7. Risk of bias 
The ROBIS tool213 was used to assess the risk of bias within included systematic 
reviews. This recently-developed tool is adapted for different systematic review 
methodologies, and incorporates questions tailored for systematic reviews of 
diagnostic test accuracy. Table 11Error! Reference source not found. shows all the 
ROBIS scores for included systematic reviews, and the complete tool is available in 
Error! Reference source not found.. 
Overall, six reviews99,141,148,198,204,205 were judged to be at low risk of bias, with one 
review141 at medium risk of bias and six120,125,221,222,236,245 reviews assessed at high 
risk of bias overall. 
Three reviews198,204,205 were judged at low risk of bias across all four domains:  
1. Study eligibility criteria 
2. Identification and selection of studies 
3. Data collection and study appraisal 
4. Synthesis and findings. 
All three of these reviews198,204,205 were Cochrane reviews, and it should be noted that 
the ROBIS tool was developed in line with the Cochrane reporting guidelines 
contained within the Cochrane Handbook for Systematic Reviews of Interventions262 
and Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy263. It is 
therefore unsurprising that there is significant resonance between systematic reviews 
following the prescriptive Cochrane method, and a risk of bias assessment tool 
designed using the same Cochrane approach. 
Two reviews120,236 were assessed as high risk of bias across all four of these domains, 
with particular concerns around lack of information on predefined objectives, data 
collection and no clear accounting for heterogeneous results236.  
One review120 pooled sensitivity and specificity data without giving a rationale, and 
accuracy was combined without reference to appropriate populations, settings and 
administration times. Most curiously the authors of this review generated a hierarchical 
summary of Receiver-operating Characteristics (HSROC) graphic, but removed the 
confidence region, thus giving a misleading view of an inappropriate combination of 
data. 
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Table 10. AMSTAR quality assessment scores across all reviews 
AMSTAR question 
Harrison 
2014 
Aravelo-
Rodriguez 
2015 
Creavin 
2016 
Lin 
2013 
Carnero-
Pardo 
2014 
Carnero-
Pardo 
2009 
Mitchell 
2010a 
Mitchell 
2010b 
Naqvi 
2015 
Tsoi 
2015 
Mitchell 
2009 
Woodford 
2007 
Brodaty 
2006 
1. Was an 'a priori' design 
provided? 
Yes Yes Yes No CA No No No No No No No No 
2. Was there duplicate study 
selection and data extraction? 
Yes Yes Yes Yes CA CA No No Yes Yes CA CA CA 
3. Was a comprehensive 
literature search performed? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No 
4. Was the status of publication 
(i.e. grey literature) used as an 
inclusion criterion? 
Yes Yes Yes CA Yes Yes No No CA No No No No 
5. Was a list of studies 
(included and excluded) 
provided? 
Yes Yes Yes Yes No No No No No No No No No 
6. Were the characteristics of 
the included studies provided? 
Yes Yes Yes No No No Yes Yes Yes Yes Yes Yes No 
7. Was the scientific quality of 
the included studies assessed 
and documented? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No 
8. Was the scientific quality of 
the included studies used 
appropriately in formulating  
conclusions? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No 
9. Were the methods used to 
combine the findings of studies 
appropriate? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No N/a 
10. Was the likelihood of 
publication bias assessed? 
N/a No No Yes No No Yes Yes No No No No No 
11. Was the conflict of interest 
included? 
Yes Yes Yes No Yes Yes No No No No No No No 
AMSTAR overall ratings  10/11 10/11 10/11 7/11 6/11 6/11 6/11 6/11 6/11 4/11 4/11 3/11 0/11 
CA, cannot assess (insufficient data); N/a, not applicable 
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Table 11. ROBIS risk of bias assessment across all included reviews 
 
Creavin 
2016 
[C] 
Harrison 
2014  
[C] 
Aravelo-
Rodriguez  
2015 [C] 
Lin 
2013 
Mitchell 
2010a 
Naqvi 
2015 
Mitchell 
2010b 
Mitchell 
2009 
Woodford 
2007 
Carnero-
Pardo 
2014 
Carnero-
Pardo 
2009 
Brodaty 
2006 
Tsoi 
2015 
Overall risk of 
bias in the 
review  
             
1. Study 
eligibility criteria              
2. Identification 
and selection of 
studies 
             
3. Data collection 
and study 
appraisal 
             
4. Synthesis and 
findings              
 
 Low risk of bias rating 
 Medium risk of bias rating 
 High risk of bias rating 
[C] Cochrane review 
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4.5. Discussion and relevance 
4.5.1. The evidence is not clear 
Despite being conducted to a high standard, with a PROSPERO-registered protocol 
published open access in a peer-reviewed journal, designed and conducted in line 
with best evidence recommendations and drawing on an array of topic and 
methodological expertise, this overview found no evidence for one brief cognitive 
assessment which demonstrates clear evidence of superior diagnostic accuracy when 
used as part of the process for identifying dementia in general practice. 
As the main aim of this overview was to address this single, seemingly-simple 
question, this was the most surprising and disappointing finding of this synthesis of 
existing evidence. To be clear, the finding was not a simple lack of evidence – which 
would account for continued uncertainty and be clearly addressed by a direct call for 
further research to address this specific issue. 
There was a great deal of evidence identified within this overview (as demonstrated in 
the Summary of findings at the systematic review level shown in Table 13Error! 
Reference source not found.), but data suffered from three main issues: 
Firstly, there is insufficient evidence at the primary study level which specifically 
addresses cognitive assessments designed and validated for use in a general practice 
population. Nor does sufficient evidence take account of standard general practice 
setting parameters, e.g. consultation length, comorbidities, mixed or indirect 
presentation, patient age, lack of clinical specialty, potential referral by a relative and 
presence of an informant. Much of the existing evidence claims to refer to such limits, 
but does not present clear empirical evidence for them.  
The second issue is that poorly-conducted primary studies are ill-suited to answer the 
questions they purport to address. Of the systematic reviews included within this 
overview, the highest quality reviews105,198,204 were unable to provide clear, 
unambiguous guidance on which assessments were most accurate for diagnosing 
dementia within a general practice population. This was despite identifying evidence 
eligible for inclusion within the included systematic reviews, although concerns were 
raised across the included systematic reviews on issues such as low study 
numbers198,204, lack of direct comparisons between cognitive assessments236, 
variation across study populations120,125,221, and concerns around patient selection105 
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and generaliseability99,148. Within the overview, all included systematic reviews 
consisted of studies adopting various designs. Systematic reviews were part of the 
overview inclusion criteria, but in the absence of specific guidance on conducting 
overviews of diagnostic test accuracy the study designs of all the component studies 
were included within the overview. This is a key point for consideration by those 
creating guidelines for the conduct of overviews.  
Finally, there is a problem with the quality of evidence at the level of systematic review, 
which does not clearly reflect the primary research. As Table 7Error! Reference 
source not found. illustrates, whilst included systematic reviews specified population 
inclusion criteria relating to general practice or primary care, dementia prevalence 
reported within primary studies of one review222 ranged from 4%250 to 51%214 – far 
from UK general practice prevalence rates of around 6%13. Some reviews made 
recommendations on individual tools, but these recommendations were based upon 
indirect study comparisons, or studies where reported data were pooled without 
reporting disaggregated factors such as population data. In effect, study data from 
memory clinic and hospital populations were combined with study data from general 
practice populations, and this resulted in findings that could not be generalised to our 
population of interest. Whilst the inclusion criteria for this overview required that the 
population of interest (general practice or primary care) was explicitly stated within the 
review, this relied upon included reviews containing eligible studies. 
4.5.2. What to do with current evidence  
Aside from the issues raised above, there are clear messages to take from this 
overview of the current evidence. The accuracy of the five brief cognitive assessments 
most frequently featured within the included reviews within this overview (MMSE, 
GPCOG, CDT, Mini-Cog, IQCODE) are summarised below.  
MMSE accuracy 
Within this up-to-date overview with all reviews conducted since 2006, the most 
commonly-used brief cognitive assessment within research studies was the MMSE, 
appearing in eight of the included systematic reviews and twenty-two of the unique 
component studies (review and study references shown in Table 12Error! Reference 
source not found.). Despite its continuing ubiquity as a research tool, the MMSE is 
not suitable for use in clinical practice and should be avoided within general practice 
simply due to the length of time it takes to administer (7.3±5 minutes144, longer than 
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practicable for the standard mean general practice appointment length of 10.7 minutes 
(6.7 standard deviation)132). In terms of diagnostic performance, the value of MMSE 
as a cognitive assessment tool for use in general practice is limited241. The MMSE has 
been found to overestimate impairment in people over 60 years old, and in those with 
lower levels of education264. Across included systematic review evidence and 
beyond265,266, high levels of heterogeneity in MMSE accuracy makes clinical practice 
recommendations highly challenging.  
Within this overview, the accuracy of MMSE in detecting dementia at different 
thresholds was highly varied, with a general pattern of higher sensitivity and lower 
specificity observed across reviews using lower thresholds of 19 to 22, and a tipping 
point of lower sensitivity and higher specificity emerging more strongly as thresholds 
increased from 23 to 27. However, this was inconsistent across all results and 
incorporated a very large range of dementia prevalence, ranging from 4% to 51% 
within a single systematic review222.  
GPCOG accuracy 
The second most commonly featured brief cognitive assessment within the overview 
was the GPCOG, assessed in five99,120,125,141,236 out of the thirteen included systematic 
reviews and two142,251 component studies (one study142 featured in four separate 
reviews). As one of the newer brief cognitive assessment tools, the GPCOG is less 
established in clinical and research applications but is growing in popularity in practice 
guidelines266 (see Chapter 3). The GPCOG is often presented within research 
literature as designed specifically for use in general practice and a suitable tool due to 
clinical acceptability and limited bias for education, ethnicity and gender130,248 with 
similar diagnostic performance to the MMSE236,251. Evidence identified in this overview 
did not refute this claim, but there was very limited evidence of direct comparisons 
between GPCOG and MMSE and indirect comparison data should be viewed with 
caution due to the likely variation introduced when viewing two different study 
populations, settings and testing protocols. 
One review exploring the best dementia screening instrument for general practitioners 
236 reported GPCOG two step sensitivity as 0.85 (95% CI 0.76-0.92) and specificity as 
0.86 (95% CI 0.81-0.91). Another review of multi-domain tests for the detection of 
dementia assessed the GPCOG from two studies142,251 but did not report sensitivity or 
specificity from these studies.  Two other reviews99,120 reported pooled accuracy data 
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across studies142 with one recurrent GPCOG reference referring to another systematic 
review236 (included both within this overview and within the systematic review of direct 
comparisons). One of these reviews reported pooled data for GPCOG, with pooled 
sensitivity of 0.92 (95% CI 0.81-0.97) and pooled specificity of 0.87 (95% CI 0.83-
0.90). 
Direct comparisons between tools were only reported in one review of clinical methods 
for cognitive assessment in the elderly125 which reported GPCOG sensitivity of 0.85 
and specificity of 0.86. This aligns with reporting of the study142 included in the three 
other reviews described above99,141,236.  
CDT accuracy 
The Clock Drawing Test (CDT) featured as an index test in four of the included 
systematic reviews99,120,231,236, with one component study223 featuring in three 
reviews99,231,236. Two reviews99,120 reporting aggregated data from a pool of non-
differentiated studies (one review99 referencing seven studies223,229,257,258,267-269; one 
review120 simply referenced the original verification studies for CDT270,271 and noted 
that they included data “from nine studies” for each verification study).  
There was no evidence found of direct comparisons between the CDT and other tools. 
In the two reviews that reported pooled data99,120 it was not possible to disaggregate 
study level evidence to see if direct comparison data were available. 
The two reviews231,236 which include evidence from the same study 223 are consistent 
in reporting that the study took place in a general practice population of normal and 
depressed elderly people, with an average age of 77 years old236 and a dementia 
prevalence of 7%. One review reported a sample population of 564 people236 whereas 
the other review reported a population of 648 people, 41 with dementia231. The 
reference standard used was clinical diagnosis combined with DSM-IV criteria. Both 
reviews reported CDT sensitivity from the single study of 0.76 (95% CI 0.60-0.88) and 
specificity of 0.81 (95% CI 0.77-0.84).  
One review231 also reported CDT accuracy data from a study224 conducted in 
community dwelling adults aged 65 years and over. CDT was compared to the 
reference standard of a field-modified version of the Consortium to Establish a 
Registry for Alzheimer's disease (CERAD) protocol and the Clinical Dementia Rating 
(CDR) scale. The sample of 1,119 participants had a reported dementia prevalence of 
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6.4%. The sensitivity of CDT was reported as 0.76, and the specificity was 0.81. Of 
the two reviews99,120 which only reported pooled study-level data, one review reported 
pooled data from six studies conducted in “primary care relevant popluations”99, with 
a total of 2170 participants. The reported reference standard was DSM criteria and the 
National Institute of Neurological and Communicative Disorders and Stroke – 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. 
Accuracy scores were reported as ranges, with sensitivity between 0.67-0.98 (95% CI 
0.39-1.00) and specificity from 0.69-0.94 (95% CI 0.54-0.97). The other aggregated 
review120 reported study data pooled across two different scoring systems: CDT 
Shulman270 and CDT Sunderland271. For CDT Shulman with a pooled study population 
of 2096 (1266 with dementia), reported sensitivity was 0.893 (95% CI 0.75-0.89) 
specificity 0.84 (95% CI 0.69-0.92). CDT Sunderland had a pooled study population 
of 1757 (528 people with dementia) and reported sensitivity of 0.76 (95% CI 0.69-0.83) 
specificity 0.85 (95% CI 0.76-0.91). Whilst individual study details were not available 
within the review, the high number of people with dementia within the study samples 
suggest they may not have been representative of a general practice population. 
Taking the systematic review evidence in total, the optimum threshold for CDT in 
detecting cognitive impairment was unclear from the data presented. 
Mini-Cog accuracy 
The Mini-Cog also featured as an index test in four of the included systematic 
reviews120,125,141,236, with one study224 featured in three reviews125,141,236 and the other 
five studies144,254-257 featuring in one review each.  
Of the three reviews reporting the findings of one study224, one review236 stated the 
setting was primary care with a dementia prevalence of 6% in a study population of 
1.179. In this review, Mini-Cog sensitivity was reported as 0.76 (95% CI 0.65-0.85) 
and specificity as 0.89 (95% CI 0.87-0.91) compared against a reference standard of 
a clinical diagnosis using DSM-III-R and NINCDS-ADRDA criteria. These findings 
corresponded with those of the second review125 which reported the study population 
of 1,179 with 6.4% dementia prevalence – although this review also stated that the 
same study was based upon a random community sample rather than primary care. 
This review reported sensitivity as 0.76 and specificity as 0.89 compared against a 
reference standard using CERAD, DSM-IV and NINCDS-ADRDA criteria. The third 
review141 stated that the same study took place in a community setting, with a study 
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population of 1,119. This review did not report any accuracy data but did state that 
compared to MMSE at a threshold of 24, Mini-Cog was less sensitive than MMSE 
whereas at an MMSE cut off of 25, Mini-Cog was more sensitive but less specific than 
MMSE. The stated reference standard in this review was MMSE and a standardised 
neuropsychological battery incorporating DSM IIIR and NINCDS-ADRDA criteria. 
Two other studies144,254 reported in one review125 reportedly drew on community 
samples yet reported dementia prevalence of 52% and 62% respectively, suggesting 
these were highly selective and atypical populations. One study144 reported sensitivity 
of 0.99 and specificity of 0.93 compared to a reference standard of CAMDEX and 
DSM-IV in a sample of 249 people with a mean age of 74 years and with 50% non-
native English speakers. The other study254 only featured in this review reported 
sensitivity of 0.84 and specificity of 0.81 compared to a reference standard of the 
Cognitive Abilities Screening Instrument (CASI) in a sample of 371 people (mean age 
=75 years old, 64% non-English speaking). 
One other review120 reported pooled study data across different brief cognitive 
assessments, with nine studies reporting accuracy data on Mini-Cog and three of 
those studies drawn from a primary care population. Three studies set in primary 
care255-257 (identified by their referenced titles) reported accuracy data although 
individual reference standards were not reported. Instead, pooled reference standards 
were reported including DSM, ICD, NINCDS-ADRDA, CAMDEX, GMS-AGECAT, 
CERAD and CDR. One study reported sensitivity of 0.78 (95% CI 0.71-0.84) and 
specificity of 0.59 (95% CI 0.50-0.67), one reported sensitivity of 1.00 (95% CI 0.84-
1.00) and specificity of 0.85 (95% CI 0.81-0.89), and one reported sensitivity of 0.80 
(95% CI 0.56-0.94) and specificity of 0.73 (95% CI 0.69-0.77). 
It is difficult to draw meaningful conclusions from the results presented within this last 
review without knowing individual study data such as population size and setting, 
individual reference standards used and other demographic details such as age, 
gender and education levels. These data are not presented within the review and 
cannot be extracted from the primary study as only pooled primary data were reported 
within the review. 
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IQCODE accuracy 
The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) is a 26-
item questionnaire administered to an informant which asks about changes in daily 
cognitive function of the person being assessed. There is also a shorter version (the 
IQCODE-short form) of 16 questions. Of the three reviews99,120,261 which featured the 
IQCODE, only one 120 reported studies using the short and long versions, and this 
review only reported pooled study level data across studies in populations including 
clinic, hospital, community, primary care and ‘others’. The other two reviews99,261 both 
reported data for the long (26 questions) IQCODE. 
One review 261 reported data from a single cross-sectional study using the long 
IQCODE compared to clinical diagnosis in order to identify dementia within a primary 
care setting. The study assessed 230 people recruited from general practice in Hawaii 
with a dementia prevalence of 7%. The majority of respondents were older women 
with limited higher education. Within this study, IQCODE accuracy was assessed at 
various thresholds, with a balance made between sensitivity and specificity. At an 
IQCODE threshold of 3.2 sensitivity was 1.00, and specificity was 0.76. At the 3.7 
threshold, IQCODE sensitivity was 0.75 and specificity was 0.98.  
One review99 reported pooled study data from 5 studies with a total of 1108 
participants. The review authors reported that these studies were conducted in 
“primary care relevant populations” but no further detail was given on this, nor were 
individual study level data reported to allow further scrutiny. The reference standard 
used was DSM criteria and the NINCDS-ADRDA. As the latter measure is specifically 
focused towards identifying Alzheimer’s disease, this suggests that at least one of the 
aggregated populations did not reflect primary care. The review reported IQCODE 
ranges of sensitivity = 0.75–0.88 (95% CI 0.41–1.00) and specificity = 0.65–0.91 (95% 
CI 0.59–1.00),. With the cut points not reported and an administration time of ≤20 
minutes given. Again, this indicates a lack of relevance for a primary care population. 
The third review120 also reported pooled study data for 7 study cohorts using the short 
IQCODE and for 17 studies using the long IQCODE. Within these studies, only one in 
each represented a primary care population, and as only aggregated data were 
reported these results are of limited relevance and applicability to our overview. For 
the short IQCODE compared against a large number of reference standards consisting 
of DSM, ICD, NINCDS-ADRDA, CAMDEX, GMS-AGECAT, CERAD, CDR, sensitivity 
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was 0.89 (95% CI 0.85-0.92) and specificity was 0.82 (95% CI 0.63-0.93). The 
thresholds used were also not reported, and again this contributes to the limited 
usefulness of these results.  
As with the Mini-Cog accuracy reported above, It is not possible to draw meaningful 
conclusions from the results presented within these two reviews reporting pooled study 
data without knowing individual study details such as test thresholds, population size 
and setting, individual reference standards used and other demographic details such 
as age, gender and education levels. These data are not presented within the review 
and, as with the Mini-Cog, cannot be extracted from the primary study as only pooled 
primary data were reported within the review.  
4.5.3. Direct comparisons between brief cognitive assessments within the 
overview 
Within this overview, only one review125 reported findings from a study142 directly 
comparing the diagnostic performance of GPCOG, MMSE (at a threshold of <25) and 
AMT (at a threshold of <8) within the same community sample (N=283). Participants 
were aged over 50, with a mean age of 80 years old. Dementia prevalence was 29%, 
and the setting was reported as general practice and a combined reference standard 
was used consisting of CAMDEX and DSM-IV criteria. The type of GPCOG measure 
was not reported in the review, but on checking the original study the authors stated 
that they used GPCOG two stage. 
4.5.4. The importance of direct comparisons 
As study design is such an important factor in determining the sensitivity and specificity 
of brief assessments, comparing these measures across different studies is of limited 
diagnostic value and may well provide misleading interpretations. The limited 
diagnostic accuracy evidence from direct comparisons of brief cognitive assessments 
was a clear deficit in seeking to understand which tool may be best suited for general 
practice as part of a clinical evaluation for possible dementia. 
The next logical phase for investigation was to carry out a systematic review of 
evidence for direct comparisons of brief cognitive assessments, using the two most 
frequently-assessed and reasonably comparable tools identified within this overview 
– the MMSE and GPCOG. This systematic review of direct comparisons would allow 
the possibility to account for variation not due to differences in study design, and to 
explore systematically which of these tools performed better within a general practice 
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population. The systematic review and discussion of findings are reported in detail in 
the following chapter. 
4.5.5. Analytical and clinical performance measures 
As expected, there was no analytical performance evidence presented within the 
thirteen systematic reviews included within the overview. As this thesis focuses 
explicitly on the diagnostic accuracy of brief cognitive assessments, It would be 
expected that clinical performance measures should feature strongly throughout the 
evidence from the overview. Diagnostic accuracy was measured and reported across 
all included systematic reviews, as this was part of the inclusion criteria in this 
overview. Other measures were less clearly present across the included evidence, 
and the patterns of how they feature within the overview are detailed in Table 12. 
Table 12 Overview-identified evidence from systematic reviews of factors beyond 
diagnostic test accuracy in indirect comparisons of GPCOG and MMSE 
 Systematic reviews Brodaty 2006 Mitchell 2010a Tsoi 2015 
Index tests GPCOG MMSE GPCOG  MMSE GPCOG  MMSE 
C
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a
l 
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rm
a
n
c
e
 
Inter-rater reliability X ?     
Test-Retest reliability X X     
C
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n
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a
l 
e
ff
e
c
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v
e
n
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s
s
 
Face validity X X     
Internal consistency X x     
Education Bias X X     
Language/ Culture 
Bias 
? X     
B
ro
a
d
e
r 
im
p
a
c
t 
Time taken (mins) 4.5 5-10 4.5 9-15 ≤10 6-10 
Ease of admin   X X   
Practicability for 
general practice 
  X X   
Clinician preference   X X   
Acceptable to 
patients 
  X X   
 x , Reported/measured; blank, not reported/ measured; ? unclear  
All 13 included systematic reviews reported diagnostic test accuracy measures of 
sensitivity and specificity and combined accuracy scores. Two systematic 
reviews222,236 also reported positive and negative predictive value and 
misclassification rates. As shown in Table 12, one review236 reported interrater and 
test-retest reliability data on GPCOG and MMSE, although there were insufficient data 
on the interrater reliability of MMSE as reported in the systematic review (i.e. it was 
noted, but no numerical data were presented). 
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All three systematic reviews that indirectly compared the performance of MMSE and 
GPCOG120,141,236 reported assessments of test administration time (i.e. the length of 
time of takes to carry out a test) as shown in Table 14. None of these reviews reported 
how these timings were reached, such as whether they were measured from the point 
the test administrator began to explain the testing process to the point the test was 
complete, results explained and patient de-briefed. Administration time for GPCOG 
was consistent across two reviews141,236 at 4.5 minutes, and in one review120 was 
reported as taking less than 10 minutes. MMSE administration time was reported as 
a range in all three systematic reviews and was less consistent, with one 
review236reporting an administration time range between 5-10 minutes, one review120 
reporting a range of 6-10 minutes and one review141 reporting a range of 9-15 minutes. 
All included reviews made some statement within their discussion section based upon 
administration time. 
One systematic review141 reported assessments on ease of administration, 
practicability for general practice, clinician preference and acceptability to patients 
(potentially assessed by GP report, although unclear) for both the MMSE and GPCOG. 
Neither of the other systematic reviews reported on these or other broader impact 
measures. 
Implications for research 
The purpose of an overview must be crystal clear. The paradox is that overviews 
intuitively seem like a good idea. The practical experience developed here is that one 
needs the findings from all included reviews to line up in order for the overview to 
usefully function; however, if all the evidence agrees in one direction, then why is an 
overview needed? Bearing this fundamental point in mind, anyone contemplating an 
overview must be able to clearly answer these two questions: in what circumstances 
would an overview a) work and b) be useful? 
Quality issues in the conduct of primary studies and systematic reviews have already 
been addressed within this chapter and the wider thesis, but this was another stark 
finding within the overview. Poorly-conducted studies were ill-suited to answer the 
questions they claimed to address, and similarly poorly-conducted systematic reviews 
amplified this problem. Related to this issue, it was found that weak systematic review 
data did not fairly reflect the primary research that does exist.  
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Recent growth in the popularity of overviews272, has not yet impelled clear guidance 
on conducting overviews of diagnostic test accuracy - although this is slowly being 
addressed by researchers within the field of overview methods development189,273-275.  
Finally, there are currently no quality assessment tools for overviews of diagnostic test 
accuracy. The recently-developed PRISMA-DTA reporting guidelines77 will only help 
to improve assessment of reporting quality, and consequently  may also improve 
conduct and quality assessment in evidence syntheses of diagnostic test accuracy 
data.  
4.6. Summary of suggested improvements  
Whilst many methodological challenges have been addressed within this chapter, two 
prominent challenges remain in the conduct of overviews – broadly, and specifically in 
relation to overviews of diagnostic accuracy – and in methods used for direct 
comparisons of test data. 
Overviews are a relatively new methodological approach and consequently a number 
of aspects of overview methodology remain uncertain.  It is the responsibility of a 
research team to decide on their approach before conducting an overview; central to 
this is determining what type of overview is to be conducted. Clear decisions relating 
to the research questions and objectives to be addressed by the overview are a 
fundamental first step during the initial planning stages for an overview, and should be 
developed with the involvement of key stakeholders. Following best practice, these 
aspects should be covered within a published overview protocol as a mechanism for 
ensuring transparency and reducing opportunities for introduction of bias in the 
conduct of the overview189.  
Despite a need for improved guidance for the conduct of overviews189, there are a 
number of resources available which support the conduct of overviews188,189,191,276, 
and updates to the relevant chapter of the Cochrane Handbook are currently in 
production191. Further guidance on the less common types of overview (such as those 
addressing reviews of diagnostic tests accuracy and prognosis) and more challenging 
aspects of overview production, such as methods for narratively synthesising findings, 
dealing with missing data, poor reporting, and dealing with complexity versus 
granularity 277 would be a great benefit to those tackling overviews. 
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Small numbers of carefully designed comparative studies offer the opportunity to 
resolve questions about whether one test is better than another. Such questions can 
remain unclear even after many primary accuracy studies focussing on individual tests 
have been conducted and reviewed. 
Authors of comparative accuracy studies need to carefully choose and justify the 
comparisons they make. Comparisons of convenience which have little clinical 
importance may simply compound difficulties making sense of traditional single arm 
accuracy studies which are often profuse yet may have limited clinical application. 
Comparative accuracy studies need careful interpretation. Sensitivities and 
specificities should not be interpreted in isolation; ROC curves provide additional 
important information. They may also increase the number of studies which can 
contribute to a review as the ROC curve is derived by measuring accuracy across a 
range of thresholds. 
Systematic reviews of ROC curves are still fairly uncommon. This may indicate a need 
for methodological development to make it easier to review and meta-analyse 
accuracy studies which produce ROC curves, or it may be a lack of available ROC 
data – although this is unlikely, given the experience in this review where ROC curves 
were produced in all five included studies. 
Quality appraisal of comparative accuracy studies remains in its infancy, yet there are 
some specific aspects of quality and reporting (such as assessing more than one index 
test and unequal reporting of key index information) as well as issues of applicability 
and bias discussed above, which would make tailored tools very useful.  
There is an opportunity for comparative accuracy studies to increase their explanatory 
value by providing information about basic functions of testing such as discordance 
(i.e. why do certain people test positive on one test and not the other when disease is 
present?), test administration time, acceptability of the test to the patient and the 
clinician, and the interaction between disease severity and test performance. Whilst 
some of these aspects would require additional targeted research, other factors such 
as administration time may require little additional data collection and simply call on 
further consideration during the analytical phase. 
The current guidance on the reporting of diagnostic test accuracy reviews from the 
PRISMA-DTA Working Group77 points to progress in diagnostic test accuracy 
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methodology development. This progress needs reinforcement by educators and 
regulators to continue this trajectory, and further guidelines are needed on the conduct 
and reporting of diagnostic accuracy information at the study level as well as in the 
conduct of systematic reviews and overviews.  
By anchoring this discussion of methodological challenges in real examples 
encountered during this PhD research, it is hoped that this has provided clear 
illustrations of the complex issues inherent in this area and offered practical solutions 
to these problems. 
4.6.1. Implications for clinical practice 
The lack of clear evidence on the most suitable brief cognitive assessments for use in  
general practice  is a clear barrier to dementia diagnosis in primary care not addressed 
within recent clinical guidelines 173or by current campaigns to improve diagnosis rates.  
To return to the points made at the start of the discussion, there are three main 
difficulties for those in clinical practice looking for evidence-based guidance on the 
most accurate cognitive assessment tools for use in general practice. These are: a 
lack of suitable primary data on which cognitive tests are most appropriate for use in 
general practice; poor quality primary evidence which adds little to current 
understanding; and poor quality secondary analysis of existing data which adds to the 
general confusion between clinical guidelines and official policy.  
This overview has demonstrated that within current evidence there is not one brief 
cognitive assessment that clearly emerges as superior to others in terms of test 
accuracy. The breadth of diagnostic test accuracy evidence is mixed, and there is a 
great deal of variation in reported levels of sensitivity and specificity. The selected 
threshold or cut-point significantly influences the dynamic between these interrelated 
scores but again, within this overview was found to be under-reported and under-
recognised within review data – and in some cases the threshold was not prespecified 
278 allowing the ‘best threshold’ to be chosen post hoc. Population prevalence also has 
a substantial influence and in the majority of studies included within these reviews the 
prevalence was either not reported or far higher than would be expected within a 
primary care population; therefore comparisons for general practice should only be 
drawn with extreme caution and close reference to prevalence data. A useful 
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conclusion that can be drawn from this overview is that some tools are not suitable for 
use in general practice.  
The MMSE has been popular for many years and is familiar in a clinical setting. 
Evidence identified within this overview for its diagnostic accuracy in assessing 
cognitive impairment in general practice is highly mixed; but it is not suitable for use in 
this population simply due to its lengthy administration time of 7.3±5 minutes144, longer 
than practicable for the standard mean general practice appointment length of 10.7 
minutes (6.7 standard deviation)132.  
Equally, the IQCODE is reported to have an estimated administration time of 10-15 
minutes248 which renders it unsuitable for clinical use in general practice. 
Some of the tools identified within this overview are not sufficiently assessed within a 
UK general practice-relevant population to be recommended for use in practice. These 
include the 3 word recall, AMTS, Eurotest, Fototest, BIMCT, John Brown Test, Verbal 
Fluency, Orientation and PCL.  
4.7. Overview review team acknowledgements 
This overview research was led by the PhD candidate, Harriet Hunt. Dr Elzbieta 
Kuzma was on the research team in the role of second reviewer. Dr Kuzma contributed 
to discussions on methodological direction, and assisted with data extraction, quality 
assessment and analysis. Professor Christopher J Hyde contributed to methodological 
discussions and provided oversight of the project. Dr Obioha Ukoumunne gave 
statistical advice to the lead reviewer (HH) which was used to inform the analysis.     
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Table 13 Summary of evidence and main findings at the level of systematic review 
Revie
w ref. 
Reference standard Index 
test(s) 
T’hold
s 
Setting Main findings Other outcomes 
considered 
beyond test 
accuracy 
204 NINCDS-ADRDA or DSM or ICD 
criteria for Alzheimer’s disease 
dementia; McKeith criteria for Lewy 
body dementia; Lund criteria for 
frontotemporal dementia; and 
NINDS-AIREN criteria for vascular 
dementia 
MMSE ≤ 21,  
≤ 26,  
≤ 28,  
≤ 29 
Participants 
were 
recruited 
from: i) 
secondary 
care - 
outpatient 
clinic (n = 3); 
ii) secondary 
care - 
memory 
clinics (n = 6) 
and iii) 
populational 
sources (n = 
2) 
No evidence supporting a substantial role of MMSE as a 
stand-alone single-administration test in the identification 
of MCI patients who could develop dementia.  
Clinicians could prefer to request additional and extensive 
tests to be sure about the management of these patients. 
An important aspect to assess in future updates is if 
conversion to dementia from MCI stages could be 
predicted better by MMSE changes over time instead of 
single measurements. It is also important to assess if a set 
of tests, rather than an isolated one, may be more 
successful in predicting conversion from MCI to dementia. 
- 
236 Clinical diagnosis/clinical diagnosis 
combined with  e.g. DSM-IV 
6-CIT 
7MS 
Bowles-
Langley 
Technology 
Ashford 
Memory Test 
MAT 
RUDAS 
STMS 
Time and 
Change Test 
SMT 
CAMCog 
CDT 
GPCOG 
Mini-Cog 
MIS 
MMSE 
SSSI 
Variou
s 
Validated in 
“two distinct 
samples” or 
Inpatient or 
Outpatient 
settings 
All others 
validated in 
general 
practice, 
community or 
population 
settings 
The authors recommend that GPs consider using the 
GPCOG, Mini-Cog or MIS when screening for cognitive 
impairment or for case detection. Quick and easy to 
administer whilst having psychometric properties similar to 
the MMSE. 
Time taken 
Face validity 
Internal consistency 
Education Bias 
Language/Culture 
Bias 
Interrater Reliability 
Test-Retest 
Reliability 
Ease of 
administration 
Practicability for 
general practice 
See separate non-
DTA data table 
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Short 
Informant 
Questionnair
e on 
Cognitive 
Decline in 
the Elderly 
220 diagnosis of dementia according to 
criteria 
DSM - IV 
 
Eurotest - Mix of 
secondary 
(specialist) 
care and 
Fase III 
primary care 
Review authors conclude that the Eurotest has adequate 
diagnostic validity to be used as an instrument to screen 
for and rule out dementia; negative results are more 
useful, allowing the presence of dementia to be ruled out 
with greater certainty. 
- 
221 Clinical diagnosis according to 
DSM-IV-TR 
Phototest - Primary care For dementia, Sn was 0.85 (95% CI, 0.82-0.88) and Sp 
0.87 (95% CI, 0.85-0.99); Authors’ conclusions: the 
Phototest offers adequate diagnostic accuracy for cogni-
tive impairment, and particularly for dementia, that is 
similar or superior to other instruments widely used in our 
milieu. Additionally, it is simple, brief, uninfluenced by 
educational variables and can even be used in individuals 
who are illiterate. These advantages make it attractive for 
use in populations with low educational level and/or in 
time-limited settings such as primary care. 
- 
 
205 
Clinical diagnosis defined by DSM, 
ICD or CRS. 
MMSE 10 cut 
points 
17-26 
incl. 
Primary care The authors could not estimate summary DTA in primary 
care due to insufficient data. “The MMSE contributes to a 
diagnosis of dementia in low prevalence settings, but 
should not be used in isolation to confirm or exclude 
disease. We recommend that future work evaluates the 
diagnostic accuracy of tests in the context of the 
diagnostic pathway experienced by the patient and that 
investigators report how undergoing the MMSE changes 
patient-relevant outcomes”, e.g. time to diagnosis, 
initiation of treatment/care package, additional testing and 
place of care. 
- 
261 
 
Clinical diagnosis defined by DSM 
or ICD  
IQCODE 3.6; 
3.5; 
3.4;  
3.3 
General 
practice/prim
ary care 
IQCODE accuracy assessed at various test thresholds, 
with a “trade-off” between sensitivity and specificity across 
these cutpoints. At an IQCODE threshold of 3.2 sensitivity: 
100%, specificity: 76%; for IQCODE 3.7 sensitivity: 75%, 
specificity: 98%. 
Author’s conclusions: 
“It is not possible to give definitive guidance on the test 
accuracy of IQCODE for the diagnosis of dementia in a 
primary care setting 
- 
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based on the single study identified. We are surprised by 
the lack of research using the IQCODE in primary care as 
this is, arguably, the most appropriate setting for targeted 
case finding of those with undiagnosed dementia in order 
to maximise opportunities to intervene and provide 
support for the individual and their carers”. 
222 Clinical diagnosis using DSM III, 
IIIR or IV 
MMSE 21v22, 
22v23, 
23v24, 
24v25, 
25v26, 
26v27 
28v29 
Primary care In those studies conducted purely in primary care the Se, 
Sp, PPV and NPV were 78.4%, 87.8%. 53.6% and 95.7%, 
respectively. MMSE offers modest accuracy with best 
value for ruling-out a diagnosis of dementia in community 
and primary care. For all other used it should be combined 
with or replaced by other methods. 
- 
141 Clinical diagnosis using DSM/IPA-
WHO criteria/GMS-AGECAT 4 or 
5+ CAMDEX 
MMSE, 
GPCOG, 
AMTS,  
Mini-Cog 
PCL,  
SPMSQ,  
MSQ,  
BIMT 
NR Primary care The authors conclude that for a primary care setting 
(where prevalence is usually modest) the best individual 
tools were the AMTS/MSQ (combined, the MSQ and the 
PCL. The AMTS was preferable to the MMSE for case-
finding, whereas the SMPSQ was inferior.  For screening, 
the MMSE was optimal and…the best tool for primary care 
physicians who want a rule in and rule out tool, if length is 
not a major consideration. 
“at least 30 well-studied alternatives to the MMSE exist 
and several seem to be briefer but no less accurate than 
the MMSE…In primary care…these methods would help 
detect on 13 of 20 possible cases but rule out 18 of 20 
healthy individuals (overall correct in 17 out of 20) 
suggesting these brief batteries may be ideally suited to a 
first step screen followed by a more comprehensive in 
those who screen positive” (p. 779). 
Comparative 
accuracy 
conducted with 5 
instruments 
(AMTS/MSQ, MSQ, 
WINDSET, PCL 
and AMTS).  
Time taken given in 
all cases. 
See separate non-
DTA data tables 
231 MiniCog and DSM criteria/DSM 
criteria and GMS-AGECAT/DSM 
criteria and NINCDS-ADRDA/DSM 
CDT,  
3 word 
recall, John 
Brown test,  
Verbal 
fluency 
(animals), 
orientation  
NR Primary care Across 9 analyses involving 4,875 individuals, the 
prevalence of dementia was 10.6%. The pooled sensitivity 
was 68.5%, “corrected to 69.5% (95% CI = 62.1% - 
76.4%)” and the pooled specificity was 85.9%, “corrected 
to 82.5% (95% CI 74.1%-89.5%) PPV 36.5% and NPV 
95.8%” (p.792).  
8 methods were compared directly to the MMSE all 
performed worse. “A fraction correct pooled relative risk 
was reported of 0.911 (95% CI = 0.865-0.959) 𝑥2 = 12.7 
(df=1) p.0.0004. Reported for both Sensitivity (pooled 
relative risk = 1.107, 95% CI = 0.902-1.360) 𝑥2 = 0.958 
(df=1) p=0.33 and Specificity (pooled relative risk = 0.872, 
95% CI=0.807-0.942, 𝑥2 = 12.072421 (𝑑𝑓 = 1)𝑝 =
0.0005). " The Clock Drawing Test was “subject to multiple 
Comparative 
accuracy was 
conducted with 5 
instruments. 
Time taken was 
given in all 
instances. 
See separate non-
DTA data tables 
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independent testing in primary care” but demonstrated no 
superiority to MMSE (p.793). 
HH N.B. I could not see reported MMSE scores within 
the review publication, so the above conclusions are 
reported direct from review authors. 
148 DSM-IV criteria RUDAS < 23 For clinicians 
to use in 
culturally and 
linguistically 
diverse 
populations 
“The RUDAS was assessed in 1236 participants and was 
found to have a pooled sensitivity of 77.2% (95% confi-
dence interval [CI] 67.4–84.5) and a pooled specificity of 
85.9% (95% CI 74.8–92.6) yielding a positive likelihood 
ratio of 5.5 (95% CI 2.9–10.7) and a negative likelihood 
ratio of 0.27 (95% CI 0.17– 0.40) 
A pooled estimate of the correlation between the RUDAS 
and the Mini-Mental State Examination (MMSE) was 0.77 
(95% CI 0.72– 0.81) and significant heterogeneity (I2 = 
63.1%). Results of the RUDAS were less affected by 
language and education level than the MMSE.” (p.E169) 
 
Comparative 
accuracy assessed 
against MMSE as 
reported in box to 
left. 
Education level, 
effect of language, 
immigrant status, 
clinician 
preference, test-
retest reliability and 
interrater reliability 
assessed in some 
studies.  See 
separate non-DTA 
data table 
 
125 
CAMDEX, DSM-IV GPCOG 
AMT 
MMSE 
 
<8 
<25 
General 
practice 
Review authors concluded that the GPCOG outperformed 
the MMSE in a general practice sample. “However, the 
composition of the test was changed post hoc, and the 
available data are incomplete” [??] 
“…the limited cognitive domains that all these tests assess 
may make them prone to miss non-Alzheimer’s 
dementias” (p.475) 
Other assessment 
domains (language, 
attention, memory, 
visuospatial skills, 
executive function,) 
and monitoring 
disease 
progression 
discussed.  
 
99 
DSM criteria and NINCDS-
ADRDA 
MMSE,  
3 word 
memory test, 
6-item 
screener, 
7MS,  
AMT, 
Benton’s 
Orientation 
Test,  
CDT, 
Cognitive 
Assessment 
Variou
s 
Primary care 
and 
community 
(primary care-
relevant 
populations) 
Review authors reported that “only 12 brief instruments 
have been studied more than once in well-designed 
diagnostic accuracy studies that evaluated their ability to 
detect dementia in primary care–relevant populations: the 
MMSE (k = 25; n = 12 348), the Clock Drawing Test (CDT) 
(k = 7; n = 2509), verbal or category fluency tests (k = 6; n 
= 2083), the short or full Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) (k = 5; n = 
1108), the Memory Impairment Screen (MIS) (MIS: k = 4; 
n = 1671; MIS by telephone: k = 1; n = 300), Mini-Cog (k = 
4; n = 1570), the Abbreviated Mental Test (AMT) (k = 4; n 
= 824), the Short Portable Mental Status Questionnaire 
Other assessments 
of benefits and 
harms, caregiver 
interventions, non-
pharma I’ventions 
aimed at the 
patients.  See 
separate non-DTA 
data table. 
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Screening 
Test,  
Free and 
Cued 
Selective 
Reminding 
Test, 
Functional 
Activities 
Q’airre, 
GPCOG, 
Hopkins 
Verbal 
Learning 
Test, 
Immediate 
Recall, 
IQCODE 
(short), 
IQCODE full, 
Katz ADL, 
Kendrick 
Cognitive 
Tests, 
Labyrinth 
Test,  
Memory 
Function 2, 
MIS,  
Memory 
Impairment 
Screen-
Telephone, 
MSQ, 
MiniCog, 
MMSE, 
Minimum 
Data Set 
Cognition 
Scale, 
MMblind, 
Oral Traits, 
Orientation 
(SPMSQ) (k = 4; n = 1057), the Mental Status 
Questionnaire (k = 
2; n = 522), the Free and Cued Selective Reminding Test 
(FCSRT) (k = 2; n = 734), the 7-Minute Screen (7MS) (k 
=2; n =553), and the Telephone Interview for Cognitive 
Status (TICS) (k =2; n =677)” (p. 604).  
…”The best-studied instrument was the MMSE. Pooled 
estimates across 14 studies (n _ 10 185) resulted in 
sensitivity of 88.3% (95% CI, 81.3% to 92.9%) and 
specificity of 86.2% (CI, 81.8% to 89.7%) for the most 
commonly reported cut points of 23/24 or 24/25. The CDT, 
Mini-Cog, MIS, SPMSQ, AMT, FCSRT, 7MS, TICS, and 
IQCODE can also have acceptable test performance; 
however, less evidence supported the use of each of 
these instruments and had limited reproducibility in 
primary care– relevant populations and unknown optimum 
cut points for each instrument. The CDT had a wider 
range of sensitivity and specificity (67% to 97.9% and 69% 
to 94.2%, respectively), and the optimum cut point is 
unclear from the body of literature we examined. The Mini-
Cog probably has better sensitivity than the CDT alone 
(76% to 100%) but with a possible tradeoff of lower 
specificity (54% to 85.2%). Although the MIS can have 
relatively good test performance in screening for dementia 
(sensitivity, 43% to 86%; specificity, 93% to 97%), the 
sensitivities in the 2 good-quality studies (n _ 948) were 
low (about 40%). Likewise, the AMT can have relatively 
good test performance in screening for dementia 
(sensitivity, 42% to 100%; specificity, 83% to 95.4%), but 
1 fair-quality study (n _ 289) had low sensitivity (42%) and 
no studies were done in the United States. The SPMSQ, 
FCSRT, 7MS, and TICS also have reasonable test 
performance, but this is based on a limited number of 
studies. The verbal fluency tests had worse performance 
than other instruments regardless of cut point. The 
IQCODE, a self-administered informant-based screening 
tool, had a sensitivity of 75% to 87.6% and a specificity of 
65% to 91.1%. The 6-Item Screener, Visual Association 
Test, General Practitioner Assessment of Cognition, 
ADL/IADL, Benton Orientation Test, Delayed Recall Test, 
and Short Concord Informant Dementia Scale all had 
greater than 80% sensitivity and specificity to detect 
dementia in a single study, but their test performance has 
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Concentratio
n Memory,  
Rey figure 
copy, 
 Self-
Administered 
Gero-
cognitive 
Examination, 
SBT,  
Short 
Concord 
Informant 
Dementia 
Scale,  
SPMSQ, 
Storandt 
Battery, 
Subjective 
Menory 
Impairment, 
Sweet 16, 
TICS, 
Trailmaking 
A and B,  
Verbal 
fluency,  
Visual 
Association 
(VAT),  
Word List 
Learning  
not been reproduced in other primary care–relevant 
populations” (p. 605). 
Review authors’ conclusions: 
“…only a handful of instruments have been studied in 
more than 1 study applicable to primary care. Although the 
MMSE is the best-studied instrument, it has the longest 
administration time and is not available for public use 
without cost. Other publicly available instruments that 
have been studied in primary care–relevant populations 
can have adequate test performance, including the CDT, 
Mini-Cog, MIS, AMT, SPMSQ, FCSRT, 7MS, and 
IQCODE. However, the AMT, SPMSQ, FCSRT, and 7MS 
have limited evidence, and each has been studied only 
once in English. Although other instruments seem to have 
adequate test performance (such as the 6-Item Screener, 
Visual Association Test, General Practitioner Assessment 
of Cognition, ADL/IADL, Benton Orientation Test, Delayed 
Recall Test, and Short Concord Informant Dementia 
Scale), each of them has been studied only once in 
primary care–relevant populations.”  
120 DSM, ICD, NINCDS-ADRDA, 
CAMDEX, GMS-AGECAT, CERAD, 
CDR (not reported individually) 
CDT,  
MiniCog,  
MIS, Verbal 
fluency test, 
AMT,  
GPCOG, 
MMSE,  
MoCA 
(query – not 
under 10 
NR Primary care From the authors – accuracy of MMSE: 
With different cut-off threshold values, we found 
considerable variation in the sensitivity and specificity 
estimates reported by individual studies. The sensitivities 
ranged from0.25 to 1.00, and the specificities ranged from 
0.54 to 1.00. The heterogeneity among studies was large, 
with I2 statistics for sensitivity and specificity of 92% and 
94%, respectively. The diagnostic accuracy is summarized 
by meta-analysis (Table 3). The combined data in the 
bivariate random-effects model gave a summary point with 
0.81 sensitivity (95% CI, 0.78-0.84) and 0.89 specificity 
Administration time, 
number of 
questions, 
components of 
screening tests 
See separate non-
DTA data table 
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mins admin 
time) 
(95% CI, 0.87-0.91). The HSROC curve was plotted with a 
diagnostic odds ratio of 35.4, and the AUC was 
92%(95%CI,90%-94%).  
Pooled accuracy of tests: 
MMSE reported pooled sensitivity of 0.81 (0.78-0.84) and 
pooled specificity of 0.89 (0.87-0.91), positive pooled LR 
of 7.45 (6.25-8.88) and negative pooled LR of 0.21 (0.18-
0.25).  
CDT (Shulman) reported pooled sensitivity of 0.83 (0.75-
0.89) and pooled specificity of 0.84 (0.69-0.92), pooled 
positive LR 5.02 (2.61-9.64) and pooled negative LR 0.20 
(0.14-0.29). CDT (Sunderland) reported pooled sensitivity 
0.76 (0.69-0.83) and pooled specificity of 0.85 (0.76-0.91), 
pooled positive LR 5.09 (3.18-8.13) and pooled negative 
LR 0.28 (0.20-0.38). MiniCog reported pooled sensitivity 
0.91 (0.80-0.96) and pooled specificity 0.86 (0.74-0.93), 
pooled +ve LR 6.56 (3.25-13.24) and poole –ve LR 0.10 
(0.04-0.25).  
MIS reported sensitivity 0.797 (0.68-0.86) and specificity 
0.91 (0.84-0.96), VF test sensitivity 0.80 (0.73-0.86) and 
specificity 0.82 (0.73-0.88), AMT sensitivity 0.88 (0.82-
0.92) and specificity 0.85 (0.81-0.89), GPCOG sensitivity 
0.92 (0.81-0.97) and specificity 0.87 (0.83-0.90; MoCA 
sensitivity 0.91 (0.84-0.95) and specificity 0.81 (0.71-
0.88). 
“All tests presented with AUCs of at least 85%, and most 
of the tests had comparable performance to that of the 
MMSE. The Mini-Cog test and the ACE-R were the best 
alternative tests. Among the studies with the Mini-Cog 
test,10,34-41 the pooled sensitivity was 0.91 (95% CI, 
0.80-0.96), and the pooled specificity was 0.86 (95% 
CI,0.74-0.93)” (p. E6). 
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Appendices 
Appendix 1 Overview protocol published on PROSPERO 02/06/2015 
Published on PROSPERO 02 June 2015 ref. CRD42015022078 
A review of existing systematic reviews summarising the accuracy 
of brief cognitive assessments for identifying dementia, particularly 
for use in primary care [protocol] 
Introduction 
Improved dementia diagnosis is a priority of the UK Government's National Dementia 
Challenge, as well as a key focus of the World Health Organisation and the G8. The 
Alzheimer’s Society’s recent report Dementia 2014: Opportunity for change (Alzheimer’s 
Society, 2014) highlights the urgent need to create a diagnostic pathway which takes people 
fluently from first presentation to their GP through to memory clinics and long-term support 
mechanisms following a diagnosis. It is therefore crucial to address delays in the early 
stages in order to increase access to care and support for the individual and the people 
around them. 
GPs are normally the first point of contact for patients and carers concerned about possible 
dementia, though general practice probably under-diagnoses the condition (Iliffe et al., 2009; 
Connolly et al., 2011). There are a number of possible reasons for this under-diagnosis. 
Many GPs report a lack of certainty in using assessment tools alongside concerns around 
the consequences of misdiagnosing dementia (Aminzadeh et al., 2012, Bradford et al., 2009; 
Cahill et al., 2006; Iliffe et al., 2003; Koch & Iliffe, 2010;  Sarkar et al., 2012;). It is unclear 
which brief cognitive assessments for dementia would be best for use in primary care, and 
how accurate they are. In the UK, there is a lack of agreement between leading 
organisations on which tests should be used for dementia identification in primary care. For 
example, the National Institute for Health and Care Excellence (NICE) recommend using the 
Mini Mental State Examination (MMSE), 6-Item Cognitive Impairment Test (6-CIT), General 
practitioner assessment of cognitive function (GPCOG) or the 7-Minute Screen,  and the 
Alzheimer’s Society who recommend using the Abbreviated mental test score (AMTS), 
GPCOG and the Mini-cog (Ballard, 2015; NICE Pathways, 2012;). The accuracy of many of 
the commonly-used brief cognitive assessments for dementia is imperfect.  
In building the evidence base, a number of Cochrane Reviews have explored the individual 
value of tests for dementia to general practitioners (Harrison et al., 2014), to secondary care 
units such as memory clinics (Quinn et al., 2013a), and in community screening (Fage et al., 
2013; Harrison et al., 2015) - or across a number of these settings (Aravalo-Rodriguez et al., 
2013; Creavin et al., 2014; Davis et al., 2013; Hendry et al., 2014).  
These Cochrane reviews and other systematic reviews have explored the diagnostic test 
accuracy of tests in isolation, and across a broad range of populations and settings.  The 
diversity of systematic review evidence now available would benefit from being summarised 
within an overview review, which is the focus of this protocol.  
This overview of reviews is positioned within a broader programme of research addressing 
the question “how can we optimize cognitive assessment in primary care to support a more 
effective route to dementia diagnosis?”, and aims to summarise the existing systematic 
review evidence for the diagnostic test accuracy of brief cognitive assessments (in addition 
to informant ratings where used), focussing particularly on their use in a primary care setting. 
Review question 
What is the existing systematic review evidence for the accuracy of brief cognitive 
assessments, plus informant ratings where used, for identifying dementia, particularly for use 
in primary care? 
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Methods 
An overview of reviews protocol with clear description of inclusion and exclusion criteria for 
reviews and a detailed search strategy will be published on the International Prospective 
Register of Systematic Reviews (PROSPERO) in advance of the overview review being 
conducted. Data collected will be from included systematic reviews, and limitations of the 
included reviews will be assessed alongside quality of evidence based – where data is 
available – on assessments reported in the included systematic reviews.  
Searches 
We will search the following databases for eligible systematic reviews:  
- Cochrane Database of Systematic Reviews (CDSR)- Medline (Ovid),EMBASE, PsychINFO 
- EMANATE (Dementia Meta-Evidence) database, created by University of Exeter Medical 
School researchers 
Reviewers will contact key authors and conduct hand searching of reference lists from 
included and review articles. 
Details of the search strategy are shown in the Appendix. 
Types of study to be included 
We will include peer-reviewed systematic reviews and meta-analyses (including Cochrane 
Reviews) of studies investigating the diagnostic test accuracy of any brief cognitive 
assessment for dementia within primary care or general practice as assessed by a 
healthcare professional. We define a brief cognitive assessment as a discrete tool designed 
to be used to conduct a quick structured evaluation of the patient directly (e.g. MiniCog, 
MMSE) or as an informant assessment of the patient (e.g. short IQCODE, GPCOG). 
Condition being studied 
All-cause dementia and key dementia subtypes including Alzheimer’s disease, vascular 
dementia, dementia with Lewy bodies, frontotemporal dementia and mixed dementia. 
Participant/population  
Inclusion criteria:  
 systematic reviews and meta-analyses of test accuracy evidence including 
Cochrane Reviews  
 adult (>18 years old) participants assessed for dementia (all-cause dementia 
and key dementia subtypes including Alzheimer’s disease, vascular dementia, 
dementia with Lewy bodies, fronto-temporal dementia and mixed dementia) at 
any stage of progression  
 using brief cognitive assessment tools, plus informant ratings where used,  
 Within primary care as assessed by a healthcare professional. 
 Updated reviews will be included, with the most recent version taking 
precedence. 
 Conference abstracts will be included and we will attempt to contact all 
relevant corresponding authors for full text versions or available test accuracy 
data. If this detail is not available or authors cannot be contacted, this data will 
be retained and reported within the review. 
Brief cognitive assessments will be limited to those that take up to 10 minutes to conduct. 
Our analysis will include the Mini Mental State Examination (MMSE); whilst the timings for 
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this test are contested, it is one of the most commonly used tests and often characterised as 
taking ‘up to’ 10 minutes (Cordell et al., 2013; RCP, 2012; Ballard et al., 2015). Brief 
cognitive assessments plus informant ratings will be included where used. A list of all 
included tests will be presented within the overview review. 
Exclusion criteria:  
 We will exclude systematic reviews of assessment tools that are not explicitly 
brief cognitive assessments (i.e. that take longer than 10 minutes to conduct, 
and are not explicitly focussed on the assessment of cognitive performance).  
 Reviews that do not contain accuracy (sensitivity and specificity) data will be 
excluded. 
 We will also exclude systematic reviews of studies conducted in environments 
other than primary care (e.g. specialist memory clinics), and any systematic 
reviews of evidence for the accuracy of combined brief cognitive assessments 
for dementia in primary care (although evidence will be retained for future 
inquiry).  
 Assessments must be conducted within primary care or general practice and 
conducted by a healthcare professional. 
Data extraction, selection and coding 
All data will be managed using the latest version of EndNote software. The first 15 sources 
will be pilot title and abstract screened by two reviewers (HH & EK) according to the 
inclusion and exclusion criteria. Subsequent discussion will inform the screening notes.  
Title/abstract screening and full text screening will be conducted by the same two reviewers. 
A third reviewer (CH) will resolve any disagreements.  
A bespoke abstraction form will be piloted by two reviewers (HH & EK) using two sources. 
Key data extracted will include characteristics of included systematic reviews (references 
and author details, overall goal of review, date review conducted, date published, participant 
details, included study details  such as authors, year of study, date of publication, country of 
study, outcomes reported, test timings and general review limitations as well as test 
accuracy data. The form will be accompanied by a briefing document explaining how it 
should be used. Data will be abstracted by one reviewer (HH) and spot-checked by a second 
(EK), with a third reviewer (CH) providing moderation as required. 
Risk of bias (quality) assessment 
There is currently no clear guidance of the quality assessment for overview reviews of 
diagnostic test accuracy studies, and evidence of the best quality assessment tools is 
unclear. The general quality of included systematic reviews will be summarised and notes 
made on variability of findings across reviews and any important flaws in individual reviews.  
We will use a checklist approach to assess the quality of systematic reviews based on the 
AMSTAR checklist (Shea et al., 2007), and will critically evaluate the suitability of this tool in 
the current application. Results will be presented narratively in the text, and in an appropriate 
graphic representation of quality assessment.  
Strategy for data synthesis and analysis 
Data will be summarised narratively and using 'Summary of findings' tables. Additional 
analyses may be possible for comparing across included reviews, in which case we will 
consult with a statistical specialist regarding the validity and suitability of further analyses. 
Discussion 
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Within the Discussion section, we will consider whether the reviews included are sufficient to 
address all of the objectives of the overview, and if not, we will highlight the gaps in 
evidence.  
As part of this scrutiny, we will consider whether all relevant participants and outcomes have 
been represented and if not, we will highlight missing evidence.  Finally we will assess the 
relevance of the evidence to the review question, which will lead to an overall judgement of 
the external validity of the Overview. The context of results of the overview within the context 
of current practice will be discussed here. 
References 
Alzheimer’s Society (2014) Dementia 2014: Opportunity for change. Alzheimer’s 
Society, London. www.Alzheimers.org.uk/dementia2014    
Aminzadeh, F., Molnar, F. J., Dalziel, W. B., & Ayotte, D. (2012). A Review of 
Barriers and Enablers to Diagnosis and Management of Persons with Dementia in 
Primary Care. Canadian Geriatrics Journal, 15(3), 85. 
Arevalo-Rodriguez I, Smailagic N, Ciapponi A, Sanchez-Perez E, Giannakou A, 
Roqué i Figuls M, Pedraza OL, Bonfill Cosp X, Cullum S. Mini-Mental State 
Examination (MMSE) for the detection of Alzheimer's disease and other dementias in 
people with mild cognitive impairment (MCI) (Protocol). Cochrane Database of 
Systematic Reviews 2013, Issue 10. Art. No.: CD010783. DOI: 
10.1002/14651858.CD010783. 
Baker, P. R., Costello, J. T., Dobbins, M., & Waters, E. B. (2014). The benefits and 
challenges of conducting an overview of systematic reviews in public health: a focus 
on physical activity. Journal of Public Health, 36(3), 517-521. 
Ballard C, Burns A, Corbett A, Livingston G, Rasmussen J (2015) Helping you to 
assess cognition: A practical toolkit for clinicians. Alzheimer’s Society website: 
http://www.alzheimers.org.uk/site/scripts/download_info.php?downloadID=1045  
Benbow, S. M., Jolley, D., & Greaves, I. C. (2015). Improving diagnosis of dementia 
in primary care. Progress in Neurology and Psychiatry, 19(1), 4-4. 
Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P., & Singh, H. (2009). Missed 
and delayed diagnosis of dementia in primary care: prevalence and contributing 
factors. Alzheimer disease and associated disorders, 23(4), 306. 
Ballard, C., Burns, A., Corbett, A., Livingston, G., Rasmussen, J. (2015) Helping you 
to assess cognition: A practical toolkit for clinicians. The Alzheimer’s Society. 
[Accessed online 05/05/2015 
http://www.alzheimers.org.uk/site/scripts/download_info.php?fileID=2532 ] 
Cahill, S., Clark, M., Walsh, C., O'Connell, H., & Lawlor, B. (2006). Dementia in 
primary care: the first survey of Irish general practitioners. International Journal of 
Geriatric Psychiatry, 21(4), 319-324. 
Connolly, A., Gaehl, E., Martin, H., Morris, J., & Purandare, N. (2011). Underdiagnosis of 
dementia in primary care: variations in the observed prevalence and comparisons to the 
expected prevalence. Aging & mental health, 15(8), 978-984. 
Cordell, C. B., Borson, S., Boustani, M., Chodosh, J., Reuben, D., Verghese, J., ... & 
Medicare Detection of Cognitive Impairment Workgroup. (2013). Alzheimer's Association 
recommendations for operationalizing the detection of cognitive impairment during the 
Medicare Annual Wellness Visit in a primary care setting. Alzheimer's & Dementia, 9(2), 
141-150 
Creavin ST, Noel-Storr AH, Smailagic N, Giannakou A, Ewins E, Wisniewski S, Cullum S. 
Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s dementia and other 
dementias in asymptomatic and previously clinically unevaluated people aged over 65 years 
CHAPTER 4: OVERVIEW  
CHAPTER 4| 115 
in community and primary care populations (Protocol). Cochrane Database of Systematic 
Reviews 2014, Issue 6. Art. No.: CD011145. DOI: 10.1002/14651858.CD011145. 
Davis DHJ, Creavin ST, Yip JLY, Noel-Storr AH, Brayne C, Cullum S. The Montreal 
Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementia 
disorders (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. 
No.: CD010775. DOI: 10.1002/14651858.CD010775. 
Fage BA, Seitz DP, Gill SS, Herrmann N, Smailagic N, Chan CCH, Nikolaou V. Mini-
Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a 
community setting (Protocol). Cochrane Database of Systematic Reviews 2013, 
Issue 11. Art. No.: CD010860. DOI: 10.1002/14651858.CD010860. 
Harrison JK, Fearon P, Noel-Storr AH, McShane R, Stott DJ, Quinn TJ. Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of 
dementia within a general practice (primary care) setting. Cochrane Database of 
Systematic Reviews 2014, Issue 7. Art. No.: CD010771. DOI: 
10.1002/14651858.CD010771.pub2. 
Harrison JK, Fearon P, Noel-Storr AH, McShane R, Stott DJ, Quinn TJ. Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of 
dementia within a secondary care setting. Cochrane Database of Systematic 
Reviews 2015, Issue 3. Art. No.: CD010772. DOI: 
10.1002/14651858.CD010772.pub2. 
Hendry K, Lees RA, McShane R, Noel-Storr AH, Stott DJ, Quinn TJ. AD-8 for 
diagnosis of dementia across a variety of healthcare settings (Protocol). Cochrane 
Database of Systematic Reviews 2014, Issue 5. Art. No.: CD011121. DOI: 
10.1002/14651858.CD011121. 
Iliffe, S., Manthorpe, J., & Eden, A. (2003). Sooner or later? Issues in the early 
diagnosis of dementia in general practice: a qualitative study. Family Practice, 20(4), 
376-381. 
Iliffe, S., Robinson, L., Brayne, C., Goodman, C., Rait, G., Manthorpe, J. and Ashley, 
P. (2009), Primary care and dementia: 1. diagnosis, screening and disclosure. Int. J. 
Geriat. Psychiatry, 24: 895–901. doi: 10.1002/gps.2204 
Koch, T., & Iliffe, S. (2010). Rapid appraisal of barriers to the diagnosis and 
management of patients with dementia in primary care: a systematic review. BMC 
Family Practice, 11(1), 52. 
Larner, A. J. (2015). Speed versus accuracy in cognitive assessment when using 
CSIs. Progress in Neurology and Psychiatry, 19(1), 21-24. 
Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. (2014) 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the 
diagnosis of dementia within community dwelling populations. Cochrane Database of 
Systematic Reviews 2014, Issue 4. Art. No.: CD010079. DOI: 
10.1002/14651858.CD010079.pub2. 
RCP (2012) Individual patient outcome measures recommended for use in older 
people’s mental health. Prepared by the Royal College of Psychiatrists’ Faculty of 
the Psychiatry of Old Age. Occasional Paper (OP)86. 
http://www.rcpsych.ac.uk/publications/collegereports/op/op86.aspx  
NICE Pathways (2012) Dementia diagnosis and assessment. Developed from 
Dementia (2006) NICE guideline CG42. [Accessed online 05/05/2015: 
http://pathways.nice.org.uk/pathways/dementia/dementia-diagnosis-and-
assessment#content=view-node%3Anodes-diagnosis-and-assessment]  
CHAPTER 4: OVERVIEW  
CHAPTER 4| 116 
Sarkar, U., Bonacum, D., Strull, W., Spitzmueller, C., Jin, N., López, A., ... & Singh, 
H. (2012). Challenges of making a diagnosis in the outpatient setting: a multi-site 
survey of primary care physicians. BMJ Quality & Safety, 21(8), 641-648. 
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., ... & 
Bouter, L. M. (2007). Development of AMSTAR: a measurement tool to assess the 
methodological quality of systematic reviews. BMC medical research methodology, 
7(1), 10. 
Smith, V., Devane, D., Begley, C. M., & Clarke, M. (2011). Methodology in 
conducting a systematic review of systematic reviews of healthcare interventions. 
BMC medical research methodology, 11(1), 15. 
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Protocol appendix 
 
Search strategy, formatted for MEDLINE (OVID) 
Database: EMBASE 
Data Parameters: 1974 – 2015 June 09 
Date Searched: 10/06/1 
Searches Results 
1 
dementia/ or aids dementia complex/ or alzheimer disease/ or aphasia, 
primary progressive/ or creutzfeldt-jakob syndrome/ or dementia, 
vascular/ or diffuse neurofibrillary tangles with calcification/ or 
frontotemporal lobar degeneration/ or huntington disease/ or kluver-bucy 
syndrome/ or lewy body disease/ 
221832   
2 dementia.ti,ab. 98978   
3 alzheimer*.ti,ab. 128772   
4 1 or 2 or 3 255335   
5 systematic*.ti,ab. 308331   
6 meta-analysis.ti,ab. 83324   
7 "systematic review".ti,ab. 72883   
8 diagnosis/ or "sensitivity and specificity"/ 1273396   
9 5 or 6 or 7 or 8 1615147   
10 brief cognitive tests.ti,ab. 66   
11 cognitive screen*.ti,ab. 1338   
12 ("screening test*" adj2 (dement* or alzheimer*)).ti,ab. 220   
13 cog*.ti,ab. 358594   
14 10 or 11 or 12 or 13 358664   
15 "primary care".ti,ab. 98787   
16 "general practic*".ti,ab. 40574   
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17 "GP".ti,ab. 41203   
18 15 or 16 or 17 166293   
19 4 and 9 and 14 and 18 257   
Search strategy, formatted for MEDLINE (OVID) 
Database: PsychINFO 
Data Parameters: 1806 – 2015 June  
Date Searched: 10/06/15 
1 
dementia/ or aids dementia complex/ or alzheimer disease/ or aphasia, 
primary progressive/ or creutzfeldt-jakob syndrome/ or dementia, vascular/ or 
diffuse neurofibrillary tangles with calcification/ or frontotemporal lobar 
degeneration/ or huntington disease/ or kluver-bucy syndrome/ or lewy body 
disease/ 
54710 
2 dementia.ti,ab. 46067 
3 alzheimer*.ti,ab. 43262 
4 1 or 2 or 3 73484 
5 systematic*.ti,ab. 83565 
6 meta-analysis.ti,ab. 15868 
7 "systematic review".ti,ab. 11626 
8 diagnosis/ or "sensitivity and specificity"/ 35862 
9 5 or 6 or 7 or 8 130463 
10 brief cognitive tests.ti,ab. 34 
11 cognitive screen*.ti,ab. 690 
12 ("screening test*" adj2 (dement* or alzheimer*)).ti,ab. 131 
13 cog*.ti,ab. 341564 
14 10 or 11 or 12 or 13 341608 
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15 "primary care".ti,ab. 21434 
16 "general practic*".ti,ab. 4560 
17 "GP".ti,ab. 3274 
18 15 or 16 or 17 26754 
19 4 and 9 and 14 and 18 86 
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Appendix 2 Search strategy formatted for the Cochrane Library 
Search Name: Dementia overview search 
Date Run: 17/08/15 
Cochrane Database of Systematic Reviews: Issue 8 of 12, August 2015 
All results (320) 
Cochrane Reviews (150) 
Other reviews (72) 
Trials (87) 
Methods Studies (10) 
Technology Assessments (1) 
ID Search Hits 
#1 MeSH descriptor: [Dementia] explode all trees 3971 
#2 dementia:ti,ab  5183 
#3 alzheimer*:ti,ab  5235 
#4 memory complaint:ti,ab  47 
#5 #1 or #2 or #3 or #4  9325 
#6 systematic*:ti,ab  31555 
#7 review:ti,ab  44131 
#8 "meta-analysis":ti,ab  23014 
#9 metaanalysis:ti,ab  433 
#10 "test accuracy":ti,ab  233 
#11 #6 or #7 or #8 or #9 or #10  64707 
#12 "brief cognitive test*":ti,ab  6 
#13 "cognitive screen*":ti,ab  63 
#14 (screening test* near/2 (dement* or alzheimer*)):ti,ab  21 
#15 screening:ti,ab  16059 
#16 (diagnosis or ("sensitivity and specificity")):ti,ab  24875 
#17 cog*:ti,ab  27752 
#18 #12 or #13 or #14 or #16 or #17  51300 
#19 "primary care":ti,ab  8628 
#20 "general practic*":ti,ab  3814 
#21 GP:ti,ab  2034 
#22 community:ti,ab  17445 
#23 #19 or #20 or #21 or #22  28971 
#24 #5 and #11 and #18  320 
#25 #5 and #11 and #18 and #23  35 
 
N.B. systematic review search filters not used as the Cochrane Reviews database only 
includes systematic reviews. 
Appendix 3 Search strategy, formatted for EMBASE (OVID) 
Embase 1974 to 2015 August 21 
1 dementia/ or aids dementia complex/ or alzheimer disease/ or aphasia, 
primary progressive/ or creutzfeldt-jakob syndrome/ or dementia, 
vascular/ or diffuse neurofibrillary tangles with calcification/ or 
frontotemporal lobar degeneration/ or huntington disease/ or kluver-bucy 
syndrome/ or lewy body disease/ 
225474  
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2 exp dementia/ 252956  
3 exp dementia assessment/ 23039  
4 exp clinical dementia rating/ 1011  
5 exp memory disorder/ 56295  
6 dementia.ti,ab. 101033  
7 alzheimer*.ti,ab. 131501  
8 1 or 2 or 3 or 4 or 6 or 7 292776  
9 systematic*.ti,ab. 317342  
10 meta-analysis.ti,ab. 87144  
11 "systematic review".ti,ab. 76490  
12 exp review/ 2082052  
13 (literature adj3 review$).ti,ab. 238313  
14 exp meta analysis/ 97571  
15 exp "Systematic Review"/ 93826  
16 or/12-15 2316420  
17 (medline or medlars or embase or pubmed or cinahl or amed or psychlit 
or psyclit or psychinfo or psycinfo or scisearch or cochrane).ti,ab. 
133763  
18 RETRACTED ARTICLE/ 7620  
19 17 or 18 141333  
20 16 and 19 103832  
21 (systematic$ adj2 (review$ or overview)).ti,ab. 95715  
22 (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or 
metanal$).ti,ab. 
105476  
23 20 or 21 or 22 211820  
24 diagnosis/ 1066933  
25 "sensitivity and specificity"/ 231631  
26 9 or 10 or 11 or 24 or 25 1642613  
27 brief cognitive tests.ti,ab. 66  
28 cognitive screen*.ti,ab. 1402  
29 ("screening test*" adj2 (dement* or alzheimer*)).ti,ab. 222  
30 cog*.ti,ab. 368545  
31 27 or 28 or 29 or 30 368615  
32 "primary care".ti,ab. 100669  
33 "general practic*".ti,ab. 40969  
34 "GP".ti,ab. 41972  
35 32 or 33 or 34 169068  
36 8 and 26 and 31 9009  
N.B. systematic review search filter 
 exp review/ 
 (literature adj3 review$).ti,ab. 
 exp meta analysis/ 
 exp "Systematic Review"/ 
 or/1-4 
 (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti,ab.  
 RETRACTED ARTICLE/ 
 6 or 7 
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 5 and 8 
 (systematic$ adj2 (review$ or overview)).ti,ab. 
 (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ti,ab. 
 9 or 10 or 11 
From BMJ Clinical Evidence strategy [undated] [Ovid] was used. 
4.7.1. Search strategy, formatted for OVID MEDLINE 
Ovid MEDLINE(R) 1946 to August Week 2 2015 
1 dementia/ or aids dementia complex/ or alzheimer disease/ or aphasia, 
primary progressive/ or creutzfeldt-jakob syndrome/ or dementia, vascular/ 
or diffuse neurofibrillary tangles with calcification/ or frontotemporal lobar 
degeneration/ or huntington disease/ or kluver-bucy syndrome/ or lewy 
body disease/ 
127632  
2 Dementia/ 39509  
3 exp dementia/ 129660  
4 exp memory disorder/ 24008  
5 dementia.ti,ab. 67035  
6 alzheimer*.ti,ab. 92544  
7 1 or 2 or 3 or 4 or 5 or 6 188618  
8 systematic*.ti,ab. 221142  
9 meta-analysis.ti,ab. 57552  
10 "systematic review".ti,ab. 50417  
11 (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or 
review* or literature)) or (meta-analy* or metaanaly* or "research synthesis" 
or ((information or data) adj3 synthesis) or (data adj2 extract*))).ti,ab. or 
(cinahl or (cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo 
not "psycinfo database") or pubmed or scopus or "sociological abstracts" or 
"web of science").ab. or ("cochrane database of systematic reviews" or 
evidence report technology assessment or evidence report technology 
assessment summary).jn. or Evidence Report: Technology Assessment*.jn. 
or ((review adj5 (rationale or evidence)).ti,ab. and review.pt.) or meta-
analysis as topic/ or Meta-Analysis.pt. 
212532  
12 diagnosis/ 17054  
13 "sensitivity and specificity"/ 295160  
14 8 or 9 or 10 or 12 or 13 562806  
15 brief cognitive tests.ti,ab. 41  
16 cognitive screen*.ti,ab. 735  
17 ("screening test*" adj2 (dement* or alzheimer*)).ti,ab. 161  
18 cog*.ti,ab. 243367  
19 15 or 16 or 17 or 18 243415  
20 "primary care".ti,ab. 71023  
21 "general practic*".ti,ab. 32013  
22 "GP".ti,ab. 27969  
23 20 or 21 or 22 121226  
24 7 and 14 and 19 2660  
N.B. systematic review search filter 
(((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or literature)) 
or (meta-analy* or metaanaly* or "research synthesis" or ((information or data) adj3 
synthesis) or (data adj2 extract*))).ti,ab. or (cinahl or (cochrane adj3 trial*) or embase or 
CHAPTER 4: OVERVIEW  
CHAPTER 4| 123 
medline or psyclit or (psycinfo not "psycinfo database") or pubmed or scopus or "sociological 
abstracts" or "web of science").ab. or ("cochrane database of systematic reviews" or 
evidence report technology assessment or evidence report technology assessment 
summary).jn. or Evidence Report: Technology Assessment*.jn. or ((review adj5 (rationale or 
evidence)).ti,ab. and review.pt.) or meta-analysis as topic/ or Meta-Analysis.pt. 
From University of Texas School of Public Health (Search filters for systematic reviews and 
meta-analyses. Accessed 06 Dec 2013), was used. 
4.7.2. Search strategy, formatted for Psychinfo (OVID)  
1806 to August Week 2 2015 
1 dementia/ or aids dementia complex/ or alzheimer disease/ or aphasia, primary 
progressive/ or creutzfeldt-jakob syndrome/ or dementia, vascular/ or diffuse 
neurofibrillary tangles with calcification/ or frontotemporal lobar degeneration/ or 
huntington disease/ or kluver-bucy syndrome/ or lewy body disease/ 
55725  
2 exp dementia/ 57951  
3 exp Neuropsychological Assessment/ 14779  
4 exp Cognitive Assessment/ 3559  
5 dementia.ti,ab. 46844  
6 alzheimer*.ti,ab. 44055  
7 1 or 2 or 3 or 4 or 5 or 6 90002  
8 systematic*.ti,ab. 85202  
9 meta-analysis.ti,ab. 16369  
10 "systematic review".ti,ab. 12154  
11 (((comprehensive* or integrative or systematic*) adj3 (bibliographic* or review* or 
literature)) or (meta-analy* or metaanaly* or "research synthesis" or ((information or 
data) adj3 synthesis) or (data adj2 extract*))).ti,ab,id. or ((review adj5 (rational or 
evidence)).ti,ab,id. and "Literature Review".md.) or (cinahl or (cochrane adj3 trial*) 
or embase or medline or psyclit or pubmed or scopus or "sociological abstracts" or 
"web of science").ab. or ("systematic review" or "meta analysis").md. 
54964  
12 8 or 9 or 10 or 11 121571  
13 diagnosis/ 36489  
14 brief cognitive tests.ti,ab. 34  
15 cognitive screen*.ti,ab. 708  
16 ("screening test*" adj2 (dement* or alzheimer*)).ti,ab. 132  
17 cog*.ti,ab. 347512  
18 14 or 15 or 16 or 17 347557  
19 7 and 12 and 13 and 18 102  
 
N.B. Search filters from University of Texas School of Public Health. Search filters for 
systematic reviews and meta-analyses. Accessed 06 Dec 2013. [Ovid] incorporated as they 
added ~30 hits. 
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4.7.3. Appendix 4 Cochrane reviews assessed for this overview 
Title Include/ 
exclude 
Arevalo-Rodriguez I, Smailagic N, Roqué i Figuls M, Ciapponi A, Sanchez-
Perez E, Giannakou A, Pedraza OL, Bonfill Cosp X, Cullum S. Mini-Mental 
State Examination (MMSE) for the detection of Alzheimer's disease and other 
dementias in people with mild cognitive impairment (MCI). Cochrane Database 
of Systematic Reviews 2015, Issue 3. Art. No.: CD010783. DOI: 
10.1002/14651858.CD010783.pub2. 
Include 
Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, Seitz DP. 
Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other 
dementias within a secondary care setting (Protocol). Cochrane Database of 
Systematic Reviews 2014, Issue 12. Art. No.: CD011414. DOI: 
10.1002/14651858.CD011414. 
Exclude 
Creavin ST, Wisniewski S, Noel-Storr AH, Trevelyan CM, Hampton T, Rayment 
D, Thom VM, Nash KJE, Elhamoui H, Milligan R, Patel AS, Tsivos DV, Wing T, 
Phillips E, Kellman SM, Shackleton HL, Singleton GF, Neale BE, Watton ME, 
Cullum S. Mini-Mental State Examination (MMSE) for the detection of dementia 
in clinically unevaluated people aged 65 and over in community and primary 
care populations. Cochrane Database of Systematic Reviews 2016, Issue 1. 
Art. No.: CD011145. DOI: 10.1002/14651858.CD011145.pub2. 
Include 
Davis DHJ, Creavin ST, Yip JLY, Noel-Storr AH, Brayne C, Cullum S. Montreal 
Cognitive Assessment for the diagnosis of Alzheimer’s disease and other 
dementias. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. 
No.: CD010775. DOI: 10.1002/14651858.CD010775.pub2. 
Include 
Fage BA, Chan CCH, Gill SS, Noel-Storr AH, Herrmann N, Smailagic N, 
Nikolaou V, Seitz DP. Mini-Cog for the diagnosis of Alzheimer's disease 
dementia and other dementias within a community setting. Cochrane Database 
of Systematic Reviews 2015, Issue 2. Art. No.: CD010860. DOI: 
10.1002/14651858.CD010860.pub2.. 
Exclude 
Harrison JK, Fearon P, Noel-Storr AH, McShane R, Stott DJ, Quinn TJ. 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the 
diagnosis of dementia within a secondary care setting. Cochrane Database of 
Systematic Reviews 2015, Issue 3. Art. No.: CD010772. DOI: 
10.1002/14651858.CD010772.pub2. 
Exclude 
Harrison, J. K., P. Fearon, A. H. Noel-Storr, R. McShane, D. J. Stott and T. J. 
Quinn (2014) Informant Questionnaire on Cognitive Decline in the Elderly  
IQCODE  for the diagnosis of dementia within a general practice (primary care)  
setting. The Cochrane database of systematic reviews 7: CD010771.Cochrane 
Database of Systematic Reviews DOI: 10.1002/14651858.CD010783.pub2. 
Include 
Hendry, K., A. Lees Rosalind, R. McShane, H. Noel-Storr Anna, J. Stott David 
and J. Quinn Terry (2014)AD-8 for diagnosis of dementia across a variety of 
healthcare settings. Cochrane Database of Systematic Reviews DOI: 
10.1002/14651858.cd011121. 
Include 
Lees Rosalind, A., J. Stott David, R. McShane, H. Noel-Storr Anna and J. Quinn 
Terry (2014) Informant Questionnaire on Cognitive Decline in the Elderly  
IQCODE  for the early diagnosis of dementia across a variety of healthcare 
settings. Cochrane Database of Systematic Reviews DOI: 
10.1002/14651858.cd011333. 
Include 
Quinn Terry, J., P. Fearon, H. Noel-Storr Anna, C. Young, R. McShane and J. 
Stott David (2014) "Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) for the diagnosis of dementia within community dwelling 
populations." Cochrane Database of Systematic Reviews DOI: 
10.1002/14651858.CD010079.pub2. 
Exclude 
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Seitz Dallas, P., A. Fage Bruce, C. H. Chan Calvin, S. Gill Sudeep, N. 
Herrmann, N. Smailagic and V. Nikolaou (2014) Mini-Cog for the diagnosis of 
Alzheimer?s disease dementia and other dementias within a primary care 
setting.  Cochrane Database of Systematic Reviews DOI: 
10.1002/14651858.cd011415. 
Include 
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4.7.4. Appendix 5 Exclusions at full text screening 
 Full reference Reason  
1 Al-Qazzaz, N. A., S. H. Ali, S. A. Ahmad and S. Islam (2014). "Cognitive 
assessments for the early diagnosis of dementia after stroke." Neuropsychiatric 
Disease and Treatment 10: 1743-1751. 
Design 
 
2 Arevalo-Rodriguez, I., O. Segura, I. Sola, X. Bonfill, E. Sanchez and P. Alonso-
Coello (2014). "Diagnostic tools for alzheimer's disease dementia and other 
dementias: An overview of diagnostic test accuracy (DTA) systematic reviews." 
BMC Neurology 14(1). 
Design 
 
3 Borson, S., M. Brush, E. Gil, J. Scanlan, P. Vitaliano, J. Chen, J. Cashman, M. M. 
Sta Maria, R. Barnhart and J. Roques "The Clock Drawing Test: utility for dementia 
detection in multiethnic elders." Journals of Gerontology Series A-Biological 
Sciences & Medical Sciences 54(11): M534-540. 
Design 
 
4 Canning, S. J., L. Leach, D. Stuss, L. Ngo and S. E. Black "Diagnostic utility of 
abbreviated fluency measures in Alzheimer disease and vascular dementia." 
Neurology 62(4): 556-562. 
Design 
 
5 Chan, C. C. and P. T. Lam (2005). "Update on dementia - Part 1: Mild cognitive 
impairment, screening and diagnostic assessment." Hong Kong Practitioner 27(6): 
235-241. 
Design 
 
6 Cossa, F. M., S. Della Sala, M. Musicco, H. Spinnler and M. C. Ubezio 
"Comparison of two scoring systems of the Mini-Mental State Examination as a 
screening test for dementia." Journal of Clinical Epidemiology 50(8): 961-965. 
Design 
 
7 Crawford, S., J. Evans, L. Whitnall and J. A. Robertson (2011). "A systematic 
review of the accuracy and clinical utility of the addenbrooke's cognitive 
examination and the addenbrooke's cognitive examination - Revised in the 
diagnosis of dementia." Brain Impairment 12: 4. 
Setting 
8 Darzins, P. and D. LoGiudice (1999). "Clinical testing in general practice. What is 
the evidence?" Australian family physician 28(12): 1241-1244. 
Design 
9 Diesfeldt, H. F. "[Discrepancies between the IQCODE (Informant Questionnaire on 
Cognitive Decline in the Elderly) and cognitive test performance]." Tijdschrift voor 
Gerontologie en Geriatrie 38(5): 225-236. 
Design 
10 Evans, I. E. M., E. Kuzma, I. A. Lang, A. L. R. Adlam and D. J. Llewellyn (2014). 
"Which brief assessment measures for dementia are currently recommended for 
use in primary care? a systematic review." Alzheimer's and Dementia 10: P439. 
Design 
11 Fage, B. A., C. C. Chan, S. S. Gill, A. H. Noel-Storr, N. Herrmann, N. Smailagic, V. 
Nikolaou and D. P. Seitz (2015). "Mini-Cog for the diagnosis of Alzheimer's disease 
dementia and other dementias within a community setting." The Cochrane 
database of systematic reviews 2: CD010860. 
Setting 
12 Flicker, L., D. Logiudice, J. B. Carlin and D. Ames "The predictive value of 
dementia screening instruments in clinical populations." International Journal of 
Geriatric Psychiatry 12(2): 203-209. 
Design 
13 Fong, T. G., M. A. Fearing, R. N. Jones, P. Shi, E. R. Marcantonio, J. L. Rudolph, 
F. M. Yang, D. K. Kiely and S. K. Inouye "Telephone interview for cognitive status: 
Creating a crosswalk with the Mini-Mental State Examination." Alzheimer's & 
Dementia 5(6): 492-497. 
Design 
14 Fuzikawa, C. S., E. Uchoa and M. F. Lima-Costa (2003). "Clock drawing test: A 
review on this cognitive screening test. [Portuguese]." Jornal Brasileiro de 
Psiquiatria 52(3): 223-235. 
Setting 
15 Gainotti, G., C. Marra, G. Villa, V. Parlato and F. Chiarotti "Sensitivity and 
specificity of some neuropsychological markers of Alzheimer dementia." Alzheimer 
Disease & Associated Disorders 12(3): 152-162. 
Design 
 Harvan, J.R. and Cotter, V.T., 2006. An evaluation of dementia screening in 
the primary care setting. Journal of the American Academy of Nurse 
Practitioners, 18(8), pp.351-360 
Design 
16 Holsinger, T., B. L. Plassman and K. M. Stechuchak (2012). "The Mini-Cog had 
sensitivity similar to the longer 3MS for detecting cognitive impairment or 
dementia." Annals of Internal Medicine 157(8): JC4-JC8. 
Design 
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17 Iliffe, S., L. Robinson, C. Brayne, C. Goodman, G. Rait, J. Manthorpe, P. Ashley 
and N. P. C. C. S. G. De "Primary care and dementia: 1. diagnosis, screening and 
disclosure." International Journal of Geriatric Psychiatry 24(9): 895-901. 
Design 
18 Inouye, S. K., J. T. Robison, T. E. Froehlich and E. D. Richardson "The time and 
change test: a simple screening test for dementia." Journals of Gerontology Series 
A-Biological Sciences & Medical Sciences 53(4): M281-286. 
Design 
19 Ismail, Z., T. K. Rajji and K. I. Shulman (2010). "Brief cognitive screening 
instruments: an update." Int J Geriatr Psychiatry 25(2): 111-120. 
Design 
 Jacova, C., Kertesz, A., Blair, M., Fisk, J.D. and Feldman, H.H., 2007. 
Neuropsychological testing and assessment for dementia. Alzheimer's & 
Dementia, 3(4), pp.299-317. 
Setting 
20 Jacqmin-Gadda, H., C. Fabrigoule, D. Commenges, L. Letenneur and J. F. 
Dartigues "A cognitive screening battery for dementia in the elderly." Journal of 
Clinical Epidemiology 53(10): 980-987. 
 
Design 
21 Jitapunkul, S., I. Pillay and S. Ebrahim "The abbreviated mental test: its use and 
validity." Age & Ageing 20(5): 332-336. 
Design 
22 Jorm, A. F. (1997). "Methods of screening for dementia: A meta-analysis of studies 
comparing an informant questionnaire with a brief cognitive test." Alzheimer 
Disease and Associated Disorders 11(3): 158-162. 
Setting 
23 Kalbe, E., J. Kessler, P. Calabrese, R. Smith, A. P. Passmore, M. Brand and R. 
Bullock "DemTect: a new, sensitive cognitive screening test to support the 
diagnosis of mild cognitive impairment and early dementia." International Journal of 
Geriatric Psychiatry 19(2): 136-143. 
Design 
24 Larner A., M., A. J. (2014). "A meta-analysis of the accuracy of the Addenbrooke's 
Cognitive Examination (ACE) and the Addenbrooke's Cognitive Examination-
Revised (ACE-R) in the detection of dementia." International psychogeriatrics / IPA 
26(4): 555-563. 
Setting 
25 Larner, A. and A. J. Mitchell (2014). "Ace and ACE-R for diagnosis of dementia: A 
meta-analysis." Journal of Neurology, Neurosurgery and Psychiatry 85 (10): A16. 
Setting 
26 Lorentz, W. J., J. M. Scanlan and S. Borson (2002). "Brief screening tests for 
dementia." Can J Psychiatry 47(8): 723-733. 
Design 
27 Mahoney, R., K. Johnston, C. Katona, K. Maxmin and G. Livingston "The TE4D-
Cog: a new test for detecting early dementia in English-speaking populations." 
International Journal of Geriatric Psychiatry 20(12): 1172-1179. 
Design 
28 Milne, A., A. Culverwell, R. Guss, J. Tuppen and R. Whelton (2008). "Screening for 
dementia in primary care: A review of the use, efficacy and quality of measures." 
International Psychogeriatrics 20(5): 911-926. 
Design 
  
29 Mundt, J. C., K. L. Ferber, M. Rizzo and J. H. Greist "Computer-automated 
dementia screening using a touch-tone telephone." Archives of Internal Medicine 
161(20): 2481-2487. 
Design 
30 Quinn Terry, J., P. Fearon, H. Noel-Storr Anna, C. Young, R. McShane and J. Stott 
David (2014) "Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) for the diagnosis of dementia within community dwelling populations." 
Cochrane Database of Systematic Reviews DOI: 
10.1002/14651858.CD010079.pub2. 
Setting 
31 Rait, G., M. Morley, A. Burns, R. Baldwin, C. Chew-Graham and A. S. St Leger 
"Screening for cognitive impairment in older African-Caribbeans." Psychological 
Medicine 30(4): 957-963. 
Design 
32 Rous, R. S., C. R. Housden, L. M. Lewis, A. Filby, M. J. Taylor, A. D. Blackwell and 
J. H. Barnett (2014). "The sensitivity and specificity of computerised or paper-and-
pencil cognitive assessments used in primary care impact the cost-effectiveness of 
the dementia diagnostic pathway." Alzheimer's and Dementia 10: P566. 
Design 
33 Stolwyk, R. J., M. H. O'Neill, A. J. D. McKay and D. K. Wong (2014). "Are cognitive 
screening tools sensitive and specific enough for use after stroke?: A systematic 
literature review." Stroke 45(10): 3129-3134. 
Setting 
34 Stuss, D. T., N. Meiran, D. A. Guzman, G. Lafleche and J. Willmer "Do long tests 
yield a more accurate diagnosis of dementia than short tests? A comparison of 5 
neuropsychological tests." Archives of Neurology 53(10): 1033-1039. 
Design 
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35 Tang, W. K., S. S. Chan, H. F. Chiu, K. S. Wong, T. C. Kwok, V. Mok and G. S. 
Ungvari "Can IQCODE detect poststroke dementia?" International Journal of 
Geriatric Psychiatry 18(8): 706-710. 
Design 
36 Tangalos, E. G., G. E. Smith, R. J. Ivnik, R. C. Petersen, E. Kokmen, L. T. Kurland, 
K. P. Offord and J. E. Parisi "The Mini-Mental State Examination in general medical 
practice: clinical utility and acceptance." Mayo Clinic Proceedings 71(9): 829-837. 
Design 
37 Tierney, M. C. and M. A. Lermer (2010). "Computerized cognitive assessment in 
primary care to identify patients with suspected cognitive impairment." Journal of 
Alzheimer's Disease 20(3): 823-832. 
Condition 
38 Uhlmann, R. F. and E. B. Larson "Effect of education on the mini-mental state 
examination as a screening test for dementia." Journal of the American Geriatrics 
Society 39(9): 876-880. 
Design 
39 Uhlmann, R. F., T. S. Rees, B. M. Psaty and L. G. Duckert "Validity and reliability of 
auditory screening tests in demented and non-demented older adults." Journal of 
General Internal Medicine 4(2): 90-96. 
Design 
40 Valverde, A. H., A. Jimenez-Escrig, J. Gobernado and M. Baron "A short 
neuropsychologic and cognitive evaluation of frontotemporal dementia." Clinical 
Neurology & Neurosurgery 111(3): 251-255. 
Design 
41 van Gorp, W. G., T. D. Marcotte, D. Sultzer, C. Hinkin, M. Mahler and J. L. 
Cummings "Screening for dementia: comparison of three commonly used 
instruments." Journal of Clinical & Experimental Neuropsychology: Official Journal 
of the International Neuropsychological Society 21(1): 29-38. 
Design 
42 Watson, Y. I., C. L. Arfken and S. J. Birge "Clock completion: an objective 
screening test for dementia." Journal of the American Geriatrics Society 41(11): 
1235-1240. 
Design 
43 Wind, A. W., F. G. Schellevis, G. Van Staveren, R. P. Scholten, C. Jonker and J. T. 
Van Eijk "Limitations of the Mini-Mental State Examination in diagnosing dementia 
in general practice." International Journal of Geriatric Psychiatry 12(1): 101-108. 
Design 
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Appendix 7 ROBIS checklist 213 [tailored by Harriet Hunt]
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Glossary 
 
ADI Alzheimer’s disease International 
AGECAT Automated Geriatric Examination for Computer Assisted 
Taxonomy 
AMT(S) Abbreviated Mental Test Score 
CAMCOG The Cambridge Cognitive Examination 
CAMDEX Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CCCDTD Canadian Consensus Conferences on the Diagnosis and 
Treatment of Dementia 
CCG Clinical Commissioning Group 
CDPC Cognitive Decline Partnership Centre 
CDR Clinical Dementia Rating 
CDT clock drawing test 
CERAD Consortium to Establish a Registry for Alzheimer's Disease 
CPG Clinical Practice Guideline 
DSM-III/ III-R/ 
IV/ IV-R 
The Diagnostic and Statistical Manual of Mental Disorders 
(version 3/ version 3 revised/ version 4/ version 4 revised 
EMBASE Excerpta Medica dataBASE 
FAB Frontal Assessment Battery 
FAQ Functional Activities Questionnaire 
FCSRT Free and Cued Selective Reminding Test 
GMS-AGECAT Geriatric Mental State Schedule - Automated Geriatric 
Examination for Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
ICD-10 International Classification of Disease – version 10 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
IPA/WHO 
criteria 
International Psychogeriatric Association/World Health 
organisation criteria 
KICA-Cog Kimberley Indigenous Cognitive Assessment  
KICA-Screen Kimberley Indigenous Cognitive screening tool 
MCI Mild Cognitive Impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MeSH Medical Subject Headings 
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MIS Memory Impairment Screen 
MMSE  Mini mental state examination 
MoCA Montreal Cognitive Assessment 
NHS  National Health Service (UK) 
NICE National Institute for Health and Care Excellence (UK) 
NINDCS-
ADRDA 
National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders 
Association 
NINCDS-AIREN National Institute of Neurological Disorders and Stroke–
Association Internationale pour la Recherche et l'Enseignement 
en Neurosciences 
NINCDR-
CERAD 
National Institute of Neurological Disorders - Clinical Dementia 
Rating -Consortium to Establish a Registry for Alzheimer’s 
Disease 
PAS Psychogeriatric Assessment Scale 
PCL Prueba cognitive de leganes 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of psychology. 
RUDAS The Rowland Universal Dementia Assessment Scale 
SASSI Short and Sweet Screening Instrument 
SIS Six item screener 
SPMSQ Short portable mental status questionnaire 
TICS Telephone Interview for Cognitive Status 
TRIP Turning Research Into Practice database 
TYM Test Your Memory 
VF-an Verbal Fluency - animals 
WHO World Health Organisation 
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5. How accurate are GPCOG and MMSE in identifying 
dementia when directly compared to each other? 
Any truth is better than indefinite doubt. 
Conan Doyle, A (1894) The memoirs of Sherlock Holmes. London, George Newnes 
The overview described in Chapter 3 revealed that whilst a large volume of systematic 
review evidence exists, the majority of evidence is often derived from a comparison of 
diagnostic accuracy across different studies (termed “indirect comparisons”). When 
diagnostic accuracy is compared across different studies, it is challenging to account 
for all the differences in setting, population, test administration and other factors which 
affect performance, yet these variations may all have a bearing on how the test is used 
and performs in a clinical setting. In order to minimise the potential influence of 
extraneous variables between different studies, a systematic review was conducted 
which exclusively assessed direct comparisons of MMSE and GPCOG, where both 
tests of interest had been compared within the same study. It was hypothesised that 
such a systematic review of direct comparisons would demonstrate which BCA had 
superior diagnostic accuracy within the same study population. In reality, this 
systematic review revealed a complex set of problems around both the findings of 
included studies, and methodological challenges of conducting a systematic review of 
direct comparisons.  
The difficulties inherent in this approach to evaluating diagnostic accuracy are 
discussed, and potential considered for combining the most useful information to form 
a more complete picture of benefit for clinical decision making. These findings lead on 
to Chapter 6 in which these factors are considered within the context of clinical practice 
using survey research, and Chapter 7 where all findings are discussed in the broader 
context of the entire thesis. 
5.1. Background to the review 
Many systematic reviews102,104-106,279-281 have explored the individual diagnostic 
accuracy of brief cognitive assessments for cognitive impairment as part of the 
process for identifying dementia in isolation, and across a range of populations and 
settings including primary care, community and memory clinics. Why it is then 
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necessary to conduct yet more syntheses of evidence when the evidence clearly 
already exists? There are several reasons. Firstly, many systematic reviews of 
diagnostic accuracy compare different test performance across different studies. This 
means that observed differences between tests and test accuracy may not be down 
to differing performance between various brief cognitive assessments, but may be due 
to other confounding factors such as variation in test threshold used, or differences in 
testing populations.  
The overview of diagnostic accuracy reported in Chapter 3 revealed many problems 
with the summarised evidence on the accuracy of brief cognitive assessments. One 
specific challenge is that the focus has been on the the accuracy of individual brief 
cognitive assessments, rather than the degree to which one brief cognitive 
assessment compares to another. Within the overview, eight99,105,120,141,148,222,231,236 of 
the 13 included systematic reviews reported data from indirect comparison studies (i.e. 
where data from individual studies assessing single brief cognitive assessments was 
compared within a single systematic review) and only one systematic review125 
reported data from a single direct within-study142 comparison of MMSE, GPCOG and 
the Abbreviated Mental Test (AMT). Within the evidence making indirect comparisons, 
there appears to be under-recognition of the degree to which confounding may be 
responsible for variation between test accuracy results for one test relative to another. 
In addition, the measures which would usually be taken to reduce this variation within 
standard multivariate analyses (such as ensuring consistency in population 
characteristics, reference standards, and study designs282) do not appear to have 
been routinely applied in many accuracy studies.    
Direct comparisons of test performance within the same study population are not often 
conducted, and this lack of directly-comparable data was the reason for carrying out 
this systematic review solely focussed upon direct comparisons of two brief cognitive 
assessments. In order to focus the question in this way, the results of the overview 
and advice from clinical colleagues were combined to identify the BCA comparison of 
most clinically relevance. 
Two brief cognitive assessments were identified as suitable to compare against one 
another in order to assess diagnostic accuracy. These tests, the Mini Mental State 
Examination (MMSE) and General Practitioner Assessment of Cognition (GPCOG), 
were the two most frequently-assessed brief cognitive assessments in the 13 
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systematic reviews88,103,105,106,120,125,141,148,221,222,231,233,236 included within the overview, 
with the MMSE featuring in eight reviews, and the GPCOG featuring in four reviews. 
The clock drawing test (CDT) was the third most frequently-assessed tool, also 
featuring in four reviews. The CDT was judged to be less comparable to the MMSE in 
terms of administration complexity, timing and domains assessed, relative to the 
GPCOG.  
As the most frequently-assessed test within the overview, the MMSE is included as 
one of the index tests within this review as, whilst copyright restrictions are now 
enforced, it remains one of the most popular brief cognitive assessments employed in 
practice88,116. The MMSE is based on a 30 point scale of 11 questions testing five 
domains of cognitive function (orientation, registration, attention and calculation, recall 
and language)115.  
The GPCOG was the second most frequently-assessed index test within the overview 
featured in Chapter 3. The GPCOG is a publicly-available test in two sections: a patient 
examination (GPCOG-Patient) with a maximum score of nine (optimum performance) 
covering time orientation, clock drawing, reporting recent events and a word-recall 
task, and an optional informant questionnaire (GPCOG-Informant) with a maximum 
score of six with questions assessing the patient’s memory of recent events and their 
executive function142. These details are summarised in Table 14. Within the survey of 
UK general practitioners (GPs) reported in Chapter 7 exploring how GPs choose and 
use brief cognitive assessments as part of the process for identifying dementia in 
primary care, MMSE and GPCOG were the two most frequently used assessments 
with 32% of respondents selecting each test. Finally, both tests have been developed 
independently whereas many other brief cognitive assessments share elements of the 
MMSE. MMSE was created by Folstein and colleagues115 in 1975 with a highly 
selected group of 69 psychiatric inpatients representing a spectrum of different clinical 
conditions. GPCOG was developed in 2002 by Brodaty and colleagues142 within a 
general practice population using a group of 283 community-dwelling participants, 
either with memory complaints of between 50-75 years old, or asymptomatic if over 
75 years.  
Both MMSE and GPCOG measure short term memory and visuospatial/constructional 
praxis, with minimal assessment data available on these domains for MMSE and 
moderate assessment of GPCOG125 – this pattern is shown in Table 14. Of the tools 
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shown, only GPCOG measures semantic memory and frontal or executive function, 
with minimal assessment data available. Both tools measure orientation, with relatively 
extensive assessment information available for the MMSE and minimal assessment 
information for GPCOG. Attention/calculation is covered by both tools, with moderate 
assessment data on this domain available for MMSE and minimal assessment data 
available on GPCOG. Finally, language is covered by MMSE with moderate 
assessment data available, whereas there is no evidence that this has been 
specifically tested in GPCOG125.  
Table 14 Features of top three brief cognitive assessments identified within the 
overview 
Cognitive domains & other details MMSE GPCOG CDT 
Short term memory  + ++ - 
Semantic memory  - + + 
Visuospatial/ constructional praxis  + ++ ++ 
Frontal/ executive function  - + + 
Orientation   +++ + 
Attention/ calculation ++ + + 
Language  ++ - - 
Informant component  No Yes No 
Maximum score 30 15 1 
Number of SR inclusions in overview (# of study inclusions across SRs) 8 (22) 4 (2) 4 (2) 
MMSE, mini mental state questionnaire; GPCOG, General Practitioner Assessment of Cognition; CDT, 
clock drawing test; BCA, brief cognitive assessment; SR, systematic review; Max., maximum; +, 
minimal assessment; ++, moderate assessment; +++, relatively extensive assessment. Adapted from 
Woodford and George 2007125 
5.2. Methods 
5.2.1. Systematic Review Protocol 
This review was registered on the International Prospective Register of Systematic Reviews 
(PROSPERO) reference 42015022078283, and conducted in line with a full pre-published 
study protocol284. The protocol was published within an open access peer-reviewed journal 
and is available in Appendix 8. A pragmatic search strategy was used, refining searches that 
built upon studies identified as part of the overview of systematic reviews of the diagnostic 
accuracy of brief cognitive assessments for identifying dementia in primary care (described in 
Chapter 4 of this thesis). The review was conducted as reported within the protocol.  
Departures from the published protocol 
There were two departures from the published protocol. One was regarding 
stratification of GPCOG. Within the protocol, it was stated that the most clinically-
relevant measures of GPCOG Patient, GPCOG Total and GPCOG Two stage (as 
GPCOG Informant has not been recommended for use by itself within a clinical 
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setting284) would be used. The studies identified for inclusion within this systematic 
review reported four individual measures for GPCOG, using GPCOG Informant, 
GPCOG Patient, GPCOG Total and GPCOG Two stage so on this occasion the data 
guided the decision and was and stratified across these four GPCOG subtypes, rather 
than the pre-stated and arguably more clinically-relevant three subtypes. 
The other departure from the protocol was in data extraction where it had been stated 
in the protocol that the data abstraction form would be piloted with two included 
studies. In the event only one study was used to pilot the form, as it was a simple 
process and necessary amendments to the form were obvious after only one trial run. 
5.2.2. Outcomes  
Primary outcome  
The primary outcome of this review was the comparative accuracy of the two tests 
assessed via direct comparisons, that is the diagnostic accuracy of the two tests 
compared within the same population in a single study.  
Secondary outcome  
The secondary outcome of the review was to identify other common test-related 
factors identified by included studies, such as acceptability or administration time. 
Whilst beyond the primary focus of test accuracy, these other factors may contribute 
to the overall usefulness of the tests when applied in a general practice setting, and 
these were incorporated in the review findings to try and make the most useful 
research and clinical recommendations. 
5.2.3. Search methods from the overview 
In order to build the search database for the overview of systematic reviews of the 
diagnostic accuracy of brief cognitive assessments for identifying dementia in primary 
care, the Cochrane Database of Systematic Reviews, EMBASE, MEDLINE and 
PsychINFO were searched for systematic reviews from inception until August 2015. 
Full search strategies are shown in Chapter 3, Appendices 3 & 4. The full search 
methods from the overview of systematic reviews summarising the accuracy of brief 
cognitive assessments for identifying dementia in primary care are presented in 
Chapter 3, section 3.3.  
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5.2.4. Identification of eligible studies included within the overview 
The 13 systematic reviews included within the overview review88,105,106,120,125,141,148,220-
222,231,236,285 were reanalysed for all component studies that directly compared 
diagnostic accuracy of GPCOG and MMSE aginst one another within a primary care 
setting. The process of identifying eligible studies (directly comparing MMSE and 
GPCOG) from the 13 systematic reviews included within the overview is shown in 
Figure 4.  
Five studies within the 13 systematic reviews included direct comparisons of more 
than one brief cognitive assessment. Of these, three studies 142,286,287 compared 
GPCOG and MMSE and were screened for inclusion in our systematic review.  
Citation searching was conducted using Google Scholar to identify all indexed hits that 
cited these three studies. This identified two further eligible studies43,288, giving a total 
of five studies identified via the overview review. 
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Figure 4 Flow chart of studies identified via the overview 
 
Grey box = systematic review data; blue box = study data 
5.2.5. Identification of novel eligible studies 
The entire process for identifying novel eligible studies for this systematic review is 
shown in Figure 5. One further study119 was identified via Zetoc alerts using the terms 
“MMSE”, “GPCOG”, “test accuracy” and “dementia”. This study had been published 
since the overview was conducted, so had not been identified within the original 
included reviews and component studies. 
In line with the published protocol284, a standard search was run using Embase (1974 
to current), PsychINFO (1806 to current) and Ovid MEDLINE (1946 to current) 
databases using the search terms (((Dementia and GPCOG and MMSE) or Mini 
CHAPTER 5: SYSTEMATIC REVIEW 
   CHAPTER 5 | 143 
Mental State Exam) and Accuracy).af.. In order to identify new studies published since 
searches were conducted for the overview (see Chapter 4) the starting date parameter 
was set to 2015. This is one year previous to the published date of the latest included 
systematic review, Creavin 2016105.  
After deduplication, database searches identified a further 77 sources which were 
added to the 5 identified from the overview and the one study identified via a Zetoc 
alert. Screening notes were written to assist in decision making (shown in Appendix 
9). Two screening reviewers (HH and SvK) independently piloted the first 15 hits 
organised alphabetically to make sure the process was understood and the notes 
helpful and clear. All 83 titles and abstracts were then independently screened by the 
same two reviewers using the online web application Rayyan QCRI289, with 100% 
agreement reached on all decisions.  
Seventy-six sources were excluded at title and abstract screening, with 7 studies 
identified for full text screening (see Table 15). 
Table 15 Sources screened at full text and inclusion/exclusion decisions 
Studies screened at full 
text  
Inclusion/exclusion 
decision 
Reason for exclusion (if 
applicable) 
Basic 2009287 Inclusion  - 
Brodaty 2002142 Inclusion  - 
Brodaty 2006236 Exclusion Assessment across different 
populations  
Brodaty 2016119 Inclusion  - 
Culverwell 200843 Exclusion  Assessment across different 
populations 
Li 2013288 Inclusion  - 
Pirani 2010286 Inclusion  - 
Two studies43,236 were excluded at the full text stage because they assessed brief 
cognitive assessments within different populations, so lacked direct comparisons. 
Five studies119,142,286,288,290 were included directly comparing the diagnostic accuracy 
performance of MMSE and GPCOG as part of the process for identifying dementia 
within a primary care/general practice population.  
CHAPTER 5: SYSTEMATIC REVIEW 
   CHAPTER 5 | 144 
Figure 5 Flow chart of all identified studies 
 
5.2.6. Index tests 
The index tests of interest were the MMSE115 and the GPCOG142. The MMSE is one of the 
most widely used brief cognitive assessments used the within research literature291, and 
development of the GPCOG has been independent to the development of the MMSE119. 
The conventional threshold for the MMSE is 24 (also shown as <24), where out of a 
maximum possible 30 points, scores below 24 indicate impairment. The GPCOG 
comprises of two sections: the section completed by the individual being assessed, 
known as GPCOG Patient, and an optional section for a relative or friend to complete 
(if present) known as GPCOG Informant. GPCOG Patient has 9 items with possible 
total scores of between 0 (indicating severe impairment) and 9 (indicating no 
impairment). GPCOG Informant has 6 items with possible total scores of between 0 
(indicating severe impairment) and 6 (indicating no impairment). GPCOG Patient can 
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be conducted by itself, with a conventional threshold of 8 out of 9 (<8). If informants 
are available, a score of GPCOG Patient between 5 and 8 precipitates the GPCOG 
Informant and the scores are combined (“GPCOG Total”) with a conventional 
threshold of 11 out of a maximum 15 (<11). If no informant is available, the GPCOG 
Informant is not completed and the conventional threshold of 8 stands. It is also 
possible to conduct a staged GPCOG assessment where GPCOG Informant is only 
required if GPCOG Patient is scored between 5 and 8 out of 9. This is known as 
“GPCOG Two stage”.  
Originally the plan was to stratify GPCOG into three types of test (GPCOG Patient, 
GPCOG Total and GPCOG Two stage). This was in order to maximise clinical 
relevance of the review, as GPCOG Informant is not used independently for 
assessment in the clinical setting. Once included studies had been identified, it 
became clear that GPCOG Informant had been assessed as an individual tool in four 
out of the five included studies. The GPCOG subsets were therefore included as 4 
categories of test in line with the data presented within identified studies: GPCOG-
informant with a threshold of >5 and <8; GPCOG-Patient with a threshold of <8, 
GPCOG Total with a threshold of <11 and GPCOG Two stage.  
Terminology around the GPCOG subtypes also differed between studies. Two 
studies286,287 referred to GPCOG/GPCOG-It Participant as ‘GPCOG/GPCOG-It 
Cognitive’. One study287 referred to GPCOG Total as ‘GPCOG Combined’. Throughout 
this systematic review the conventional labels have been used, but the different terms 
used by authors are reflected in Table 16 for completeness. 
5.2.7. Reference standard  
There is currently no 100% accurate (“gold standard”) test for identifying dementia in 
primary care or general practice. Because of this, the identification of an appropriate 
benchmark assessment (“reference standard”) for assessing dementia is not a 
straightforward one. In addition, some reference standards which assess cognitive 
impairment (e.g. CAMDEX, CAMCOG) incorporate elements of the MMSE within the 
tool. As an example, CAMCOG is the cognitive section of the longer Cambridge 
Examination for Mental Disorders of the Elderly (CAMDEX) and incorporates 19 
questions from the MMSE292,293.  
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Reference standards were judged to be acceptable for this systematic review based 
upon their common identification within research literature (as identified within the 
overview reported in Chapter 3), and advice from clinical neuropsychologists and old 
age psychiatrists within the research team and Project Advisory Group. Acceptable 
reference standards included the following tools alone, clinical diagnosis alone or 
clinical diagnosis combined with one or a combination of the following assessment 
tools: 
 Diagnostic and Statistical Manual (DSM) III/III-R/IV/IV-R,  
 Clinical Dementia Rating (CDR),  
 International Classification of Diseases (ICD) 10,  
 Geriatric Mental State – Automated Geriatric Examination for Computer Assisted 
Taxonomy (GMS-AGECAT),  
 Cambridge Mental Disorders of the Elderly Examination (CAMDEX),  
 International Psychogeriatric Association World Health Organisation (IPA-WHO) 
criteria. 
Generally, reference standards are selected on the basis of many variables such as 
common practice within individual clinics, practitioner preference, specialisation and 
experience of healthcare professionals and practice managers. Reference standards 
are also subject to changes in cost and fashion. For example, since 2001 the holders 
of the MMSE copyright have been enforcing a cost per use of the test as well as 
pursuing tests based upon the MMSE (such as the Sweet-16) though the courts, 
leading to debates around the use and ethics of copyright for ubiquitous and 
previously-free materials265,294-296.  
Many of the globally-accepted reference standards such as the World Health 
Organisation-supported ICD and the DSM produced by the American Psychiatric 
Association are updated regularly; the DSM-5 (sometimes referred to as DSM-V) was 
released in 2013297, and the ICD-11 was released in 2018298. It was therefore decided 
that the criterion was valid within this wider context. 
5.2.8. Data extraction, selection and coding 
All sources were managed using EndNote X7.7 software. Two reviewers (HH and 
SvK) independently piloted the process for screening titles and abstracts on the first 
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15 sources and screening notes were produced to guide our decisions on title and 
abstract and full text screening. Title and abstract and full text screening were 
conducted independently by the same two reviewers, and a third reviewer (Chris 
Hyde) was available to resolve any disagreements. In the event, this was not 
necessary and both review authors reached consensus without contention.  
A bespoke data extraction form (see Appendix 10) was piloted independently with one 
included study287 by the two reviewers, and small improvements were made to the 
form following discussion between the reviewers. Key data extracted included 
characteristics of included studies (such as authors, year of study, date of publication, 
country of study, outcomes reported, test timings) and general limitations as well as 
components of the 2x2 table (TP, FP, TN, FN) or other accuracy data such as 
sensitivity, specificity and disease prevalence if raw numbers were not available. The 
data extraction form was accompanied by briefing notes. Data were abstracted by one 
reviewer (HH), with all extractions spot-checked by a second (SvK), and a third 
reviewer (CH) acting as moderator as necessary. Again, this was not needed in the 
circumstances as small queries were resolved by discussion between the two 
reviewers. 
5.2.9. Assessment of methodological quality 
 The QUADAS-2299 tool was used to assess methodological quality of diagnostic 
accuracy studies for systematic reviews. While this tool is developed for studies 
focussing on a single index test, its’ suitability was assessed for studies that focus on 
direct comparisons of two index tests by piloting the QUADAS-2 tool on one of the 
included studies. QUADAS-2 uses prompts (or ‘signalling questions’) to explore 4 main 
areas of potential bias and applicability: patient selection, index test, reference 
standard, and flow of patients through the study and timing of the index test(s) and 
reference standard. The tool was tailored to fit this particular review, with a domain 
assessing each index test (MMSE and GPCOG) separately. Questions within Domain 
2 were tailored accordingly; where ‘Index tests’ states: “If a threshold was used, was 
this pre-specified?” this was changed to simply ask “Was/were the threshold(s) pre-
specified?” as both of the index tests (GPCOG and MMSE) have thresholds that 
should be reported. 
Domain 3: Reference standard asks “Were the reference standard results interpreted 
without knowledge of the results of the index test?” This was amended to ask “Were 
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the reference standard results interpreted without knowledge of the results of both 
index tests?” to include consideration of both MMSE and GPCOG. Two reviewers (HH 
and SvK) piloted the tailored QUADAS-2 and accompanying notes on one study287, 
and one reviewer (HH) quality assessed the included studies with spot checks 
provided by a second reviewer (SvK). An example of the QUADAS-2 form is shown in 
Appendix 11, and our tailored quality appraisal notes are shown in Appendix 12. 
5.2.10. Data synthesis and analysis 
Study specific estimates of the sensitivity and specificity (and their 95% confidence 
intervals) of GPCOG and MMSE are presented graphically via forest plots. Forest plots 
and summary receiver operating characteristic (SROC) plots are used to visually 
explore heterogeneity. Results are summarised narratively and displayed within a 
summary of results table (Table 20 Summary of results from included studies). 
Possible subgroup analyses were considered for investigating tests using lower and 
higher thresholds and variations in cases and control groups (e.g. confirmed dementia, 
probably dementia, people with memory problems, healthy people). Reporting bias 
was not assessed, in line with the recommendations of the Cochrane Diagnostic Test 
Accuracy Handbook300. This is because the impact of reporting bias on studies of 
diagnostic accuracy is unclear, and tools for its investigation are in the early stages of 
development301. 
5.3. Results 
5.3.1. Characteristics of included studies 
Key study characteristics (lead author, date of publication, country of origin, study 
design, setting, dementia severity, number of patients mean age plus standard 
deviation, participants, reference standard, index tests, thresholds and total score, 
other outcomes measured) across all five included studies are shown in Table 16. 
Study design 
Of the five studies119,142,286-288 within this review, three studies employed cross-
sectional designs, where all patients are recruited and receive the reference standard 
and index tests prior to identification of the target condition302. One study reported 
comparisons of diagnostic accuracy between MMSE, GPCOG and the Rowland 
Universal Dementia Scale (RUDAS) using a cross-sectional study design within a 
symptomatic population of 151 community-dwelling older people with early 
dementia287. One study142 adopted a cross-sectional design to examine diagnostic 
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accuracy comparisons between GPCOG, MMSE and the Abbreviated Mental Test 
(AMT) within a mixed symptomatic and asymptomatic population of 283 community 
dwelling patients. One study119 used a cross-sectional study design to compared the 
diagnostic accuracy of GPCOG and MMSE in a mixed symptomatic and asymptomatic 
population of 2,028 community dwelling patients, although the precise mix of 
symptomatic versus asymptomatic participants and how they were identified and 
allocated is unclear in the reporting of this study.  
Two studies used two-gate case-control study designs286,288, where groups of 
participants with and without the target condition are identified before the index test is 
performed302. One study288 explored diagnostic accuracy of the Chinese version of 
GPCOG (GPCOG-C), MMSE and Hasegawa’s Dementia Scale (HDS) in a sample 
comprising 253 symptomatic community-dwelling volunteers with concerns about their 
memory (controls) and 103 psychogeriatric clinic outpatients with subjective memory 
complaints (cases). One study286 examined the diagnostic accuracy of an Italian 
version of GPCOG (GPCOG-It) compared to the MMSE using a case-control design 
in a sample of 182 community-dwelling patients aged 55 years and over with 
subjective memory complaints (cases) and 78 patients without memory complaints 
identified for inclusion by their GPs (controls). For the purposes of this systematic 
review, results of the RUDAS, AMT and HDS were excluded. 
Study populations 
Recruitment was from the community and general practice, with one study288 also 
recruiting from a hospital and the psychogeriatric department of a local mental health 
centre. Li 2013288 and Brodaty 2002 142 excluded participants who had signs of 
delirium, as well as those with visual or hearing impairments. Basic 2009287 also 
excluded on this basis but added an exclusion for people with physical impairments. 
Brodaty 2002 also excluded people with a diagnosis of depression or if they had poor 
English language abilities. Brodaty 2016119 excluded people with neurological disease, 
psychotic symptoms, developmental disabilities, substance abuse, progresive 
malignancy, or an illness that the GP judged may impede study completion119. Pirani 
2010 excluded all patients with known cognitive impairment, or comorbidity 
“predisposing to cognitive disorders such as metabolic and cardiovascular disorders” 
(p.83286).  
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Recruitment  
Recruitment of study participants was from the community and general practice, with 
one study288 also recruiting from a hospital and the psychogeriatric department of a 
local mental health centre.  
Setting, timings and blinding 
Participants were recruited from various locations (see above), but all were assessed 
by aged care psychiatrists, geriatricians or senior registrars in specialist geriatric or 
psychiatric disciplines286-288 except in two studies where follow up assessments were 
carried out by research psychologists142 or research nurses119.  
In one study there was a lack of clear separation in process between administration of 
the reference standard and index tests. Within the case control study by Pirani 2010, 
the patient group (‘cases’) were recruited over 6 months either after referral to a 
Dementia Assessment Unit (DAU) by GPs “trained in administering the GPCOG-It in 
their daily practice” (p.83286), or self-referred to the DAU seeking medical advice. The 
study flow diagram makes it clear that GP referral was based upon results of the 
GPCOG-It. The control group were recruited by GPs from their “well known attendees 
without known cognitive impairment” (p.84) and referred on to the DAU without 
undergoing the GPCOG-It. At one month follow up, GPCOG-It was administered to 
those who had not undergone previous assessment (i.e. self-referred cases or GP-
recruited without symptoms) alongside MMSE, CAMCOG and ADAS-Cog 
assessment. Dementia diagnosis was made by expert geriatricians blinded to 
GPCOG-It scores using a semi-structured interview, physical exam and results of 
MMSE, CAMCOG and ADAS-Cog assessments. The MMSE results used to compare 
against the GPCOG-It were derived from this process, meaning the MMSE 
assessment formed both part of the reference standard and the index test. As referred 
to in the Methods section (5.2.6), Cambridge Cognitive Examination (CAMCOG)119 
also incorporates the MMSE. The Alzheimer’s Disease Assessment Scale – Cognitive 
section (ADAS-Cog) was designed to measure aspects of cognition in Alzheimer’s 
disease including components on memory language and praxis303 and appears to 
have been developed independent of both MMSE and GPCOG.  
Whilst the assessment of GPCOG-It in this study appeared to be independent of the 
reference standard, the assessment of MMSE clearly was not independent. Therefore 
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the ability of the MMSE to accurately identify people with cognitive impairment may 
have been overestimated or underestimated due to incorporation bias.  
Li 2013 used GPs or junior psychogeriatricians to assess participants using the 
GPCOG-C, MMSE and HDS. Following this (with timings between assessments 
unreported), one of four senior geriatricians blinded to the earlier results interviewed 
participants and their informants in order to make a diagnosis of dementia using DSM-
IV and clinical judgment. Part of this process involved assessment of the participant’s 
cognitive and functional abilities, but no detail was provided within the paper on how 
this was done or whether a cognitive assessment tool was used. 
Within the 2002 study by Brodaty142, following recruitment GPs administered an 
unrefined version of GPCOG plus the AMT to consecutive patients and contacted an 
informant known to the patient for at least 5 years, either by telephone or in person. 
Presumably this was in order to conduct the Informant section of the GPCOG, 
although this is not stated within the paper. Around 5 weeks later, a research 
psychologist visited the participant at home and carried out assessments including the 
CAMDEX and GPCOG with an informant interview where possible. It was not reported 
whether the research psychologist was blinded to previous assessment results. The 
CAMDEX incorporates the MMSE (as part of the cognitive subscale CAMCOG) and 
so, as with Pirani 2010, this introduces a potential source of incorporation bias where 
the CAMDEX is used as part of the reference standard as was the case in this study.  
Basic 2009287 recruited participants from memory clinics to which they had been 
referred by GPs, themselves and relatives, or community aged care teams. Before 
recruitment, they were assessed for cognition by a senior geriatrician, aged care 
psychiatrist or senior registrar with geriatric or psychiatry specialty and were then 
assessed by a research assistant at their home, the clinic another location. Timings 
between assessments are not reported within the manuscript, and no details of 
blinding are provided. One other brief cognitive assessment (the RUDAS) was 
conducted by a research assistant blinded to scores, so the inference could be that 
other assessments were not blinded as otherwise this would have been noted. Data 
from both the MMSE and GPCOG were used to decide DSM-IV diagnoses, again 
introducing the potential for incorporation bias which may result in an overestimation 
of effect.  
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Study size 
Basic 2009287 reported the smallest study sample size with 151 participants, in a study 
using a cross-sectional design. Participants were ‘older’ (age limits not given), 
community-dwelling with mixed symptomatology. Pirani 2010286 included a sample 
size of 200 participants using a case-control design consisting of 132 people within a 
symptomatic patient group and 68 people in an asymptomatic control group. Brodaty 
2002142 employed a cross-sectional study design which included 283 participants of 
mixed symptomatic and asymptomatic presentation, with asymptomatic patients being 
aged 75 years and over, and symptomatic patients suspected of having a memory 
problem aged between 50 and 74 years old. Within this study there were discrepancies 
amongst sample sizes presented, with different sample sizes reported across all 
measures (GPCOG Patient: N=282, GPCOG Two Stage: N=246, MMSE: N=283 and 
AMT: N=269) except GPCOG Informant and GPCOG Total: N=202). The only 
explanation offered by the authors was that sample sizes varied due to missing data 
(see Table 1 in the original study142). Li 2013288 included 356 participants within a 
double-gate case-control design consisting of 103 people who were outpatients of a 
psychogeriatric clinic with memory complaints (cases) and 253 people living in the 
community aged over 50 years old with memory concerns (symptomatic controls).  
Finally, Brodaty 2016119 included 2028 participants in a Single-gate cross-sectional 
study design. Participants were living in the community with mixed symptomatic and 
asymptomatic presentation, although the exact mix of symptoms and allocation within 
the study is unclear from the manuscript. Within this study, all participants did not 
complete all the brief cognitive assessment measures; 2028 participants were 
administered the MMSE, but only 1717 undertook GPCOG with missing GPCOG data 
of 311 participants unaccounted for. For this reason, these data have been analysed 
separately within this thesis as this discrepancy is not explained within the study text.  
Study authors and locations 
One study author (Henry Brodaty, developer of GPCOG) was lead author on two of 
the included studies119,142 and co-author on another two of the included studies286,288. 
Three of the studies119,142,287 were based in three states (Victoria, New South Wales, 
South Australia) across Australia, with one study288 based in Shanghai, China and one 
study286 based in Modena and Cento, Italy.  
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Index tests 
MMSE, GPCOG, GPCOG-C, GPCOG-It, RUDAS, AMT, and HDS were all employed 
as index tests across included studies. As the focus of this systematic review is solely 
MMSE and GPCOG (or national adaptations), results of RUDAS, AMT and HDS are 
reported (see Table 16) but were not included in the analysis.  
GPCOG subtypes were given slightly different names across studies. Basic 2009287 
refers to GPCOG Cognitive. Pirani 2010286 similarly refers to GPCOG-It Cognitive. 
GPCOG and GPCOG-It Cognitive in these studies correspond to GPCOG-C Patient 
referred to in Li 2013288, and GPCOG Participant referred to in the most recent 
included study, Brodaty 2016119.  
GPCOG/GPCOG-It/GPCOG-C consistently refer to GPCOG Informant for the 
informant section of the tool. GPCOG Total, however, which combines the scores of 
GPCOG Participant and GPCOG Informant, is referred to by Basic 2009287 as GPCOG 
Combined whereas all other studies refer to GPCOG Total. 
GPCOG Two-stage is only referred to in these terms across all four studies in which it 
features. 
Diagnostic thresholds  
MMSE was assessed at three different diagnostic thresholds (<24, <25 and <27) 
across different studies: one study based in Italy286used both <25 and <27 as 
thresholds for dementia. The study authors reported <25 as the ‘standard’ threshold, 
and <27 as approved under Italian law to identify people eligible for free cholinesterase 
inhibitors under a programme titled “Progetto Chronos”.  
The greatest number of included studies comparing MMSE at a single threshold and 
GPCOG was three119,287,288, which reported an MMSE threshold of <24 compared to 
GPCOG Total and this is arguably the most clinically-relevant comparison. These 
distributions are illustrated in Table 17. 
Reference standards 
Reference standards differed between studies, with four studies using DSM-IV 
criteria119,286-288 and one using CAMCOG142. One study used DSM-IV without 
reference to other tools288. Three studies used DSM-IV and at least parts of the 
MMSE119,286,287. Two of these studies used DSM-IV, MMSE and CAMCOG (which 
incorporates the MMSE and is part of the wider CAMDEX293). 
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As detailed in ‘Setting, timings and blinding’ above, CAMCOG incorporates the MMSE 
as part of the measure. DSM-IV decisions in one study explicitly used MMSE and 
GPCOG scores as part of the decision-making process287 and two studies used MMSE 
as part of the DSM-IV assessment119,286. Only one study solely referred to using the 
DSM-IV288 as a reference standard. ICD-10 criteria did not feature in any of the five 
included studies. 
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Table 16. Summary of characteristics of included studies 
Source 
(year) 
Country  
[sd; pop] 
Setting  Dementia 
severity 
(measure) 
# 
patients,  
𝒙 age yrs 
± SD 
Participants Reference 
standard 
Index test, threshold 
indicating impairment/ total 
score 
Other 
outcomes 
measured 
Basic (2009) 
Australia 
[SG; symp] 
CALD 
community  
Early 
dementia 
(Lawton 
IADL & 
GDS) 
151, 77.1 
± 8.9 
Community dwelling 
older people (no age 
limit given) 
DSM-IV using 
MMSE and 
GPCOG 
MMSE, <24/30 
GPCOG Cognitive†, <8/9 
GPCOG Informant, <5/6 
GPCOG Combined‡, <11/15 
RUDAS, <23/30  
MBI; GDS; 
Lawton IADL 
Brodaty 
(2002) 
Australia 
[SG; 
unclear] 
PC 
doctors’ 
offices 
NR 283, 79.6 
± 6.1 
Community dwelling 
people 50-74yrs with 
MC; and patients ≥75 
yrs  
DSM-IV using 
CAMDEX, 
CAMCOG and 
MMSE  
MMSE, <24/30 
GPCOG Participant, <8/9 
GPCOG Informant, <5/6 
GPCOG Total, <11/15 
GPCOG Two-stage, >5 <8/15 
AMT, <8/10 
GDS; SFHS 
Brodaty 
(2016) 
Australia 
[SG; mixed] 
GP 
practices 
NR 2028, 81.1 
± 4.12  
Community dwelling 
people ≥75 yrs who had 
visited their GP within 
the last 24 months 
CAMCOG MMSE, <24/30 
GPCOG Total, <12/15 
GPCOG Two-stage, >5<8/15 
GDS 
Li (2013) 
China 
[2G; 
‘healthy’] 
PC facility, 
MH centre 
and 
community 
NR 356, 72.5 
± 8.9  
People aged 50-90 yrs 
from the community, 
attending Waitan 
Hospital or the 
psychogeriatric 
department of the 
Shanghai MH Center 
DSM-IV MMSE, NR 
GPCOG-C Patient, <8/9 
GPCOG-C Informant, <5/6 
GPCOG-C Total, <11/15 
GPCOG-C Two-stage, >5 
<8/15 
HDS, <21/32.5 
Administration 
time 
Pirani 
(2010) 
Italy 
[2G; symp] 
Community 
& GP 
practices 
NR 200, 76.1 
± 7.2 
People aged over 55 yrs 
with an available 
informant referred to 
DAUs by GPs 
DSM-IV using 
CAMCOG, MMSE, 
and ADAS-Cog 
MMSE, <25/30 
MMSE, <27/30 
GPCOG-It Cognitive†, <8/9 
GPCOG-It Informant, <5/6 
GPCOG-It Total, <11/15 
GPCOG-It Two-stage, >5 
<8/15 
Administration 
time; dementia 
severity (not 
explicitly 
assessed a 
priori) 
sd = study design; pop = population; SG = single-gate cross-sectional design; 2G = two-gate case-control design; symp = symptomatic [controls]; unclear = unclear symptomatic/asymptomatic; mixed = symptomatic & 
asymptomatic participants; ‘healthy’ = healthy controls, without memory complaints; MMSE = Mini Mental State Examination; GPCOG = General Practitioner Assessment of Cognition; NR = not reported; PC = primary care; 
CALD = culturally & linguistically diverse; MH = mental health; yrs = years; SD = standard deviation; GPs = general practitioners; CACT = community aged care teams; MCs = memory clinics; Lawton IADL = Lawton 
Instrumental Activities of Daily Life scale; GDS = Geriatric Depression Scale; DSM-IV = Diagnostic and Statistical Manual version 4; MBI = Modified Barthel Index; MC = memory complaints; SFHS = short form health survey; 
AMT = Abbreviated Mental Test; GPCOG-C = General Practitioner Assessment of Cognition – Chinese version; HDS = Hasegawa’s Dementia Scale; SMC = subjective memory complaints; DAUs = Dementia Assessment 
Units; GPCOG-It = General Practitioner Assessment of Cognition - Italian version; †GPCOG Cognitive = GPCOG Participant; ‡GPCOG Combined = GPCOG Total.)
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Table 17. Distribution of included studies reporting on GPCOG and MMSE at 
different thresholds 
 MMSE GPCOG 
<24 <25 <27 Informant Patient Total Two-stage 
Basic 2009        
Brodaty 
2002 
       
Brodaty 
2016 
       
Li 2013*        
Pirani 2010†        
* contain comparisons between MMSE<24 and GPCOG-C, the Chinese version of the GPCOG 
† contains comparisons between MMSE<25, MMSE<27 and GPCOG-It, the Italian version of GPCOG 
The distribution of included studies examining GPCOG and MMSE at different 
thresholds is shown in  
GPCOG-Total was measured in all five of the included studies, and GPCOG Informant 
and Patient were measured in the same four studies142,286-288. GPCOG Two-stage was 
measured in four studies119,142,286,288.  
Table 17. It is most informative to read across the table to see which studies report at 
the same MMSE threshold and the same GPCOG subsection. For example, Basic 
2009287, Brodaty 2016119 and Li 2013288 all reported MMSE <24, but of these all three 
only reported GPCOG Total scores. Only two287,288 out of these studies reported 
GPCOG Informant, Patient and Two-stage sections (one of which288 actually reported 
GPCOG-C, the Chinese variant). At the conventional MMSE threshold of <25, two 
studies142,286 measured GPCOG Informant, Patient, Total and two-stage (although one 
of those studies286 used the Italian variant of GPCOG, GPCOG-It). Only one study286 
directly compared MMSE at two different thresholds (<25 and <27) against GPCOG 
Total Italian version (GPCOG-It Total).  
GPCOG-Total was measured in all five of the included studies, and GPCOG Informant 
and Patient were measured in the same four studies142,286-288. GPCOG Two-stage was 
measured in four studies119,142,286,288.  
5.3.2. Quality assessment 
Study quality was assessed using a tailored version of QUADAS-2299, following 
coproduction of quality assessment notes by Harriet Hunt and Sanne Van Kampen. 
These notes are shown in the appendix (Appendix 12). The QUADAS-2 tool tailored 
for this review and accompanying notes were independently piloted on Basic 2009287 
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by two reviewers (HH and SvK) and we compared our assessments and experiences 
of the process after this. The quality of the remaining four studies119,142,286,288 was 
assessed, and another reviewer (SvK) spot-checked assessments. From these 
assessments we produced both a summary graph (Figure 6) and a table of 
judgements across domains for each included study (Figure 7) to illustrate these 
quality assessment decisions. 
Figure 6. QUADAS-2 Risk of bias and applicability concerns graph: review authors' 
judgements about each domain presented as percentages across included studies 
 
As shown in Figure 6, we assessed patient selection as introducing a moderate to high 
(50-75%) risk of bias when summarised across all five studies. Two studies286,288 
employed two-gate case-control designs, with Li 2013 including symptomatic controls 
with memory concerns, and Pirani 2010 including “healthy” controls recruited from 
routine general practice excluding symptomatic patients and those with conditions 
“predisposing to cognitive disorders”.  
A challenge of the QUADAS-2 instrument is that, whilst case-control designs are 
highlighted as a potential source of bias, there is no further advice or recommendation 
on how to then handle these studies. There is also no assessment of the type of case-
control design studies use, for example the sampling strategies employed and whether 
they are single-gate (from the same sample) or two-gate (from two different samples). 
These approaches vary considerably and introduce different types of biases and 
potential variables depending on the target population, recruitment, and sampling 
framework. If a single sample is used, one might reasonably expect less variation than 
if two distinct samples are recruited as in a two-gate study design. Test accuracy will 
vary across different subsets of participants, so particular attention should be given to 
diagnostic accuracy studies with two different sampling schemes for symptomatic 
cases and healthy controls, as was the case with the case control designs included in 
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this review. One major issue of systematic reviews including studies of direct 
comparisons is the potential for spectrum effect, where highly-selected symptomatic 
participants, or conversely an overly-narrow range of ‘healthy’ participants, can 
overestimate any observed differences in diagnostic accuracy. Equally, the presence 
of alternative conditions in ‘healthy’ individuals, and the presence of comorbidities in 
either group, can introduce systematic bias as a result of the study design used. These 
factors are not explored in the current version of QUADAS-2, but another iteration of 
this tool for assessing the quality of diagnostic accuracy studies would benefit from 
specifically considering these scenarios. 
Risk of bias concerns for use of GPCOG as an index test were similarly moderate to 
high when summarised across studies. Three of the included studies (Basic 2009287, 
Li 2013288 and Pirani 2010286) blinded raters of GPCOG to results of the reference 
standard. Two of the included studies (Brodaty 2002142 and 2016119) did not blind 
raters of the GPCOG to results of the reference standard or the other index test 
(MMSE, which in four  cases 119,142,286,287 formed both an index test and reference 
standard, either in isolation or as part of the CAMCOG).   
Figure 7. QUADAS-2 Risk of bias and applicability concerns: review authors' 
judgements about each domain for each included study 
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When summarised across all studies (see Figure 6), risk of bias concerns for use of 
the MMSE as an index test were high (100%). This was primarily due to interpretation 
of the index test taking place without blinding to the results of the reference standard. 
In four studies, the reference standard incorporated the MMSE index test either as 
part of the CAMCOG119,286, the broader (and encompassing) CAMDEX142 or simply as 
part of the composite tools used by assessors to arrive at a DSM-IV diagnosis287.  
Whilst not specifically assessed within QUADAS-2, Li 2013288 did not prespecify the 
MMSE threshold used within the study, meaning optimum diagnostic thresholds could 
have been selected post-hoc. Introducing the potential for data-driven selection of 
optimal thresholds is a significant concern304, because such discrimination can lead to 
overly-optimistic assessments of sensitivity and specificity. This risk is heightened in 
studies with smaller sample sizes as is the case with Li 2013288 (N=253).    
Risk of bias concerns around the reference standard were also high (75-100%) when 
summarised across all five included studies. This was due to the potential for 
incorporation bias in using an index test (MMSE) as part of the reference standard in 
four studies119,142,286,287, either as a discrete tool or as part of the CAMCOG. One study 
(Li 2009288) solely used a psychogeriatricians’ clinical judgment based upon DSM-IV 
criteria as the reference standard, which we judged to contribute a low risk of bias to 
reference standard assessments.  
A moderate risk of bias (25-50%) was found for flow and timing summarised across 
all studies. This was negatively skewed by two studies, Brodaty 2002142 and 2016119, 
where all participants were not included in the analysis and were recorded as missing 
data without explanation or discussion within the manuscripts. Within Brodaty 2016, 
311 participants were recorded as “missing GPCOG data” meaning the total samples 
of participants differed between those assessed using MMSE (n=2028) and those 
assessed using GPCOG (n=1717). These missing data were explicitly reflected within 
the study flow diagram but not elsewhere. This constitutes a loss of 15% of participants 
(2028/1717), distributed asymmetrically and solely within the GPCOG sample.  
Within Brodaty 2002, 81 patients were missing between recruitment and 
administration of the MMSE to conduct of the GPCOG, although with no study flow 
diagram provided it is unclear at what stage the participants went missing. This 
constitutes a loss of 29% of participants (283/202) and again, is distributed 
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asymmetrically within the GPCOG sample. These are not small losses, and this 
substantial percentage of missing data alongside the asymmetry of the loss indicated 
a ‘high’ risk of bias rating for flow and timing. These losses were not initially obvious 
within the manuscript and only emerged during synthesis, and so these ratings were 
revised from an initial rating of ‘low’ risk of bias. This raises additional issues for quality 
assessment ratings generally and handling of the data, which will be addressed in 
more detail within the Discussion section of this chapter. 
In terms of applicability of the individual studies to the research question “How 
accurate are GPCOG and MMSE in identifying dementia within a general practice 
setting when directly compared to each other?”, patient selection was assessed as 
being particularly problematic with a moderate to high (50-75%) concern of 
applicability. Basic 2009287 and Pirani 2010286 excluded patients with delirium or visual, 
hearing or physical impairments287 and known cognitive impairment or comorbidity 
related to cognitive disorders including metabolic and cardiovascular diseases286. 
Similarly, Brodaty 2016119 excluded patients with neurological disease, psychotic 
symptoms, developmental disability, substance abuse, progressive malignancy, or an 
illness that the general practitioners judged may prevent patients completing the study. 
Brodaty 2002142 excluded patients with delirium, depression, poor English language 
abilities, sight or hearing. Li 2013288 excluded participants with acute or unstable 
psychiatric disorders “such as major depression”, as well as delirium, anxiety, or a 
vision or hearing impairment. This study also excluded people without a suitable 
informant available. It was concluded that these exclusions meant the patient group 
assessed were less suited for a typical general practice population, where 
multimorbidities and concurrent impairments would not be unusual51. 
Applicability of the MMSE as index test was assessed as a low to moderate concern 
(25-50%). Four studies were rated as a low concern except Li 2013288 which was rated 
as a high concern. In this study, the authors did not pre-state the MMSE threshold 
used, and so raised doubts over whether post-hoc selection of an optimum threshold 
had been introduced.  
There were no notable concerns in applicability to the research question for the 
remaining domains, so in these remaining areas all studies were rated as low 
concerns.  
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Brodaty 2002 was judged as a high risk of bias across all five domains (Patient 
selection, index test: GPCOG, index test: MMSE, reference standard, and flow and 
timing). These ratings were due to the non-randomised recruitment of participants and 
the number of potentially-inappropriate exclusions such as the exclusion of 
participants with clinically suspected dementia but without corroborative history to 
assess decline. Index tests and reference standards were measured without blinding 
of the assessors, and one of the index tests (MMSE) was incorporated into the 
reference standard as part of the CAMCOG, which in itself was part of the CAMDEX 
tool used to derive criteria for a DSM-IV-based diagnosis of dementia. There was no 
evidence that the MMSE threshold was prespecificed, and there was reference to a 
post-hoc analysis of the MMSE at a lower threshold of <24. GPCOG threshold was 
pre-specified, but was administered twice to all participants with a 5-week wait in 
between assessments. This repeat testing was in order to refine the measure, but did 
mean participants underwent the same test within a relatively short period of time 
which may have introduced further confounding. As referenced earlier, missing data 
was a major issue in this study with 29% of participants missing between recruitment 
and conduct of the MMSE to conduct of GPCOG. 
In terms of individual study quality, Brodaty 2016 was rated as a low risk of bias in one 
domain (Patient selection), with a high risk of bias rating across four domains - the 
index test: MMSE, index test: GPCOG, reference standard, and flow and timing of the 
study. Applicability concerns were low across all domains, meaning we assessed the 
study results as broadly applicable to our study question. This was a particularly 
problematic assessment. The low risk of bias in the ‘Patient selection’ domain was 
difficult for handling missing data, as the QUADAS-2 question relates to patient 
selection and recruitment, rather than patient flow but this distinction feels artificial 
compared to practical data handling. The flow and timing question does not ask about 
patients receiving the index tests, neither is there any question nor prompt to 
determine whether, if all patients were not included in the analysis, the missing data 
were reasonably accounted for. In terms of applicability concerns, recruitment seemed 
reasonable given the limited data available within the manuscript, and broadly 
matched the population in question.  
The QUADAS-2 question asks ‘Are there concerns that the index test, its conduct, or 
interpretation differ from the review question?” to which the answer in this case was 
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no, because the review question was clearly stated in terms of the population, index 
tests, condition and outcomes so searches were designed specifically to address this 
question. Answering ‘yes’ to this question would imply that searches were poorly-
designed or conducted, and/or that the review protocol was inappropriate for 
answering the research question. Both Basic 2009287 and Pirani 2010286 were rated 
as high risk of bias and high applicability concerns in patient selection as they used 
double-gate case-control designs, which have been shown to exaggerate overall 
diagnostic accuracy305.  
Translated versions 
Two of the included studies included variants of GPCOG adapted for languages other 
than English; one variant is translated into in Italian, the GPCOG-It286 and one into 
Chinese, the GPCOG-C288. Both measures were formed as a translation of the original 
GPCOG142 maintaining the original format and scoring system. Both adapted 
measures were developed by research teams including the originator of GPCOG, and 
both measures maintained all aspects of the test except the source language. 
Rater differences 
There were differences between the raters of the included measures. None of the 
included studies incorporated test assessors who were explicitly identified as general 
practitioners, although all studies stated the test of interest would be for use in a 
general practice or community population. In the study by Li 2013288, six out of ten of 
their raters were psychogeriatricians who were “well trained and experienced in 
dementia screening” with between eight and 20 years’ experience of screening 
practice. In this study, raters used clinical judgment rather than any pre-specified 
diagnostic criteria. 
In the study by Basic 2009287, raters were aged care clinicians and not explicitly GPs 
– although these assessors were potentially closest to the target rater population. In 
the study by Brodaty 2002142, the tests were administered by research psychologists 
and in Brodaty 2016 119 both GPCOG and MMSE were administered by trained 
research nurses. Finally, the study by Pirani 2009 286 included test administration by 
expert geriatricians or neurologists rather than GPs. 
Incorporation bias 
There was significant potential for incorporation bias across four of the five included 
studies, where elements of one or more of the index tests under assessment are 
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included within the reference standard, thus risking overestimation of agreement 
between measures. In Basic 2009, data from both MMSE and GPCOG were used to 
arrive at DSM-IV assessments. Brodaty 2002 used a modified version of the CAMDEX 
as their reference standard, which contains elements of the MMSE. Brodaty 2016 used 
CAMCOG as the reference standard, which again contains elements of MMSE. Pirani 
2010 included a reference standard of DSM-IV assessment based upon a semi-
structured interview with both patient and informant, a physical examination, as well 
as scores on Italian versions of MMSE, CAMCOG and ADAS-COG. Only Li 2013 used 
a reference standard of clinical judgment that was assessed by raters (geriatricians) 
blinded to MMSE, GPCOG-C and HDS scores.  
5.3.3. Comparing sensitivity and specificity 
The Forest plot in Figure 8 shows sensitivity, specificity and confidence intervals 
across all included tests (GPCOG Informant, Patient, Total and Two Stage) as well as 
MMSE at three thresholds (<24, <25 and <27).  
In GPCOG Total, the one measure where all five included studies119,142,286-288 report 
data, sensitivity ranges from 0.79 to 0.98, with specificity ranging from 0.78 to 0.92. 
The balance between sensitivity and specificity scores also vary without a consistent 
direction of effect, with Basic 2009 reporting higher sensitivity of 0.98 (95% CI 0.91-
1.00) and lower specificity of 0.78 (95% CI 0.68-0.86) and Brodaty 2016 reporting 
lower sensitivity of 0.79 (95% CI 0.71-0.86) and higher specificity of 0.92 (95% CI 0.91-
0.93). 
GPCOG Informant accuracy measures show consistent direction of effect, with the 
four smaller studies142,286-288 which included this measure all reporting higher 
sensitivity (0.83-0.98) and lower specificity (0.49-0.83). GPCOG Patient performance 
shows the same pattern across the same four studies, with higher sensitivity (0.82-
0.98) and lower specificity (0.54-0.70).  
GPCOG Two-stage accuracy reveals similar variability to GPCOG Total, with the four 
studies119,142,286,288 reporting a mix of higher sensitivity (0.97, 95% CI 0.91-1.00) and 
lower specificity (0.89, 95% CI 0.85-0.93) in Li 2013 compared to lower sensitivity 
(0.80-0.85) and higher specificity (0.86-0.93) in the other three studies. 
MMSE accuracy measures across thresholds demonstrated similar variability, with 
MMSE <24 measured in three studies ranging from sensitivity 0.51-0.89 and specificity 
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0.88-0.97. MMSE <25 was without clear direction across two studies142,286 reporting 
sensitivity 0.78-0.80 and specificity 0.76-0.98. At the highest threshold of MMSE <27, 
Pirani 2010 reported sensitivity of 0.93 (95% CI 0.87-0.97) and specificity of 0.91 (95% 
CI of 0.82-0.97).  
 Figure 8. Forest plot displaying sensitivity and specificity of all brief cognitive 
assessments across studies  
N.B. 0.1 sensitivity difference from that reported in Brodaty 2002142 due to rounding up in the original 
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paper – recalculated here using actual figures. Brodaty 2002 and 2016 measures of MMSE and 
GPCOG report imbalanced sample sizes. 
GPCOG Total was assessed in all five included studies119,142,286-288, MMSE <24 was 
assessed in three of the included studies119,287,288 and MMSE <25 was assessed in 
two 142,286 out of the five included studies.  
These measures are clinically relevant for comparison in terms of being used 
individually within a general practice setting as part of the process for assessing 
cognitive function, so may be fairly compared to one another (as opposed to, for 
example, MMSE versus the GPCOG Informant which is unlikely to be used in isolation 
within clinical practice). MMSE thresholds of <24 and <25 are both commonly used in 
practice and research, with their relative strengths and weaknesses for a general 
practice population not yet certain 65,105,106,119,146,265,306. Therefore it would seem to be 
of benefit to assess the directly comparable accuracy of these two MMSE thresholds 
separately, in order to identify any variation in sensitivity or specificity that would 
suggest one threshold to have benefits over the other in specific situations (e.g. if 
ruling out dementia was the clinical priority). 
5.3.4. GPCOG Total versus MMSE<24 
Table 18 illustrates that at an MMSE threshold of <24, there was an absolute 
difference between GPCOG and MMSE sensitivity of 8.77% in Basic 2009, and 
10.26% in Li 2013. The absolute difference in specificity between MMSE <24 and 
GPCOG Total was -10.64% in Basic 2009, and 1.57% in Li 2013.  
At an MMSE threshold of <25, the absolute difference in sensitivity was 0.87% for 
Brodaty 2002 and 13.64% for Pirani 2010. The absolute difference in specificity for 
these measures was 7.10% in Brodaty 2002 and 10.25% in Pirani 2010, as shown in 
Table 18.  
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Table 18. Sensitivity and specificity comparing GPCOG Total versus MMSE 
thresholds <24 and <25 
Study Sensitivity [true 
positives/total cases] 
Difference 
(95% 
Confidence 
Interval) 
Specificity [true 
negatives/total non- 
cases] 
Difference 
(95% 
Confidence 
Interval) 
 GPCOG 
Total 
MMSE<2
4 
 GPCOG 
Total 
MMSE<2
4 
 
Basic 
2009287 
0.98  
[56/57] 
0.89 
[51/57] 
8.77  
(-0.62 to 19.47) 
0.78  
[73/94] 
0.88  
[83/94] 
-10.64  
(-21.31 to 
0.19) 
Brodat
y 
2016119 
0.79  
[99/125] 
0.51  
[76/148] 
27.85 
(16.64 to 37.95) 
0.92 
[1465/1592] 
0.97 
[1824/188
0] 
-5.00 
(-6.59 to -
3.49) 
Li 
2013288 
0.97  
[76/78] 
0.87 
[68/78] 
10.26  
(1.75 to 19.64) 
0.86 
[238/278] 
0.94 
[261/278] 
-8.27 
(-13.41 to -
3.25) 
 GPCOG 
Total 
MMSE<2
5 
 GPCOG 
Total 
MMSE<2
5 
 
Brodat
y 
2002142 
0.81*  
[48/59] 
0.80* 
[66/82] 
0.87 
(-12.86 to 13.50) 
0.83 
[119/143] 
0.76 
[153/201] 
7.10  
(-1.71 to 
15.33) 
Pirani 
2010286 
0.92 
[121/132] 
0.78  
[103/132] 
13.64 
(5.03 to 22.23) 
0.88  
[60/68] 
0.98  
[67/68] 
-10.29 
(-20.14 to -
1.74) 
* Reported in Brodaty 2002142 as sensitivity 0.82 and 0.81, due to rounding up in the original paper. N 
varies due to missing data - Brodaty 2002 and 2016 report imbalanced sample sizes. 
Within the studies included in this systematic review, GPCOG Total demonstrated 
consistently higher sensitivity compared to MMSE<24, at the expense of reductions in 
specificity.  
This is similarly illustrated in the Summary Receiver Operating Characteristic (SROC) 
plot shown in Figure 9. This SROC shows paired accuracy of GPCOG Total and 
MMSE summarised across the studies that reported these data, in contrast to the 
study level ROC plots presented and discussed further in this chapter which simply 
present individual study-level sensitivity and specificity scores. 
As shown in Table 18, accuracy data reported within two studies287,288 directly 
comparing MMSE<24 and GPCOG Total shows a mixed relationship between these 
two tests.  
As referenced earlier, both Brodaty 2002 and Brodaty 2016 reported different sample 
sizes for each index test. Brodaty 2002 reported a sample size of 202 for GPCOG 
Total, and 283 for MMSE <25 with no clear reason given for the loss of 29% of the 
recruited sample. Brodaty 2016 reported 1717 for GPCOG and 2028 for MMSE, and 
whilst the samples seem to include the same participants, as reported within the study 
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flow diagram, there is no explanation for the loss of 311 people between tests within 
the original study paper. Whilst this population is relatively large which accounts for 
the lower confidence intervals, this is still an unaccounted loss of 15% of the recruited 
study sample, distributed asymmetrically between tests (the loss was in the GPCOG 
arm) and it is difficult to say what effect this may have on results. This study reported 
lower sensitivity across both MMSE <24 and GPCOG Total, and specificity was higher 
in both tests. The gap between sensitivity and specificity was most marked in MMSE 
<24 where sensitivity was near chance at 0.51 [95% CI, 0.43-0.60] and specificity was 
0.97 [95% CI, 0.96-0.98]. With GPCOG Total, sensitivity was 0.81 [95% CI, 0.69-0.90], 
whereas specificity was 0.92 [95% CI, 0.91-0.93].  
When direct comparisons of GPCOG and MMSE are viewed within the same paired 
accuracy SROC plot the comparative performance of individual tests is plainly 
illustrated, as shown in Figure 9.  
Figure 9 Paired accuracy of GPCOG Total and MMSE SROC plot from studies that 
reported MMSE at the <24 threshold [Basic 2009, Brodaty 2016 and Li 2013] 
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The SROC plot in Figure 9 illustrates the paired sensitivity and specificity of GPCOG 
Total compared to MMSE from studies that reported MMSE accuracy at the <24 
threshold (Basic 2009287, Brodaty 2016119 and Li 2013288) with MMSE shown as a red 
diamond and GPCOG Total as a black circle.  
The size of the diamond or circle represents the number of participants within the 
study, with Brodaty 2016 having the largest sample (N=2028/1717 – note the 
unaccounted discrepancy) and Basic 2009 having the smallest sample (N=151). There 
is an observable pattern of higher sensitivity in the GPCOG Total and higher specificity 
of MMSE across the three studies, suggesting that there may be a trade-off between 
the higher sensitivity of GPCOG Total and marginally higher specificity of MMSE – 
although this is based upon small samples within imperfect studies, so results should 
be treated with caution.  
5.3.5. GPCOG Total versus MMSE <25 
Only two of the included studies (Brodaty 2002142 and Pirani 2010286) reported MMSE 
diagnostic accuracy at a threshold of <25 compared to that of GPCOG Total. Within 
the study by Brodaty 2002142, at an MMSE threshold of <25, GPCOG Total 
demonstrated superiority in both sensitivity and specificity as shown in Table 18. 
Higher sensitivity scores were statistically significant in Pirani 2010286, as judged by a 
lack of overlap in 95% confidence intervals.  
Paired comparisons between GPCOG Total and MMSE reported by Brodaty 2002142 
and Pirani 2010286 illustrated in Figure 10 reveal a similar pattern in the set of paired 
accuracy scores from Pirani 2010 to those observed in data reported at the MMSE<24 
threshold shown in Figure 9 – but again, a small number of samples and variable study 
quality means any inferences drawn are highly limited.  
One set of paired accuracy scores from Brodaty 2002, however, appears to be an 
outlier. As illustrated in both Table 18 and Figure 10, GPCOG Total and MMSE 
accuracy scores appear to be similar, with reported GPCOG Total sensitivity of 0.81 
and specificity of 0.83, and MMSE sensitivity of 0.80 and specificity of 0.76 (N.B. these 
sensitivity figures differ by 0.1 from the sensitivity scores reported in the original paper, 
due to rounding up by the study authors). This lower specificity of 0.76 reported in the 
MMSE accuracy score is at odds with the other included studies, where MMSE 
specificity ranged from 0.88 to 0.98. The GPCOG Total specificity of 0.83 is the middle 
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range of GPCOG Total specificity scores reported within the other included studies, 
where GPCOG Total specificity ranged from 0.78 to 0.92.  
In Brodaty 2002142, the authors suggest two main reasons for MMSE and GPCOG 
accuracy displaying similar performance. Firstly, rater bias may have been present as 
test administrators were clinical psychologists rather than general practitioners. 
Secondly, MMSE formed part of the DSM-IV-based reference standard so there was 
circularity of process which may have inflated the MMSE accuracy performance. 
Whilst these two sources of potential bias are present in this study, they are also 
present in other included studies. Within Li 2013288, tests were administrated and rated 
by a combination of GPs and psychogeriatricians, Brodaty 2016119 used trained 
research nurses, Pirani 2010286 used geriatricians, neurologists and psychologists to 
administer the tests, and Basic 2009286 used research assistants and aged care 
clinicians for test administration. As described under ‘Quality assessment’, in four of 
the included studies119,142,286,287 the reference standard incorporated the MMSE index 
test either as part of the CAMCOG119,286, CAMDEX142 or as part of the composite tools 
used by assessors to arrive at a DSM-IV diagnosis287.  
As these sources of potential bias are present in both Brodaty 2002 and Pirani 2010, 
it may be fairly hypothesised that any biases would be operating similarly on test 
performance across each of the tests. Therefore observable differences are less likely 
due to these potential biases, as they would be equally present across all studies 
vulnerable to these sources of bias and so hold a degree of symmetry across included 
studies.  
This may not be the case with incorporation bias, where the potential bias introduced 
may affect different aspects of test performance differently. It could therefore be 
suggested that incorporation bias is asymmetric, as in a topic area such as where the 
reference standard is a composite measure formed of e.g. neuropsychological 
assessment and clinical judgment based on international disease classifications, the 
degree to which an index test is “incorporated” into a reference standard is not a binary 
result and will vary across studies. 
In the present systematic review (where in four out of the five included studies the 
MMSE has been used as at least part of the reference standard), this may well mean 
that scores on the MMSE as index test will carry greater congruence with the reference 
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standard (against which it is being assessed) and higher sensitivity and specificity will 
result. The degree to which incorporation bias is present and has the potential to 
influence results of the study varies between included studies, however carefully the 
study parameters have been decided and prespecified. 
Figure 10 Paired accuracy of GPCOG Total and MMSE SROC plot from studies that 
reported MMSE at the <25 threshold [Brodaty 2002 and Pirani 2010] 
 
This SROC plot illustrates inconsistent accuracy scores of MMSE across studies, with 
GPCOG Total displaying slightly higher sensitivity in both studies and MMSE showing 
varied specificity. This would suggest two things: primarily, two studies are insufficient 
to show a clear direction of accuracy between these two brief cognitive assessments; 
secondly, that the specificity of MMSE may vary depending on the influence of other 
factors.  
5.3.6. Comparing Receiver Operating Characteristic (ROC) curves 
For every individual test threshold, there is a pair of sensitivity and specificity values 
which can be plotted on a graph. Conventionally this graph displays sensitivity-1 on 
the x axis, and specificity on the y axis - although as can be seen in figures 8-12 below 
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this convention is not always followed. The further into the top left hand corner of the 
graph a curve is drawn, the higher the sensitivity and specificity of the test being 
plotted. Optimum thresholds can be viewed within the context of interactions between 
sensitivity and specificity, although these thresholds may not always be practicable 
depending on the test in question. When assessing optimal thresholds for a clinical 
setting, we should interpret ROC curves within this wider context307.  
 The five individual ROC curves within included studies are shown below in figures 8 
to 12, reproduced with the kind permission of the study authors. The individual study 
ROC plots are described, and then discussed in summary presenting Area Under the 
Curve (AUC) data in a table and re-plotted as a summary ROC (SROC) curve. It is 
worth noting that, currently, the only way to include ROC curves in a systematic review 
is to reproduce the figures used to generate the curves and then re-plot them.  
Basic 2009 created an ROC curve plotting three different tests (RUDAS, MMSE and 
GPCOG) with the GPCOG reporting three different measures shown in Figure 11. The 
focus has not been on RUDAS (the solid line in the ROC curve) as this was not a 
measure of interest for this systematic review. 
Figure 11. Basic 2009 ROC curve comparing RUDAS, MMSE, GPCOG Patient, 
Informant & Total 
Reproduced with kind permission of the study authors.  
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According to the ROC curve in Figure 11, MMSE displays similar sensitivity and 
specificity to GPCOG Patient and GPCOG Total until a point on the curve when MMSE 
sensitivity and specificity dip lower than GPCOG. MMSE, GPCOG Patient and 
GPCOG Informant converge at the mid-point of the curve, whilst GPCOG Total 
maintains a higher curve on both sensitivity and specificity until MMSE reaches and 
maintains higher sensitivity with falling specificity. None of the measures display a 
clear and consistently superior ROC curve within this plot.  
Figure 12 Brodaty 2002 ROC curve comparing AMT, MMSE, & GPCOG Patient, 
Informant and Total 
 
Reproduced with kind permission of the authors.  
Brodaty 2002 created an ROC curve plotting three different tests (AMT, MMSE and 
GPCOG) with the GPCOG reporting four different measures. GPCOG Two-Step is 
reflected in the ROC curve, but it uses a binary outcome of patients scoring above 5 
but below 8 out of a possible 9. In their later paper119 the authors highlight their 
decision not to represent GPCOG Two Step on the ROC curve in Figure 15 “because 
it provides a dichotomous outcome rather than a continuous range of scores” 119 
(p.327).  
In According to the ROC curve in Figure 11, MMSE displays similar sensitivity and 
specificity to GPCOG Patient and GPCOG Total until a point on the curve when MMSE 
sensitivity and specificity dip lower than GPCOG. MMSE, GPCOG Patient and 
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GPCOG Informant converge at the mid-point of the curve, whilst GPCOG Total 
maintains a higher curve on both sensitivity and specificity until MMSE reaches and 
maintains higher sensitivity with falling specificity. None of the measures display a 
clear and consistently superior ROC curve within this plot.  
Figure 12, the lines of interest are the MMSE which is the finest dashed line, the 
GPCOG Informant represented by a thick dashed line, GPCOG Patient represented 
by a thin continuous line, and GPCOG Two Step, which is a thick continuous line. As 
with Basic 2009, AMT results (shown as a thick dashed line on the ROC curve) were 
discounted as this test was not a focus of this systematic review. 
This curve shows slight variation between the two tests at different points, not 
dissimilar to those observed in the ROC plot produced by Basic 2009 (see According 
to the ROC curve in Figure 11, MMSE displays similar sensitivity and specificity to 
GPCOG Patient and GPCOG Total until a point on the curve when MMSE sensitivity 
and specificity dip lower than GPCOG. MMSE, GPCOG Patient and GPCOG 
Informant converge at the mid-point of the curve, whilst GPCOG Total maintains a 
higher curve on both sensitivity and specificity until MMSE reaches and maintains 
higher sensitivity with falling specificity. None of the measures display a clear and 
consistently superior ROC curve within this plot.  
Figure 12) and there is little obvious overall superiority of one test over another. 
Pirani 2010 created an ROC curve plotting MMSE and GPCOG, with the GPCOG 
reporting three measures. Figure 13 shows the ROC curve produced by Pirani 
2010.This ROC curve shows that MMSE accuracy (thick dashed line) performs similar 
to GPCOG-It Total (thick solid line), with minimal variation between these measures 
as observed in the ROC curves for MMSE and GPCOG produced by Basic 2009, 
Brodaty 2002 and Brodaty 2016. 
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Figure 13. Pirani 2010 ROC curve comparing MMSE, GPCOG-It Patient, Informant & 
Total 
 
Reproduced with kind permission of the authors. Legend from study authors states GPCOG rather than 
GPCOG-It. 
Li 2013 created an ROC curve shown in Figure 14 comparing three different tests 
(HDS, MMSE and GPCOG-C) with GPCOG-C plotted across 4 different measures.  
GPCOG-C Two-stage (also known as GPCOG-C Two-Step) was also plotted on the 
ROC curve but, similar to Brodaty 2002, no threshold is reported as it uses a binary 
outcome so it is unclear what scores were used to plot the ROC curve. MMSE is 
plotted on the ROC curve created by Li 2013, but the authors do not state which 
threshold was used. There is no focus on HDS (the yellow line with asterisk scores 
marked on the ROC curve) as this was not a measure of interest for this systematic 
review. 
CHAPTER 5: SYSTEMATIC REVIEW 
   CHAPTER 5 | 175 
Figure 14. Li 2013 ROC curve comparing Hasegawa's Dementia scale, MMSE, and 
GPCOG Patient, Informant, Two Step and Total 
 
Reproduced with kind permission of the authors  
This ROC curve shows that MMSE (regular dashed line with circles) performs similar 
to GPCOG-C Total (irregular dashed line with diamonds), with minimal variation 
between these measures as observed in the ROC curves displaying MMSE and 
GPCOG produced by Basic 2009, Brodaty 2002, Brodaty 2016 and Pirani 2010. 
Figure 15. Brodaty 2016 ROC curve comparing MMSE & GPCOG Total 
 
Reproduced with kind permission of the authors.  
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Brodaty 2016 created a ROC curve shown in Figure 15, plotting MMSE and GPCOG 
Total. These results are displayed with the caveat that sample sizes between the two 
tests differed without clear explanation, and as this may have contributed an unknown 
degree of bias to the results. GPCOG Two-Step was not reflected in the ROC curve 
as the outcome is dichotomous rather than a set of continuous variables which could 
be plotted on an ROC curve. As see in Basic 2009 and Brodaty 2002, both curves 
follow similar trajectories and differences are minimal, with no clear superiority of one 
test over another. 
These ROC plots display little variation in curve shape across the five included studies. 
In theory, it is possible to compare global diagnostic performance by observing the 
Area Under the Curve (AUC), which can vary from 1.0 (a perfect diagnostic test) to 0.5 
(a non-discriminatory diagnostic test). Whilst AUC gives no information about 
sensitivity and specificity, it can indicate overall accuracy of a diagnostic test307. 
Reported AUC of four included studies are shown in Table 19. 
Table 19 Comparing AUC across GPCOG Total and MMSE 
 GPCOG (total) MMSE  Effect 
AUC 95% CI AUC  95% CI  
Studies reporting MMSE main threshold as <24 
Basic 2009 0.97 0.91, 0.99 0.93 0.88, 0.97 GPCOG better 
Li 2013 0.97 0.96, 0.99 0.97 0.96, 0.99 No difference 
Brodaty 2016 0.92 0.89, 0.95 0.91 0.89, 0.94 GPCOG better 
Studies reporting MMSE main threshold other than <24 
Brodaty 2002 0.91 0.86, 0.95 0.85 0.80, 0.90 GPCOG better 
Pirani 2010 0.96 0.93, 0.98 0.96 0.93, 0.98 No difference 
 
In studies that reported diagnostic accuracy of MMSE at the threshold of <24, 
differences in performance based on ROC curves between GPCOG Total and MMSE 
were marginal and not significant in two studies119,287 with no observable difference in 
a third study288. In studies that reported diagnostic accuracy of MMSE at other 
thresholds, ROC curves illustrate that differences were marginal and not significant. 
5.3.7. Other comparative data 
Whilst other comparative data were recorded wherever it was found within included 
studies, there was little additional reporting of common factors across studies.  
Ancillary accuracy data were not identifiable from published studies, and whilst 
aggregate disease severity data were reported, specific information was lacking on 
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the severity of missed diagnoses in false negatives, or whether false positives were 
free of all disease. It was not possible to identify whether there was concordance 
between false negatives and false positives identified by each test. 
There was also a lack of additional information which may have proved useful to help 
general practitioners to make a decision on the best brief cognitive assessment to use 
and would be feasible to collect in a comparative accuracy study. In particular, data 
on administration time and acceptability of the test to patient, carers and primary care 
team would prove invaluable for decision makers when considering how available brief 
cognitive assessments compare to one another in a clinical setting. 
Only two of the included studies empirically addressed other aspects of the test 
performance142,286 and clearly reported data from which conclusions were derived. 
Brodaty 2002142 was the only included study which reported a GP satisfaction survey, 
and concluded that the GPCOG Two stage was efficient in terms of time, with the 
majority of GPs surveyed on test satisfaction (N=67) rating the GPCOG as being 
practical [87.8%], economically viable [87.8%] and acceptable to patients [98%]. The 
study authors report test administration time for the GPCOG Total as taking “less than 
4 minutes” with the informant section administered in “less than 2 minutes” (p.533). 
Pirani 2010 was the only included study to report actual administration time for the 
included tests, and is worth noting to highlight the absence of this information within 
the other included studies. Reported administration time (with standard deviations in 
minutes) required for GPCOG-It was significantly lower than for other cognitive scales 
(p.88): GPCOG-It Patient = average 2.97 minutes (Standard Deviation (SD)±0.20); 
GPCOG-It Informant = average 1.53 minutes (SD±0.22); GPCOG-It Total score = 
average 4.45 minutes (SD±0.42); MMSE = average 8.9 minutes (SD±1.1). It is unclear 
who measured and assessed administration time, and they may not have been 
general practitioners - leaving questions about generalisability of these results to a 
general practice population and applicability of findings to a clinical setting.  
5.3.8. Subgroup analyses 
Subgroup analyses were considered for investigating tests using lower and higher 
thresholds and variations in cases and control groups (e.g. confirmed dementia, 
probably dementia, people with memory problems, healthy people). In the event, there 
were insufficient data to conduct subgroup analyses across more than one study in 
many cases. This decision was taken in line with our published protocol284.  
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5.4. Main findings 
5.4.1. Which test is more accurate?  
When directly comparing the diagnostic performance of MMSE and GPCOG (including 
GPCOG-It and GPCOG-C) within the same study, which test is more accurate in 
identifying people with possible dementia? Based on the limited evidence of mixed 
quality from five studies identified within this systematic review, MMSE and GPCOG 
Total perform similarly across both sensitivity and specificity when used to identify 
patients with possible dementia within a general practice setting.  
5.4.2. Optimum threshold selection 
Thresholds may have more influence on accuracy than the choice of test. The 
accuracy of MMSE and GPCOG displayed very similar curves when plotted on ROC 
curves in Figures 8-12. Whilst there was no clear superiority in threshold across MMSE 
<24, <25 and <27, with the five included studies the sample may be too small, or with 
variability due to other test factors, to draw firm conclusions. Two of the studies119,142 
had uneven sample sizes which may have adversely affected variability.  The 
challenge comes when choice of threshold is influenced by other factors such as 
professional guidelines, for example the optimum threshold is at odds with policy body 
standards, or clinical relevance, where for example the optimum threshold for a test 
does not sit within the observed clinical range of the patient group.   
5.4.3. Quality issues  
Substantial variability was observed in sensitivity and specificity across studies. 
Combined with assessments of study quality, risk of bias and applicability, this finding 
strongly suggests that the quality of included studies may be insufficient to make a fair 
comparitive valuation of  the diagnostic accuracy of MMSE and GPCOG when used 
to identify dementia within a general practice setting. It is this variability within and 
across studies that is a fundamental factor in the lack of concrete conclusions which 
can be drawn around the comparative diagnostic accuracy of MMSE and GPCOG 
within this systematic review.  
Specific examples of poor study quality were found in a lack of blinding, incorporation 
of one of the index tests (MMSE) within at least part of the reference standard, lack of 
prespecified diagnostic thresholds, missing study participants unaccounted for, 
exclusions on the basis of co-morbidities common in general practice (such as 
cardiovascular disorders, hearing loss and depression), repeat testing with index tests, 
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lack of general practitioners used as raters, and problematic study designs. Alongside 
issues of study quality, problems were found in the quality of reporting where clear, 
simple details on replicability, validation and administration were not reported for the 
two established tools being assessed.  
Test performance was highly variable across studies shown in the forest plot in Figure 
8. These disparities were potentially due to variation in assessment process, 
application of the tests, administrators, raters, blinding, reference standards, or other 
myriad sources of systematic variation presented within the Results section. This 
variability was observed across a wide area, so it is unclear whether one of these 
factors had greater influence on test performance than others or whether a 
combination of variables affected overall test performance.  
It may be that the tools themselves are not fit for purpose, and therefore these other 
variables are simply chaff masking the ‘true’ accuracy of the brief cognitive 
assessments. It is not possible to know this for sure until evidence can be accurately 
compared across studies with confounding factors accounted for and minimised as far 
as possible. This set of circumstances poses some methodological challenges – some 
general to evidence synthesis, and some specific to diagnostic accuracy – which are 
addressed further in Chapter 6 of this thesis. 
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Table 20 Summary of results from included studies 
Study  RS GPCOG Patient GPCOG Informant GPCOG 
Total/combined 
GPCOG Two-stage MMSE <27 MMSE <25 MMSE <24 
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n 
% 
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p 
% 
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C 
Basic 
2009287 
1,2,3,
4 
15
1 
98 67 0.95 
15
1 
94 49 0.97 151 98 77 0.97             151 90 88 0.93 
Brodat
y 
2002142 
5:1,3,
6 
28
2 
82 70 0.86 
20
2 
89 66 0.86 202 82 83 0.91 246 85 86 0.91     
28
3 
81 76 0.91     
Brodat
y 
2016119
˧ 
1,3,6         
171
7 
79 92 0.92 
171
7 
80 91 NR         
202
8 
51 97 0.91 
Li 
2013†28
8 
1,7 35
6 
97 66 0.97 
20
0 
99 82 0.96 356 97 86 0.97 356 97 89 0.97         356 87 94 0.97 
Pirani 
2010‡28
6 
1,3,6, 
7,8,9 
20
0 
98 54 0.96 
20
0 
83 75 0.86 200 92 88 0.96 200 82 92 0.96 
20
0 
93 91 0.96 
20
0 
78 98 0.96     
N, number in study population; Sn, sensitivity; Sp, specificity; AUC, area under the curve; NR, not reported [“binary data”]; RS, reference standard 
†GPCOG-C (General Practitioner Assessment of Cognition – Chinese version) 
‡ GPCOG-It (General Practitioner Assessment of Cognition – Italian version 
˧ Data based on different sample sizes, 313 participants missing between MMSE and GPCOG assessments 
Reference standards: 
1 DSM-IV (Diagnostic and Statistical Manual version 5) 
2 CDR (Clinical Dementia Rating) 
3MMSE (Mini Mental State Examination)  
4GPCOG (General Practitioner Assessment of Cognition)  
5CAMDEX (Cambridge Examination for Mental Disorders of the Elderly Examination)  
6CAMCOG (Cambridge Examination for Mental Disorders of the Elderly Cognitive Scale-Revised)  
7clinical judgment (of attending clinician) 
8ADAS-Cog (Alzheimer's Disease Assessment Scale Cognitive Subscale) 
9physical exam  
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5.5. Discussion 
A summary table of results of included studies is presented in Table 20. It is clear from 
this table that there is a great deal of variation across the five included studies. 
Inconsistency was not only observed at the test level. Both within and across included 
studies, substantial variation was observed in accuracy, sampling, test administration, 
rating, application of reference standard and analysis as described within the quality 
issues above. This is a suprising finding, given the comparative nature of the included 
studies identified according to clear prespecified criteria published in PROSPERO and 
within an open access peer-reviewed journal. Test performance varied widely across 
both MMSE and GPCOG when directly compared to one another, as well as within 
test categories when viewing MMSE accuracy and GPCOG accuracy individually.  
Whilst it is important to establish how good a test is at discriminating between people 
with and without a condition, it is equally important to recognise accuracy as part of a 
bigger process for evaluating a medical test. The ultimate value of a test is in the 
impact it has on the patient, and this cannot solely be measured through diagnostic 
accuracy308. As part of the overview and systematic review processes described in 
previous chapters, the data were revisited to see what information was available on 
outcomes beyond diagnostic accuracy. A substantial body of work was found on test 
administration time (how long a test takes to conduct), and some evidence on aspects 
of clinical effectiveness such as face validity and bias. Some evidence was also found 
of the broader impacts of using brief cognitive assessments. 
5.5.1. Analytical and clinical performance measures 
There was no analytical performance evidence presented within the five studies 
included in the systematic review of comparative diagnostic accuracy (see Table 21).  
Clinical performance is the ability of a test to distinguish patients with a particular 
clinical condition or physiological state. Methods of distinguishing patients in this way 
could include assessing the accuracy of a diagnostic test, assessment of prognostic 
factors that predict a certain outcome, or carrying out a test that monitors a disease 
state or treatment outcomes (see Figure 16).  
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Figure 16 Some purposes of medical tests at different stages of the clinical pathway 
 
Adapted with permission from Patrick Bossuyt. 
As these issues deal with validating the test in a clinical sample and setting, this can 
be termed ‘clinical validity’ and includes features of test performance or operation, and 
the various measures of efficacy of a test309, including the diagnostic or prognostic 
accuracy.  
As this thesis focuses explicitly on the diagnostic accuracy of brief cognitive 
assessments, it would be expected that clinical performance measures should feature 
strongly throughout the evidence from both the overview and systematic review of 
direct comparisons.  
In reality, there was scant evidence of clinical performance beyond diagnostic 
accuracy. Inter-rater and test-retest reliability were reported for GPCOG, GPCOG-It 
and GPCOG-C in three studies142,286,288 and inter-rater reliability for MMSE in one 
study288 as shown in Table 21.  
5.5.2. Cost effectiveness evidence  
There was no evidence on cost effectiveness found within the systematic review. This 
finding is expected given that studies of diagnostic accuracy rarely include health 
economic data, and these assessments are often conducted as stand-alone studies 
of cost effectiveness.  
Data on the cost effectiveness of dementia diagnosis does exist and is widely available 
for primary care and community settings310-312 but these data were not presented 
either within the overview or systematic review. 
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5.5.3. Broader impact evidence 
Within the context of assessing brief cognitive assessments as part of the process for 
identifying dementia, there is much resonance between the patient focus of measures 
of clinical utility, and the wider assessment of the impact on patients including 
emotional, social, legal and ethical effects313. An example of these patient-centred and 
broader societal effects of testing is the commonly-quoted psychological effect of 
earlier dementia diagnosis where brief cognitive assessment contributes to the 
reassurance that a diagnosis may offer a patient and their carers. This benefit is not, 
however, guaranteed and both patients and clinicians report valuing the “right time” 
over early dementia diagnosis 7,314.  Equally, the ethical and legal implications of a 
diagnosis of dementia on individual autonomy in driving are well researched315-317. 
Timings were reported in a variety of ways from exact timings to mean averages, 
ranges and ‘less than’ statements and these issues have been discussed in some 
detail above. 
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Table 21 Systematic review-identified evidence from studies of factors beyond diagnostic test accuracy in direct comparisons of 
GPCOG and MMSE 
Studies Basic 2009 Brodaty 2002 Brodaty 2016 Pirani 2010 Li 2013 
Index tests 
GPCOG MMSE GPCOG MMSE GPCOG MMSE GPCOG-
It 
MMSE GPCOG-
C 
MMSE 
C
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ic
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l 
p
e
rf
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rm
a
n
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e
 Inter-rater reliability   X    X  X X 
Test-retest reliability   X    X  X  
C
li
n
ic
a
l 
e
ff
e
c
ti
v
e
n
e
s
s
 Face validity           
Internal consistency   X      X  
Education bias X X     X    
Language/cultural 
bias 
X X     X    
B
ro
a
d
e
r 
im
p
a
c
t Time taken (mins)   *
1  4-6 10 4.45*2 8.9*2 4.3*3 6.5*3 
Ease of admin   X   X     
Practicability for 
general practice 
  X   X     
Clinician preference   X        
Acceptable to 
patients 
  X        
Economically viable   X        
x  , Reported/measured; blank, not reported/ measured  
*1 3.3 mins for patient section (±1.08, range 2-5.8 minutes); 1.23 mins for informant section (±0.64, range 0.5-2.5 minutes) 
*2 4.45 for GPCOG-It total (±0.42); 8.9 for MMSE (±1.1) 
*3 4.3 for GPCOG-C total (± 2.4); 6.5 for MMSE (±2.1) p < 0.05 
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In addition to extensive variability within this systematic review, various challenges 
have been encountered. Some of these are specific to conducting systematic reviews 
of comparative accuracy studies, and some are problems applicable to all accuracy 
studies. These issues are now addressed in detail.  
5.5.4. Issues specific to systematic reviews of comparative accuracy 
Of particular relevance to systematic reviews of comparative accuracy studies were 
the questions presented by the use of summary ROC plots. It was possible to pair the 
two tests for each study, as shown in Figure 9 and Figure 10 – but beyond observed 
variability, particularly clear in Figure 10, this was not greatly additive to the information 
presented by study authors within individual ROC curves. More generally, there may 
be a challenge in the topic of study when considering how useful ROC curves are for 
further analysis of the data. Within psychometric testing, the benefit of assessing ROC 
curves may be more clear (where thresholds are often more readily tailored to the 
population and setting under assessment) than in other areas of interest where – for 
example – cut points are restricted or tightly defined in practice. 
Incorporation bias 
Whilst incorporation bias may be more commonly observed in comparative diagnostic 
accuracy studies due to the greater number of index tests and greater complexity in 
study design, the risk of bias introduced by incorporating an index test into the 
reference standard is not well understood305. It is often assumed that incorporation 
bias would risk overestimating the size of effect of an index test due to artificially close 
agreement with the reference standard318. Alternatively, in some cases, incorporation 
bias may provide a disadvantage in the extent to which asymmetry is observed. 
Inadequacies of the index test when used in practice may lead to system changes 
which mean when the test is used subsequently as an index test it performs less well 
compared to another test not used in practice. These are scenarios worth considering 
for the impact of incorporating index tests as reference standards on pragmatic test 
performance, without fully exploring the testing pathway.        
Study design 
The underlying premise of comparative accuracy studies is that by excluding possible 
confounding variables introduced through indirect evaluations, such as deviations in 
populations, recruitment and sampling, comparisons made are more equal and 
differences more likely due to actual variation in accuracy. This does depend in part 
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on study design, with common designs including cross-sectional and case-control 
designs. In cross-sectional designs, participants are recruited as a single sample and 
stratified into cases and non-cases using the reference standard, with the performance 
of the index test assessed against the performance of the reference standard301. With 
case-control designs, a sample of known cases are compared to a different sample of 
controls. This may introduce variation between sample populations, either as an 
artefact of the sampling or some unknown quality of the selected populations. These 
differences may not be known, and yet still present a source of variation within the 
study. Whilst cross-sectional designs draw on a single sample so potential bias would 
theoretically affect both arms equally, case control study designs have the potential to 
introduce asymmetric variation due to systematic differences at the population and/or 
sampling levels302. Systemic variation of this type becomes more difficult to anticipate 
or account for when different study designs are combined as was the case in this 
systematic review.  
In practical terms, case control designs will feature in systematic reviews unless 
excluded as part of the selection criteria (which is not recommended within the 
Cochrane Handbook for Diagnostic Test Accuracy301), and so systematic reviews of 
comparative accuracy should stratify analysis by study design. How this is 
methodologically handled in a systematic manner is yet to be established. 
Uneven sample sizes 
Brodaty 2002142 used a cross-sectional study design of 283 participants with mixed 
symptomatic and asymptomatic presentation. Asymptomatic patients were aged 75 
years and over, and symptomatic patients were aged between 50 and 74 years old 
with a ‘suspected’ memory problem. In this study there were discrepancies amongst 
all the sample sizes presented, and different numbers reported across all measures 
(GPCOG Patient: N=282; GPCOG Two Stage: N=246; MMSE: N=28; AMT: N=269; 
GPCOG Informant and GPCOG Total: N=202). Eighty-one participants went missing 
between recruitment and administration of the MMSE to conduct of the GPCOG Total, 
although without a study flow diagram provided it is unclear at what stage the 
participants went missing. This constitutes a loss of 29% of participants (283/202) and 
this loss is distributed asymmetrically within the GPCOG sample (i.e. all the missing 
data relates to GPCOG Total, whereas the total sample is reflected in the MMSE data). 
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The study authors noted that sample sizes varied due to missing data but made no 
further reference to the data 142.  
In a later single-gate cross-sectional study, Brodaty 2016119 recruited 2028 
participants living in the community with mixed symptomatic and asymptomatic 
presentation. The exact mix of symptoms and allocation within the study is unclear 
from the manuscript. All participants did not complete all the brief cognitive 
assessment measures; 2028 participants were administered the MMSE, but only 1717 
undertook GPCOG with missing GPCOG data of 311 participants unaccounted for. 
This loss represents 15% of all participants within the study (1717/2828) and as with 
Brodaty 2002 the distribution of missing data is asymmetric, as only the GPCOG data 
is missing.  
This missing data is recognised within the QUADAS-2 quality assessment, but was 
not immediately obvious within the research papers – partly due to several sub-tests 
being administered, and partly due to a lack of PRISMA-type flow diagrams presented. 
The reality was that there was a need to explore the 2x2 table before realising there 
were flaws in the detail of the study, including missing data. This led to a dilemma of 
conducting the systematic review; whilst these studies had been included within the 
review, was the potential bias introduced by this unaccounted-for missing data so 
severe that these studies should be excluded on this basis? The primary author on 
these two studies was contacted to ask for reasons for this imbalance and whilst he 
confirmed he would investigate the data, and a response has not yet been received. 
It was decided to treat this missing data as a major limitation for these studies, but 
rather than excluding them from analysis to acknowledge this limitation throughout 
and draw inferences with additional caution, bearing in mind both the missing data and 
asymmetry in the potential bias this may introduce.  
QUADAS-2 quality assessment tool 
The assessment of quality was carried out with the help of the QUADAS-2 tool. This 
was designed to aid quality assessment of diagnostic accuracy studies for inclusion in 
systematic reviews, and was well suited to the task. One limitation of this tool is that it 
was not specifically designed for use in systematic reviews of direct comparisons of 
diagnostic test accuracy, where more than one index test will be present. One of the 
foundational beliefs in assessing diagnostic accuracy across direct comparisons is that 
this direct comparison allows the researcher to minimise all confounding effects 
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normally observed in the comparison of indirect studies (such as differences in 
population, setting and administration) so that the comparisons of accuracy are as fair 
and equal as they can be. If this is accepted, then variations in sampling (e.g. using 
two gate designs) and study design (such as case-control) become far more important 
markers of study quality302 and need to be addressed specifically and in a more 
sophisticated manner within appropriate quality assessment tools.  
The current version of QUADAS-2 lacks specific questions on comparative accuracy 
where more than one index test is present, incorporation of index tests into reference 
standards and assessment of factors beyond sensitivity and specificity. The quality of 
primary comparative accuracy studies presented challenges where in four out of five 
studies the reference standard was at least partly formed by one of the index tests 
(MMSE), two studies 119,142 had a substantial volume of missing data, two studies286,288 
used a case control study design which is known to exaggerate diagnostic accuracy305, 
and there was poor reporting of key information such as test thresholds.   
A modified version of QUADAS-2 making it more relevant to comparative diagnostic 
accuracy studies has been suggested by Wade and colleagues319, with specific 
additional questions relating to clinical practice (was the execution of both tests as 
they should be performed in clinical practice?), independence between tests (were the 
index and comparator test independent? Were the reference standard and the 
index/comparator tests independent of each other?), verification (were the results of 
both tests verified using the same reference standard?), consistency (did the whole 
sample undergo both tests?), and missing data (was there a difference in the number 
of uninterpretable or indeterminate results between tests, which is likely to have biased 
the study results?). Incorporating these items into a modified version of the QUADAS-
2 suitable for comparative accuracy studies would be an invaluable starting point to 
improve the methodological and qualitative evaluation of this design.      
5.5.5. Issues applicable to all accuracy studies 
Whilst challenges observed so far have been more applicable to comparative accuracy 
reviews, there are other issues common across all accuracy studies. It is common for 
studies of diagnostic accuracy to report sensitivity and specificity figures, and in some 
studies authors report actual numbers of patients distributed within the 2x2 binary 
classification table. It is unusual for study authors to explore the nature of 
misclassification as well as the actual numbers of false positives and false negatives, 
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yet this would be valuable information when comparing two or more index tests, even 
as indirect comparisons.  
Understanding why individual patient scores differ between index tests may also help 
to identify key factors of the test or testing process which affect test performance. An 
extension of this idea would be the potential offered in being able to identify individual 
patient-level data where, for example, a participant’s scores were high on one test and 
low on another. Arguably even more useful would be the ability to identify where all 
index tests correctly identified the same person, and whether there were any 
characteristics of the tests or the participant which made this concordance more or 
less likely. 
Common problems of study quality were found where study participants did not match 
the target general practice population, but were instead designated based on 
symptoms, recruited from specialist clinics and selected for synthetic factors without 
credibility for the target population (such as having an informant available). In some 
cases, test administrators were specialised research nurses, geriatricians and 
psychogerontologists and did not correspond to the intended general practitioner user. 
Potential participants were excluded on the basis of common general practice 
comorbidities and potential confounders (e.g. delirium, cardiovascular conditions, 
hearing impairment), and there was a lack of blinding across a number of studies to at 
least one of the index tests. 
The general quality of reporting varied substantially, and in some cases index test 
thresholds were not prespecified - or specified at all. Finally, on other factors that could 
affect test performance, only three studies142,286,288 reported test administration time 
with limited detail, and one study142 reported summarised findings of a GP satisfaction 
survey and a patient five-point attitude scale (findings of the patient attitude scale were 
not reported within the included paper). 
Study designs were also varied and posed particular challenges. Three 
studies119,142,287 employed two-gate, cross-sectional designs with either 
symptomatic287 or mixed symptomatic and non-symptomatic119,142 populations. Whilst 
mixed presentation populations may mean findings are better suited for general 
practice, a study population presenting with known symptoms is already a different 
group of people than one may expect to encounter in general practice. Perhaps of 
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more concern, two studies used a case-control single-gate study design. This meant 
that the study population was already problematic for generalisability due to the 
selection of the participants for cases or controls unrelated to the wider setting. Also 
for this reason, prevalence calculations are inappropriate with case control studies as 
they cannot fairly be related to a particular setting.  
A key conclusion is therefore that comparative accuracy studies do not guarantee 
optimum study quality or superiority over non-comparative diagnostic accuracy 
studies. There are many methodological issues that need to be addressed in order to 
realise the potential that comparative studies offer to improve the evidence base of 
tests.  
5.6. Recommendations  
A major challenge within this systematic review is that the brief cognitive assessment 
tools are designed to measure cognitive function, and in many cases only some 
aspects of cognitive function. Whilst dementia as an umbrella term incorporates 
cognitive decline, there are many other aspects of dementia that are not assessed 
using brief cognitive assessment tools. The stated aim within included studies of 
identifying dementia primarily using these tools is therefore highly problematic and 
misrepresentative both for research purposes and for clinical practice. It is 
recommended that researchers moderate their language around identifying dementia, 
and instead specify the particular aspects of dementia diagnosis being addressed 
within the specific study. 
For evidence based research and practice, we must ask whether the questions posed 
within these studies and the wider research arena are actually addressing the issues 
that general practitioners and patients are interested in. There is a growing need to 
address functional issues related to the dementia syndrome, rather than to bolster 
uninformative and misleading labels based upon research requirements at odds with 
the clinical reality of patients and GPs. Particularly at the level of primary care, taking 
a functional approach means focussing on individual patient needs and abilities rather 
than applying a catch-all term with little consequent post-diagnostic support. This 
would seem a more progressive approach to research with direct clinical application 
at its centre. 
CHAPTER 5: SYSTEMATIC REVIEW 
   CHAPTER 5 | 191 
Addressing research methods, the use of case-control designs in diagnostic accuracy 
studies raises questions about the presence of spectrum bias, alternative conditions 
and comorbidities. When considering spectrum bias, it is important to recognise that 
the ability of a test to identify a target condition depends on the severity of the condition 
320. Dementia is a good example of this situation. As severity of dementia increases 
so symptoms become more marked, and thus more readily-identified with even 
relatively crude measures321. Within this systematic review, the brief cognitive 
assessments under investigation (MMSE and GPCOG) assess cognitive impairment. 
This is highly likely to be present in dementia, but is also present in many other 
conditions and therefore alternative diagnoses are a real possibility, leading to an 
increased risk of false positive results. Finally, in the general practice setting where 
target populations are over 50 years old, there is an increased likelihood of comorbid 
conditions322,323 which in turn also elevates the risk of false positive results302 although 
as many potential comorbid conditions were excluded within included studies this 
obfuscates actual diagnostic performance yet further. 
Incorporation bias was a substantial concern within the studies included in this review, 
as the MMSE formed some or part of the reference standard in four out of five included 
studies leading to increased potential for overestimating the accuracy of MMSE as an 
index test. Substantial uneven sample sizes of 15%119 and 29%142 were unaccounted 
for, both within the study manuscripts and in following up with the study author. The 
asymmetric distribution of these missing data solely within the GPCOG arm meant that 
any bias introduced would not have affected both index tests equally, which was an 
additional cause for concern.   
Within the limited evidence provided by a small number of included studies, the 
inference is that GPCOG offers similar performance to MMSE. Decisions need to be 
made on which threshold gives the optimum balance between sensitivity and 
specificity for referrals by GPs to secondary care. Arguably a threshold which 
minimises errors would be reasonable, as it is difficult to decide whether the disutility 
of false positive (FP) results or false negative (FN) results is greater without further 
investigation beyond the scope of this review. Some information on the severity of 
disease missed in FNs, and the extent of additional investigation required as a result 
of FPs would be helpful to inform this level of clinically-relevant decision making. 
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Considering the problems with the evidence identified within this systematic review, 
this raises the question of how to handle challenges to validity that are so substantial 
the review author might consider excluding the evidence? In this current example, 
there were three major concerns in a) study design; b) missing data; and c) 
incorporation bias. These factors could all have been eradicated by good study design 
and conduct. It is this simple – by avoiding case-control designs, ensuring even 
sample sizes distributed equally across both/all testing arms, and using a reference 
standard independent of the index tests (as appeared to be the case in one study288) 
these issues would be minimised or eliminated. Where case-control designs cannot 
be avoided, systematic reviews can explicitly either exclude other study designs or 
stratify synthesis so that these study designs are kept separate from others, with 
implications drawn relevant to that design and associated conduct. The major 
improvement is that studies should be well-conducted and well-reported.  
There would be significant value in a well-conducted systematic review of comparative 
diagnostic accuracy for MMSE and GPCOG including test performance factors such 
as administration time, acceptability for clinicians and patients, and cost-effectiveness. 
Additional value may be added by taking a three-stage approach to analysis, firstly 
assessing the evidence according to the number of arms there are to the study, i.e. 
single-gate, double-gate; assessing differences between arms of individual studies; 
and finally assessing any overall difference. This would allow disaggregation of 
variation observed within and across different arms of different studies, which could 
highlight actual differences between tests set against variation due to other factors.  
This systematic review of comparative accuracy studies has further highlighted the 
importance of well-conducted studies of direct comparisons, and the need to better 
understand factors influencing diagnostic performance beyond accuracy measures of 
sensitivity and specificity. It is these aspects of a test’s performance beyond diagnostic 
accuracy that will be explored further in the next chapter.
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Appendix 8. Review protocol
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5.7. Appendix 9. Screening notes for title/abstract screening 
 
Primary outcome: comparative accuracy of the two tests assessed via direct comparisons, 
i.e. the diagnostic accuracy of the two tests are compared within the same population in a 
study (comparative study). 
Secondary outcome: to identify other common test-related factors identified by included 
studies, such as ease of administration or administration time. Whilst beyond our primary 
focus of test accuracy, these other factors may contribute to the overall usefulness of the 
tests when applied in a primary care setting, and we will incorporate them in our findings in 
order to make useful research and clinical recommendations. 
5.7.1. Eligibility criteria  
Adults aged 18 years or over recruited from a primary care or general practice population 
were included, and we did not exclude patients who were selected on the basis of an 
existing diagnosis or condition which might reasonably be expected to feature in primary 
care (e.g. stroke). 
The target condition was all-cause (non-differentiated) dementia. We also included reviews 
that focused specifically on differentiated forms of dementia such as Alzheimer’s disease, 
vascular dementia and dementia with Lewy bodies. We excluded reviews that focused on 
mild cognitive impairment (MCI). Where reviews investigated both dementia and MCI, we 
extracted data referring to dementia and excluded data referring solely to MCI. 
5.7.2. Inclusion criteria 
Population: Adults aged 18 years and over 
Conditions: 
 All-cause dementia 
 Alzheimer’s disease 
 Vascular dementia  
 Dementia with Lewy bodies 
 Other differentiated forms of dementia 
Setting: Primary care or general practice 
Index tests: The following two index tests should both be assessed in the same population: 
 Mini Mental State Examination (MMSE)  
 General Practitioner assessment of Cognition (GPCOG) 
Reference standard: reference standards consisting of the following tools alone, clinical 
diagnosis alone or clinical diagnosis combined with one or a combination of the following 
assessment tools: 
 Diagnostic and Statistical Manual (DSM) III/III-R/IV/IV-R  
 Clinical Dementia Rating (CDR)  
 International Classification of Diseases (ICD) 10  
 Geriatric Mental State – Automated Geriatric Examination for Computer Assisted 
Taxonomy (GMS-AGECAT)  
 Cambridge Mental Disorders of the Elderly Examination (CAMDEX)  
 International Psychogeriatric Association World Health Organisation (IPA-WHO) criteria 
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Outcomes: The following outcomes are relevant if they are compared between both index 
tests in the included study: 
 Diagnostic accuracy  
 Ease of test administration 
 Test administration time 
 Other test-related characteristics 
Study design: all (no limits) 
Geography: worldwide (no limits) 
Time period: all time periods (no limits) 
Languages: English, Dutch 
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5.8. Appendix 10. Data extraction form 
Full study reference 
(author/date/title/journal) 
 
Date study published  Date study conducted  
Study design and timing of data 
collection (prospective, retrospective) 
 Country of study  
Stated aim(s) of the study  
Study population – age, sex (% female 
where given)  
 
Recruitment and 
setting (e.g. 
community) 
 
Dementia severity (including 
assessment measures, e.g. CDR) and 
disease prevalence where reported 
 
Timings and combinations of tests 
conducted (e.g. ordering, 
randomisation) 
 
Reference standard (detail, including 
threshold[s] where reported, who 
assessed, timings of assessments 
etc.) 
 
Index tests (list, including version if 
reported) 
#1 
Threshold 
used 
 
#2 
Threshold 
used 
 
Etc. 
Threshold 
used 
 
Index test #1 accuracy data – name of 
test 
Sensitivity 
(%) 
 
Specificity 
(%) 
 
PPV (%)  NPV (%)  
Other Index test #1 accuracy data (e.g. 
AUC) 
 
Index test #2 accuracy data – name of 
test 
Sensitivity 
(%) 
 
Specificity 
(%) 
 
PPV (%)  NPV (%)  
Other Index test #2 accuracy data (e.g. 
AUC) 
 
Index test #3 accuracy data – name of 
test 
Sensitivity 
(%) 
 
Specificity 
(%) 
 
PPV (%)  NPV (%)  
Other Index test #3 accuracy data (e.g. 
AUC) 
 
Review limitations  
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5.9. Appendix 11 QUADAS-2 tool 
QUADAS-2  
  
Phase 1: State the review question:  
  
Patients (setting, intended use of index test, presentation, prior testing):  
  
Index test(s):  
  
Reference standard and target condition:  
  
  
5.9.1. Phase 2: Draw a flow diagram for the primary study  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
5.9.2. Phase 3: Risk of bias and applicability judgments  
QUADAS-2 is structured so that 4 key domains are each rated in terms of the risk of 
bias and the concern regarding applicability to the research question (as defined 
above).  Each key domain has a set of signalling questions to help reach the 
judgments regarding bias and applicability.   
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DOMAIN 1: PATIENT SELECTION   
A. Risk of Bias  
Describe methods of patient selection:  
  
  
  
 Was a consecutive or random sample of patients enrolled?  Yes/No/Unclear  
 Was a case-control design avoided?  Yes/No/Unclear  
 Did the study avoid inappropriate exclusions?  Yes/No/Unclear  
Could the selection of patients have introduced bias? RISK: LOW/HIGH/UNCLEAR  
    
B. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting):  
  
  
  
Is there concern that the included patients do not match  CONCERN: 
LOW/HIGH/UNCLEAR the review question?  
  
  
DOMAIN 2: INDEX TEST(S)  
If more than one index test was used, please complete for each test.  
A. Risk of Bias  
Describe the index test and how it was conducted and interpreted:  
  
  
  
 Were the index test results interpreted without  Yes/No/Unclear knowledge 
of the results of the reference standard?  
 If a threshold was used, was it pre-specified?  Yes/No/Unclear Could the 
conduct or interpretation of the index test  RISK: LOW /HIGH/UNCLEAR 
have introduced bias?    
    
B. Concerns regarding applicability  
Is there concern that the index test, its conduct, or  CONCERN: LOW 
/HIGH/UNCLEAR interpretation differ from the review question?  
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DOMAIN 3: REFERENCE STANDARD  
A. Risk of Bias  
Describe the reference standard and how it was conducted and interpreted:  
  
  
  
 Is the reference standard likely to correctly classify the target  Yes/No/Unclear 
condition?  
 Were the reference standard results interpreted without  Yes/No/Unclear 
knowledge of the results of the index test?  
Could the reference standard, its conduct, or its  RISK: LOW /HIGH/UNCLEAR 
interpretation have introduced bias?      
    
B. Concerns regarding applicability  
Is there concern that the target condition as defined by  CONCERN: LOW 
/HIGH/UNCLEAR the reference standard does not match the review question?  
  
  
DOMAIN 4: FLOW AND TIMING  
A. Risk of Bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram):  
  
  
  
Describe the time interval and any interventions between index test(s) and reference 
standard:  
  
  
  
 Was there an appropriate interval between index test(s)  Yes/No/Unclear and 
reference standard?  
 Did all patients receive a reference standard?  Yes/No/Unclear  
 Did patients receive the same reference standard?  Yes/No/Unclear  
 Were all patients included in the analysis?  Yes/No/Unclear Could the patient 
flow have introduced bias?  RISK: LOW /HIGH/UNCLEAR  
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5.10. Appendix 12 Tailored quality appraisal notes
QUADAS-2 quality assessment of the evidence for the comparative diagnostic 
accuracy of the Mini Mental State Examination (MMSE) and the General 
Practitioner assessment of Cognition (GPCOG) for identifying dementia in 
primary care – Raters’ notes 
From the protocol: 
We will use the QUADAS-2 tool to assess methodological quality of diagnostic 
accuracy studies for systematic reviews. While this tool is developed for studies 
focussing on a single index test, we will assess the suitability of using the tool for 
studies that focus on direct comparisons of two index tests by piloting the QUADAS-
2 tool on one of the included studies. We will tailor QUADAS-2 in line with suitability 
in assessing quality of studies using direct comparisons, for example assessing the 
reference standard against MMSE, and then the reference standard against GPCOG. 
QUADAS-2 is a tool designed to assess the quality of primary diagnostic 
accuracy studies. QADAS-2 uses prompts (or ‘signalling questions’) to explore 4 
main areas of potential bias and applicability: patient selection, index test, 
reference standard, and flow of patients through the study and timing of the 
index test(s) and reference standard.  
Tailoring  
We have tailored the tool to fit our particular review, which is looking at direct 
comparisons of two distinct index tests: MMSE and GPCOG. Therefore we have 
a domain assessing each index test, MMSE and GPCOG.  
We will follow the QUADAS-2 advice for tailoring as shown in Figure 1. 
Figure 1 Tailoring of QUADAS-2 
 
 
Taken from Background Notes document accessed: http://www.bristol.ac.uk/population-
health-sciences/projects/quadas/quadas-2/ [19/10/17] 
 
‘Domain 2: Index tests’ asks “If a threshold was used, was this pre-specified?” This 
was changed to simply ask “Was/were the threshold(s) pre-specified?” as both of 
the index tests (GPCOG and MMSE) have thresholds that should be reported. 
‘Domain 3: Reference standard’ asks “Were the reference standard results 
interpreted without knowledge of the results of the index test?” This was amended 
to ask “Were the reference standard results interpreted without knowledge of the 
results of both index tests?” to include consideration of both MMSE and GPCOG.  
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Glossary  
ADI Alzheimer’s disease International 
AGECAT Automated Geriatric Examination for Computer Assisted 
Taxonomy 
AMT(S) Abbreviated Mental Test Score 
APEx Exeter Collaboration for Academic Primary Care 
BCA Brief cognitive assessment 
BOS Bristol Online Surveys 
CAMCOG The Cambridge Cognitive Examination 
CAMDEX Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CCCDTD Canadian Consensus Conferences on the Diagnosis and 
Treatment of Dementia 
CCG Clinical Commissioning Group 
CDPC Cognitive Decline Partnership Centre 
CDR Clinical Dementia Rating 
CDT clock drawing test 
CERAD Consortium to Establish a Registry for Alzheimer's Disease 
CHAIN Contact, Help, Advice and Information Network 
CHERRIES Checklist for Reporting Results on Internet E-Surveys 
CPG Clinical Practice Guideline 
DSM-III/ III-R/ 
IV/ IV-R 
The Diagnostic and Statistical Manual of Mental Disorders 
(version 3/ version 3 revised/ version 4/ version 4 revised 
EMBASE Excerpta Medica dataBASE 
FAB Frontal Assessment Battery 
FAQ Functional Activities Questionnaire 
FCSRT Free and Cued Selective Reminding Test 
GMS-AGECAT Geriatric Mental State Schedule - Automated Geriatric 
Examination for Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
ICD-10 International Classification of Disease – version 10 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
IPA/WHO 
criteria 
International Psychogeriatric Association/World Health 
organisation criteria 
KICA-Cog Kimberley Indigenous Cognitive Assessment  
CHAPTER 6: SURVEY OF GPS 
   CHAPTER 6 | 208 
KICA-Screen Kimberley Indigenous Cognitive screening tool 
MCI Mild Cognitive Impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MeSH Medical Subject Headings 
MIS Memory Impairment Screen 
MMSE  Mini mental state examination 
MoCA Montreal Cognitive Assessment 
NHS  National Health Service (UK) 
NICE National Institute for Health and Care Excellence (UK) 
NINDCS-
ADRDA 
National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders 
Association 
NINCDS-AIREN National Institute of Neurological Disorders and Stroke–
Association Internationale pour la Recherche et l'Enseignement 
en Neurosciences 
NINCDR-
CERAD 
National Institute of Neurological Disorders - Clinical Dementia 
Rating -Consortium to Establish a Registry for Alzheimer’s 
Disease 
PAS Psychogeriatric Assessment Scale 
PBKDF2 A password hashing algorithm 
PCL Prueba cognitive de leganes 
PROSPERO International Prospective Register of Systematic Reviews 
PsychInfo Database of abstracts of literature in the field of psychology. 
RUDAS The Rowland Universal Dementia Assessment Scale 
SASSI Short and Sweet Screening Instrument 
SHA256 A cryptographic hash function 
SIS Six item screener 
SPMSQ Short portable mental status questionnaire 
SSL Secure Sockets Layer 
TICS Telephone Interview for Cognitive Status 
TRIP Turning Research Into Practice database 
TYM Test Your Memory 
UK United Kingdom 
VF-an Verbal Fluency - animals 
WHO World Health Organisation 
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6. The clinical reality of identifying dementia using brief 
cognitive assessments as part of the primary care consultation 
“Case finding” is the recourse of those who do non-evidence based screening but 
can’t seem to admit it. 
Margaret McCartney, general practitioner in BMJ 2018; 362:k3745 
This chapter presents findings from a survey of GPs exploring how general 
practitioners choose and use brief cognitive assessments in practice as part of the 
process for identifying possible dementia in primary care. It was expected that GPs 
would select the most suitable BCA based on best current evidence and national 
clinical practice guidelines and the major barrier reported would be administration time 
and lack of clinician understanding for how to interpret the test. The survey was carried 
out between June and September 2017. MMSE, GPCOG and 6CIT were the most 
frequently-used tests for initial assessment of cognition and for monitoring function 
over time. How long a test took to administer was the most popular factor influencing 
respondents’ choice of brief cognitive assessment. On average, GPs felt that 5 
minutes was an acceptable length of time for a brief cognitive assessment to take if a 
GP carried it out, and 10 minutes was acceptable if another member of practice staff 
carried out the assessment. Qualitative data revealed that major issues for GPs 
surveyed included the length of the assessment process, and tensions between the 
quality of a test and how quick or easy it was to carry out. 
6.1. Background: why this survey was needed 
Whilst the timely identification of dementia and referral to specialist services is 
generally acknowledged to be important to improve the chances of living well with 
dementia for as long as possible, general practice assessment needs to be balanced 
with implications of the increased likelihood of false positives and moderate test 
performance of brief cognitive assessments within this setting129,156,324. 
Recommendations for operationalizing the assessment of cognitive performance and 
detection of dementia have been created as part of national dementia strategies by 
several countries including the United States325, the UK326, and Australia327. These 
national dementia strategies all discuss brief cognitive assessment tools in detail, as 
well as highlighting the value of employing appropriate tools as part of an iterative 
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diagnostic process. These strategies also commonly acknowledge many of the 
challenges in finding the most suitable tool for the primary care setting. What they lack 
is explicit, current and evidence-based guidance on how the best tool should be 
chosen by the primary care practitioner, and when tools should – and should not – be 
recommended for use as part of the diagnostic routine.  
Despite the existence of many brief cognitive assessment tools in primary care and 
increasing evidence that people prefer to receive a diagnosis of dementia as soon as 
possible35, current evidence is mixed for how GPs view and value the place of these 
brief cognitive assessments within the diagnostic process. GP attitudes to diagnosis 
of possible dementia in family practice have been investigated widely in recent years, 
commonly finding a reticence in GPs to diagnose dementia early, or to even use the 
word ‘dementia’328-331. Whilst GP trainees report feeling positive about their future role 
in identifying people with dementia earlier332, existing practitioners can be reluctant to 
either investigate dementia or disclose the diagnosis where the practitioner perceives 
no consequential benefit to the patient (such as access to effective therapy or 
additional support services)17,49,329,333-335. A recent survey found GPs did not tend to 
refer their oldest patients for further diagnostic testing unless specifically requested to 
do so, as they felt there was insufficient support for further treatment49. Even in 
countries where post-diagnosis support is broadly considered adequate, GPs report 
feelings of therapeutic nihilism and a reluctance to speak openly to patients about 
dementia328. Many GPs and GP trainees reported they had received insufficient 
education in dementia recognition, or would like more330,332. These findings may 
suggest motives behind continued low rates of diagnosis reported globally336, despite 
national and international drives to increase diagnosis rates at earlier stages of the 
syndrome326,337.  
The picture, however, is unclear around how useful GPs consider brief cognitive 
assessment tools, how they actually choose and use these tools and which tools they 
favour if any. In one survey338, when asked specifically about the effectiveness of brief 
cognitive assessments used most frequently in their practice, GPs rated most tools as 
‘good’ – the mid-point on a 5 point scale from ‘very poor’ to ‘excellent’. When 
respondents were asked to rank the top attributes of a cognitive screening tool for use 
in general practice, ‘validity/accuracy’ was the top element identified followed by ‘ease 
of administration’ and ‘time required’ 339.  
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Recent interviews with Dutch GPs explored their practices and views of diagnosing 
dementia. When questioned on their preferences for future roles in the diagnostic 
process for dementia, most GPs were keen for further involvement yet a number 
identified the inadequacy of current tests and lack of time for assessment as a barrier 
or concern 49. This finding was echoed in interview research from Ireland, where GPs 
highlighted the complexity of interpreting the results of some brief cognitive 
assessment tools such as the MMSE, citing educational bias and a lack of useful 
thresholds as a concern 340. Concerns around the applicability of MMSE for people 
with language challenges, as well as a lack of sensitivity in identifying subtle changes 
were also voiced in interviews with Dutch GPs 49.  
Reported practitioner concerns of a lack of suitable assessment tools or a lack of tools 
perceived as helpful was a common finding in the literature 50,69,72,340-342, yet there is 
sparse evidence for how GPs actually use – or do not use - these tests within clinical 
practice. Recent survey evidence indicates GP uncertainty when interpreting the 
results of brief cognitive assessments and incorporating results to help form a 
management strategy 340 yet does not identify if or how this uncertainty is dealt with. 
In addition to diagnostic accuracy, many other factors affect a tool’s use such as how 
long it takes to administer 10,49,341, suitability for the target population 10,343, adaptability 
for different scenarios 340, clarity for clinical and patient users 10, cost 43, and possible 
increased value in combination with other tests 84,343. Whilst all of these factors 
commonly feature in comments or side references amongst GP concerns when asked 
about brief cognitive assessments, they have not yet been the specific focus of survey 
research in this area. These elements contribute important features to help understand 
GP use of and attitudes towards the current available brief cognitive assessments 
available to help identify dementia in primary care.  
The aim of this survey was therefore to investigate current clinical practice in the use 
of brief cognitive assessments to evaluate patients presenting with cognitive concerns, 
and how that correlates with current research and the established evidence base for 
the use of such assessments. 
Through a survey with general practitioners, these issues are explored:  
a) How GPs’ use brief cognitive assessments as part of their decision making to 
identify patients likely to have as-yet undiagnosed dementia; 
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b) The most commonly-used brief cognitive assessment tools; and  
c) How information from the assessment affects GPs’ management decisions. 
These insights help build a better picture of how GPs choose and use brief cognitive 
assessments as part of the process for identifying patients with probable dementia in 
general practice, to better inform policy makers, test developers, researchers and 
healthcare professionals and help primary care to support a more effective route to 
dementia diagnosis. 
6.2. Methods 
6.2.1. Design 
Following a cross-sectional survey design using purposive sampling, participants were 
presented with a self-completion questionnaire of ten questions and several sub-
questions. Questions took three forms: fixed response alternatives; statements where 
agreement is marked on a five point Likert scale (strongly 
disagree/disagree/neither/agree/strongly agree); and open free-text comments. 
Respondents were allocated a number to be used in coding and analysis, as well as 
to allow differentiation between respondents in any illustrative quotations from free text 
responses. 
The questionnaire was designed for and distributed using Bristol Online Surveys (BOS 
- www.onlinesurveys.ac.uk). This is a stable and robust academic and research survey 
tool developed by the University of Bristol. All data is stored securely by JISC hosted 
in a secure cloud based infrastructure with servers located in the Republic of Ireland, 
ensuring data is held and processed in compliance with UK Data Protection legislation.  
Survey data are encrypted and survey responses were sent over an encrypted SSL 
connection. BOS user passwords are encrypted using PBKDF2 with a SHA256 hash 
and a random salt, which fundamentally is a high level of security in web data transfer 
344. 
6.2.2. Participants  
 All UK general practitioners (including those employed on part time, full time and 
sessional bases) were eligible to complete the questionnaire. As the population is 
opportunistically drawn from professional and personal networks within the wider PhD 
research team as well as via Twitter, the likelihood was always going to be that the 
survey would identify a greater proportion of people recruited from the South West of 
England. This is evident in Figure 19 showing clustered locations of general practices 
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associated with survey participants, but the distribution of respondents is greater than 
imagined – it is lively that this is mainly due to respondents reached via Twitter. 
Participants were informed that by continuing they consent to taking part in the survey, 
and they could withdraw at any point without giving a reason. A contact email address 
was given for any concerns or questions participants may have had.  
Respondents were informed that all participant data would be anonymised and 
potential identifiers (such as age, years in practice) were banded into ranges. No 
names were recorded unless feedback was asked for by respondents (which it was 
not), and personal data included in these responses would kept confidential beyond 
the immediate data analyst. In the event no feedback or correspondence was received 
from individuals, so this was not an issue.  
6.2.3. Questionnaire development 
In consideration of GP time pressures the questionnaire was designed to take less 
than 6 minutes to complete. The questionnaire was constructed iteratively with an 
advisory panel of clinical and academic experts, and was piloted with research 
colleagues to ensure it ran smoothly and functioned as expected.  
Initial survey questions were developed through detailed critical reading of the 
evidence base including key research in the field of brief cognitive assessment use for 
identifying dementia in general practice10,15,17-19,21,27,42,43,49,72,92,134,329,331-333,335,336,345-
353. These were developed and refined with close reference to the aims of this project, 
in order to address the question “how do general practitioners choose and use brief 
cognitive assessments in practice as part of the process for identifying possible 
dementia in primary care?”. Once questions were structured in a logical way to allow 
flow from one topic to another and maintain interest across the questionnaire, these 
were discussed with PhD supervisors and selected Project Advisory Group members 
consisting of two general practitioners (Willie Hamilton and Nick Cartmell) and one 
qualitative researcher and research ethicist (Anne-Marie Boylan). Through this 
process a number of questions were removed and the wording of others was refined 
in order to improve comprehension and maximise the usefulness of the responses. 
The questionnaire was revised further following testing with practicing general 
practitioners (those named, plus Sam Creavin in Bristol) to identify any GP-specific 
issues such as difficulties with terminology, jargon or interpretation. All feedback was 
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used to improve the questionnaire structure and content. Finally, feedback received 
from the Chair of the University of Exeter Medical School Ethics Committee during the 
Ethics review process (see Ethics application form in Appendix 14 and Ethics 
Committee certificate in Appendix 15) was incorporated to further improve aspects on 
consent and storage of survey data.  
6.2.4. Procedure  
The survey was distributed using the Contact, Help, Advice and Information Network 
(CHAIN - http://www.chain-network.org.uk) which has approximately 170 general 
practitioners on the mailing list. Professional networks such as the South West Clinical 
Research Network and the Exeter Collaboration for Academic Primary Care (APEx) 
research group helped to publicise the survey. The survey was promoted within the 
regular newsletter of the South West Clinical Research Network (SWCRN), as well as 
on Twitter. Retweets were requested from the Royal College of General Practitioners 
(@RCGP), Devon Local Medical Committee (@Devon_LMC) and practitioner 
magazines such as GPOnline.com (@GPonlinenews) and PulseToday 
(@pulsetoday), as well as from individuals associated with those groups and with 
general practice as a whole.  
Originally it was anticipated that the survey would reach around 200 people, based on 
estimates of reach for Twitter, CHAIN and individual contacts. Once the survey had 
been launched, this was revised to an estimated 100 people due to the timings of 
holidays and workload pressures, with an anticipated response rate of around 50%, 
based on previous experiences of colleagues who have undertaken similar work with 
comparable target groups 354-356.  
6.3. Survey analysis 
A copy of the questionnaire is available in Appendix 13. 
Data were collected anonymously via the Bristol Online Survey tool and analysed 
using Microsoft Excel 2013 and Microsoft Word 2013.  
Quantitative data are reported via ranked preferences of test, with percentage 
groupings with confidence intervals reported. Univariate descriptive analyses are used 
to explore demographic variables and GP attitudes to the use of cognitive 
assessments in general practice.  
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6.4. Free text responses  
Within the free text responses in the survey, the coding strategy was purposively 
developed using emergent themes rather than preconceived ideas357. This is not to 
overlook the place of the author’s preconceptions and bias inherent in identifying these 
emergent themes, and within the discussion section of this chapter there is reflection 
on the influence of the researcher in surfacing particular elements within the data. 
First level coding was carried out manually with pen and paper, and identified a 
number of common words, phrases and ideas within the GP responses. These codes 
were refined through revision of the texts within context of first level codes, and 
discussion of observations with Project Advisory Group members expert in qualitative 
analysis and survey design. Themes were developed through this process of revisiting 
and refining the codes, using Excel and Word to create data tables which allowed 
identification, allocation and grouping of codes from which themes were drawn358. 
After analysing emergent themes at their different levels, a thematic network was 
developed to structure and characterise these themes. After the network had been 
created, it was then possible to explore and summarise the thematic network in order 
to finally interpret patterns discovered within the data359. This process drew on 
expertise and experience within the wider research team to test and refine the 
analytical framework within which themes are developed.  This follows a similar 
approach to one taken by a member of the Project Advisory Group analysing free text 
comments from GPs about stroke assessments360 where data were collated and 
analysed as previously established for survey responses361. In the study on stroke 
assessment, the analyst [AMB] assigned codes to each comment to explain its 
meaning and coded extracts were further explored to derive themes from collected 
responses, using NVivo 10 software to manage data and coding.  The reporting of 
qualitative research follows the recommendations in the Checklist for Reporting 
Results on Internet E-Surveys (CHERRIES)362 . 
6.5. Overview of responses 
The survey was open from 30th June until 8th September 2017, and distributed via 
email, Twitter and word of mouth. Fifty-two responses were received in total, and all 
respondents completing the survey in full. To be eligible, people had to be actively 
working in UK general practice as general practitioners (GPs – sometimes referred to 
as family doctors or primary care practitioners). 
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All survey participants answered all questions fully, and whilst anyone with questions 
or issues was asked to contact the candidate, there were no reported issues or 
problems with the survey or the questions posed.  
6.5.1. Age of respondents 
Of the fifty-two people who responded to the survey, the majority (64%) were between 
35 and 55 years old. Sixteen per cent of people were less than 35 years old (8/52) and 
20 per cent were over 55 years old (10/52). Age ranges are shown in Figure 17. 
Figure 17 Age of respondents 
 
6.5.2. Number of years in general practice 
Twenty seven per cent (14/52) of GPs who took part in the survey had been in practise 
for less than 10 years. Thirty-five per cent (18/52) had between 10 and 20 years’ 
experience, and 39 percent (20/52) had over 20 years’ experience in general practice, 
with one GP having been in practice for 32 years. All responses are shown in Figure 
18. 
Figure 18 Years since first GP appointment
 
Geographically, participants were distributed across the United Kingdom with GPs 
based in general practices across Scotland, Northern Ireland, Wales and England. 
There was greater representation from GPs based in Devon (31%; 16/52) and in the 
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South East (23%; 12/52), and lower representation from Wales and the north of 
Scotland. Clusters of respondents by geographical area are shown in Figure 19. 
Figure 19 Clustered locations of survey participants by general practice
 
6.5.3. General practice details   
Eighty-nine per cent of GPs surveyed did not have access to dementia specialists in 
their practice. Six GPs reported dementia specialists in their practice, which included 
a community dementia nurse, a dementia liaison nurse, a dementia service run by a 
foundation trust co-located within the same building as the general practice, a Primary 
Care Memory Assessment Service run under a Local Enhanced Service (LES) 
agreement, and three GPs who are dementia leads or have a special interest in 
dementia. 
The number of patients assessed for cognitive impairment by GPs per month was 
highly varied, with a mean number of 4 assessments per month (SD = 5.74). Some 
GPs reported assessing one patient for cognitive impairment every 4 months, whilst 
others reported assessing 30 patients a month. 
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Figure 20 Number of patients assessed for cognitive impairment per month
 
6.6. Brief cognitive assessment selection and use 
6.6.1. The most commonly-used assessment tools 
There were two brief cognitive assessments that was most commonly-used amongst 
the surveyed GPs: the Mini Mental State Examination (MMSE) at 32%, and the 
General Practitioners assessment of Cognition (GPCOG), also at 32%. The third most-
frequently used test was 6-CIT chosen by 17% of respondents. The Clock Drawing 
Test (CDT - used as a discrete assessment tool rather than as part of another test) 
was chosen by 5 respondents (7%), and the MiniCog, Montreal Cognitive Assessment, 
Addenbrooke’s Cognitive Assessment third edition (ACE-III) and Informant 
Questionnaire for Cognitive Decline in the Elderly (IQCODE) were each chosen by 1 
respondent (1.4%).   
GPs were able to select more than one test, and the most popular combination was 
MMSE and GPCOG chosen by 8 respondents (15%) with 3 of these GPs adding the 
CDT, one adding the 6CIT and one using the “Addenbrooke’s scale” for younger 
patients (assumed to be ACE-III). Two of the GPs who selected GPCOG also selected 
CDT, IQCODE and Bristol Activities in Daily Living (B-ADL). One respondent indicated 
that they did not have a brief cognitive assessment they used most often.  
6.6.2. Factors affecting tool selection 
Respondents were asked “what guides your choice of brief cognitive assessment?”, 
with multiple choice options shown in Figure 21. “Time taken to administer” was the 
most popular answer from 36% of GPs, and “cost” was only selected by one 
respondent.  
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Of the 9 GPs who selected other reasons, 3 people had different tools embedded in 
their clinical EMS software (used within a number of practices of respondents), and 
one GP had taken advice from a specialist colleague. One GP noted that their tool of 
choice (GPCOG) was needed for memory clinical referral. One GP commented that 
they felt the ACE-III has good face validity and they felt a normal range score on ACE-
III offered greater reassurance: 
“… [A] normal-range score is more reassuring (as important as its 
use in identifying actual cognitive impairment)” GP respondent-1 
One GP noted the value of a test (GPCOG) in allowing the involvement of a relative if 
needed, and one participant mentioned possible barriers to tool selection: 
remembering its’ name; and finding it on the system. 
Figure 21 Factors affecting GPs' choice of brief cognitive assessment 
 
6.7. Brief cognitive assessment use as part of GP decision making to 
identify dementia 
6.7.1. Use of brief cognitive assessments in practice: for initial assessment; and for 
monitoring over time 
GPs were asked which of the tools they had used in the last two years for a) initial 
assessment of a patient (see Figure 22); and b) decline over time.    
Tests were most often used for initial assessment of a patient, and tests were less 
often used for monitoring decline in cognition over time. The majority of respondents 
(67%) used MMSE for initial assessment, and MMSE was also the most popular for 
monitoring decline over time (40%).  
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Figure 22. Have you ever used this brief cognitive assessment for initial 
assessment? 
 
Within the ‘Other’ category, 13 out of 52 GPs (25%) had used 6CIT for initial 
assessment of patients, with three others using ACE-II (6%), two GPs (4%) referring 
to the Montreal Cognitive Assessment (MoCA) and Bristol Activities of Daily Living and 
AMT each referred to by one GP (2%).  
Fewer GPs had used brief cognitive assessment tools for monitoring decline over time 
(see Figure 23) but the same pattern remained as in conducting initial assessments, 
with MMSE most popular (40%), followed by GPCOG (19%), CDT (4%) and 6CIT 
(under ‘Other’ – 14%). Also under ‘Other’ two GPs selected ACE-III (4%) and one GP 
selected MoCA (2%) for monitoring decline over time. 
IQCODE and MiniCog were not selected by any respondents for monitoring decline 
over time.  
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Figure 23. Have you ever used this brief cognitive assessment for monitoring decline 
over time?
  
6.7.2. Acceptable test administration time 
GPs were asked what they would consider an acceptable administration time of a brief 
cognitive assessment within general practice in two different scenarios: if they 
themselves carried out the assessment; and if another member of staff such as a 
practice nurse carried out the assessment. The data were entered into a free text box, 
so GPs were free to choose any number or add other figures if they chose to.  
Of the 50 eligible GP responses regarding test time if a GP carried out the assessment, 
14% stated an acceptable test time of 2 minutes, 22% stated between 2 and 3 minutes, 
and 38% chose between 4 and 5 minutes (one GP chose 4 minutes and the rest chose 
5 minutes).  One GP selected 6 minutes, one chose 7 minutes, six (12%) selected 10 
minutes, one chose 15 minutes, two (4%) selected 20 minutes and two (4%) selected 
30 minutes. The range of scores are shown in Figure 24. Out of the 52 respondents, 
one GP entered ineligible data in this section (“yes” rather than a number) so their 
responses could not be counted. One GP entered a question mark (“?”) with the 
comment “Not really sure. I suppose less than 10 mins ideally”.  
The accompanying question “how long would be an acceptable test time if another 
member of staff (such as a practice nurse) carried out the assessment?” had 49 
eligible responses. In addition to the two ineligible replies above which were repeated 
across both questions, one other respondent had typed “practice nurse” within this 
section rather than giving a number. Of the 49 eligible responses, several GPs had 
entered a range rather than a single figure (e.g. 10-20 minutes). For analysis, the mid-
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point of the range was taken (e.g. from 10-20 minutes this was 15). Combined data 
are shown in Figure 24.  
Figure 24 Acceptable brief cognitive assessment administration time if: (see legend)
 
It is clear from Figure 24 that on the whole, GPs felt it acceptable for another member 
of staff such as a practice nurse to spend longer administering a brief cognitive 
assessment than a GP.  
Comments made reinforced this finding, and indicated other areas of influence: 
“Needs to be consistent within the practice, not have different tests 
used by different staff” [GP respondent-3] 
“if shown to be more reliable test” [GP respondent-46] 
Many participants highlighted common subjects of time, efficiency and system factors: 
 “[another member of staff would be] able to have longer as can 
concentrate on assessment only” [GP respondent-17] 
“If booked as a separate appointment” [GP respondent-26] 
“GP’s time probably more productively spent doing something else 
and anyone trained could do [it]” [GP respondent-29] 
Funding or financial issues were also consistently mentioned: 
 “again, the nurse would usually take more time over most things but 
we pay for nurse appointments and time and they are part of the 
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total pressure on the system, so nurse appointments are not 
resourced” [GP respondent-28] 
6.8. Confidence in practice 
6.8.1. GP confidence in interpreting test results  
GPs were asked how confident they would be in interpreting the results of a specific 
named test, on a scale of 0 to 5 where 1 was ‘not at all confident’ and 5 was ‘very 
confident’. For GPs who selected MMSE as the brief cognitive test they used the most 
(N=22), results of confidence in interpreting results are shown in Figure 25 with the 
legend showing the level of confidence (2-5). For those GPs who selected GPCOG as 
the brief cognitive test they used the most (N=18), results of confidence in interpreting 
results are shown in Figure 26 with the legend showing the level of confidence (2-5). 
 
 
 
      
Nobody responded with 1 (not at all confident); one GP rated their confidence in 
interpreting GPCOG as a 2 (not very confident), and added the following comment: 
“it [MMSE] is such a basic scale it can be skewed by anxiety/a bad 
day etc., and it doesn't pick up subtle issues” [GP respondent-28] 
Other participants rated their confidence in interpreting results of the MMSE at 4 
(fairly confident) or 5 (very confident), and there were comments on the difficulty of 
interpreting results that were closer to the normal thresholds or bias may be an 
issue: 
Language can be issue.  Very intelligent folk score well even when 
in decline so [I] feel less confident then [GP respondent-20] 
Figure 25. GP confidence in 
interpreting the results of MMSE 
[N=22] 
Figure 26. GP confidence in 
interpreting the results of 
GPCOG [N=18] 
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6.8.2. GP confidence in explaining test results to patients 
GPs were asked how confident they would be in explaining results of a specific 
(named) test to patients using the same scale described above, and results are shown 
in Figure 28 for those GPs who selected MMSE [N=22] and Figure 29 for those GPs 
who selected GPCOG as their most frequently used test [N=18]. 
 
 
   
Nobody responded with 1 (not at all confident), but one GP rated their confidence in 
explaining the results of the GPCOG to patients as a 2 (not very confident). This 
respondent was the same person as had responded with a 2 to the previous question 
asking how confident they were in interpreting results. This respondent made the 
following comment: 
“Able to reassure if normal (and if clinical picture is one of worried 
well) but not if more complex picture /subtle problem or high IQ. Also 
useful if low score to say - needs referral for further testing - looks 
like a possible memory issue.”  
[GP respondent-28] 
More GPs responded to this question with a 3 (moderately confident) but did not 
explain this result further. The final question (Question 10) within the survey asked 
GPs for any further comments about brief cognitive assessments, particularly in 
relation to identifying possible dementia. Twenty out of the 52 respondents chose to 
comment at question 10. 
Figure 28. GP confidence in 
explaining the results of MMSE 
to patients [N=22] 
 
Figure 29. GP confidence in 
explaining the results of GPCOG 
to patients [N=18] 
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6.9. Analysis of free test responses within the questionnaire 
As a first step in assessing the responses within all the free text sections in the 
questionnaire, a word cloud was produced to visually explore the content of responses 
for frequency of terms, concepts and words used by respondents. These word clouds 
are in essence a list of words weighted by frequency through a simple algorithm and 
used primarily to visualize the frequency distribution of metadata entered – in this 
case, the free text responses given within this questionnaire. It is designed as a visual 
check to detect potential patterns and associations between different words. As shown 
in Figure 30, ‘Time’ and ‘need’ were the most frequent terms used, with assessment-
related terms (such as ‘tool’, ‘score’, and ‘assessment’) also appearing frequently.  
Figure 30 Word cloud of all free text participants responses  
 
Initial coding of data was carried out by creating segments of text fragments focussing 
specifically on the aims of the survey: to investigate current clinical practice in the use 
of brief cognitive assessments to evaluate patients presenting with cognitive concerns, 
and how that correlates with current research and the established evidence base for 
the use of such assessments. 
These codes were then critically assessed and re-read in the context of the survey 
text segments, extracting and refining emergent themes as they developed359. 
Following discussion of these developing themes within the research team, themes 
were arranged and summarised to reflect the principal findings within the data. A 
simplified table showing the process of coding and theme development is available in 
Appendix 16. 
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These themes are discussed in detail below. 
6.10. Barriers and facilitators for practice identified by respondents  
Responses reflected a view of different factors as barriers or facilitators to clinical 
practice. These elements could be assessed in a number of ways, but the themes split 
simply into GP factors, patient factors, test factors and system factors. 
6.10.1 GP factors 
A number of GP responses suggested confidence in their clinical decision making 
which would influence how they conduct and interpret the results of an assessment. 
Some GPs voiced scepticism in the ability of brief cognitive assessments to influence 
their clinical judgment: 
“Most patients score fairly poorly on it and need referral regardless.”  
 “…if I have enough clinical suspicion, I will refer regardless of high 
score” [GP respondent-10] 
Some respondents reflected on the importance of interpersonal dynamics between 
patient and practitioner in conducting the assessment: 
“People can be really upset (angered) by the dementia screening 
questions. It's worth not rushing.” [GP respondent-43] 
I find that patients on first presentation may need rapport-building.  
Often hard of hearing. Need time to digest what's going on.  
However, what usually happens is that there is almost always a 
social or physical need that presents at the same time.  They 
present because of a problem.“ [GP respondent-10] 
One respondent questioned the role of the GP, although it was unclear whether this 
was around the diagnosis of dementia, use of brief cognitive assessments or another 
element: 
“As a GP I don't believe that I am the best placed person to do it.” 
[GP respondent-47] 
6.10.2 Patient factors 
A number of GPs highlighted their prior knowledge of the patient as having an impact 
on how the brief cognitive assessment was used. Although it was not clear how this 
prior knowledge would influence them, this familiarity was sometimes paired with 
discussion of cognitive decline: 
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“Takes into account prior knowledge of the patient” [GP respondent-
39] 
“It depends if you know the patient already & have identified 
cognitive decline” [GP respondent-34] 
Patient behaviour and particularly the tendency to present to general practice with 
several issues was remarked on as a factor in how GPs carried out brief cognitive 
assessments: 
“We are often trying to implement these with an aging population, 
who need time, sufficient hearing and motor function to complete 
many of them. They often have many issues in the consultation” [GP 
respondent-10] 
Finally, the perceived role of the GP in reassuring patients was commonly mentioned: 
 “Able to reassure if normal (and if clinical picture is one of worried 
well) but not if more complex picture /subtle problem or high IQ” [GP 
respondent-28] 
 “I do the longer Addenbrooke’s one for high IQ/young patients but it 
takes ages and feels like a hassle but can be useful to reassure 
worried well and avoid a referral“ [GP respondent-29] 
6.10.3 Test factors 
Common characterisations assigned to tools were either assistive, using language 
such as “helpful” or “useful”, or flawed, with language such as “skewed” or “crude”: 
“It is such a bad scale it can be skewed by anxiety/ bad day etc. and 
it doesn’t pick up subtle issues”[GP respondent-28] 
“Clock drawing often really helpful” [GP respondent-29] 
 “…the quicker ones are quicker but less useful” [GP respondent-28] 
The length of time that a test takes was a popular and recurring theme across the 
survey. The need for a test to be short, quick or to fit within a standard consultation 
time was the point most frequently made by GPs: 
“If you only have 10 mins, the assessment is the thing that gets 
squeezed” [GP respondent-10] 
 “I think a brief assessment tool should be just that, brief” [GP 
respondent-17] 
“Needs to be quick” [GP respondent-21] 
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6.10.4 System factors 
Several respondents mentioned the computer systems within their general practice – 
either EMIS or SystemOne. A number of these systems have one or more brief 
cognitive assessments incorporated as part of the general practice software, which 
allows GPs to use specific tools such as 6CIT directly from the computer with scoring 
and assessment conducted automatically.  
“I have personalised a version of MMSE and embedded it within 
EMIS…  This makes it easy to administer.” [GP respondent-39] 
“Available on EMIS system” [GP respondent-31] 
“It's written on the screen... would I remember scoring? Not a 
chance but I don't need to.” [GP respondent-43] 
Other responses highlighted the influence of test availability and increased challenges 
following enforced copyright of the MMSE: 
“Stopped using MMSE when charges introduced for using it” [GP 
respondent-3] 
“Can be very time consuming. Also MMSE now copyrighted...” [GP 
respondent-18] 
Time pressures were also commonly mentioned, with some GPs commenting on how 
considerations of time allowed within the general practice consultation affected their 
clinical decision making: 
“Pressure on time and appointments drives lots of GP decision 
making” [GP respondent-28] 
“They need to be short in time to facilitate a realistic assessment in 
general practice” [GP respondent-1] 
“Lots more to do in the 10 minute consultation” [GP respondent-46] 
Other members of the general practice such as nurse practitioners were viewed as 
having more time to conduct brief cognitive assessments and – by one GP respondent 
– was viewed as conducting brief cognitive assessments more accurately: 
“Done more slowly and accurately by the nurse” [GP respondent-52] 
“Again nurse would usually take more time over most things…” [GP 
respondent-28] 
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However these members of staff were also viewed as under-resourced, and possibly 
less skilled: 
“Nurse appointments are not resourced” [GP respondent-28] 
“GP’s time probably more productively spent doing something else 
and anyone trained could do” [GP respondent-29] 
Some GPs also emphasised the importance of considering the whole process of 
assessment beyond brief cognitive testing:  
“The test is usually for someone else's need/purpose. Diagnosis is a 
shared interpretive process of weighting up risk and benefit with 
patient” [GP respondent-48] 
Value judgments 
The language used around brief cognitive assessments and the testing process was 
often weighted; tests were good or poor, helpful and useful or flawed and crude. 
Respondents used language with comparative undertones of quality or worth: 
“Need the best tool available” [GP respondent-5] 
“No perfect one!” [GP respondent-42] 
Quality versus efficiency 
One GP’s comments carried an implicit suggestion that brief cognitive assessments 
might replace or overrule other aspects of general practice assessment such as history 
taking: 
“They can be useful, but as with depression scores, they're no 
substitute for a good history. The danger can be that they lead to a 
tick box approach” [GP respondent-2] 
This caution against taking a ‘tick box approach’ contrasts with comments on 
balancing the demands for quality – and particularly accuracy - in the brief cognitive 
assessment with efficiency and speed of process.  
 “Not always accurate” [GP respondent-21] 
 “Needs to be fitted into surgery time” [GP respondent-18] 
“Needs to be 'brief'” [GP respondent-1] 
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Generalism versus specialism 
The place of specialist skills within general practice was another theme that emerged 
amongst the responses; one GP referred to getting “advice from a specialist colleague” 
[GP respondent-27] and lack of expertise was referenced by another couple of 
respondents: 
“Done more slowly and accurately by the nurse” [GP respondent-52] 
“I have not seen much cognitive decline. Working part-time may 
contribute to this.” [GP respondent-1] 
The role of GP as gatekeeper or enabler for patients to be referred on for further 
assessment was referenced obliquely by other respondents: 
Able to reassure if normal (and if clinical picture is one of worried 
well but not if more complex picture /subtle problem or high IQ” [GP 
respondent-28] 
 “…it's a case of "this seems fine we need to think more about your 
problems (or not)" or "this suggests you would benefit from seeing 
someone else to review things further.” [GP respondent-43] 
One GP clearly queried the role of the GP in cognitive assessment:  
“As a GP I don't believe that I am the best placed person to do it 
[cognitive assessment].” [GP respondent-47] 
Other GPs questioned the place of screening in general practice: 
“I'm not convinced of the evidence base or practical utility of 
asymptomatic screening” [GP respondent-5] 
“I don't like the screening aspect. I prefer to use [the test] when 
someone is worried about their memory” [GP respondent-7] 
Evidence-based practice 
The question which this survey sought to address is: how do general practitioners 
choose and use brief cognitive assessments in practice as part of the process for 
identifying possible dementia in primary care? There are clearly many systemic factors 
which may contribute to constraining GP practice and are referred to by GPs 
responding to this survey. These potential constraints include length of time of 
consultations, funding for other staff such as nurse practitioners, and the use of 
practice-based computer systems with in-built software. 
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Areas which were less well-characterised by respondents than had been anticipated 
by reading the wider literature were levels of experience related to patterns of working 
(full time versus part time, partnership versus locum status), low reported numbers of 
dementia speciality within general practices, and sparse mention of relatives or carers 
– particularly given the popularity of the GPCOG, which is often preferred as it contains 
a section for assessment via an informant.  
6.11. Summary of main findings  
The MMSE and the GPCOG were the most frequently-used tests according to 
respondents, and were equally popular with 32% of those surveyed using one or the 
other (or both) most regularly. CDT, 6CIT, ACE-II, IQCODE and the Bristol Activities 
in Daily Living tool were also mentioned. 
Of the factors which guided tool selection, ‘time taken to administer’ was the most 
prominent reason to choose a test (chosen by 35.3%), followed by ‘local factors’ 
(chosen by 20.6%), including availability of the test and preferences of the individual 
surgery. Nineteen respondents (18.6%) selected ‘it’s what I’ve always used’, with 9.8% 
of people choosing ‘patient factors’ such as age, education or impairments.  
The majority (67%) of people surveyed used MMSE for initial assessment of a patient, 
and 40% of people had used MMSE to monitor decline over time. Fewer respondents 
generally had used any of the tests to monitor decline over time, and neither IQCODE 
nor MiniCog were used by any contributors for monitoring decline over time.  
Thirty-eight per cent of respondents felt that the optimum length of time for a test to 
administer was between 4 and 5 minutes. Those who responded consistently felt that 
another member of staff (such as a practice nurse) could reasonably spend longer 
administering a brief cognitive test compared to a GP.  
When asked how confident they were in interpreting results on a scale of 1-5, with 5 
being most confident, 11 out of 22 (50%) who used the MMSE felt they were fairly 
confident (4 out 5) and 9 out of 22 (41%) were very confident (5 out of 5). For GPCOG, 
of the 18 respondents, 9 (50%) were very confident (5 out of 5) in interpreting results, 
6 (33%) were fairly confident (4 out of 5), two (11%) were quite confident (3 out of 5) 
and one was not very confident (2 out of 5).  
In terms of confidence in explaining test results to patients, patterns were similar with 
10 out of the 22 people who used the MMSE (45%) being very confident in explaining 
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results to patients, 7 out of 22 (32%) fairly confident and 5 out of 22 (23%) were quite 
confident. For the 18 people who chose the GPCOG, 6 out of 18 (33%) were very 
confident in explaining results to their patients, 9 out of 18 (50%) were fairly confident 
(4 out of 5), two (11%) were quite confident (3 out of 5) and one was not very confident 
(2 out of 5).  
Within free text responses, GPs noted scepticism in the ability of brief cognitive 
assessments to influence clinical judgment, identifying the doctor-patient relationship 
as more important and voicing doubts over whether the GP was the best person to 
conduct a brief cognitive assessment. The role of the GP in ressuring the patient 
regarding test results and managing complex conditions was a common theme. Tests 
were characterised as assistive or flawed, and the length of time a test takes to 
administrate was a recurring topic. Systemic factors were seen as helpful (with some 
tests embedded within the computer system) or obstructive (such as time pressures, 
costs for using tests and under-resourcing of other practice staff).  GPs questioned the 
role of screening in general practice, and several respondents referred to tensions 
between specialist skills and the role of the generalist in general practice. 
6.12. Threats to validity 
Most responses were from England, but replies were received from Northern Ireland, 
the Scottish Highlands and North Wales. Geographically respondents were fairly well 
dispersed, with clusters (suspected to be around prominent respondents who would 
have forwarded on requests to colleagues) around London, Bristol, Birmingham, 
Exeter and Torquay. Other demographic details such as sex and ethnicity were not 
collected, as these were not a priori motivations of the survey and these data were not 
guaranteed to be used within the final analysis.  
Data were not collected on career breaks or whether hours were full or part time. Whilst 
this may have been interesting in assessing how work patterns related to the reported 
number of patients assessed for possible dementia per month, the survey was 
designed to be quick and easy to complete with as small a number of questions posed 
as would be informative to the research. The central research aims were to discover: 
how GPs’ use brief cognitive assessments as part of their decision making to identify 
patients likely to have as-yet undiagnosed dementia; the most commonly-used brief 
cognitive assessment tools; and how information from the assessment affects GPs’ 
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management decisions. Therefore any non-essential items (i.e. not relating to the core 
research aims) were removed during the refining and development process. 
By employing an opportunity sample publicised using professional networks, social 
media and word of mouth, a fair response rate of 52% (52 out of an expected 100 
people) provided a rich source of data for analysis. This sampling framework does 
introduce a number of potential biases. All participants are self-selected, volunteered 
their time and are active on Twitter. It is most likely that respondents are actively 
interested and engaged in dementia diagnosis within general practice, as they agreed 
to take part in a survey on this topic for free. Many respondents were colleagues and 
referrals on from people either within the PhD project team or GPs who had piloted 
the survey. The topic itself and the nature of self-report may have introduced social 
desirability bias, where respondents were motivated to appear engaged, active and 
‘doing the right thing’ with their own practice regarding dementia diagnosis. Questions 
were designed to capture a range of responses and avoid explicit bias towards one 
course of action, but this element of desirability may not have been eliminated.  
6.13. Triangulation of the data, incorporating perspectives from other parts of 
the thesis and existing literature 
In order to assess the richness and authenticity of these findings, and – where possible 
– to generate innovation in framing of concepts, cross verification of the survey data 
was conducted with evidence from the rapid review, overview and systematic reviews 
conducted as part of this thesis, as well as with the known body of existing literature 
around GP selection and use of BCAs when used as part of the process for identifying 
dementia in general practice363. 
This triangulation of the survey data provided a rare and valuable opportunity to 
provide new insights and deepen understanding of the existing evidence base 
alongside new information generated through the GP survey364.  
Triangulation was achieved through assessment of these survey findings alongside 
results of the rapid review of clinical practice guidelines, the overview of BCAs 
available for use in general practice, the systematic review of direct comparisons of 
the diagnostic accuracy of MMSE and GPCOG when used for identifying dementia in 
general practice, and a thorough review of the literature around BCA selection and 
use when applied in a general practice setting for the purpose of identifying dementia 
as part of the diagnostic process.   
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Within the rapid review of CPGs, four guidelines were identified that fitted the criteria 
of identifying themselves as being CPGs, explicitly suitable for general practice, 
directly focussed to identifying dementia and available in English language.  
All CPGs were single national guidelines, published in the last 13 years. One was from 
the UK173, one from Australia174 and two from Canada110,175. All included CPGs were 
created for an audience wider than general practice, including hospitals, community 
care, specialist assessment, and care homes. There were a number of guidelines 
within all three CPGs not applicable to general practice.  
In terms of procedure for conducting diagnostic assessments, the UK CPG 
recommends that at the initial consultation a patient history is taken from the individual 
and ideally from someone who knows the person well. If dementia is still suspected 
the patient should have a physical examination, alongside appropriate blood and urine 
tests to rule out other causes of cognitive problems, and cognitive tests should be 
conducted. The Australian CPG are based closely on the UK CPG, but the guideline 
committee noted caution and adaptation when assessing people from indigenous 
communities as there may be different perceptions of alterations in cognition in some 
cultures, leading to individuals and their carers seeking diagnosis at a later stage of 
the dementia progression. The Canadian CPG does not give guidance on diagnostic 
procedure in general practice.  
These findings were not confirmed or refuted within the survey of GPs, as none of the 
GPs surveyed mentioned specific CPGs. As the survey was conducted in the UK, only 
the NICE guidance would be relevant or easily accessible but it is notable that these 
– or any – named clinical practice guidelines are not specifically referred to in any of 
the closed response questions or any of the free text responses.  
A 2002 survey of clinicians in six United States Department of Veterans Affairs medical 
centres365 found that whilst clinician practice broadly followed dementia clinical 
guideline recommendations, roughly one third of those surveyed (N=200) did not 
routinely use a recommended BCA. One third of respondents did not routinely discuss 
care or management needs arising from the assessment with the patient or carers, 
and one third of clinicians did not discuss the diagnosis or prognosis directly with their 
patient. 
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A randomised controlled trial of 35 UK GP practices in 2009366 found that only 28% of 
patients with a diagnosis of dementia received BCA testing in primary care, with the 
test results recorded correctly in only 23% of cases. Of those patients that received a 
diagnosis of dementia, only 15% of patients were told they had dementia within 
primary care. This study highlights the potential anomaly that whilst GP records may 
not have recorded a diagnostic or management process, it may have taken place but 
not been recorded within standard record-keeping software and other work clearly 
reinforces this common discrepancy between GP practice and record keeping17,367-369. 
A 2015 analysis of GP records relating to dementia diagnosis in the UK370 reported 
general improvements in GP concordance with guidelines on diagnosis and 
management of people with dementia, following publication of the 2006 NICE clinical 
guideline 42371 and the 2014 UK Dementia Strategy372. Only 40% of practices 
surveyed recorded carrying out BCA tests. Of the patients with cognitive tests 
recorded, 57% were for the MMSE, 36% were for the AMT and 4% were for 6-CIT. 
This is out of step with the findings of the survey reported here, where MMSE made 
up 32% of the BCAs reported, GPCOG featured in 32% of responses and 6-CIT in 
17% of responses. The Abbreviated Mental Test was not mentioned by any of the GP 
respondents in the survey conducted within this thesis.  
In terms of the actual BCAs identified by GP respondents to the survey, these were 
broadly in line with those identified in the overview of BCAs available for use as part 
of the process for identifying possible dementia within general practice. In the 
overview, MMSE was the BCA which featured most frequently within the included 
systematic reviews, as it appeared in 8 out of the 13 systematic reviews. GPCOG 
featured in 5 out of the 13 reviews, with both CDT and MiniCog featuring in 4 reviews 
each. Within the survey, MMSE and GPCOG both featured in 32% of responses, with 
6-CIT appearing in 17% of responses and others (CDT, MiniCog, MoCA, ADAS-Cog 
and IQCODE) all mentioned by at least one respondent. Within the overview, both 
ADAS-Cog and MoCA were not included as tests suitable for general practice as they 
both take longer to administer42,104 than the 10 minute threshold set within the overview 
selection criteria as suitable for use in general practice.  
One of the main findings of the overview in relation to suitability for general practice 
was that the MMSE is not suitable as the administration time is consistently longer 
than the average time allowed for most GP consultations133,134. The survey identified 
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that other BCAs may be growing in popularity compared to the MMSE, and this may 
be a pragmatic response – at least in part - to increasing demands on the GP 
consultation and limited time allowed for a number of activities373, alongside growing 
GP understanding of bias within the MMSE relating to education and culture254,264,374.  
Within the systematic review directly comparing the diagnostic accuracy of GPCOG 
and MMSE when used as part of the process for identifying dementia in general 
practice, it was shown that MMSE and GPCOG Total performed similarly in terms of 
sensitivity and specificity. This finding was reflected within the survey, where equal 
numbers of GPs surveyed most commonly chose MMSE and GPCOG for use in their 
practice as part of the process for assessing patients for possible dementia.  
Whilst a major finding within the systematic review was that the threshold selected 
may have more influence on test accuracy than the test itself, the issue of appropriate 
thresholds and tailoring of the test did not feature within the survey of GPs. Whilst 
there was not one question which addressed this explicitly, it may have been expected 
to have featured within one of the free text responses. It may be that GPs surveyed 
were not sufficiently familiar with the BCAs to acknowledge the potential variation at 
different thresholds, or it may simply have been missed amongst other considerations 
around BCA selection and use.  
One insight provided by this survey which was strongly resonant with the systematic 
review findings is the place and importance of factors beyond classic diagnostic 
accuracy measures to consider within general practice concerning BCAs. Concerns 
around pragmatic factors were raised, such as the time allowed within the consultation 
for actual conduct of the BCA, including explanation to the patient, gathering of pre-
assessment information, conduct of the assessment, analysis, explaining to the patient 
what the results mean and then discussing with the patient and family as appropriate 
the potential prognosis and options for ongoing treatment and management. Free text 
responses within the survey identified GP concerns around patient factors including 
implications of a diagnosis, lack of caregiver support, and not wanting to upset the 
patient unduly through the process of testing.  
These findings resonate strongly with the literature around patient factors beyond 
accuracy that concern GPs when conducting an assessment for dementia10,43,69,348. It 
has been proposed that in the current model of dementia diagnosis in general practice, 
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patient preference may be viewed as subsidiary to clinical ability, where the dominant 
medicolegal framework with government targets and institutional narrative driving 
early diagnosis discounts the role of the patient in managing their own health journey 
and right to challenge medical intrusion375. Topics related to the patient’s ability to 
function on a daily basis, and the implications of a dementia diagnosis on a patient’s 
daily activities, did not feature within the free text sections of the survey. It was 
surprising to find how little these wider implications of the diagnosis and understanding 
of the testing were mentioned by GPs, yet these factors are identified regularly in the 
literature16,370,376,377. 
There was also scant mention of relatives or carers within the survey responses. This 
was another surprising finding as the GPCOG was so popular amongst respondents, 
and is often preferred as it contains a section for informant assessment unlike the 
MMSE. Research literature makes frequent reference to caregiver perspectives, in 
terms of perceived support376, a lack of coordination for care347, and poor 
communication within general practice378-380. This oversight may have been due - in 
part at least - to a lack of explicit questioning within the survey directed towards 
interactions with family and caregivers.  
One of the singularly most surprising findings from the overview was echoed within 
the survey – that there was no evidence for one BCA perceived as most suitable for 
GP use as part of the process for identifying dementia. The lack of clear evidence at 
the level of primary studies, systematic review or within clinical practice guidelines 
reflected strongly in the disunity across GP preferences and concerns around current 
BCAs used in clinical practice. In addition, the mixed levels of knowledge, 
understanding and confidence in testing generally and in the choice and application of 
specific BCAs which was revealed by the survey of GPs can be understood as a direct 
and logical product of the findings of the overview – that current evidence is unclear, 
of mixed quality, and not fit for purpose in informing general practice. Equally the rapid 
review of CPGs relating specifically to the use of BCAs in general practice similarly 
found a lack of evidence to help guide general practice in choosing and using BCAs 
appropriate to their individual needs and populations.  
In terms of practical improvements, new insights were gained from the survey around 
the convenience of incorporating assessments within the general practice software, 
generally EMIS or SystemOne. Respondents indicated the convenience of having 
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assessments already installed on the system which meant the GP no longer had to 
find the right assessment or think about what BCA to use. Conversely, respondents to 
this survey spoke of guarding against a tick-box approach to cognitive assessment. 
There is little research literature on this topic relating specifically to dementia diagnosis 
in primary care, but in the area of blood testing a qualitative assessment of patient and 
clinician perspectives found that there may be value in adopting online systems to 
reduce areas for error (such as interpretation or transposition) and increase fluency in 
communicating results to patients and between different clinical areas such as 
pharmacies and general practices381. This may be an area where simple pragmatic 
changes can significantly improve current practice, but there is work to be done on 
assessing costs as well as benefits that greater efficiency and convenience may 
introduce.  
This process of triangulation of the survey data with findings from the rapid review, 
overview and systematic review, alongside investigation of current research, has 
allowed a deeper and more nuanced assessment of the discoveries made within this 
thesis. Moreover, the process of triangulation has highlighted areas of resonance as 
well as contrasts within what is already known and what has been discovered in the 
course of this thesis, such as the potential for incorporating approved BCAs into GP 
systems to improve adoption and consistency in recording of assessments. This has 
enabled further insights to be made, and these are discussed in more detail within the 
final chapter.  
6.14. Recommendations to practice 
From the results of this survey, there appears to be a limited pool from which GPs are 
selecting brief cognitive assessments. The continued popularity of the MMSE despite 
its copyright enforcement now carrying a cost (or risk of legal action) for individual 
practices is a major concern, both in terms of a lack of evidence-based practice and 
from a cost-effectiveness perspective. There appears to be a clear deficit in the range 
of brief cognitive assessments that GPs are considering for practice, and the reasons 
given for selecting particular tests need further examination. Administration time was 
the most prominent influence in this decision-making yet the MMSE takes longer than 
the average consultation length to administer from start to finish382. As has been 
recommended elsewhere in this thesis, establishing actual administration times for the 
most popular tests is long overdue. 
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Policy recommendations for conducting brief cognitive assessments in practice must 
take account of limited time available within the GP consultation, limited expertise of 
dementia diagnosis and management within practices, and finite resources from other 
practice staff who may be asked to carry out assessments. In addition, guideline 
developers and policy makers must recognise the limits of current knowledge in 
identifying dementia. The judicious use of cognitive assessment should be 
encouraged alongside other measures particularly for people who may be 
disadvantaged by common tests, such as those with higher education levels, where 
English is not their first language, or from diverse ethnic backgrounds. These factors 
are well recognised within general practice, yet both the tests available and the policies 
behind current practice often do not take full account of these features. 
It was interesting to note that tests that are integrated into the practice software are 
seen as useful, and this type of service integration to ease administration for GPs and 
the wider practice should be investigated as a simple benefit for administration and 
management.   
Finally, the increased drive towards asymptomatic screening within the general 
practice population (‘case finding’, or ‘targeted screening’) is clearly a concern and 
some respondents voiced discomfort with pressures in this direction. Until the 
evidence base is better built and understood, policies designed to increase case 
finding should be suspended.  
6.15. Recommendations to research  
Whilst the popularity of MMSE as a brief cognitive assessment for use in practice is 
waning following the imposition of copyright regulations meaning tests now have a 
licensing charge, it is still a highly popular measure within research. This should 
change, as a matter of priority – particularly for research focussed towards primary 
care and general practice.  
Whilst GPCOG was also popular amongst survey respondents, these two tests may 
not suit the general practice setting where short consultation times mean tests need 
to be shorter than both of the most popular measures within this survey (MMSE and 
GPCOG). The development and evaluation of brief cognitive assessments designed 
for and suited to general practice within the UK and beyond must be a priority for 
research, taking into account not only administration time but also adaptability for 
administration by various practitioners, both medical and nursing.   
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A major research priority should focus upon GP attitude and management of the 
patient and their family within the context of brief cognitive assessments. It was notable 
that few GPs mentioned patients at all beyond the targeted questions, and when they 
did it was in terms of using the tests to reassure patients. The discovery that some 
GPs would consider knowledge of the patient and patient history to be as important or 
more important than test performance needs further exploration; is this due to 
uncertainty with the tests, or prioritising patient management beyond assessment? 
The common difficulty voiced by GPs when managing patients who present with a 
number of conditions or issues is also worthy of further research; how does this impact 
patient testing, and how can the patient journey be improved to aid the testing process 
within the practical time constraints of the GP consultation? Development of new tests, 
new testing methods and new technologies such as decision-making algorithms also 
need assessment and full evaluation using appropriate methodological approaches.  
One final topic worth further exploration is the drivers for referral from general practice 
to specialist services such as psychiatry or gerontology. The results of this survey 
suggest that the results of brief cognitive assessments have little bearing for many 
general practitioners when considering further investigation and management 
decisions. A recent randomised controlled trial by Gill Livingston and colleagues92 
investigating the effectiveness of an intervention to aid prompt referral to memory 
clinics in the United Kingdom found little effect of the intervention. The authors propose 
that persistently-low referral rates may have been due to GP concerns around service 
availability, length of waiting lists for diagnostic services and limited resources for post-
diagnostic support92. These issues may well impact on GP referral decisions and our 
survey results suggest this would be a worthwhile area for further investigation.  
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Appendix 13 Copy of the survey
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SECTION A: GENERAL 
1 Title of the Study: General practitioners’ clinical practice and attitudes to using brief 
cognitive assessments to identify dementia  
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2 Full name of applicant: Harriet Hunt 
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Fax: - 
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Contact details (e-mail/ telephone/fax): C.J.Hyde@exeter.ac.uk  
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Oxford 
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Name(s): Dr Nick Cartmell 
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Location: Ashburton 
Contact details (e-mail/ telephone/fax): nickcartmell@nhs.net 
Name(s): Dr Mark Pearson 
Position Held: Senior Research Fellow in Implementation 
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Supervisor 
Location: Exeter/Plymouth 
Contact details (e-mail/ telephone/fax): Mark.Pearson@exeter.ac.uk 
Name(s): Dr David Llewellyn 
Position Held: Senior Research Fellow in Clinical 
Epidemiology and secondary PhD Supervisor 
Location: Exeter 
Contact details (e-mail/ telephone/fax): David.Llewellyn@exeter.ac.uk 
Name(s): Professor Willie Hamilton 
Position Held: GP & Professor of Primary Care Diagnostics 
Location: Exeter 
Contact details (e-mail/ telephone/fax): W.Hamilton@exeter.ac.uk 
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If yes, please complete the remainder of this section. 
Year of Study: 3 
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Committee for continuing review approval. 
I shall ensure that any changes in approved research protocols are reported promptly 
for approval by the relevant University Ethics committee. 
I shall ensure that the research study complies with the appropriate regulations and 
relevant University of Exeter policies on the use of human material (if applicable) 
and health and safety. 
I shall ensure that any external permissions necessary for the research to be 
undertaken are obtained prior to the research taking place.   
I am satisfied that the research study is compliant with the Data Protection Act 1998, 
and that necessary arrangements have been, or will be, made with regard to the 
storage and processing of participants’ personal information and generally, to 
ensure confidentiality of such data supplied and generated in the course of the 
research. 
(Note: Where relevant, further advice is available from the University of Exeter 
Medical School 359 Data Protection Officer). 
I will ensure that all adverse or unforeseen problems arising from the research 
project are reported in a timely fashion to the Chair of the relevant University 
Research Ethics Committee.  
I will undertake to provide notification when the study is complete and if it fails to start 
or is abandoned. 
I have met and advised the student on the ethical aspects of the study design and 
am satisfied that it complies with the current professional (where relevant), 
School and University guidelines. 
I have read this application and believe it to be scientifically and ethically sound  
 
Signature of Applicant:  Date: 22/06/17 
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Signature of Supervisor:  Date: 25/06/17 
 
Departmental Approval 
 
 I give my consent for the application to be forwarded to the University of Exeter 
Medical School Research Ethics Committee with my recommendation that it be 
approved. 
 I confirm that this submission has been appropriately peer reviewed. 
 
Signature of Head of Research Institute/Centre or Vice Dean (Education) (or 
approved nominee)  
Signature:       Date: 27th June 
2017 
Printed Name: Professor Stuart Logan 
 
 
5 Name and affiliation of Peer Reviewer(s) 
Name: Rebecca Whear Position held: Research Fellow 
Institution: PenCLAHRC/UEMS 
Contact details 
(email/telephone/fax): 
R.S.Whear@exeter.ac.uk 
01392 726064 
 
SECTION B: FUNDING 
 
6 If the research is externally funded, what is the source of the funding? 
This research is part of a PhD project funded by PenCLAHRC under the Diagnostics theme 
6.1 What is the value of the grant?  n/a 
6.2 Are there any conditions attached to the funding which could have an impact 
on this application? 
YES  NO   
If yes, please specify.  
  
 
 
SECTION C:  THE RESEARCH 
 
Background  
In the UK, general practice is often the first place that people will present with concerns 
about their or a relative’s cognition, yet efforts to identify dementia in this setting can often 
be hampered by non-specific symptoms, multi-morbidities and lack of resources such as 
consultation time and ability to use complex cognitive assessment tools. Surveys have 
explored general practitioners’ attitudes to dementia identification and diagnosis within 
primary care, yet the selection and extent to which GPs actually use brief cognitive 
assessments to identify dementia and refer to memory clinics is unclear. 
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Factors which affect a tool’s utility beyond diagnostic accuracy include: time to administer: 
suitability for the target population; adaptability for different scenarios; clarity for clinical 
and patient users; cost; and possible increased value in combination with other tests.  
Aim 
To investigate current clinical practice in the use of brief cognitive assessments to 
evaluate patients presenting with cognitive concerns, and how that correlates with current 
research and the established evidence base for the use of such assessments. 
Research methodology 
Through a survey with general practitioners, we will explore:  
a) GPs use of brief cognitive assessments as part of their decision making to identify 
patients likely to have as-yet undiagnosed dementia; 
b) The most commonly-used assessment tools; and  
c) What, how, and to what extent, does information from the assessment affects GPs’ 
management decisions? 
These insights will help build a better picture of how GPs choose and use brief cognitive 
assessments as part of their process for identifying patients with probable dementia in 
general practice, to better inform policy makers, test developers, researchers and 
healthcare professionals and aid primary care in supporting a more effective route to 
dementia diagnosis. 
Before launching, the survey has been tested for flow and technical fluency, and piloted 
with general practitioners to check sense and facility. This has led to several refinements 
in the final survey (see attachment). 
Quantitative data will be reported via ranked preferences of test and percentage groupings 
with confidence intervals reported. Univariate descriptive analyses will be used to explore 
demographic variables and GP attitudes to the use of cognitive assessments in general 
practice. Qualitative data responses will be analysed thematically to code and develop 
emerging commonalities, using expertise within our research team to test and refine the 
analytical framework within which themes will be developed.  
Contribution of research 
This survey is the final component in a programme of doctoral research aiming to address 
the second part of question 3 from the 2013 James Lind Priority Setting Partnership on 
Dementia: how can primary care support a more effective route to dementia diagnosis? 
The James Lind Alliance is an organisation that gathers the views of patients, clinicians, 
researchers and experts on a specific topic and through a series of workshops identifies a 
core set of research priorities for that topic. Our intention is that this survey will provide 
initial data to contribute to a larger research project exploring further how practitioners and 
patients communicate and understand diagnostic information within the general practice 
setting. 
Justification of benefit  
Whilst the timely identification of dementia and referral to specialist services is important to 
improve the chances of living well with dementia for as long as possible, general practice 
assessment needs to be balanced with implications of the increased likelihood of false 
positives and moderate test performance of brief cognitive assessments within this setting 
(Pond et al., 2013; Jacova et al., 2007; Yokomizo, Simon & de Campos Bottino, 2014). 
Recommendations for operationalizing the assessment of cognitive performance and 
detection of dementia have been created as part of national dementia strategies by 
several countries including the United States (GSA, 2015), the UK (DH, 2016), and 
Australia (GAC, 2016), and they all discuss brief cognitive assessment tools in detail, as 
well as highlighting the value of employing appropriate tools as part of an iterative 
diagnostic process. These strategies commonly acknowledge many of the challenges in 
finding the most suitable tool for the primary care setting. What they lack are clear 
recommendations and guidance on how the best tool should be chosen by the primary 
care practitioner, and when tools should – and should not – be used as part of the 
diagnostic routine.   
This survey will contribute towards a PhD. 
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Include any questionnaires, psychological tests, etc. at the end of your application. 
 8 Location of study  
8.1 Where will the study take place?  
In the UK 
8.2 If the study is to be carried out overseas, what steps have been taken to secure 
research and ethical permission in the country of study? (Please attach evidence of 
approval if available.) 
n/a 
9 Multi-centre and off-campus studies 
If this is a multi-centre or off-campus study, please answer the appropriate 
questions below; otherwise, go to Question 11. 
9.1 Does this project involve a consortium (other research partner organisations)? 
YES  NO   
If yes, please complete the details below in Question 9.2. 
9.2 Who has overall responsibility for the study? 
 
 
Please provide details of the contractual agreement between UEMS and the other 
organisation(s).  
 
9.3 Is this an off-campus study? 
YES  NO   
If yes, please provide signed, written permission from an appropriate level of 
management within the relevant organisation(s). 
10 Has approval been sought from other Ethics Committees and LRECs? 
YES  NO   
11 Who will have overall control of the data generated? 
Harriet Hunt at the University of Exeter 
12 How do you propose to disseminate the results of your research? 
 Peer reviewed journal publications, PhD thesis, academic conferences and via workshops 
and focus groups for follow-up work (subject to post-doctoral funding). 
 
 
13 METHODS AND PROCEDURES 
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Describe the nature of the task required of participants and the various precautionary 
measures to be taken to avoid harm or discomfort if appropriate.  If the study is likely to 
cause discomfort or distress to subjects [?], estimate the degree and likelihood of 
discomfort or distress. 
Participants are to complete a survey exploring clinical practice and attitudes towards 
using brief cognitive assessment to identify dementia in general practice. This will be via 
an electronic survey taking around 7 minutes to complete. Participants will be asked if 
they consent to taking part in the survey, and told they can withdraw at any point without 
giving a reason. It is not anticipated that the survey is likely to cause discomfort or distress 
to participants. 
I have included a copy of the survey form at the end of this application. 
N.B. I note the use of ‘subjects’ in the question above (my bold and boxed question mark) 
and query if it is appropriate, or would be better replaced with ‘participants’.  
 
13.1 Does the study include any of the following interventions / invasive procedures? 
 
 YES NO  YES NO 
Participant-observation /  
non participant-observation 
 
 
 
 
 
 
 
 
Self-completion 
questionnaires 
 
 
 
 
 
 
Interviews 
 
 
 
 
 
Video / audio recording 
 
  
Focus Groups   
 
Administration of 
substance / drug 
(e.g. caffeine / doubly 
labeled water etc) 
 
  
 
Physical examination   
 
Manipulation of diet 
 
  
 
Arterial puncture* 
 
  
 
Venepuncture* 
 
  
 
Urine sample* 
 
  
 
Fingertip blood sample* 
 
  
 
 
Body Imaging  
(e.g. MRI, DEXA, X-rays) 
 
 
 
 
 
Saliva sample* 
 
 
  
 
 
* if yes, will samples be retained for subsequent testing for factors other 
than described in this proposal?    
 
   If yes, will samples be anonymised? 
 
 
 
 
 
 
 
 
 
 
 
 
If you are using human tissue in your project, you must complete section E. 
 
14 Products and devices 
14.1 Does the research involve the testing of a product or device? 
YES  NO   
14.2 If this research involves a drug, is it being used in accordance with its licensed 
uses?  
         
YES  NO   
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d) SECTION D:  THE PARTICIPANTS 
 
For the purposes of this section, “participants” include human subjects, their data, their 
organs and/or tissues. For participants to be recruited to the research, please state:  
15 Number of participants: Approximately 200 
16 If data are to be collected on different sites, please state the number of 
participants at each site: n/a 
17 How have you arrived at this number?  Please state proposed 
inclusion/exclusion criteria. If appropriate has the protocol been reviewed by a 
Statistician? 
We are employing an opportunistic sampling strategy to conduct an exploratory survey, and 
are therefore unable to give precise numbers. All UK general practitioners (including those 
employed part time, full time and locums) are eligible to complete the survey. We will 
distribute the survey using the Contact, Help, Advice and Information Network (CHAIN - 
http://www.chain-network.org.uk) which has approximately 170 general practitioners on the 
mailing list. We will also use our professional networks such as the South West Clinical 
Research Network (SWCRN) and  Exeter Collaboration for Academic Primary Care (APEx) 
research group to publicise the survey and to post on a GP-specific Facebook group. In 
addition, we will use Twitter to promote the survey, using the hashtag #gpnews and 
requesting retweets from the Royal College of General Practitioners (@RCGP), Devon 
Local Medical Committee (@Devon_LMC) and practitioner magazines such as 
GPOnline.com (@GPonlinenews) and PulseToday (@pulsetoday). I also plan to place a 
note in the Devon Local Medical Committee newsletter to promote the survey. 
Using CHAIN and our professional networks as outlined, we anticipate reaching ~200 
people and anticipate a response rate of around 50%, based on previous experiences of 
colleagues who have undertaken similar survey work with similar target groups. This 
should allow approximately 100 responses to the survey. 
I have discussed this protocol with Obi Ukoumunne, Associate Professor in Medical 
Statistics at the University of Exeter Medical School. 
18 Age group or range (e.g., 
under 60s): 
18 – 80 
18.1 
Sex: 
Male   Female   
19. Is this a single sex study? 
 YES  NO   
If yes, please justify the reason(s) for gender selection  
 
 
 
While some studies explicitly focus on gender specific experiences, care should be taken 
to ensure that women or men are not unnecessarily excluded from participating in 
research. 
 
20 Do participants belong to any of the following vulnerable groups? 
Children: YES  NO   
Participants unable to give informed consent in their own right (e.g., people with 
learning difficulty): 
 YES  NO   
Other vulnerable groups (please specify)  
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 YES  NO   
 
Care will need to be taken to formulate inclusion/exclusion criteria that clearly justify why 
certain individuals are to be excluded, to avoid giving the impression of unnecessary 
discrimination.  On the other hand, the need to conduct research in “special” or 
“vulnerable” groups should be justified and it needs generally to be shown that the data 
required could not be obtained from any other class of participant. 
If the answer to any of the above is yes, please complete Questions 21 to 25; otherwise 
proceed to Question 26. 
 
21 Please explain why it is necessary to conduct the research in such vulnerable 
participants and whether required data could be obtained by any other means. 
22 Please state what special or additional arrangements have been made to deal 
with issues of consent and the procedures to safeguard the interests of such 
participants. 
23 Please describe the procedures used to ensure children (i.e., persons under 18 
years) are able to provide consent/assent to participation. 
24 If appropriate, please state whether and how parental consent, or the consent of 
the legal guardian and/or order/declaration of the court, will be sought in relation to 
the participation of children in the research. 
25 If the participant is unable to consent in their own right, will you seek the prior 
approval of an informed independent adult and any other person or body to the 
inclusion of the participant in the research? 
 
 YES  NO   
State precisely what arrangements will be put in place. 
 
 
Recruitment and Selection 
The Research Ethics Committee will need to be satisfied with the effectiveness and 
propriety of recruitment and selection procedures given the participant involved, e.g., that 
the participant will not feel in any way obliged to take part, that advertisements do not 
appear to offer inducements.  The Committee will be particularly interested in cases where 
a participant’s relationship with the investigator could raise issues about the voluntary 
status or motive of the participant’s involvement in the research (e.g., students). 
26 How will the participants in the study be selected, approached and recruited 
(please indicate the inclusion and exclusion criteria)?  
We are employing an opportunistic sampling strategy to conduct an exploratory survey. All 
general practitioners (including those employed part time, full time and locums) are eligible 
to complete the survey. We will distribute the survey using the Contact, Help, Advice and 
Information Network (CHAIN - http://www.chain-network.org.uk) which has approximately 
170 general practitioners on the mailing list. We will also use our professional networks such 
We will also use our professional networks such as the South West Clinical Research 
Network (SWCRN) and the Exeter Collaboration for Academic Primary Care (APEx) 
research group to publicise the survey and to post on a GP-specific Facebook group. We 
will also use Twitter to promote the survey, using the hashtag #gpnews and requesting 
retweets from the Royal College of General Practitioners (@RCGP), Devon Local Medical 
Committee (@Devon_LMC) and practitioner magazines such as GPOnline.com 
(@GPonlinenews) and PulseToday (@pulsetoday). 
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Potential participants will follow a weblink to the online survey, and once they have read the 
information and given informed consent they will be guided through the survey via the BOS 
portal. 
If you are proposing to advertise, please include a copy of the advert to be used at the end 
of your application. 
27 Where are you recruiting the participants? 
We will distribute the survey using the Contact, Help, Advice and Information Network 
(CHAIN - http://www.chain-network.org.uk) which has approximately 170 general 
practitioners on the mailing list. We will also use our professional networks such as the South 
West Clinical Research Network (SWCRN) and Exeter Collaboration for Academic Primary 
Care (APEx) research group to publicise the survey and to post on a GP-specific Facebook 
group. We will also use Twitter to promote the survey, using the hashtag #gpnews and 
requesting retweets from the Royal College of General Practitioners (@RCGP), Devon 
Local Medical Committee (@Devon_LMC) and practitioner magazines such as 
GPOnline.com (@GPonlinenews) and PulseToday (@pulsetoday). 
28 Relationship of participant to 
investigator: 
 
 
29 Will the participants take part on a fully voluntary basis? 
 YES  NO   
30 Will students (e.g. PCMD, UEMS, other Schools or Colleges) be involved as 
participants in the research project?  
 YES  NO   
If yes, please provide full details. 
 
31 Will payments or other inducements be made to participants? 
 YES  NO   
If yes, give amounts, type and purpose. 
 
Information to Participants and Consent  
If your study involves the collection and storage of human samples, please refer to the 
University Human Tissue Act Management Handbook and follow the guidelines for 
obtaining informed consent. 
32 Will participants be informed of the purpose of the research?  
 YES  NO   
If no, please explain why. 
 
33 Will the participants be given a written information sheet?  
 YES  NO   
If no, please explain why and delete Appendix 1. 
This information is given as the front page of the survey with a forced choice tick box for 
consent – ‘yes/no’ at the bottom on the page. If the ‘no’ tick box is selected, the participant 
is directed to an information page with a message to clarify they have not consented and 
thanking them for their time. 
34 Will written consent be obtained? 
 YES  NO   
Please see the survey attached to this application. 
35 Where potential participants will/may suffer from any difficulties of 
communication, state the methods to be employed both to present information to 
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the participants and achieve consent.  If written, please include a copy at the end of 
your application. 
As distribution will be via email and Twitter, and response will be via an online survey, only 
respondents with the means to access these modes will be eligible and this will be 
acknowledged within the survey.  
36 Ensure that the Information Sheet includes details of the participants’ right to 
withdraw from the study at any time without penalty. 
Where relevant (should incidental significant findings emerge during the course of a study)  
36.1 Will any  information be given to the participants’ GP (if deemed necessary)? 
 YES  NO   
36.2 Have the participants consented to having their GP informed? 
 YES  NO   
 
37 Please state what measures will be taken to protect the confidentiality of the 
participant’s data (i.e., arising out of the research and contained in personal data). 
All data will be anonymised and potential identifiers (such as age, years in practice) will be 
banded into ranges. No names will be recorded unless personal feedback is asked for by 
respondents via an email link.  
38 How will the data be stored during the life of the project?  
The survey will be designed and distributed using Bristol Online Surveys (BOS - 
www.onlinesurveys.ac.uk). This is a stable and robust academic and research survey tool 
developed by the University of Bristol. All data is currently stored securely in the UK via 
the University of Bristol servers, although we have recently been notified that this service 
is transferring from the University of Bristol to Jisc (see letter in Appendix). This will not 
change storage details except that after 30th June 2017 the raw survey data will be hosted 
by Jisc in a secure cloud based infrastructure with servers located in the Republic of 
Ireland, ensuring this data is held and processed in compliance with Data Protection 
legislation. 
Survey data is encrypted and survey responses are sent over an encrypted SSL 
connection. BOS user passwords are encrypted using PBKDF2 with a SHA256 hash and 
a random salt. 
Analytical data will be stored securely on the University of Exeter secure servers in line 
with University Guidelines (see below). 
39 University of Exeter Guidelines state that primary data generated in the course of 
research must be kept securely in paper or electronic format, as appropriate and 
held normally for a period of five years (or as required by the funding body) after the 
completion of a research project. 
http://www.exeter.ac.uk/research/toolkit/throughout/ethics/goodpractice/  
Please provide details of how data will be stored, how long  the data  will be retained 
following completion of the study and how  the data  will be disposed of once this 
period has ended  
Data will be stored electronically on University of Exeter Medical School secure servers, 
with data backup on the University secure cloud-based system. Data relating to the survey 
(e.g. downloaded .csv files, all analytical programmes used and reported produced from 
these data) will be retained for 5 years until 31/08/2022 with Professor Chris Hyde 
responsible for the data until that point and responsible for disposing of the data after that 
date. Disposal will be in line with current technology through electronic deletion of files and 
copies associated with them. 
40 Who will be ultimately responsible for data storage and disposal  for this project? 
Harriet Hunt will be ultimately responsible for the data storage and disposal after 31/08/2022. 
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41  How will participants be informed of the results of the study if they so wish? 
Participants will be offered the opportunity to feedback on the survey and be kept up to date 
with the survey results by email. They will also have the opportunity to see these results in 
the wider context of my PhD thesis if that is of any interest to them!  
 
42  Risk to research participants 
42.1 do you think there are any ethical problems or special considerations/hazards 
with the proposed Study? If so, please describe  
No 
43 Does your  proposed study require a Health and Safety risk assessment and if 
so, has this been carried out? 
YES  NO   
44 Are there any potential conflicts of interest arising from the project, deriving 
from relationships with collaborators/sponsors/participants/interest groups? 
 YES  NO   
Please disclose all relevant personal and commercial interests. 
NC and WH are both practising GPs so have personal and professional interests from 
being employed within the profession. 
NC also provides consultancy services to a private company in Plymouth, Re:Cognition 
Health, which involves recruiting people to new drug Alzheimer’s Disease clinical trials 
and monitoring them during such trials. He is paid for this work on a sessional rather than 
per-patient basis. 
 
 
 
 
 
University of Exeter Medical School Research Ethics Committee 
 
Reviewer Form 
 
Name of Reviewer: Rebecca Whear 
Employing Organisation: 
 
PenCLAHRC/UEMS 
Qualifications and area of 
expertise: 
 
Health services researcher 
Details of any potential 
conflict of interest: 
 
 
N/A 
Name of Researcher: Harriet Hunt 
Project Title: General practitioners’ clinical practice and attitudes to using 
brief cognitive assessments to identify dementia 
 
 Yes No N/A 
Is there a clear research question/aim? ☒ ☐ ☐ 
Are the methods of data collection adequately outlined?                   ☒ ☐ ☐ 
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Are the methods of data collection appropriate? ☒ ☐ ☐ 
Are the methods of data collection adequately described? ☒ ☐ ☐ 
Are the methods of data analysis appropriate? ☒ ☐ ☐ 
Have ethical issues been addressed appropriately?  ☒ ☐ ☐ 
 
Please grade each feature (where appropriate) from excellent to very poor: 
Evaluation Scale:     (5) Excellent    (4) Very Good     (3) Good    (2) Fair     (1) Poor  
 
Originality Excellent 
Reliability  Very Good 
Importance  Excellent 
 
What is your overall assessment of the quality of the study?.  (please continue overleaf) 
 
The overall quality of this study is excellent with clear thought as to how the questionnaire 
might be received and the time available to practitioners to complete it. This is good 
evidence of secure data collection and storage although how the two marry together could 
be better described (see below). I could not identify any ethical issues that would be of 
concern to the participants outside of what has already been covered by the researcher. 
However, there are a few points I would like to see clarified as below. 
 
What specific improvements would you like to see the applicant make in relation to the 
quality of the study?.   
I am not sure that the current survey captures the third research objective ‘to what extent, 
does information from the assessment affects GPs’ management decisions?’ as there are no 
questions related to what GP’s do with the information they gain or how it impacts further 
decisions. Could this be clarified or improved. 
 
HH response: my intention is that this objective is addressed more obliquely through ‘other’ 
options and comments sections.  
Q.7 “Have you ever used this brief cognitive test for initial assessment?” and “Have you ever 
used this brief cognitive test for monitoring decline over time?” are designed to surface the 
different management decisions GPs commonly make with these tests, and Q.9 "…please 
select the brief cognitive assessment you use the most, and indicate how confident you feel 
on a scale of 1 (not at all confident) to 5 (very confident)” should allow me to link previous 
responses to show confidence in use of specific tests used for purposes selected in Q.7. 
 
This should indicate – where the information is provided – level of confidence in the tests 
used for the purposes indicated.  
 
You’re quite right that the impact on further decision making is not explicitly addressed, 
although I anticipate there will be some open question responses which touch on this in Q.10 
"Please add any further comments you have about brief cognitive assessments, particularly 
in relation to identifying possible dementia”.  
 
In the dissemination would a seminar for local GPs/clinics that got involved in the survey be 
beneficial?  
 
HH - I’d love to do this sort of activity but don’t have time or funds within the bounds of the 
research project. I have thought long and hard about the balance between this being an 
entirely anonymous survey and the consequent benefits of attracting comments ‘with no 
strings attached’ versus asking people for follow up activities. And as my supervisors asked 
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“when will you have time for that?” I’ve taken a pragmatic course whilst also offering to share 
results and discuss findings at the end of the survey. 
 
Clarification as to how the data will be collected by JISC and transferred and stored by 
Exeter would be beneficial. 
 
HH – thank you – I’ve further clarified sections 38 and 39 to address this point. 
 
Would the researcher consider it beneficial to ask a question about how long the GP thinks it 
takes them to use the tool they are using in practice in order to further inform their 
use/barriers to use in practice.  
 
HH – this is an insightful suggestion as administration time is highly contentious with large 
ranges reported amongst the evidence and very few empirical measurements of time 
reported. However this is also highly subjective and varies depending on disease severity. 
I’m not convinced this data from the survey would add anything further to current evidence, 
which is similarly based on anecdote – so to keep it short I’ll leave this out. 
 
Lastly, are there any potential ethical issues/risks you would like to bring to the attention of 
the Committee?   
None  
Signed:  
(Electronic signature required) 
Date: 27/06/17 
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e) Comments from the Chair 28/06/17 and actions 
taken 
 
Chair’s comments HH responses 
I can’t see the “advert” or email 
text that you will be sending 
through the various networks 
to recruit people.  Can you 
send a copy of this as an 
appendix to the application 
please? 
I’ve added a copy of this to Appendix 2 of the 
application. 
On this and the front of the 
survey, you may want to 
include  - information that tells 
them no personal data will be 
collected, what you are 
interested in collecting, and 
what will happen to the data 
they submit (use to calculate 
descriptive statistics about 
current practice for example).   
I’ve added the suggested information highlighted in the 
copy of the updated survey in Appendix 3. 
Will you use any of the free 
text they put in the other 
boxes? How?  Also this may 
need to be anonymised before 
use if they give, for example, 
information like the name of 
practice, in the answer. 
I will use the free text data provided for narrative 
description within the final research paper and thesis 
chapter; for example: 
Q.4 asks about dementia specialists in the GP’s 
practice. Where people provide information on dementia 
specialists, I hope to comment upon the number of 
respondents with dementia specialists and different 
characteristics (e.g. 90% of respondents mention 
dementia nurses, lack of resources noted by 20/113 
respondents); 
Q.6 asks for ‘other’ brief cognitive assessment tools – 
there are around 15 other relatively uncommon tests I 
haven’t listed, but these vary in popularity by 
geographical cluster (e.g. dementia champions in an 
area promote successfully) or  time (e.g. Alzheimer’s 
Society released guidelines ~6 months ago which 
recommended specific tools). I’d simply like to capture 
as many tools that are actually used without listing all of 
them which risks putting off the majority. 
Q.7 asks for factors which guide the choice of test. Here 
I have listed factors which commonly appear in the 
research literature, but I’m trying to surface factors 
currently overlooked or under recognised and hope this 
may be a way of doing it. Again, this data will be 
reported narratively with comment made on 
common/contrasting issues, themes and language. 
Q.8 ‘other’ option covers similar issues as Q.6 in terms 
of allowing inclusion of less common tools. 
Q.11 asks for ‘any further comments’ and whilst I can 
see this may be a hostage to fortune in its breadth, much 
of the research literature is deductive in terms of the 
questions asked about clinical use of tools. I wanted to 
CHAPTER 6: SURVEY OF GPS 
   CHAPTER 6 | 262 
allow space for issues not yet surfaced to feature, plus 
any partisan or sceptical views to be voiced (anecdotally 
it is likely that some responders will express views on 
clinical futility or cynicism around the benefit of tool use, 
but I didn’t want to direct this too firmly to the exclusion 
of other views). 
 
Data will be ‘cleaned’ before analysis so that any 
identifiable information (e.g. Practice name) will be 
removed by the lead reviewer before the data is shared 
more widely within the research team. 
You might think about the 
consent process. For an online 
survey, we often consider that 
consent is given by the survey 
being undertaken, rather than 
having an explicit consent 
box.  You can make a 
statement saying that 
completion of the survey is 
taken as consent for data to be 
used in the ways you describe, 
on the front page of the online 
survey.  In addition, you need 
to think about what you will do 
with partially completed 
surveys – both from an ethics 
point of view – how many 
questions count as consent to 
do the survey? (this may 
happen even if they tick a box 
that says they consent to take 
part!) And a data perspective – 
what will you do with part 
completed surveys – will you 
include in the analysis?  Again, 
whatever you decide can go 
on the front page of the 
survey. 
Thank you, this is helpful. 
 
I have removed the need to explicitly consent by ticking 
a box, and replaced this with a statement as suggested. 
This should improve flow and make the survey 
easier/quicker to complete. 
 
Partially completed surveys will be included if a 
threshold of 10 out of 11 questions are completed.  
In my view we may reasonably suppose that one 
response may be missed accidentally or deliberately, but 
the positive intent is there to complete the survey. Fewer 
responses will not be included in analysis, and I have 
added a line to this effect (“Please answer all questions 
as partially completed surveys will not be included in 
analysis”) to the opening instructions. Non-eligible 
survey responses will be kept separately from those to 
be analysed, but handled the same in terms of 
anonymity and destruction after 5 years. 
 
Hopefully partial completion will be minimal for several 
reasons: 
Most questions are forced choice and alert the 
responder if they have left an answer blank; 
The survey is designed to be short (5-7 minutes, N=6) to 
reduce fatigue and drop out; 
There is no facility to complete the survey later. 
In terms of data storage, we 
usually suggest that the 
supervisor is responsible for 
destruction as 5 years is 
beyond the end of your PhD. 
I have changed this to reflect your advice, i.e. that 
Professor Chris Hyde will be responsible for destruction 
(and have notified him of this change). 
 
f)  
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g) Email/contact text for survey launch 
 
For individual GPs who have agreed to forward this on to their 
networks: 
Dear Dr X, 
Short survey: how do GPs choose and use brief cognitive assessments as part of the 
process for identifying dementia in general practice? 
Thank you for agreeing/offering [delete as appropriate] to share this survey with GP 
colleagues.  
The survey takes around 7 minutes to complete, and no personal data will be collected. I am 
interested in GPs’ views on the use of brief cognitive assessment tools (such as the MMSE) 
as part of the process for identifying dementia in general practice. The survey can be found 
here: [link to the survey]. 
I will use survey responses to create summary and descriptive statistics about current 
clinical practice and attitudes towards the use brief cognitive assessments, and this will 
contribute to my PhD research at the University of Exeter Medical School. More information 
on the broader research can be found here: 
http://medicine.exeter.ac.uk/testgroup/research/dementia/ 
If you have any questions or are interested in this work please feel free to contact me at the 
address below, or my supervisor Professor Chris Hyde at C.J.Hyde@exeter.ac.uk. 
The survey closes at midnight on Friday 14th July, so please do encourage others to share 
this with their GP colleagues. 
Many thanks for your help, 
Harriet Hunt 
PhD candidate – PenCLAHRC Diagnostics theme 
University of Exeter Medical School 
South Cloisters | St Luke’s Campus | Exeter | EX1 2LU 
01392 726074 
h.a.hunt@exeter.ac.uk  
http://medicine.exeter.ac.uk/testgroup/ 
Twitter: @HarrietAHunt  
For circulating to CHAIN: 
For the CHAIN team: Please would you share this with your ‘dementia’ special interest 
group? 
How do GPs choose and use brief cognitive assessments as part of the process for 
identifying dementia in general practice? 
I am conducting a brief (7 minutes) survey of general practitioners (GPs) on the topic of brief 
cognitive assessment use for identifying dementia. I would be grateful if any GPs could take 
part in the survey here: [survey link] or if people could share with GP colleagues who may be 
interested. 
No personal data will be collected. I am interested in GPs’ views on the use of brief cognitive 
assessment tools (such as the MMSE) as part of the process for identifying dementia in 
general practice.  
I will use survey responses to create summary and descriptive statistics about current 
clinical practice and attitudes towards the use brief cognitive assessments, and this will 
contribute to my PhD research at the University of Exeter Medical School. More information 
on the broader research can be found here: 
http://medicine.exeter.ac.uk/testgroup/research/dementia/ 
The survey closes at midnight on Friday 14th July, so please do encourage others to share 
this with their GP colleagues. 
Many thanks for your help, 
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Harriet Hunt 
PhD candidate – PenCLAHRC Diagnostics theme 
University of Exeter Medical School 
South Cloisters | St Luke’s Campus | Exeter | EX1 2LU 
01392 726074 
h.a.hunt@exeter.ac.uk  
http://medicine.exeter.ac.uk/testgroup/ 
Twitter: @HarrietAHunt  
For the SW Clinical Research Network who have agreed to 
place this in their newsletter: 
How do GPs choose and use brief cognitive assessments (such as the MMSE) as part 
of the process for identifying dementia in general practice? 
Harriet Hunt, a University of Exeter Medical School PhD candidate, is conducting a brief (7 
minutes) survey of general practitioners (GPs) on the topic of brief cognitive assessment use 
for identifying dementia. She would love to hear from any South West GPs who can take 
part in the survey here: [survey link]  
No personal data will be collected, and survey responses will be used to create summary 
and descriptive statistics about current clinical practice and attitudes towards the use brief 
cognitive assessments. This will contribute to Harriet’s PhD research at the University of 
Exeter Medical School. More information can be found here: 
http://medicine.exeter.ac.uk/testgroup/research/dementia/ She can be contacted for more 
information by email: h.a.hunt@exeter.ac.uk  
The survey closes at midnight on Friday 14th July, so do encourage others to share this with 
their GP colleagues. 
 
For Twitter [140 characters]:  
Variants on (i.e. adapted and retweeted every couple of days depending on responses): 
 
 
 
Requesting RTs from the Royal College of General Practitioners (@RCGP), Devon Local 
Medical Committee (@Devon_LMC) and practitioner magazines such as GPOnline.com 
(@GPonlinenews) and PulseToday (@pulsetoday) plus influencers @Maureenrcgp (former 
Chair RCGP), @HelenRCGP (current Chair RCGP), @ClareGerada, @muirgray and 
@trishgreenhalgh. 
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Appendix 15 University of Exeter Medical School Ethics 
Committee Certifical of Approval 
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Appendix 16 Coding and thematic framework summarising key themes 
 
Codes Issues discussed  Themes identified 
Usefulness of the 
test  
“Need the best tool available” [Q8] 
“Seems to be a very good 
discriminatory test” [Q5] 
“I don’t find this tool particularly 
discriminating…However, it seems to 
do the job for reassuring those with 
no problems and ensuring onward 
investigation for those in which there 
are concerns within the history” [Q9] 
 “language can be an issue” [Q9] 
“it is such a bad scale it can be 
skewed by anxiety/ bad day etc. and 
it doesn’t pick up subtle issues” [Q9] 
“fewer false negatives” [Q9] 
“although I’m also looking at verbal 
fluency, functional changes” [Q9] 
“Although useful if a low score to say 
– needs referral for further testing- 
looks like a possible memory issue” 
[Q9] 
“they’re no substitute for a good 
history” [Q10] 
“…but if I have enough clinical 
suspicion, I will refer regardless of 
high score” [Q10] 
None of them include questions 
about functional ability as opposed to 
cognitive ability” [Q10] 
“Not always accurate” [Q10] 
“clock drawing often really helpful” 
[Q10] 
“…the quicker ones are quicker but 
less useful” [Q10] 
“Difficult to assess how much anxiety 
and depression affects the results” 
[Q10] 
“Would be helpful to have an idea of 
how to assess premorbid level of 
functioning for both ends of 
intellectual spectrum. And how that 
might affect results of simple tests.” 
[Q10] 
“It would be useful to have a score 
system with comments e.g. 0 - 10, 
10 - 20, 20 - 30 etc“ [Q10] 
“No perfect one!” [Q10] 
“I find them a very crude tool and as 
a GP I don't believe that I am the 
best placed person to do it.” [Q10] 
The best test 
Good/bad test 
Functional “does the job” 
Assistive “helpful” “useful” 
or flawed “crude” “skewed” 
Not discriminating 
Not accurate 
Imperfect 
 
Speed of the 
test/timing 
“in the past it was there as a quick 
tool until MMSE went” [Q5] 
Quick tool 
Brief  
In context 
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“Needs to be 'brief' but for cognitive 
decline 2 minutes I think should be 
fine recognising that the brief 
interventions for smoking for 
example are different in context.” 
[Q8] 
“In the context of a total ten minute 
appointment” [Q8] 
[Patients] “need time to digest what's 
going on. “ [Q8]  
“for a GP, you need an extra 10-15 
minutes on top of the assessment to 
deal with this” [Q8] 
“if you only have 10 mins, the 
assessment is the thing that gets 
squeezed” [Q8] 
“I think a brief assessment tool 
should be just that, brief” [Q8] 
“Needs to be quick” [Q8] 
“They feel like a huge time burden, 
the quicker ones are quicker but less 
useful” [Q10] 
“They need to be short in time to 
facilitate a realistic assessment in 
general practice” [Q10] 
Competition for time 
Time burden 
Trade-off between speed 
and accuracy 
Efficiency/ systemic 
factors 
Clinical software - in the past it was 
there as a quick tool until MMSE 
went” [Q5] 
“GPCOG needed for memory clinic 
referral” [Q5] 
“Available on EMIS system” [Q5] 
“I have personalised a version of 
MMSE and embedded it within 
EMIS…  This makes it easy to 
administer.” [Q5] 
“1. I remember its name  2. I can find 
it on the computer” [Q5] 
“Needs to be 'brief'” [Q8] 
“I'll sometimes arrange a double 
appointment” [Q8] 
“I would make time” [Q8] 
“less than 10 mins ideally” [Q8] 
“if only to do the assessment, 15 
minutes is ideal” [Q8] 
“Needs to be consistent within the 
practice” [Q8] 
“Needs to be fitted into surgery time” 
[Q8] 
“More time to spend in discussion” 
[Q8]  
“if funded” [Q8] 
“If booked as a separate 
appointment” [Q8] 
“we have 10 minute appointments” 
[Q8] 
Software as facilitator 
Software as barrier 
Tests as access points  
Personalisation 
Personal agency 
Working within system 
constraints 
Ideal versus reality 
Consistency 
Culture within the general 
practice 
GP time is precious 
Resourcing pressures 
Technology absolves GP 
of some responsibility (e.g. 
remembering scoring) 
Pressure 
Process over judgment 
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“We are time poor and offering 
double or review appointments 
means we are then under more 
pressure for appts from other 
patients” [Q8] 
“gps time prob more productively 
spent doing something else and 
anyone trained could do” [Q8] 
“nurse appts are not resourced” [Q8] 
“These tend to be long consultatins 
without the test” [Q8] 
“lots more to do in the 10 minute 
consultation” [Q8] 
“assuming a 10 minute appointment, 
if a longer appointment the test could 
take longer” [Q8] 
“done more slowly and accurately by 
the nurse” [Q8] 
“I always have to re-google the 
normal range scores” [Q9] 
“its the one I know” [Q9] 
“if clincial picture is one of worried 
well but not if more complex picture 
/sutle problem or high IQ” [Q9] 
“More difficult if scores between 25 – 
29” [Q9] 
“Familiarity” [Q9] 
“It's written on the screen... would I 
remember scoring? Not a chance but 
I don't need to.” [Q9] 
“They need to be short in time to 
facilitate a realistic assessment in 
general practice” [Q10] 
“Stopped using MMSE when 
charges introduced for using it” [Q10] 
“They are not 'brief'. “ [Q10]  
“Can be very time consuming. Also 
MMSE now copyrighted...” [Q10] 
“We use 6-CIT as per local guidance 
and it's part of the referral form. It's 
complex to score but embedded in 
SystmOne (computer system used 
by GP, psych, district nurses etc) so 
quick to score. More difficult on a 
home visit” [Q10] 
“Pressure on time and appointments 
drives lots of GP decision making” 
[Q10] 
“I am rarely surprised by results & do 
it since I am supposed to” [Q10] 
“as a GP I don't believe that I am the 
best placed person to do it” [Q10] 
“as a single element  of testing the 
serial months backwards is a 
fantastic discriminator” [Q10] 
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Context “assuming a 10 minute appointment, 
if a longer appointment the test could 
take longer” [Q8] 
“lots more to do in the 10 minute 
consultation” [Q8] 
“People can be really upset 
(angered) by the dementia screening 
questions. It's worth not rushing.” 
[Q8] 
“As a pre-arranged appointment with 
a single objective” [Q8] 
“Takes into account prior knowledge 
of the patient” [Q8] 
“it depends if you know the patient 
already & have identified cognitive 
decline” [Q8] 
“We are time poor and offering 
double or review appointments 
means we are then under more 
pressure for appts from other 
patients” [Q8] 
“If booked as a separate 
appointment” [Q8] 
“Needs to be fitted into surgery time” 
[Q8] 
“It should be easily accomplished in 
1 appt alongside other parts of the 
consultation i.e. Physical checks” 
[Q8] 
“). I find that patients on first 
presentation may need rapport-
building.  Often hard of hearing. 
need time to digest what's going on.  
However, what usually happens is 
that there is almost always a social 
or physical need that presents at the 
same time.  They present because of 
a problem. “ [Q8] 
“In the context of a total ten minute 
appointment” [Q8] 
“Needs to be 'brief' but for cognitive 
decline 2 minutes I think should be 
fine recognising that the brief 
interventions for smoking for 
example are different in context.” 
[Q8] 
“The test is usually for someone 
else'sneed/purpose. Diagnosis is a 
shared interpretive process of 
weighting up risk and benefit with pt” 
[Q9] 
“I don't just use tools  to assess is 
part of assessment” [Q9] 
What else needs to 
happen within the 
consultation 
Interpersonal factors 
Familiarity with the patient 
Consultation objectives 
Time allocation 
Guardian of consultation 
time 
Diagnosis as a shared 
interpretative process 
GP as the appropriate 
space for processes 
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“it is such a basic scale it can be 
skewed by anxiety/a bad day etc and 
it doesn't pick up subtle issues” [Q9] 
“Most experience with this” [Q9] 
“Most patients score fairly poorly on 
it and need referral regardless.  
However, it seems to do the job for 
reassuring those with no problems 
and ensuring onward investigation 
for those in which there are concerns 
within the history.  Therefore, I find it 
hard in pitching the outcome at 
times, to prepare the patient 
accordingly.  Just how trustworthy is 
the score?” [Q9] 
“Rarely used an assessment as I 
have not seen much cognitive 
decline. Working part-time may 
contribute to this” [Q9] 
“Language can be issue.  Very 
intelligent folk score well even when 
in Decline so feel less confident 
then” [Q9] 
 
“They can be useful, but as with 
depression scores, they're no 
substitute for a good history. The 
danger can be that they lead to a 
tickbox approach” [Q10] 
“We are often trying to implement 
these with an aging population, who 
need time, sufficient hearing and 
motor function to complete many of 
them.  They often have many issues 
in the consultation” [Q10] 
“as a GP I don't believe that I am the 
best placed person to do it” [Q10] 
Generalism vs 
specialism/expertise 
“advice from specialist colleague” 
[Q5] 
“done more slowly and accurately by 
the nurse” [Q8] 
“I have not seen much cognitive 
decline. Working part-time may 
contribute to this.” [Q9] 
“Most experience with this.” [Q9] 
“able to reassure if nromal (and if 
clincial picture is one of worried well 
but not if more complex picture /sutle 
problem or high IQ” [Q9] 
“I think I can give a reasonable 
explanation to patient and family” 
[Q9] 
“As before but it's a case of "this 
seems fine we need to think more 
about your problems (or not)" or "this 
General practitioner not 
specialists 
Inaccurate in assessment 
Reassurance role  
Challenge of complexity  
Reasonable explanations 
Non-definitive language 
Unconvinced by need for 
screening 
Lack of knowledge 
General practitioners not 
best suited for assessment 
of dementia 
Variation in number of 
patients seen/levels of 
experience, partly due to 
part-time working? Less 
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suggests you would benefit from 
seeing someone else to review 
things further.” [Q9] 
“. I'm not convinced of the evidence 
base or practical utility of 
asymptomatic screening.” [Q10] 
“Would be helpful to have an idea of 
how to assess premorbid level of 
functioning for both ends of 
intellectual spectrum. And how that 
might affect results of simple tests” 
[Q10] 
“I find them a very crude tool and as 
a GP I don't believe that I am the 
best placed person to do it.” [Q10] 
emergent as an issue than 
expected 
Not a clear link between 
number of patients seen 
(up to 30 per month) and 
dementia speciality in the 
practice. Surprising 
 
 
Screening “I don't like the screening aspect” 
[Q10] 
“Pressure on time and appointments 
drives lots of GP decision making  
Alos increased awareness of 
memory clinics has driven high 
demand and increased requests for 
testing and referral” [Q10] 
“To clarify, I'm not here talking about 
screening - that is, where a 
patient/family/me doesn't have 
concerns about cognition, but where 
there is something that had already 
raised the question. I'm not 
convinced of the evidence base or 
practical utility of asymptomatic 
screening.” [Q10] 
What does screening 
mean? 
Screening as a political 
drive 
Increasing pressure on 
limited resources 
 
“doing things 
properly”  
“I'll sometimes arrange a double 
appointment to do things properly if 
there's a concern about cognition” 
[Q8] 
“nees to be done, and need the best 
tool available so I would make time” 
[Q8] 
“However, what usually happens is 
that there is almost always a social 
or physical need that presents at the 
same time.  They present because of 
a problem.  Therefore, for a GP, you 
need an extra 10-15 minutes on top 
of the assessment to deal with this.  “ 
[Q8] 
“Able to have longer as can 
concentrate on assessment only” 
[Q8] 
“we have 10 minute appoiintments- 
these are time consuming 
consultations, even of brought back 
for a double appt after bloods it takes 
Justification needed to do 
things properly 
Professional pride 
Conflict with the system 
“what usually happens” 
Value of ‘doing things 
properly’ 
Hassle/burden of ‘doing 
things properly’ 
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ages and the informant 
interview/history” [Q8] 
“As a pre-arranged appointment with 
a single objective, to allow a non 
pressured approach, and to allow me 
to look out for fluctuating function or 
attention during the process” [Q8] 
“It's worth not rushing.” [Q8] 
“done more slowly and accurately by 
the nurse” [Q8] 
“they're no substitute for a good 
history” [Q10] 
“We are often trying to implement 
these with an aging population, who 
need time, sufficient hearing and 
motor function to complete many of 
them.”[Q10] 
“I have recently asked care home 
managers if they would be willing to 
train staff to do MMSE.” [Q10] 
“I do the longer addenbrookes one 
for high IQ/young patients but it 
takes ages and feels like a hassle 
but can be useful to reassure worried 
well and avoid a referral  “ [Q10] 
“Difficult to assess how much anxiety 
and depression affects the results” 
[Q10] 
Subtlety I feel that the ace-iii has good face 
validity; is better at identifying more 
subtle presentations off dementia 
than e.g. MOCA” [Q5] 
“it is such a basic scale it can be 
skewed by anxiety/a bad day etc and 
it doesn't pick up subtle issues” [Q9] 
Feel, intuition 
Basic versus complex 
scales 
 
Reassuring (patients 
and themselves - 
GP) 
“a normal-range score is more 
reassuring (as important as its use in 
identifying actual cognitive 
impairment)” [Q5] 
“if only to do the assessment, 15 
minutes is ideal (including 
explanation of what will happen next” 
[Q8] 
“I find that patients on first 
presentation may need rapport-
building.  Often hard of hearing. 
need time to digest what's going on.” 
[Q8] 
“More time to spend in discussion” 
[Q8] 
“.   People can be really upset 
(angered) by the dementia screening 
questions. It's worth not rushing.” 
[Q8] 
Normal = reassuring 
Importance of reassuring 
patients 
Reassurance as important 
as identifying cognitive 
impairment 
Rapport-building 
Time to discuss 
Value of time  
Reassurance and GP 
confidence in diagnosis 
Preparing the patient 
“Worried well” 
Patient being protected by 
GP from worry 
Avoiding referral 
Also concept of people 
visiting the GP with 
concerns; if borderline or 
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“Very intelligent folk score well even 
when in Decline so feel less 
confident then” [Q9] 
“it seems to do the job for reassuring 
those with no problems and ensuring 
onward investigation for those in 
which there are concerns within the 
history.  Therefore, I find it hard in 
pitching the outcome at times, to 
prepare the patient accordingly. “ 
[Q9] 
“able to reassure if nromal (and if 
clincial picture is one of worried well 
but not if more complex picture /sutle 
problem or high IQ,” [Q9] 
“As before but it's a case of "this 
seems fine we need to think more 
about your problems (or not)" or "this 
suggests you would benefit from 
seeing someone else to review 
things further” [Q9] 
“, I do the longer addenbrookes one 
for high IQ/young patients but it 
takes ages and feels like a hassle 
but can be useful to reassure worried 
well and avoid a referral” [Q10] 
‘worried well’ cases, what’s 
driving them to seek help?  
 
 Relatives “facilitates relative involvement if 
required” [Q5] 
“I think I can give a reasonable 
explanation to patient and family” 
[Q9] 
“I am rarely surprised by results & do 
it since I am supposed to - 
discussing problems with patient & 
carer is more useful to identify 
dementia” [Q10] 
Relatives often missing 
Relatives to be explained 
to 
Patient and carer as a unit 
Relatives mentioned less 
than expected  
Trust “…I find it hard in pitching the 
outcome at times, to prepare the 
patient accordingly.  Just how 
trustworthy is the score?” [Q9] 
GP trust of the test score 
Ideal vs reality “lots more to do in the 10 minute 
consultation” [Q8] 
“It can take 30 minutes though not 
the 6CIT alone but the whole 
discussion.” [Q8] 
“As a pre-arranged appointment with 
a single objective, to allow a non 
pressured approach, and to allow me 
to look out for fluctuating function or 
attention during the process” [Q8] 
“These tend to be long consultatins 
without the test and if the patient is 
reporting memory probs they get 
fereed irrespective of the result” [Q8] 
Tensions between the 
ideal scenario versus 
reality 
Planning in advance  
Ideal 
Lack of pressure 
Time to monitor through 
the appointment 
Brief test 
Reality  
Referral decision 
irrespective of consultation 
Time pressures – other 
tests & exams to do 
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“it depends if you know the patient 
already & have identified cognitive 
decline” [Q8] 
“again nurse would usually take 
more time over most things… nurse 
appts are not resourced “ [Q8] 
“Needs to be quick/ other tests/ 
exams to do as well” [Q8] 
“I think a brief assessment tool 
should be just that, brief. It should be 
easily accomplished in 1 appt 
alongside other parts of the 
consultation i.e. Physical checks” 
[Q8 
“Therefore, for a GP, you need an 
extra 10-15 minutes on top of the 
assessment to deal with this.  Or, if 
you only have 10 mins, the 
assessment is the thing that gets 
squeezed.  “ [Q8] 
“other tasks to do” [Q8] 
“if only to do the assessment, 15 
minutes is ideal” [Q8] 
“less than 10 mins ideally.” [Q8] 
“nees to be done, and need the best 
tool available so I would make time” 
[Q8] 
“Needs to be consistent within the 
practice, not have different tests 
used by different staff” [Q8] 
“it is such a basic scale it can be 
skewed by anxiety/a bad day etc and 
it doesn't pick up subtle issues” [Q9] 
“I don't find this tool particularly 
discriminating.  Most patients score 
fairly poorly on it and need referral 
regardless” [Q9] 
“They need to be short in time to 
facilitate a realistic assessment in 
general practice” [Q10] 
“Stopped using MMSE when 
charges introduced for using it” [Q10] 
“. I'm not convinced of the evidence 
base or practical utility of 
asymptomatic screening” [Q10] 
“Also MMSE now copyrighted so 
using out with this” [Q10] 
“Rebranding on the 'brief' nature of 
these would be helpful!” [Q10] 
“if I have enough clinical suspicion, I 
will refer regardless of high score” 
[Q10] 
“The danger can be that they lead to 
a tickbox approach” [Q10] 
“More difficult on a home visit” [Q10] 
Conflict with other tasks 
within GP appointment 
timeframe ‘unrealistic’ 
 
Need versus ideal 
 
Danger, difficulty 
 
Tick-box approach vs. 
efficiency/ease of use 
 
Complexity/detail vs. 
indiscriminate, easily 
skewed 
 
Difficulties in context – 
home visit vs. in office  
 
Complexity in mixed  
presentation with e.g. 
depression, anxiety 
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“Difficult to assess how much anxiety 
and depression affects the results” 
[Q10] 
“discussing problems with patient & 
carer is more useful to identify 
dementia” [Q10] 
Technology/ process “Clinical software - in the past it was 
there as a quick tool until MMSE 
went” [Q5] 
“1. I remember its name  2. I can find 
it on the computer” [Q5] 
“Available on EMIS system” [Q5] 
“I have personalised a version of 
MMSE and embedded it within EMIS 
so it launches a personalised sheet 
with the questions pre-printed and 
then I can answer the score and 
scan into the record.  This makes it 
easy to administer.” [Q5] 
“if you only have 10 mins, the 
assessment is the thing that gets 
squeezed” [Q8] 
“we have 10 minute appoiintments” 
[Q8] 
“I'll sometimes arrange a double 
appointment to do things properly” 
[Q8] 
“again nurse would usually take 
more time over most things but We 
pay for nurse appts and time and 
they are part of the total pressure on 
the system so nurse appts are not 
resourced” [Q8] 
“It's written on the screen... would I 
remember scoring? Not a chance but 
I don't need to.” [Q9] 
“We use 6-CIT as per local guidance 
and it's part of the referral form. It's 
complex to score but embedded in 
SystmOne (computer system used 
by GP, psych, district nurses etc) so 
quick to score. More difficult on a 
home visit” [Q10] 
Tests available on the 
computer system (EMIS or 
SystemOne) 
Ease of use/access 
Local guidance, local 
processes 
Difficulty outside usual 
processes (e.g. home 
visits) 
 
Familiarity With the test 
 “Rarely used an assessment as I 
have not seen much cognitive 
decline. Working part-time may 
contribute to this.” [Q9] 
“I always have to re-google the 
normal range scores” [Q9] 
“its the one I know” [Q9] 
“its the one I use” [Q9] 
With the patient 
Lack of familiarity, 
experience 
Part time vs. full time 
Levels of exposure to 
cognitive decline 
The one I know 
Certainty in practice and/or 
knowledge 
Patients’ needs 
Prior knowledge of the 
patient 
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“I find that patients on first 
presentation may need rapport-
building. “ [Q8] 
“it depends if you know the patient 
already & have identified cognitive 
decline” [Q8] 
“Takes into account prior knowledge 
of the patient” [Q8] 
  
Recognition of cognitive 
decline through familiarity 
with the patient 
Difficult patients – 
age, education – 
acknowledged 
“I find that patients on first 
presentation may need rapport-
building.  Often hard of hearing. 
need time to digest what's going on.  
However, what usually happens is 
that there is almost always a social 
or physical need that presents at the 
same time.” [Q8] 
“able to reassure if nromal (and if 
clincial picture is one of worried well 
but not if more complex picture /sutle 
problem or high IQ, Also useful if low 
score to say - needs referral for 
further testing- looks like a possible 
memory issue.” [Q9] 
“More difficult if scores between 25 - 
29 but I feel able to use it 
confidently” [Q9] 
“it is such a basic scale it can be 
skewed by anxiety/a bad day etc and 
it doesn't pick up subtle issues” [Q9] 
“I don't find this tool particularly 
discriminating.  Most patients score 
fairly poorly on it and need referral 
regardless. “ [Q9] 
“Language can be issue.  Very 
intelligent folk score well even when 
in Decline so feel less confident 
then” [Q9] 
“Not always accurate in early 
dementia or persons with high 
intellect” [Q10] 
The usual patient (presents 
with multiple needs) 
The unusual patient 
Normal levels; worried well 
Complexity from education 
levels, high IQ, high 
intellect 
Language can be an issue 
– language used in the 
test? Or Language used by 
the patient? Or GP? 
Patient in decline – a 
continuum  
 
 
Unwillingness/duress “Pressure on time and appointments 
drives lots of GP decision making  
Alos increased awareness of 
memory clinics has driven high 
demand and increased requests for 
testing and referral” [Q10] 
“They feel like a huge tiem burden” 
[Q10] 
“I do the longer addenbrookes one 
for high IQ/young patients but it 
takes ages and feels like a hassle 
but can be useful to reassure worried 
well and avoid a referral “ [Q10] 
Pressure, demand, burden, 
hassle 
Increased awareness of 
memory clinics driving 
demand 
Increased numbers 
requesting tests and 
referral (to memory clinics) 
Expertise vs. external 
pressures 
Crude tools 
GP not best placed person 
– as a role? As an 
environment? 
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“I am rarely surprised by results & do 
it since I am supposed to” [Q10] 
“I find them a very crude tool and as 
a GP I don't believe that I am the 
best placed person to do it.” [Q10] 
Is general practice the 
appropriate place for 
assessment? 
 “Are GPs using evidence 
based practice?” In answer 
to the question this clearly 
suggests that they are not. 
GPs not necessarily able 
to follow evidence based 
practice due to system 
factors such as System 
1/EMS 
“As a GP I don’t believe I 
am the best placed person 
to do it” Does this mean 
they don’t think that a GP 
is in the best position 
systemically, or that they 
lack the knowledge, or 
something else?  
Language use “can be useful to reassure worried 
well” [Q10] 
Worried well still in use 
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Glossary  
6-CIT 6 Item cognitive impairment test 
7MS 7 minute screen 
10-CS 10 point Cognitive Screener 
Aβ42 Amyloid beta peptide 42 
ACE (-R/III) Addenbrooke’s Cognitive Evaluation (- revised/version three) 
ADAS-Cog The Alzheimer’s Disease Assessment Scale - Cognition 
ADI Alzheimer’s disease International 
AD  Alzheimer’s disease 
AD8  Alzheimer’s disease brief screening tool 
AGECAT Automated Geriatric Examination for Computer Assisted 
Taxonomy 
AMSTAR (2) A MeaSurement Tool to Assess systematic Reviews (2nd edition) 
AMT(S) Abbreviated Mental Test Score 
APEx Exeter Collaboration for Academic Primary Care 
BCA Brief cognitive assessment 
BOS Bristol Online Surveys 
CAMCOG The Cambridge Cognitive Examination 
CAMDEX Cambridge Mental Disorders of the Elderly Examination 
CASI Cognitive Abilities Screening Instrument 
CCCDTD Canadian Consensus Conferences on the Diagnosis and 
Treatment of Dementia 
CCG Clinical Commissioning Group 
CDIG Cochrane Dementia and Cognitive Improvement Group 
CDPC Cognitive Decline Partnership Centre 
CDR Clinical Dementia Rating 
CDT clock drawing test 
CERAD Consortium to Establish a Registry for Alzheimer's Disease 
CFAS II Cognitive Function and Ageing Study II 
CHAIN Contact, Help, Advice and Information Network 
CHERRIES Checklist for Reporting Results on Internet E-Surveys 
CLAHRC Collaboration for Leadership in Applied Health Research and 
Care 
CPG Clinical Practice Guideline 
CSF Cerebrospinal fluid 
DLB Dementia with Lewy bodies 
DSM-III/ III-R/ 
IV/ IV-R 
The Diagnostic and Statistical Manual of Mental Disorders 
(version 3/ version 3 revised/ version 4/ version 4 revised 
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EMBASE Excerpta Medica dataBASE 
FAB Frontal Assessment Battery 
FAQ Functional Activities Questionnaire 
FCSRT Free and Cued Selective Reminding Test 
FTD Frontotemporal dementia 
GMS-AGECAT Geriatric Mental State Schedule - Automated Geriatric 
Examination for Computer Assisted Taxonomy 
GP General Practitioner 
GPCOG The General Practitioner assessment of Cognition 
GSA Gerontological Society of America 
ICD-10/11 International Classification of Disease – version 10/11 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
IPA/WHO 
criteria 
International Psychogeriatric Association/World Health 
organisation criteria 
KICA-Cog Kimberley Indigenous Cognitive Assessment  
KICA-Screen Kimberley Indigenous Cognitive screening tool 
MCI Mild Cognitive Impairment 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MeSH Medical Subject Headings 
MIS Memory Impairment Screen 
MMSE  Mini mental state examination 
MoCA Montreal Cognitive Assessment 
MRI Magnetic Resonance Imaging 
NHS  National Health Service (UK) 
NIA-AA National Institute for Aging and the Alzheimer’s Association 
NICE National Institute for Health and Care Excellence (UK) 
NIHR National Institute for Health Research 
NINDCS-
ADRDA 
National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders 
Association 
NINCDS-AIREN National Institute of Neurological Disorders and Stroke–
Association Internationale pour la Recherche et l'Enseignement 
en Neurosciences 
NINCDR-
CERAD 
National Institute of Neurological Disorders - Clinical Dementia 
Rating -Consortium to Establish a Registry for Alzheimer’s 
Disease 
PAS Psychogeriatric Assessment Scale 
PBKDF2 A password hashing algorithm 
PCL Prueba cognitive de leganes 
PROSPERO International Prospective Register of Systematic Reviews 
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PsychInfo Database of abstracts of literature in the field of psychology. 
ROBIS Risk of Bias in Systematic reviews 
RUDAS The Rowland Universal Dementia Assessment Scale 
SASSI Short and Sweet Screening Instrument 
SHA256 A cryptographic hash function 
SIS Six item screener 
SPMSQ Short portable mental status questionnaire 
SSL Secure Sockets Layer 
TICS Telephone Interview for Cognitive Status 
TRIP Turning Research Into Practice database 
TYM Test Your Memory 
UK United Kingdom 
VAD Vascular Alzheimer’s Disease 
VF-an Verbal Fluency - animals 
WHO World Health Organisation 
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7. Discussion  
"On veut le beurre, l'argent du beurre et baiser la crémière" 
[We want the butter, the money for the butter, and to kiss the milkmaid] 
- French proverb 
There is no simple answer to the question “how can the accuracy of BCAs be improved 
when used as part of the process for identifying dementia in general practice?”. The 
lack of clear evidence on the most accurate BCAs for use in primary care is an 
inconvenient truth, as much of the discussion around improving diagnosis rates 
presupposes that the best tool for diagnosing dementia in general practice is well 
established. This is not the case. There are, however, a range of measures that could 
contribute to improving the accuracy of these assessments within primary care. By 
scrutinising current evidence, generating new survey data on how GPs use BCAs, and 
critically analysing research methodology, this research contributes to how we might 
better understand and improve the accuracy of BCAs when used as part of the process 
for identifying dementia in general practice.  
This chapter discusses the findings made throughout this process, what these findings 
mean in practical terms, and makes recommendations for research and practice. The 
chapter concludes with reflections on the PhD as a whole, considering what has been 
learned and acknowledging those who have helped along the way. 
7.1. Aim and objectives  
The primary aim of this thesis was to address the question “how can the accuracy of 
BCAs be improved when used as part of the process for identifying dementia in 
general practice?” by establishing a clear picture of the evidence for diagnostic 
accuracy of BCAs for identifying dementia within general practice. 
The objectives of this thesis were: 
 To assess the diagnostic accuracy of BCAs used to identify dementia 
specifically in primary care;  
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 To review the diagnostic test accuracy evidence by assessing studies that have 
directly compared GPCOG and MMSE for identifying dementia in general 
practice;  
 To explore the views of general practitioners around dementia screening tests; 
and 
 To make practical recommendations for improving the accuracy of BCAs, 
specifically for use in general practice based on evaluation of the evidence in 
the objectives listed above. 
The phases of this work across PhD chapters and how they interact are shown in 
Figure 31. 
Figure 31 PhD thesis by chapter: how results from chapters of the thesis informed 
other chapters 
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7.2. Chapter summaries 
Chapter 1: Background  
Dementia is under-recognised globally, and there are many gaps in understanding 
how to improve dementia diagnosis in general practice. Many national strategies 
promote earlier or more timely diagnosis of dementia within primary care. 
Paradoxically, recommendations for the best tools to use as part of this process are 
unclear, vary widely and – where data are presented – the evidence base is mixed. 
BCAs are the main tool available to family doctors for measuring cognitive 
performance, but evidence of their diagnostic accuracy is unclear. It is essential to 
understand the diagnostic accuracy of BCAs when used as part of the diagnostic 
process for identifying dementia in general practice in order to judge their suitability 
and make clear clinical recommendations on their use. As a wider aim, greater 
understanding of the challenges of identifying dementia in general practice and – in 
particular – of the assessment of cognitive function as part of a wider diagnostic 
assessment for possible dementia is needed as a priority. 
Chapter 2: Aims and objectives 
The primary aim of this thesis was to address the question “how can we improve the 
accuracy of brief cognitive assessments when used as part of the process for 
identifying dementia in general practice?” by establishing a clear picture of the 
evidence for diagnostic accuracy of brief cognitive assessments for identifying 
dementia within general practice. 
 This was addressed through the following objectives: 
 establishing current clinical practice guidelines relating to the use of brief cognitive 
assessments used to identify dementia in primary care; 
 reviewing the evidence on the diagnostic accuracy of brief cognitive assessments 
used to identify dementia in primary care;  
 assessing the diagnostic accuracy evidence in studies that have directly compared 
GPCOG and MMSE for identifying dementia in general practice; and 
 exploring the views of GPs around BCAs for identifying dementia in general 
practice ,and triangulation of survey data with other identified evidence.  
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This assessment of the evidence allowed the building of practical recommendations 
for improving the accuracy of brief cognitive assessments specifically for use in 
general practice. 
Chapter 3: Rapid review of CPGs relating to the use of BCAs used as part of the 
process for diagnosing dementia within general practice  
This rapid review was invaluable in identifying what CPGs published in the English 
language are available for advising BCA use in general practice. The review also 
established a high degree of variation across the three CPGs identified, and found a 
paucity of English language CPGs from other countries. The lack of consistent 
recommendations amongst BCAs in terms of the tools themselves, in their application 
and in their selection was an important discovery and worth further investigation. In 
addition, the scarcity of guidance given within the identified CPGs on tailoring BCA 
choice and use for specific populations was particularly notable given the three 
countries where CPGs were identified (Australia, Canada and the UK) all have cultural 
and linguistically diverse populations where tailoring of tools would be highly 
appropriate. This rapid review indicates that greater clarity and consistency is needed 
from CPGs relating specifically to the use of BCAs as part of the process for identifying 
dementia in general practice.  
Chapter 4: Overview of diagnostic accuracy 
The systematic review evidence identified within the overview on the accuracy of 
BCAs was overwhelmingly focussed towards assessing the MMSE despite 
diminishing clinical relevance and reduced recommendations for use in general 
practice. Highly selective study populations did not relate consistently to general 
practice populations, even where ‘general practice’ was the stated population of 
interest. The prevalence of dementia in included study populations ranged from 4% to 
51%.  BCA thresholds varied widely, and were not clearly reported in all cases. 
Standardised diagnostic accuracy data (sensitivity and specificity) were not explicitly 
reported in all reviews, and in many cases was pooled across included studies without 
disaggregated information provided. Variability is amplified in overviews. 
Inconsistency across populations, settings, tests and thresholds made comparison 
across different reviews very challenging. In several cases such as those illustrated 
above, there was insufficient evidence found to draw conclusions on the accuracy of 
CHAPTER 7: DISCUSSION 
   CHAPTER 7 | 286 
particular tests for identifying dementia in primary care, and this lack of evidence 
needs addressing as a priority. 
Chapter 5: Systematic review of direct comparisons 
Direct within-study comparisons of two BCAs (MMSE and GPCOG) were possible but 
highly limited due to variation in sample size, study design, language and different 
MMSE thresholds used. Based on the limited evidence of mixed quality studies in the 
review, MMSE and GPCOG Total perform similarly across both sensitivity and 
specificity when used to identify patients with possible dementia in a general practice 
setting. The review highlighted the need for better conducted studies. 
Chapter 6: Survey of General Practitioners 
The survey of 52 UK general practitioners was designed to reflect the reality of general 
practice experiences, in order to contrast this with findings generated by evidence 
syntheses and review of the literature. Eighty-nine per cent of GPs surveyed did not 
have access to dementia specialists in their practice. The most commonly used BCAs 
amongst surveyed GPs were the MMSE and GPCOG (both at 32%), 6-CIT (17%), and 
the Clock Drawing Test (7%) with Mini-Cog, MoCA, ACE-III and IQCODE all chosen 
by one respondent each. GPs reported confidence in interpreting tests results and 
explaining them to patients. A number of potential barriers to clinical practice identified 
by respondents were the length of time a test takes to administer, ease of use and the 
perceived appropriateness of screening in general practice. Triangulation of the survey 
findings with identified evidence elsewhere in the thesis and evidence already 
published in the literature led to several insights: CPG use was only mentioned in 6% 
of GPs’ survey responses when asked what affected their choice of BCA, and this was 
in line with the wider literature where CPGs did not feature regularly in features 
affecting GP choice of measures. A key finding of the survey that resonated strongly 
with the results of the systematic review and overview were considerations of 
associated factors beyond the accuracy of tests, such as the time the test took to 
administrate, patient understanding and further discussion of prognosis and 
management options.  These results were strongly supported within the literature 
around influential factors beyond accuracy that are an added concern for GPs when 
conducting an assessment for dementia.  
In summary, whilst a heightened need to identify dementia in primary care is 
recognised in policy and research, the research presented in this thesis shows:  
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 Clinical practice guidelines are incomplete, inconsistent and uncommon;  
 Despite a wealth of research, there is still no clear evidence to recommend 
any specific BCA for use in primary care; 
 Whilst evidence is still lacking on the accuracy of the most common BCAs 
being used in primary care, accuracy itself is not all that counts; administration 
time and confidence in using the test are important; 
 GPs recognise these issues alongside the need for greater understanding of 
patient factors (multi-morbidity, education levels and treating patients with 
particular needs, such as physical impairments or where English is not their 
first language) and improved management processes such as the integration 
of tests into practice software; 
 Many GPs also question the role of screening and case finding in general 
practice. 
This is the first rapid review of CPGs directly focussed on the use of BCAs to be 
used as part of the process for identifying dementia in general practice.  
As far as the author is aware, this is also the first systematic review to assess direct 
comparisons of the diagnostic accuracy of MMSE and GPCOG used as part of the 
process to identify dementia in primary care.   
This is also the first overview looking at BCAs for identifying dementia in primary 
care, and through this several issues have been identified which contribute to the 
development of overview methodology. 
7.3. Comparison with what is currently known 
In comparison with the wider literature, these findings are broadly in line with current 
evidence with some notable exceptions.  
7.3.1. BCAs and Clinical Practice Guidelines 
The rapid review identified a number of clear recommendations for practitioners, whilst 
recognising the limitation that only CPGs in the English language were identified. 
Taking this into account, there was still a lack of diversity and breadth found in CPGs 
published in the English language. The three countries from which CPGs were 
identified (Australia, Canada and the UK) all have culturally and linguistically diverse 
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populations, and whilst the Australian CPGs recognised BCAs tailored for particular 
groups there was no mention of tailoring or different population needs within the BCAS 
for Canada or the UK.  
Greater agreement between CPGs will help improve adoption, clinical practice and 
understanding of the place of BCAs within the diagnostic assessment in a non-
specialist setting. Whilst this agreement is needed, it needs to be seen in the context 
of understanding which BCAs are best for these requirements, and the place of BCAs 
within general practice. To improve consistency and standardisation in the use of 
CPGs these questions first need to be answered.  
The majority of existing BCAs demonstrate insufficient validation and replication of for 
general practice use. In order to assess BCA suitability for different general practice 
populations, variations in setting, and performance in identifying differing levels of 
severity of cognitive impairment these validation and replication studies need to be 
completed.  
Once there is greater understanding of the critical features of BCAs for general 
practice use, it is highly likely that CPGs will be far more available, coherent and 
cohesive for the intended general practice audience. 
The most recent dementia clinical practice guidelines issued by NICE in the UK383 
support the use of the 
 10-point cognitive screener (10-CS),  
 6-item cognitive impairment test (6CIT),  
 6-item screener,  
 the Memory Impairment Screen (MIS),  
 the Mini-Cog and  
 Test Your Memory (TYM) 
as part of the process for identifying dementia in primary care. Members of the 
Guideline Committee stated that these tests were broadly similar, and did not 
recommend one over another384.  
In contrast to the NICE guidelines, study-level evidence was found supporting the use 
of Mini-Cog for people where English was not their first language, and for people with 
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low levels of education144 but no clear systematic review-level evidence to support the 
use of Mini-Cog as a tool for use in primary care.  
This finding is in line with conclusions of the authors of the single primary study255 cited 
within the NICE CPG383 which advised “against the use of the Mini-Cog, particularly in 
settings where the proportion of unrecognized dementia is low”255. There was no 
evidence presented within the NICE guidelines on the use of GPCOG, whereas this 
was found to be the second most popular test used by GPs in the survey, and the 
second most commonly used within research literature for the evidence syntheses.  
These NICE guidelines vary from the tools recommended by the Gerontological 
Society of America (GSA) in 201766,67 – the Mini-Cog, GPCOG, MIS, Short IQCODE 
and AD8.  
Within the overview summarising the accuracy of BCAs, no systematic review-level 
evidence was found on the diagnostic accuracy of 10-CS, 6CIT, the 6-item screener, 
or TYM for identifying dementia in primary care. In support of recommendations made, 
NICE guidelines cite: one study for 10-CS385 based in secondary care; one study for 
6CIT386 based in secondary care; one study for the 6 item screener387 based in 
secondary care; and two studies for the Test Your Memory388,389 both based in 
secondary care. Alongside this evidence, the NICE Guideline Committee based these 
recommendations on their ‘experience and opinion’384.  
In line with the 2017 survey of 52 GPs in the UK finding MMSE, GPCOG and CDT as 
the most popular BCAs reported in this thesis, a contemporary survey of 445 doctors 
across 25 European countries390 found the MMSE and CDT were the most common 
BCAs used by primary care practitioners. This Europe-wide survey also found that 
GPCOG was popular amongst GPs in the UK, and MMSE was the recommended BCA 
in many countries; in 12 out of 25 countries it was mandatory to conduct the MMSE 
before prescription drugs for dementia could be prescribed. The UK based survey 
findings reported in this thesis broadly agree with this wider European survey, as well 
as findings from earlier surveys based in the USA391 and Canada339. 
A recently published systematic review by Chan and colleagues392 compared the 
diagnostic accuracy of computerised BCAs against pen and paper BCAs, with the 
primary aim of MCI diagnosis and the secondary aim of dementia diagnosis. 
Participants were recruited from a number of different populations and results were 
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pooled, making disaggregation impossible without contacting authors for original data. 
However, as respondents within the GP survey indicated a preference for 
computerised tests, the distinction between manual and computerised tests would be 
worth exploring in terms of administration time and acceptability for a general practice 
population. 
One factor not assessed within this thesis was the potential value of using BCAs in 
combination with other tests such as CSF biomarkers (Aβ42, total tau, and p-tau) and 
imaging biomarkers measured via MRI scans. A recent multicentre study combined 
these factors for identifying dementia compared to no dementia, and for identifying 
subcategories of dementia such as Alzheimer’s disease (AD), frontotemporal 
dementia (FTD), vascular dementia (VAD) and dementia with Lewy bodies (DLB)393. 
The study authors found that included cognitive tests (MMSE, memory (learning), 
memory (recall), Trail Making Test A, Trail Making Test B, Animal fluency) showed fair 
or good performance in separating people with dementia from controls when used in 
isolation. Cognitive tests were unsurprisingly found to be poor at discriminating 
between subtypes, probably due to insufficient discriminatory power and symptomatic 
overlap across some subtypes. Improved diagnostic value was reported when 
combining BCAs, CSF biomarkers and MRI to differentiate between AD and VAD, AD 
and DLB and FTD and DLB – although as the authors testify these results provide 
more of an indication about the potential additional value of combining measures, 
rather than definitive guidance on optimal combinations. Understanding of the 
diagnostic significance of biomarkers for dementia and subtypes is still developing, 
and the additional value of biomarkers as part of the diagnostic process for people 
with possible cognitive impairment is not yet proven394. 
7.3.2. Availability and preferences around BCAs 
In much of the discourse around dementia diagnosis, there is the implicit assumption 
that improving levels of investigation for possible dementia within general practice will 
naturally lead to increased diagnosis rates. The evidence does not yet support this 
assumption, and may increase the degree of misclassification.  
A recent UK trial92 assessed the effectiveness of an intervention designed to help 
improve diagnosis rates within a general practice population using letters from GPs 
sent to their patients aged 70 or over without a diagnosis of dementia inviting them in 
for assessment. The intervention prompted a significant increase in the proportion of 
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patients consulting with their GPs over suspected memory problems, compared to 
patients in the ‘usual practice’ control arm (odds ratio = 1.4; 95% Confidence Interval 
= 1.28, 1.54) but no increase in referral on to memory clinics for diagnosis. The study 
did not show whether participants were without symptoms, were symptomatic with 
other causes, or whether GPs were not able to correctly identify cognitive impairments 
or dementia. Future research could usefully unpick these potential underlying reasons 
for increased consultations not translating to increased referrals or diagnoses. 
In contrast to these findings, another study395 conducted in the wake of NICE 2006 
guidance on dementia diagnosis396 and the 2009 UK National Dementia Strategy397 
explored whether there was an increase in the use of cognitive assessments reported 
in referrals from primary to secondary care over the period encompassing the launch 
of these guidelines, compared to use of assessments before guidelines were issued. 
The study authors found that, over a two year period, the number of GP referrals rose 
but the percentage of dementia diagnoses fell. The rate of cognitive assessment use 
did not change over the two years. The authors suggest this is due to guideline 
pressures driving up the number of healthy people visiting their GP, resulting in no 
new (or fewer) diagnoses. There are other potential reasons, such as a lessening of 
practitioner confidence in available tests and testing (resulting in fewer BCAs being 
conducted), a lack of clarity around dementia treatment and management options 
(meaning clinicians are less likely to initiate tests or further testing and patients are 
less likely to follow GP advice or seek follow-up appointments), or symptomatic 
presentation becoming more complex (for example, comorbidities making diagnosis a 
more complicated process). There may be many other explanations or a combination 
of some already posed, and this is another area where future research would benefit 
clinical practice by exploring the reasons underlying observed increases in 
presentation and decreases in diagnosis.  
Several studies have highlighted the difficulty of using clinical diagnosis as a reference 
standard within research, where dementia diagnosis is complex, shows substantial 
comorbidity with other conditions398, and agreement between clinical diagnosis of 
dementia and diagnosis using post mortem pathology is between 70% and 90%399,400 
– leaving between 10% and 30% of diagnoses in doubt. Comorbidities are a real 
challenge to diagnosis, with one study reporting a large minority of people with 
dementia have other unaccounted for underlying pathologies (20% to 40%)401. 
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Understanding common comorbidities and how they may affect clinical presentation 
when investigating possible dementia would improve understanding of dementia 
diagnosis. 
A thought-provoking new finding reported in an abstract from the UK-based Cognitive 
Function and Ageing Study II (CFAS II) Dementia Diagnosis Study402 suggests there 
may be little demonstrable improvement in health outcomes for people with a 
diagnosis of dementia compared to those without a diagnosis of dementia. The 
reasons behind this may not be obvious, in that it may be an artefact of measurement 
(i.e. the improvement of health outcomes are not captured within the study), design, 
or some other aspect not directly related to a lack of actual benefit to the individual. 
The possibility remains, however, that there is little measurable benefit for health 
outcomes, and this should be explored as a priority in order to improve and progress 
the wider discussion of dementia diagnosis, where improved health outcomes 
following a diagnosis are often assumed. 
7.3.3. Findings from GP surveys 
Continuing the theme of assumed benefit versus existing evidence, the concept of 
timely diagnosis is now well-established within mainstream dementia 
discourse7,22,26,27,46,48,73,332,403,404. ‘Timeliness’ or a timely diagnosis has several 
nuanced definitions based upon either a readiness to undergo assessment directed 
by the person and their family15,73,314,404 or when the patient wants it or when the carers 
need it7,27,348,405. The 2009 Nuffield Council on Bioethics paper ‘Dementia: ethical 
issues’78 makes it clear that timeliness should be dictated by the patient and that 
“diagnosis is likely to be timely at the point when the cognitive and other changes they 
are experiencing begin to affect their lives and the lives of people close to them”. The 
report also cautions that timeliness should be dictated by the person with suspected 
cognitive issues and their family78 rather than any outside agency.  
The GP survey found respondents had concerns around the timeliness of the 
diagnosis, alongside questioning whether general practice was the most appropriate 
place for dementia diagnosis. The importance of a timely diagnosis is heavily 
emphasised across national strategies and international guidelines, including recent 
reports by the World Health Organisation406 and Alzheimer’s Disease International26, 
yet the evidence of benefit such as improved health outcomes, as discussed above402, 
is less well established.  
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An often-stated benefit of timely diagnosis is the empowerment of patients to plan for 
the future. In a recent study from Israel which interviewed people with dementia and 
their families to explore their perceptions of the barriers to timely diagnosis, and 
benefits of diagnostic evaluation407, patients stated a number of perceived benefits 
such as starting medication, reducing anxiety, confirming suspicions and increasing 
awareness of possible treatments. None of the 26 patients and 27 family members 
mentioned planning for the future as a benefit, and some of those interviewed found 
no benefit in diagnosis at all.  
This patient perspective is often overlooked, and was not assessed within the survey. 
A recent Australian study15 which conducted in-depth interviews with nine people with 
dementia found a great deal of variation in views and preferences for diagnosis and 
the processes surrounding diagnosis. Diversity amongst people with suspected 
dementia is rarely acknowledged amongst guidance and research, yet emerged within 
this study as one of the most important factors to recognise when planning services. 
The important and often under-recognised role of GPs in helping people negotiate 
those services was highlighted within the abovementioned Australian study, as well as 
another study of interviews with people with dementia in the UK380. This finding was 
echoed by respondents in the GP survey.  
The lack of definitive BCAs appropriate for use in general practice, and limited access 
to diagnostic tools, are barriers to diagnosis reported within the wider 
literature19,48,343,408,409 and echoed within the GP survey and evidence syntheses. Also 
in common with respondents from the survey, many GPs report that they often favour 
clinical judgment over formal tests when assessing someone for dementia410-412. 
The potential benefits of case finding are unclear to many GPs, and the distinction 
between case finding (as supported by the Alzheimer’s Society and UK NICE 
guidelines61,109) and screening has come under intense scrutiny in recent years31,85,413-
416. One recent study that sought to assess the potential benefit of screening all 
patients over the age of 75 for dementia beyond those patients already identified by 
‘passive case-finding’ found that symptomatic case finding was better than 
screening81, but these findings were limited by an imperfect reference standard 
(CAMCOG) and an artificial testing scenario which did not translate to a standard GP 
consultation81.  
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No benefit was found in a recent RCT exploring the effect of an educational 
intervention targeting case-finding and subsequent care on diagnostic yield and 
patient mental health417, and the authors recommended against the use of case finding 
within family practice but instead suggested improving diagnostic procedure for 
symptomatic patients. In another study exploring the effect of case-finding in hospitals 
with primary and secondary care practices, GPs reported barriers to practice in terms 
of lack of access to hospital data, and lack of clarity in roles and expectations418, and 
these concerns were echoed within the survey of GPs with a number of respondents 
voicing concern over the validity of case-finding policies. The UK National Screening 
Committee83 and US Preventative Services Task Force419 have made clear policy 
statements that do not support the use of screening for dementia within primary care. 
The UK National Screening Committee is currently reviewing guidance on dementia 
screening, and latest published evidence is supportive of current recommendations420. 
From limited research to date on the impact of policies aiming to increase dementia 
diagnosis rates in general practice, there is insufficient evidence of effect to support 
further use of case-finding in primary care417,421. 
Lack of time was found to be a barrier to formal diagnosis in much of the evidence30,390, 
in line with responses to the GP survey. Practitioners want more time for consultations, 
and a shorter BCA test. Partly attributed to the lack of time available, GPs report often 
relying on personal judgment to assess patients for potential dementia324,411. 
7.4. Limitations 
7.4.1. Limitations relating to BCAs 
Within this PhD project, the specific focus was on BCAs for use as part of the process 
for identifying dementia in primary care and general practice. The definition of “BCA” 
has proved difficult and contentious, as discussed within Chapter 3. There is no 
consensus definition within the research or clinical literature. The use of the word 
“brief” is commonplace and often used to refer to tests taking ten minutes or fewer to 
administer88,116,225,303,395, but whilst test administration time is often stated, empirical 
measurement is rarely reported 119,422. This lack of evidence to support common 
practice means the term ‘brief’ can be very misleading, whatever the intention in its’ 
use. 
This emphasis required judgment on what constituted a BCA and what was suitable 
for primary care and general practice, as well as exclusion of other conditions such as 
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Mild Cognitive Impairment. a conscious decision was made to comply with a generally-
accepted concept of BCAs as ‘dementia tests’ or tests for identifying dementia, rather 
than the more accurate specification of BCAs as cognitive assessment tools, with 
capacity to assess particular aspects of an individual’s cognitive function. Dementia 
as a syndrome is far more complex than a discrete disorder of cognition423, yet all the 
tools assessed within this thesis are primarily tools that assess cognition in various 
ways. Some, such as those with informant components like GPCOG, gather additional 
information on functional abilities - but the underlying premise of this PhD thesis is that 
BCAs are conceptually-valid tools to be used as part of the process for identifying 
dementia. It is recognised that this is not an irrefutable position, and there is increasing 
discussion of the value of taking a more pragmatic approach to dementia 
identification424, where the abilities and disabilities of the individual are most prominent 
and prioritised beyond making diagnoses – at least until a time that the label is 
indisputably useful to the individual and their families425-427.  
The cost-effectiveness of using different BCAs as part of the process for identifying 
dementia in general practice was not explored as part of this PhD thesis. This would 
provide valuable information for commissioners as well as potentially useful additional 
data for practitioners when deciding between different BCAs, but was beyond the 
scope of this thesis and would warrant a separate study by itself. Recent work looking 
at the cost-effectiveness of using GPCOG, MMSE and 6-CIT for detecting dementia 
in primary care428 found that GPCOG provided the most cost-effective option 
compared to clinical (GP) judgment alone, due to earlier access to medications. It 
would be valuable to unpick some of the assumptions made within this work, for 
example that all diagnoses reached using these BCAs would be 100% accurate – 
which we know is not the case. The complexities of dementia as a syndrome and 
different dementia subtypes were not accounted for within this research, and different 
downstream treatment options beyond drug therapy were also unaccounted for within 
the model. Still, this work demonstrates a useful starting point for future investigations 
of cost effectiveness of the process for identifying dementia within general practice. 
It may have been valuable and provided more population-specific data if the condition 
of interest had been extended to include Mild Cognitive Impairment (MCI) as well as 
dementia. Whilst MCI is sometimes referred to as ‘pre-dementia’429,430, conversion 
from MCI to dementia is not guaranteed431,432. Some studies show a 60% conversion 
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rate from MCI to AD within a population-based sample433 but there is little current 
evidence of conversion rates within a general practice sample. It was therefore 
concluded that the link between dementia and MCI is insufficiently established or 
understood to include MCI as a condition of interest alongside dementia within the 
evidence syntheses.  
7.4.2. Limitations relating to research methods   
Rapid review 
The rapid review of CPGs was conducted as a highly specific and targeted evidence 
synthesis, to be conducted within time and resource allowances to enrich the 
understanding of current CPGs for this thesis. It addressed the research question fully 
and was highly valuable for greater comprehension of current BCA guidance, yet given 
more capacity for search specialisms and additional reviewer resource this could have 
covered the question to a greater depth and breadth, for example removing the English 
language restriction and translating texts identified in languages other than English.  
Settings and prevalence  
The prevalence of a condition or disease is the presence of that disease in a particular 
population at a certain point in time. This is often contrasted with incidence, which is 
the number of new cases of a condition or disease in a particular population within a 
certain time period86.  
Many of the most established and timeworn cognitive tests were first validated in a 
clinical population such as a memory clinic where the prevalence of dementia is far 
higher (up to 56%434) than in a normal primary care population where the prevalence 
is around 7%90 70,113,435. This means that in a memory clinic population (i.e. people 
registered with a specialist memory clinic) out of every 100 people 56 will have 
dementia – compared to a prevalence of 7% in general practice population where for 
every 100 people within a general practice area, 7 people will have dementia.  
Generally people attending a memory clinic will be older adults, and will have memory-
related symptoms which brought them to the clinic in the first place. In contrast a 
primary care population is a more mixed age-group (16.9% over 65 years old, 7.8% 
over 75 years old and 2.2% over 85 years old for the England General Practice 
Average435) presenting with a variety of symptoms to their GP.  
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This difference in prevalence matters, because it has a substantial impact on the 
accuracy of the test being used. Below is a worked example to illustrate this point. 
Imagine a test for dementia with 95% specificity (i.e. 95% of people without dementia 
will be correctly diagnosed as not having it, specificity = 0.95) and 80% sensitivity (i.e. 
80% of people with dementia will be correctly identified as having the condition, 
sensitivity = 0.80). These sensitivity and specificity scores are better than many tests 
currently used in the health care system and sound fairly good to many people.   
Imagine that we test 1000 for dementia from a memory clinic population with a 
dementia prevalence of 56% as shown in 32. 
If we test 1000 people from a memory clinic population with a prevalence of 56%, 560 
(56%) will have dementia and 440 (44%) will not. Of the 440 people without dementia, 
418 (95%) will correctly receive a negative test result (true negative) whereas 22 
people (5%) will receive an incorrect positive test result, i.e. they will be told they have 
dementia when they do not (false positive). Of the 560 people with dementia, 448 
(80%) will be detected and 112 (20%) will be missed. 
In combination, 448+22= 470 people will test positive for dementia, of which are 22 
false positives. Therefore the false discovery rate is 22/470= 4%. This means that if 
you test positive for dementia within this population, the chance that you really do have 
dementia is 96%, which is a very high discovery rate. 
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Figure 32 Tree diagram to illustrate the false discovery rate in diagnostic tests used 
in a memory clinic population 
 
Now imagine that we test 1000 people for dementia from a general practice population 
with a prevalence of 7%. As shown in Figure 33, 70 (7%) will have dementia and 930 
(93%) will not. Of the 930 people without dementia, 884 (95%) will correctly receive a 
negative test result (true negative) whereas 46 (5%) will receive an incorrect positive 
test result, i.e. they will be told they have dementia when they do not (false positive). 
Of the 70 people with dementia, 56 (80%) will be detected and 14 (20%) will be missed. 
Figure 33. Tree diagram to illustrate the false discovery rate in diagnostic tests used 
in a general practice population 
 
In combination, 56+46 = 102 people will test positive for dementia, of which 46 are 
false positives. The false discovery rate is 46/102 = 45%. This means that if you test 
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positive for dementia within this population, the chance that you really do have 
dementia is only 55% - slightly better than chance. 
Population 
From the illustration above, it is clearly important to take into account the population 
within which the test is intended to be used when choosing between tests, yet 
guidance is often unclear about the suitability of different tests for different 
population159,436.  
Within the overview, there was a lack of consistency amongst the reporting of both 
individual study populations and systematic review populations. The population of 
interest as stated in the overview protocol was “primary care” and “general practice”, 
and this was specified in search terms and inclusion criteria at the title and abstract 
screening stage. When study data were investigated, they were clearly from highly 
selected clinical populations with reported disease prevalence within study samples 
as high as 51%214, This figure is far more suited to the dementia prevalence of a highly 
selected memory clinic population compared to a dementia prevalence of around 6.5% 
in general practice437. With this level of variation and inconsistency within the 
population data, it offers a poor opportunity to fairly compare across review evidence. 
In the systematic review, studies excluded participants on the basis of common 
diagnoses such as delerium142,288, visual, hearing and physical impairments142,288,438 
and depression142. These are comorbidities regularly found within a general practice 
population and in people living with a diagnosis of dementia439-441, and are present 
amongst the complexity of conditions and confounders when assessing cognitive 
impairment in this population442,443. Excluding these conditions therefore risks 
destabilising the generalisability and applicability of findings to general practice.  
Identification of evidence 
Searches were developed for the overview by identifying key terms within background 
scoping papers29,42,45,130,379,391, consulting information specialists and running 
exploratory searches using different terms. Whilst this was a logical approach, studies 
may have been missed which used tests that did not make explicit reference to 
cognition in the article title or abstract. Equally studies may have been overlooked that 
were conducted with family practitioners, as searches were only conducted for primary 
care and general practice, as well as ‘community’ within the Cochrane Library. There 
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is the potential that papers were missed due to the searches employed, but no papers 
have yet been identified that were missed via other components of the search strategy 
such as forward or backwards citation chasing that would have been suitable for 
addressing the aims of the thesis. As a result it may be comfortably concluded that the 
searches were well designed.  
The overview methods used to explore systematic review data summarising the 
accuracy of BCAs for identifying dementia in primary care were exploratory in some 
areas, and without clear precedent. There were areas where new and emerging 
methodological approaches could have been explored more thoroughly by contacting 
more authors in the field of overview methods development in order to make 
methodological decisions based upon the latest advances. For example, assessing 
study quality and risk of bias was not well established within overviews of diagnostic 
accuracy, and using ROBIS and AMSTAR meant there was some overlap in process 
but also gaps in assessment such as the inability to tailor assessments and the 
AMSTAR question 10 “Was the likelihood of publication bias assessed?”444. This 
specific question carries a negative weight for a negative answer, i.e. if the likelihood 
of publication bias was not assessed, the quality of the review is marked down. This 
is not in line with current guidance from the Cochrane Handbook for Systematic 
Reviews of Diagnostic Test Accuracy75, which advises that further understanding of 
the interaction between publication bias and asymmetry within diagnostic accuracy 
research is needed before publication bias assessments can be applied in the same 
way as in systematic reviews of interventions445,446. These methods have been 
reflected upon with colleagues from the Cochrane Collaboration275,447, and we have 
highlighted a number of methodological decisions, alongside key features and 
objectives, which may be of benefit to others for considering during the development 
of an overview protocol. A recent update to AMSTAR, AMSTAR2448 has substantially 
reworked a number of the original questions in order to encompass randomised and 
non-randomised study evidence – but this tool is still explicitly not designed for 
diagnostic accuracy data. A new piece of research is underway assessing the 
usability, applicability and reliability of the AMSTAR, AMSTAR2 and ROBIS tools449 
and this may provide valuable insights into how these tools compare. If this exercise 
can be related specifically to diagnostic accuracy data this would be a useful addition 
to current knowledge. 
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In a 2011 systematic review of the accuracy of family physicians’ diagnoses of 
dementia450, similar issues were found to those reported regarding imperfect reference 
standards, unaccounted missing data, unclear timings between administration of the 
index test and reference standard, lack of blinding in interpretation of tests, and non-
representative patient populations. In the context of a systematic review, it would have 
been possible to pre-state exclusion criteria based upon some of these issues 
alongside specifying studies would only be included if they used a particular reference 
standard reported with a base set of information. This may well have resulted in a 
higher quality but a smaller pool of study-level information, and in the context of the 
overview, the available systematic review-level evidence would potentially be even 
more limited. It is unlikely that this route would have resulted in identifying data 
sufficient for meta-analysis, although this may have provided better quality information 
which would have allowed firmer conclusions to be drawn, allowing for more directive 
practice recommendations. 
Discordant results 
It was not possible to explore, even partially, the reasons behind discordant results 
due to the lack of data. For example, if Mrs Smith has a positive test result on the 
MMSE, but a negative test result on the GPCOG, why is this? What is the difference 
(or differences) between the tests, and what are they actually identifying? These 
factors could probably be investigated from existing datasets using personal identifiers 
for individual participants, and it would be of great value to follow the testing journey 
of specific people in order to tease out potential intra-test variations, and explore some 
of these greater complexities in the testing pathway. If this could be combined with 
knowledge of other test factors then the spectrum of understanding around the testing 
process would significantly broaden. 
Diagnostic accuracy is a narrow indication of test performance451 with outcomes 
influenced by key aspects such as disease prevalence 452, yet is frequently measured 
and (sometimes poorly) reported452-456. Quality issues are common around technical 
aspects of diagnostic accuracy such as the reporting of accuracy estimates, but also 
more simply in reporting of inclusion criteria and sampling details455. Context is often 
missing in the reporting of diagnostic accuracy studies, yet is a fundamental aspect of 
understanding how diagnostic accuracy fits within the clinical pathway457. Nowhere is 
this context more important than in dementia assessments, where disease prevalence 
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varies significantly between different settings and reporting of key details is highly 
varied. By using diagnostic accuracy as the lens to investigate dementia diagnosis in 
primary care as has been done within this thesis, there is a risk of further contributing 
to this artificially narrow focus of test evaluation. The intention here was to use 
diagnostic accuracy as a device to highlight inconsistencies in dementia diagnosis in 
general practice, but also to ‘reverse the perspective’ and view diagnostic accuracy 
through the lens of dementia diagnosis in order to identify and discuss practical 
challenges for test evaluation in clinical settings. Both these aims have been 
successful, but have left gaps in understanding of wider issues around test evaluation 
such as the effects on patient health, clinician practice and joint decision making as 
discussed in depth by di Ruffano and colleagues451 in their influential 2012 paper. 
7.4.3.  Limitations of the research process 
An early plan of this research was to follow a cohort of patients over 12 months from 
the point of diagnosis in general practice to see who improved (indicating a false 
positive diagnosis) and who developed further symptoms or stayed the same 
(indicating a true positive diagnosis). This would have allowed assessment of a 
number of factors including discordant results, as well as investigation of other parts 
of the test process such as acceptability to the individual and to the clinician, GP 
referral and additional testing in secondary care.  
Another plan was to conduct in-depth interviews with GPs in order to fully explore their 
choice of tests and testing decisions when using BCAs as part of the process for 
identifying dementia in clinical practice, but funding was not available to pay GPs for 
interview time. With reduced ambition and funding requirements, it was hoped to carry 
out a paid GP survey, as based on previous experiences118 this may have secured a 
higher response rate than with an unpaid survey. Unfortunately there was insufficient 
funding available for this, and so the unpaid survey conducted was the clearest route 
for gathering a number of GPs’ views on a range of questions relating to BCAs choice 
and use in practice. Focus groups with GPs could have been another option, and this 
may have exploited the group dynamic to elicit more responses and create discussion 
between respondents. This may also have resulted in less variation amongst 
responses and dominance of individual voices either between respondents 
themselves or between respondents and the moderator458,459. In addition, sample 
sizes are not guaranteed to have been higher or samples more representative than 
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they were in the survey. Response rates were relatively low for the survey (50% 
response rate - 52 practitioners responded, from a potential pool of at least 100 GPs) 
compared to previous surveys based on samples from a professional register which 
secured a 91% response rate460 and a survey of GPs which explored how clinicians 
apply existing test accuracy metrics for diagnostic decision making which gained a 
95% response rate118. Whilst low, the rate secured within this survey was in line with 
some other GP surveys distributed without cash or voucher incentives. One study 
characterizing response rates to mail-based surveys published in medical journals 
reported an average response rate of 54%461. A survey of Irish GP attitudes and 
practices in relation to screening, diagnosing, and disclosing a dementia diagnosis to 
patients also reported a response rate of useable surveys of 50%19. Another study 
looking at response rates of GPs and internal medicine specialists to combinations of 
mail survey followed up by a web-based survey, and vice versa, reported response 
rates of 63-71%462. Resource constraints and budget limitations meant that no 
financial incentives could be offered to potential contributors within a profession 
acknowledged to be short on time 134,136,373,463. If resources had been available, 
financial incentives and the use of professional surveying providers such as 
Doctors.net.uk would have allowed a larger survey sample and may well have secured 
a higher number of responses such as those reported in the unpublished 2012 survey 
of 996 GPs across 5 countries conducted on behalf of Lilly464. Responses to this 
survey were not representative of GPs who were inactive on Twitter, were not 
members of the CHAIN network and were not known to the candidate’s network of 
GPs who helped to distribute the survey. The distribution of responses showed fewer 
replies from the North East of England, Northern Ireland, the Scottish Highlands and 
Wales. Age of respondents and number of years in general practice was well 
distributed in line with national patterns of distribution51. Whilst it would have been 
valuable to ensure better general representation to the UK GP population and 
therefore greater generalisability, conclusions were tailored accordingly and designed 
not to make claims to broader generalisability of results than was justified within the 
data. 
The rapid review of CPGs is likely to have missed some CPGs not published within 
the databases searched, as well as all relevant CPGs not published in English. This 
review was rapid by dint of time and resource allowed, and was a specific requirement 
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of examiners following the PhD viva in order to systematically investigate CPGs 
available for the use of BCAs as part of the process for identifying dementia in general 
practice. A future review would benefit from more detailed and thorough searches of 
more than 4 databases, as well as the greater procedural  rigour introduced within the 
conduct of a full systematic review compared to a rapid review – namely the publication 
of the protocol as an open access peer reviewed article, searches including grey 
literature and forwards/backwards citation searching,  and the carrying out of the 
review with a minimum of two reviewers conducting key processes (such as screening 
and data extraction) blindly and independently. 
It would have been valuable to conduct a full review of how guideline advice matches 
cited supporting evidence, as in the process of this research it has been discovered 
that this cited evidence is not guaranteed to match guidance. This was not something 
recognised at the start of this project, and by the time it was realised quite how 
dissonant these elements can be it was too late to work this into the thesis without 
changing focus of the PhD significantly. This would be worth pursuing as a separate 
research project, and would continue and develop a theme that has emerged through 
this PhD thesis – that formal guidance is not always supported by best evidence. 
The systematic review of direct comparisons of diagnostic accuracy focussed on two 
BCAs – MMSE and GPCOG. The rationale for this specific emphasis is clear, in that 
these were the two most commonly used tests identified within the overview of BCAs 
and the GP survey that was conducted, and the two most commonly quoted tests 
within guidelines. There are direct comparisons of diagnostic accuracy conducted with 
other tests, and an analysis including more BCAs would probably generate useful 
additional information. The main reasons behind the decision to limit the systematic 
review purely to two BCAs were that the justification for using these two tests due to 
their pre-eminence amongst existing evidence was strong, and there were limited 
resources to conduct a larger scale systematic review. It was judged to be better to 
carry out a specific and focused review looking at two BCAs, particularly using 
relatively new methods in a systematic review of direct comparisons of diagnostic 
accuracy, so the scope was restricted accordingly. 
Finally, a clear limitation was that the primary focus was on reviews of diagnostic test 
accuracy, with other information (such as aspects of broader impact) reported as of 
secondary interest. It has become clear through the course of this PhD that whilst 
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accuracy is a useful measure for test evaluation, it is rarely the most important 
measure when considering the impact of a test and testing on patient related 
outcomes. In a future review, it would be valuable to explore analytical performance 
(e.g. validation, replication) of BCAs, as well as cost-effectiveness and broader impact 
(e.g. admin time, acceptability to patients and clinicians) within a specific, targeted 
review of the evidence. These factors are discussed in more detail in section 7.5. 
7.4.4.  Changes within the thesis 
Little has been changed in the course of the PhD from the original plan stated in the 
registration documents and PhD midpoint transfer report. Within the overview, the only 
change between protocol and review was in the search strategy. It was intended to 
search an evidence database being developed by the University of Exeter Medical 
School. The database however was not complete at the time of searching and 
therefore searches were restricted to the priority databases.  
Within the systematic review, there were two departures from the published protocol. 
One was regarding stratification of GPCOG where it had originally been stated that 
the most clinically relevant measures of GPCOG Patient, GPCOG Total and GPCOG 
Two stage (as GPCOG Informant has not been recommended for use by itself within 
a clinical setting284) would be used. Included studies reported four individual measures 
for GPCOG (Informant, Patient, Total and Two stage) so these four GPCOG subtypes 
were stratified, rather than across the pre-stated and arguably more clinically-relevant 
three subtypes. 
The other departure from the protocol was in data extraction where it had been stated 
in the protocol that the data abstraction form would be piloted with two included 
studies, but in the event only one study was used to pilot the form, as it was a simple 
process and further trials were not needed. 
Post-viva, the rapid review of CPGs was an additional piece of work conducted at the 
request of the examiners and has helped to asses and strengthen the evidence base 
and known context for conclusions around the availability of CPGs for this specific 
population and setting. Further work has also been carried out in triangulation of data 
from the survey, which has allowed a greater depth and context to be drawn from the 
findings within the wider context of published research literature and evidence 
identified elsewhere within this thesis. Recommendations 
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7.4.5. Background to the recommendations 
New Research Framework proposals for Alzheimer's diagnosis from the National 
Institute for Aging and the Alzheimer’s Association465 (NIA-AA) provide an outline for 
defining Alzheimer’s disease using biomarkers. This amounts to a fundamental 
reassessment of how we define Alzheimer’s disease, moving from a clinical syndrome 
to a set of explicit biological features based upon neurofibrillary tangles and amyloid 
plaques. This new agenda has been positively welcomed by many institutes already 
active in the use of biomarkers. Such institutions have highlighted perceived benefits 
to clinical trials in driving improved biological profiling of trial participants, and the 
adoption of universal measures and language for the Alzheimer’s research 
community. There are, however, fundamental questions still remaining around the 
exact nature of the disease, how biomarkers and clinical presentation interact and why 
many people with indicator biomarkers present may never develop clinical symptoms. 
A critique of this NIA-AA research framework for Alzheimer’s disease by editors of the 
Cochrane Dementia and Cognitive Improvement Group (CDIG)394 highlighted the 
danger of shifting diagnostic criteria and therefore disease boundaries from the 
research sphere into clinical practice, resulting in promoting the use of biomarkers 
within the clinic. This is already a feature of the latest NICE dementia guidelines, which 
support the use of CSF and imaging biomarkers to assist clinical diagnosis383. It has 
been indicated elsewhere in this thesis that not enough is known about the false 
positives and potential discordance between BCA results (i.e. if one person tests 
positive on test A but negative on test B, what are the underlying discrepancies?). 
What is emphasised in this critique of this new NIA-AA framework is that the potential 
for misclassification when using biomarkers as the sole diagnostic criteria is 
substantial, with ensuing implications of psychological, financial, legal and social costs 
for individuals and wider society466. Whilst these critiques of emergent biomarker 
technologies are compelling, they are not conclusive – and it may be that combinations 
of different test modalities using approaches such as staging, triaging or as add-ons 
to existing diagnostic pathways 467 may provide the much needed improvements to 
the early phases of the process for dementia identification within general practice468. 
A large volume of evidence was found around BCAs and their place in identifying 
dementia in general practice. This evidence is mixed in quality and findings, and there 
is a deficit of clear, robust evidence showing that BCAs have a high or acceptable 
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degree of accuracy and are fit for purpose. Considering all these weaknesses, we 
should ask: are BCAs the best methods for assessing cognitive performance in 
general practice? Are they actually cost effective, effective for patient reported 
outcome measures, effective for clinician reported outcome measures, with a clear 
benefit for clinical decision making and ongoing management decisions?  
In addition to these questions, we should ask: what are BCAs? They are not brief, 
whatever brief means – many take well over ten minutes to complete in full, without 
allowing for set up, briefing and discussion of results. They are not always solely 
related to cognition, as many cover multiple domains which also incorporate other 
measures such as informant assessments and activities of daily living metrics. We 
also need better evidence on the role and value of informant reporting. Several BCAs 
such as the GPCOG, IQCODE and AD864,65,125,142,469 have sections for informants to 
complete, but the additional value in terms of other outcomes beyond cognitive 
function is currently underexplored.  
As dementia is an umbrella term covering a range of disorders with varied 
presentations, only some of which are chiefly characterised by cognitive dysfunction, 
is cognition the one aspect of function to be focussing on within assessments? Or is a 
functional approach470, as supported by the latest DSM-VI and ICD-11 guidelines, the 
future of dementia assessment? If we can address these questions rationally, we may 
find that there are other tools and assessments such as blood tests which are 
emerging as at least as effective in terms of diagnostic accuracy – and perhaps more 
acceptable to patients, clinicians, with improved cost-effectiveness. These alternatives 
may provide a great improvement on current available tests, and should not be 
discounted in the mistaken belief that current BCAs are adequate.  
7.4.6. List of recommendations  
From the research presented, 6 key recommendations are proposed: 
1. More studies are needed which measure the diagnostic accuracy of BCAs and 
consistently address the general practice population, in terms of disease 
prevalence, sampling, recruitment, allocation, inclusion strategies and test 
administration. As detailed in Chapters 4 and 5, there is a paucity of studies carried 
out within a population relevant to general practice, using general practitioners to 
conduct assessment. Evidence identified within this thesis (detailed in Chapters 3, 
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4, 5 and 6) was broadly inconsistent in the way that participants were recruited, 
common groups found in general practice were excluded (such as people with 
cardiovascular problems or sensory impairments), general practitioners did not 
feature as assessors for the tests, and missing data were a significant problem.  
2. The quality of overviews, systematic reviews and primary studies which assess the 
diagnostic accuracy of BCAs need to be improved in order to clearly and accurately 
report source data, employ clinically relevant BCAs, consistently use a study 
population that relates closely to the target population of interest, report basic 
accuracy data such as disease prevalence, and make the contents of the 2x2 table 
available to allow for further analysis as required. Evidence on the accuracy of 
BCAs disproportionately featured the MMSE, study populations did not relate 
consistently to general practice populations, BCA thresholds varied widely, and 
were not clearly reported in all cases. Sensitivity and specificity were not clearly 
reported and data were pooled in many cases. Variability found at the levels of 
study and systematic review was amplified within the overview.  
3. To qualify as a BCA, a test should have the following 7 features: 
i. Maximum 5 minutes administration time including time for instruction, 
interpretation and explanation – derived from guideline evidence presented 
in Chapter 3, and GP survey responses presented in Chapter 6; 
ii. Free and simple to access – derived from guideline evidence presented in 
Chapter 3, clinically relevant outcomes presented in Chapter 5 and GP 
survey responses presented in Chapter 6; 
iii. Validated in a general practice population – derived from evidence 
syntheses presented in Chapters 3, 4, and 5, clinically relevant outcomes 
presented in Chapter 5 and GP survey responses presented in Chapter 6; 
iv. Can be administered within general practice – derived from evidence 
syntheses presented in Chapters 3, 4, and 5, and GP survey responses 
presented in Chapter 6; 
v. Can be administered by practice staff who are not general practitioners – 
derived from GP survey responses presented in Chapter 6; 
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vi. Simple to use with clear instructions for interpretation – derived from 
clinically relevant outcomes presented in Chapter 5 and GP survey 
responses presented in Chapter 6; 
vii. Free from education, language, and cultural bias – derived from guideline 
evidence presented in Chapter 3, evidence syntheses presented in 
Chapters 3, 4, and 5, clinically relevant outcomes presented in Chapter 5 
and GP survey responses presented in Chapter 6. 
4. There needs to be further assessment of other equally important factors for BCAs 
in primary care alongside diagnostic accuracy. These factors should certainly 
include acceptability to the patient; acceptability to the clinician; cost-effectiveness; 
test administration time; and possibly other factors. None of the evidence assessed 
within this thesis addresses the ability of tests to monitor performance over time. 
This was not a topic that was purposefully targeted within this PhD research, yet a 
number of GPs within the survey development and conduct referred to using BCAs 
to measure change or take a snapshot at different time points in order to measure 
decline or maintenance. Anecdotally, performance over time would be a useful 
measure for general practitioners and tests are already used in this way, yet there 
is little evidence on whether any of the current BCAs are useful for this purpose. 
There was little evidence found within primary and secondary sources on patient 
views, acceptability and understanding of BCAs. This is another significant gap 
which would benefit investigating as a priority. As patient and public involvement 
and shared decision making becomes more integrated within general practice, this 
lack of evidence will become more prominent and at odds with wider public health 
policy. Related to this, there was little evidence on GP views and GP understanding 
of testing in the context of BCA use as part of the process for identifying dementia 
within general practice. Whilst professional nihilism is often quoted as one of the 
barriers to improved dementia diagnosis rates within general practice18,136,331-
333,339,348,390, there may be many other reasons for missed diagnosis and 
misdiagnosis which have not yet been fully explored within this specific context.  
More work should focus on this aspect of the testing process in the context of 
dementia diagnosis, particularly asking what test factors are considered most 
important and useful for GPs when first assessing potential dementia within the 
general practice setting. Specifically we need to understand how social and 
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interpersonal elements of the consultation may influence the GP’s diagnostic 
decision making; what aspects of the diagnostic process are given greater weight 
(such as physiological symptoms; functional features such as Activities of Daily 
Living; or informant reports); and in the absence of some information (e.g. 
informant testimony), what other features are given greater prominence? 
Alongside understanding these factors better, there appears to be a corresponding 
gap in understanding the patient perspective during the diagnostic process. What 
factors are most valued by patients during diagnosis? What aspects are most 
problematic? If these more nuanced and complex elements of the diagnostic 
process can be better understood this will help to design processes that address 
some of the barriers in the system.  
5. We need to interrogate the assumption that BCAs are the best measures to be 
using in general practice, and ask whether instead we should we be investing in 
different technologies and exploring the acceptability, feasibility and accuracy of 
other measures such as biomarkers. It may be that combinations of different test 
modalities using approaches such as staging, triaging or as add-ons to existing 
diagnostic pathways 467 may provide the much-needed improvements to the early 
phases of the process for dementia identification within general practice. 
6. MMSE should not be the predominant BCA used either in research or in the clinic, 
and should not be considered as suitable for use as part of the process for 
identifying dementia in general practice. Whilst MMSE was prominent and the most 
popular BCA across many examples, the administration time of MMSE – where 
empirically established within a clinically relevant population - was found to be 
beyond the time allowed within standard general practice consultations. According 
to recent research390, the use of MMSE as part of the assessment for potential 
dementia in general practice is mandatory in 12 European countries. Yet the 
ubiquity of MMSE may act as a barrier to progress; as long as it occupies a 
standard position of trust amongst BCAs within dementia diagnosis, there may be 
little progress in developing better tools.  
Finally, it is important to return to the purpose of the test; where does it sit in the 
diagnostic pathway, and in the patient’s healthcare journey? The BCA is used primarily 
as a triage tool within general practice, where an initial assessment is carried out and 
only patients with a positive test result are then referred on for further testing and work-
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up in specialist memory clinics. If we are truly aiming to improve dementia diagnosis 
within general practice, it is imperative that accuracy be improved or new measures 
are found to replace current BCAs, which are not fit for purpose.  
The Alzheimer’s Society recently announced priorities for improving dementia 
research by 2025471. The second priority identified was to maximise the benefits of a 
dementia diagnosis to patients and their carers, and as part of this to research the 
acceptability, cost‐effectiveness and health outcomes of innovations in diagnostics, 
including non-invasive tests that support making a diagnosis in primary care.  
This thesis goes some way to addressing these aims by drilling down into the specific 
areas where current knowledge is lacking and shedding light to improve our 
understanding around the accuracy of BCAs within the context of general practice. 
7.5. What does this PhD thesis add? 
Through this PhD research, a number of important areas of uncertainty in the 
diagnostic accuracy of BCAs used as part of the process for identifying dementia 
within general practice have been identified. These uncertainties are often hidden 
within guidelines where it is assumed that much of the supporting evidence is 
grounded within general practice populations, with dementia prevalence similar to or 
the same as the real life populations where guidance and policies will be applied.  
What has been discovered and demonstrated within this thesis is that much of the 
evidence assessing the diagnostic accuracy of BCAs when used as part of the process 
for identifying dementia in primary care is based upon studies with ill-suited 
populations, disease prevalence, sampling, recruitment, allocation, inclusion 
strategies and test administration.  
Published CPGs relating specifically to BCA use in general practice are not common, 
and for those that were identified and analysed in the course of this PhD thesis, the 
recommendations are both inconsistent and not tailored for target populations. There 
is little information available on specific BCAs, the evidence behind recommendations 
and how CPGs are suited for culturally and linguistically diverse audiences. Key 
aspects of BCA selection and performance such as tailoring and disease prevalence 
are overlooked within current guidance, and there is a strong need to improve and 
broaden the evidence for CPG recommendations.  
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Very few studies assess BCAs using direct comparisons of diagnostic accuracy within 
the same study population. This is an issue as diagnostic accuracy assessments are 
open to a great deal of variation across a number of factors beyond variation in 
populations, settings, conditions of interest and administration. Test factors such as 
versions, assessors, testing environment, ordering and timings between testing all 
make a difference to how a test or tests perform. Reference standards are often 
imperfect and sometimes complex, made up of several tests (composite) or requiring 
a different administrative process compared to the index test. In many cases observed 
within the overview, reference standards were based upon one or more of the index 
tests being assessed. All this variation contributes in subtle and significant ways to the 
testing environment and may influence the results of a diagnostic accuracy 
assessment. Where two or more tests are directly compared within the same 
population, a number of these influences can be expected to affect both tests more-
or-less equally, as they apply to the same participants in the same environment in the 
same way. One clear exception in this scenario is when there is missing data from one 
testing arm and not another, leading to an asymmetry in potential bias. This was one 
of the weaknesses identified within the systematic review looking at the accuracy of 
MMSE and GPCOG when directly compared to one another. 
The paucity of high quality study level evidence designed and conducted specifically 
to assess the diagnostic accuracy of BCAs within a general practice population is a 
surprising and concerning finding. Whilst a lack of evidence was identified which 
allowed the robust assessment of diagnostic accuracy of BCAs with a general practice 
population, a great deal of evidence assessing BCA accuracy was found that was of 
average quality or poorly conducted and reported. This meant that not only were 
research findings highly limited in their usefulness, but the participants, finance and 
resources that had contributed to this evidence were ill served due to avoidable 
failures in conduct of the studies and reporting of the evidence.  
Similarly, many of the evidence syntheses assessed were poorly suited for applying 
evidence to general practice due to methodological weaknesses, yet in many cases 
this incompatibility was difficult to identify. Even after having used established quality 
assessment tools such as QUADAS-2, the evidence needed unpicking in detail to 
reveal deficiencies in methodology and conduct such as missing data, inappropriate 
study designs and high degrees of incorporation bias. 
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Another discovery of this PhD research is the lack of evidence around the assessment 
of other test factors which impact on accuracy and test performance. These include 
acceptability to the patient, acceptability to the clinician, cost-effectiveness of the test 
and the testing process, test administration time, and test validity. Whilst these factors 
were not the primary focus of the systematic review and overview, instances within the 
evidence reviewed were positively identified where these measures were included 
alongside diagnostic accuracy evidence, and yet there were few examples where 
these data were reported. These factors beyond test accuracy have a strong influence 
on how testing improves health outcomes relative to the best alternative, such as no 
testing or another testing scenario 472. Little systematically gathered evidence on these 
broader factors was found. 
As detailed in Chapters 4 and 5, a number of studies which aimed to directly compare 
the diagnostic accuracy of two or more BCAs used as part of the process for identifying 
dementia in general practice fell short of this goal, through unclear or poor research 
methods, mixed methodological quality and poor reporting.  
Many index tests were compared on an uneven basis, where the MMSE was also used 
at least in part as the reference standard within the CAMDEX or CAMCOG, leading to 
overestimation of effect and greater potential for incorporation bias282. The asymmetry 
of bias in this approach is a particular concern, as one index test (GPCOG) which does 
not feature within the reference standard would be disadvantaged when directly 
compared to another test (MMSE) which does. Many other biases observed within 
direct comparisons of diagnostic test accuracy assessments may affect both index 
tests relatively equally, as they influence the same population, setting and – broadly – 
administration process. Indeed, this is one of the stated benefits of direct comparisons 
of diagnostic accuracy over indirect comparison studies of diagnostic accuracy473-475.   
In summary, the thesis identifies and characterises these key issues: 
 a lack of robust study level evidence specifically addressing a general practice 
population, in terms of disease prevalence, sampling, recruitment, allocation, 
inclusion strategies and test administration;  
 The failure of evidence – where it does exist - to clearly and accurately convey 
source data, employ clinically relevant BCAs, consistently use a study population 
that relates closely to the target population of interest, report basic accuracy data 
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such as disease prevalence, and make the contents of the 2x2 table available to 
allow for further analysis as required; 
 Ill-defined BCAs suitable for use in general practice; and  
 A paucity of evidence on other equally important factors such as patient and 
clinician acceptability; cost-effectiveness; and test administration time for BCAs in 
primary care; alongside diagnostic accuracy. 
Therefore the next step within this research would not be to conduct any more 
systematic reviews. It has been demonstrated that there are plenty of reviews into 
BCA accuracy, but the evidence is not particularly helpful in identifying which BCAs 
are most accurate or suitable for identifying dementia in general practice. 
Instead, the suggestion would be to design and conduct a robust primary research 
comparative accuracy study to precisely address the weaknesses identified within this 
thesis.  This study would also be designed to deliver detail on wider aspects of the 
testing process that impact on patient outcomes, such as clear empirical measurement 
of test administration time, acceptability to the patient, to clinicians and to wider 
society; cost-effectiveness; and ease of use. As part of this, a stakeholder reference 
group would be an essential feature of the research, with members made up of 
patients, relatives and clinicians who would be involved from inception in developing 
research questions, interrogating the data and disseminating the findings to greatest 
effect. The tools themselves would be clearly defined as BCA tools, being free at the 
point of use, with administration times suited to general practice application, possibly 
with an informant element, and independent from the reference standard. The GPCOG 
would be compared alongside one other test such as Mini-Cog, as although MMSE is 
the most prominent in research and (possibly) practice, it is not free and administration 
time has not reliably been shown to be suitable for general practice.  
Alongside this study, work would be conducted to understand further what the general 
practitioner is actually trying to do within the diagnostic process for identifying 
dementia. Currently, the common perception is that there is a single, simple route to 
diagnosis15,476 and this needs to be grounded in the reality of clinical consultation. It 
would be highly valuable to characterise in detail the variety of roles the GP is trying 
to fulfil here through the diagnostic process, from initial consultation through to 
assessment, referral and follow up. This would be conducted with general practitioners 
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on the research team, to ensure that the views of the clinicians were fully represented 
and built into the design, conduct and communication of the research.  
In addition to the primary comparative accuracy study outlined above, it would be 
reasonable to conduct a trial of the effectiveness of BCAs when used to identify 
dementia in general practice with outcomes designed to translate clearly into benefits 
for patients477. This randomised controlled trial would involve a relevant stakeholder 
group from the start, with patients, relatives and clinicians involved meaningfully 
throughout the research from the design of research questions to the conduct of the 
trial and dissemination of research findings. Factors that the trial would measure 
include the direct effects of testing, using a clinical measure as the primary outcome, 
such as changes in clinical management (e.g. starting, stopping, or modifying 
treatment; ordering more tests; or watchful waiting) and decision-making, guided by 
these test results472. Assessments of the effects of testing on clinicians’ diagnostic 
thinking and subsequent clinical decision making and management feature 
prominently in proposals for evaluation schemes of medical tests308. 
Secondary measures would consist of the indirect (non-clinical) effects of testing, in 
order to represent outcomes of relevance to patients, clinicians or other stakeholders 
such as emotional, behavioural, social or cognitive effects. It would be important to 
conduct scoping searches and focus groups with stakeholders to identify the most 
meaningful and relevant outcomes for people directly and indirectly affected by the 
process. In addition, an assessment of cost-effectiveness would be included in order 
to establish the actual costs of using individual BCAs as part of the process for 
identifying dementia in general practice. A model of the cost effectiveness of using 
BCAs within UK general practice428 based upon a simulated cohort found that the use 
of MMSE, 6CIT or GPCOG would be a cost-effective strategy compared to clinical 
judgment within general practice. Another recent study looked at the cost-
effectiveness of memory assessment services for the diagnosis and early support of 
patients with dementia in the UK478. The researchers found that diagnosis, treatment 
and follow-up care given to people with suspected dementia was effective but not cost-
effective over the first six months after diagnosis. Another recent study of cost-
effectiveness conducted in a German memory clinic479 found a high range of costs 
and variation across diagnostic demands in this setting. There would be real value in 
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building upon these findings to assess cost-effectiveness alongside other patient and 
clinician relevant outcomes within a UK general practice setting. 
The purpose of investigating the effectiveness and diagnostic value of BCAs for 
identifying dementia in general practice would be to objectively and systematically 
assess the suitability of BCAs as a tool for use in this population and setting. Whilst 
the suspicion may be that BCAs generally, or specific BCAs, may not be ‘fit for 
purpose’ in terms of identifying dementia within general practice, we still need to 
establish that this is the case using robust methodological and statistical approaches 
and reported in the fullest and most accurate ways possible. It is also important to 
establish what is meant by ‘fit for purpose’ in this context, as identifying dementia is 
not a straightforward process of GPs diagnosing a single discrete condition. It is likely 
that there is a far more complex problem being addressed here, and at present all the 
component parts of this process are grouped under the heading of dementia 
diagnosis.  
What is needed is clear, specific, well designed primary research to begin to unpick 
these complexities and realistically address the challenges presented by the 
identification of dementia within general practice and primary care.  
7.6. Reflections on the PhD 
7.6.1. Evolution and development 
The research ideas behind this PhD have been part of an ongoing conversation 
between me and Professor Chris Hyde, my Director of Studies, since at least 2013. 
The kernel of the research question came about as we considered the challenge of 
diagnosis in a condition such as dementia with uncertain aetiology, limited treatment 
options and initial presentation commonly at the level of general practice.  
Following an unsuccessful application for an NIHR PhD Fellowship in the 2013/2014 
funding round, the original research idea was revised from 20 interviews with GP 
practices and a cohort study of people initially diagnosed with dementia with a 12 
month follow-up to a more modest research plan with scaled down ambition and 
making full use of existing research skills. This led to an application to the Alzheimer’s 
Society Project Grant scheme for an overview, two systematic reviews, and a survey 
of GPs followed by in-depth interviews to explore issues arising from the previous 
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work. This application was rejected by the funders who predicted difficulties in 
involving GPs in research and ensuring clinical adoption of research findings. 
Further refinement of the project plan proposed semi-structured interviews with a 
smaller sample of GPs, and this application was submitted to the Royal College of 
General Practitioners Scientific Foundation Board. Although positively received, the 
application was rejected on the basis of over ambition in the number of research 
objectives, and uncertainty around the impact of this research on clinical practice.  
These comments directly influenced the final iteration of the research plan which 
scaled down ambition to two evidence syntheses and a survey of GPs to explore 
clinical reality of test selection and use, and to compare these views against the 
existing evidence base. Following post-viva requests from the Examiners, an 
additional piece of evidence synthesis work was conducted alongside further analysis 
of the survey results to triangulate findings with current evidence and evidence already 
identified within the PhD. This PhD research has been generously supported by the 
Diagnostics Theme of the National Institute for Health Research (NIHR) Collaboration 
for Leadership in Applied Health Research and Care (CLAHRC) South West Peninsula 
(PenCLAHRC), and the resources and associated support provided by this 
organisation has helped immeasurably in conducting this PhD thesis. 
The judgements and comments received from all of these research boards and 
organisations reflect careful consideration by many experts within their areas who 
judge funding applications on a regular basis. This current research has been refined 
as a direct result of their careful consideration of proposals, and this work has evolved 
into a leaner, more efficient and well defined piece of research because of the time 
taken by each reviewer at the various stages described above. Whilst the process of 
securing support has not been straightforward and has - at times - proved challenging, 
this passage of refinement and evolution has proved ultimately beneficial to both the 
research project and my experience as an independent researcher. 
7.7. Thanks and acknowledgements 
7.7.1. Project Advisory Group 
At the beginning of this venture, I had a strong sense that a Project Advisory Group 
would be a significant addition to my PhD studies. This view was based principally 
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upon previous research experience with Project and Research Advisory Groups which 
had been generally positive and beneficial to the work being undertaken.  
My rationale was that not only would a range of expertise and experience help in 
shaping and interrogating my research decisions, but working with a group of ‘critical 
friends’ would force me to be clearer than I might otherwise be on motivations behind 
decisions, directions taken within the PhD, and to articulate these processes even at 
times when it felt uncomfortable to do so.  
What I never anticipated was the level of engagement, generosity and tenacious 
goodwill I have experienced throughout the course of my studies. I am outstandingly 
grateful for the kindness I have been shown by Project Advisory Group members, 
shown in Error! Reference source not found..  
Table 22 Project Advisory Group Members 
Anne-Marie Boylan - Departmental Lecturer & Senior Research Fellow NIHR 
CLAHRC Oxford, Nuffield Department of Primary Care Health Sciences, Medical 
Sciences Division at the University of Oxford.  
Nick Cartmell - General Practitioner in Asburton, Devon. 
Teresa Dyer - Expert by experience 
Willie Hamilton - Professor of Primary Care Diagnostics at the University of Exeter 
Medical School and General Practitioner in Exeter, Devon. 
Ian McKeith - Professor of Old Age Psychiatry, Newcastle, Theme lead of Newcastle 
NIHR Biomedical Research Unit in Lewy Body Dementias and Biomedical Research 
Centre in Ageing and Neurodegenerative conditions, Hon. Consultant in Old Age 
Psychiatry, Newcastle North Tyneside and Northumberland Mental Health NHS 
Trust; DLB International Consortium Lead  
Rupert McShane - Associate Professor, Dementia Clinical Network Lead for the 
Oxford Academic Health Science Network, Consultant Old Age Psychiatrist, 
Coordinating Editor of the Cochrane Dementia & Cognitive Improvement Group.  
Yemisi Takwoingi - Senior Research Fellow in Biostatistics at the University of 
Birmingham.  
Malcolm Turner - Expert by experience. 
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The eight individuals I approached were chosen as friends and colleagues of 
supervisors, members of other groups at the University of Exeter Medical School, 
people I have worked with previously and people whose work I have admired.  
Everyone I asked to join my Project Advisory Group agreed with enthusiasm, and has 
stayed with me to the end. Not only have Project Advisory Group members remained 
steadfastly engaged and supportive of my undertakings, as individuals they have 
eagerly reviewed chapters of this thesis and provided many insightful and helpful 
comments along the way.  
Having such a breadth of expert input from lay experts, old age psychiatrists, general 
practitioners, qualitative and quantitative research methodologists, research ethics 
specialists, diagnosticians, medical statisticians, epidemiologists, neuropsychologists 
and implementation specialists has enriched my understanding and examination of 
this area immeasurably. I hope the work I have produced within this thesis has justified 
their kind involvement, and that some of us may have the opportunity to work together 
again in years to come.  
7.7.2. Supervisory team 
I have been supported throughout my PhD research by an expert and engaged team 
of supervisors in Professor Chris Hyde, Professor of Public Health and Epidemiology 
at the University of Exeter Medical School (Director of Studies), Dr Mark Pearson, 
Senior Lecturer in Implementation Science & Knowledge Mobilisation at Hull York 
Medical School (secondary supervisor),  and Dr David Llewellyn, Senior Research 
Fellow in Clinical Epidemiology at the University of Exeter Medical School (secondary 
supervisor). In particular, Professor Chris Hyde as my Director of Studies has given 
unstinting and good-humoured support throughout the project and beyond, providing 
links to international experts in the field and always making time to address issues and 
answer questions however menial. This opportunity to work with and learn from 
Professor Hyde has been a privilege as well as a sincere pleasure. 
7.7.3. Wider networks 
In addition to the enthusiastic and expert input I have received from my Project 
Advisory Group throughout my PhD research, I have been astonished by the amount 
of help I have received from the wider academic community.  
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Within the sometimes claustrophobic isolation of a PhD, the friendship, 
encouragement and willingness to help I have experienced from various academic 
sources has surpassed all expectations and provided many moments of respite from 
the morass of PhD scholarship. From Twitter support via the Shut Up and Write 
organisation (@SUWTUK) and various new networks using the #PhDForum and 
#PhDlife hashtags, to colleagues who have reviewed various drafts of papers, ethics 
applications, thesis chapters and conference presentations, I have been exceptionally 
fortunate in the support I have benefitted from throughout my research.  
More widely, I have been moved by the number of researchers, authors and 
professionals from international organisations who have willingly provided assistance 
including individuals from the World Health Organisation, Alzheimer’s Disease 
International (who shared a valuable pre-publication report), Eli Lilly (who shared 
unpublished research), the National Institutes of Aging in the United States of America 
and the Alzheimer’s Society in the UK.  
Individuals who have provided particular help include Becca Abbott, Yemisi Takwoingi, 
Louise Crathorne, Alison Bethel, Sanne van Kampen, Elzbieta Kuzma, Obi 
Ukoumunne, Jo Thompson Coon, Steph Powell, Jenny Lowe, Sue Whiffin, Becky 
Hardwick, Pim van den Dungen, Molly Wagster, and Jennifer Hill. 
Finally, none of this would be possible without my husband John and our dog Kipper. 
Between them, they have kept me sane, exercised and fed and I’m inexpressibly 
grateful for our lives together.
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